

OM protein - protein search, using sw model

Run on: April 8, 2004, 15:30:06 ; Search time 43.3077 Seconds  
(without alignments)  
71.766 Million cell updates/sec

Title: US-09-787-443A-21  
Perfect score: 11  
Sequence: 1 AKSRKGNSSLM 11

Scoring table: OLIGO  
Gapop 60.0 , Gapext 60.0

Searched: 1586107 seqs, 282547505 residues

Word size : 0

Total number of hits satisfying chosen parameters: 22883

Minimum DB seq length: 11

Maximum DB seq length: 11

Post-processing: Listing first 100 summaries

Database : A\_Geneseq\_29Jan04:\*  
1: geneseqp1980s:\*  
2: geneseqp1990s:\*  
3: geneseqp2000s:\*  
4: geneseqp2001s:\*  
5: geneseqp2002s:\*  
6: geneseqp2003as:\*  
7: geneseqp2003bs:\*  
8: geneseqp2004s:\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

| Result<br>No. | Score | %     |        | DB | ID       | Description        |
|---------------|-------|-------|--------|----|----------|--------------------|
|               |       | Match | Length |    |          |                    |
| 1             | 11    | 100.0 | 11     | 3  | AAY88549 | Aay88549 NCAM Igl  |
| 2             | 11    | 100.0 | 11     | 5  | ABG69349 | Abg69349 Human neu |
| 3             | 4     | 36.4  | 11     | 2  | AAR04739 | Aar04739 Deduced s |
| 4             | 4     | 36.4  | 11     | 2  | AAY07532 | Aay07532 Laminin-d |
| 5             | 4     | 36.4  | 11     | 2  | AAY07531 | Aay07531 Laminin-d |
| 6             | 4     | 36.4  | 11     | 2  | AAW76689 | Aaw76689 Plasmid p |
| 7             | 4     | 36.4  | 11     | 4  | AAM98749 | Aam98749 Human pep |
| 8             | 4     | 36.4  | 11     | 4  | AAB68771 | Aab68771 Human FAS |
| 9             | 4     | 36.4  | 11     | 4  | ABP17604 | Abp17604 HIV B58 s |

|    |   |      |    |   |          |                    |
|----|---|------|----|---|----------|--------------------|
| 10 | 4 | 36.4 | 11 | 5 | ABB74319 | Abb74319 Simple nu |
| 11 | 4 | 36.4 | 11 | 6 | ABP99717 | Abp99717 Human sec |
| 12 | 4 | 36.4 | 11 | 6 | ABP72546 | Abp72546 Peptide e |
| 13 | 4 | 36.4 | 11 | 6 | ABR01199 | Abr01199 Human gen |
| 14 | 4 | 36.4 | 11 | 7 | ADC22397 | Adc22397 Nuclear l |
| 15 | 3 | 27.3 | 11 | 1 | AAP50987 | Aap50987 FTS-deriv |
| 16 | 3 | 27.3 | 11 | 1 | AAP50941 | Aap50941 Hepatitis |
| 17 | 3 | 27.3 | 11 | 1 | AAP82901 | Aap82901 Activated |
| 18 | 3 | 27.3 | 11 | 1 | AAP80854 | Aap80854 Sequence  |
| 19 | 3 | 27.3 | 11 | 1 | AAP81302 | Aap81302 Atrial na |
| 20 | 3 | 27.3 | 11 | 2 | AAY07371 | Aay07371 Matrix me |
| 21 | 3 | 27.3 | 11 | 2 | AAR07165 | Aar07165 Synthetic |
| 22 | 3 | 27.3 | 11 | 2 | AAR10045 | Aar10045 N-termina |
| 23 | 3 | 27.3 | 11 | 2 | AAR14094 | Aar14094 Pre-S(1-1 |
| 24 | 3 | 27.3 | 11 | 2 | AAR44308 | Aar44308 Ballast c |
| 25 | 3 | 27.3 | 11 | 2 | AAR31358 | Aar31358 Antimicro |
| 26 | 3 | 27.3 | 11 | 2 | AAR24850 | Aar24850 Weight re |
| 27 | 3 | 27.3 | 11 | 2 | AAR28088 | Aar28088 Cell-to-c |
| 28 | 3 | 27.3 | 11 | 2 | AAR25763 | Aar25763 Histone H |
| 29 | 3 | 27.3 | 11 | 2 | AAR27520 | Aar27520 Effector  |
| 30 | 3 | 27.3 | 11 | 2 | AAR26085 | Aar26085 Immunisin |
| 31 | 3 | 27.3 | 11 | 2 | AAR26084 | Aar26084 Immunisin |
| 32 | 3 | 27.3 | 11 | 2 | AAR26832 | Aar26832 TY-11(6)  |
| 33 | 3 | 27.3 | 11 | 2 | AAR26834 | Aar26834 CY-11(8)  |
| 34 | 3 | 27.3 | 11 | 2 | AAR26833 | Aar26833 CY-11(7)  |
| 35 | 3 | 27.3 | 11 | 2 | AAR26835 | Aar26835 CY-11(9)  |
| 36 | 3 | 27.3 | 11 | 2 | AAR36904 | Aar36904 Insulin-1 |
| 37 | 3 | 27.3 | 11 | 2 | AAR36924 | Aar36924 Insulin-1 |
| 38 | 3 | 27.3 | 11 | 2 | AAR36905 | Aar36905 Insulin-1 |
| 39 | 3 | 27.3 | 11 | 2 | AAR36894 | Aar36894 Insulin-1 |
| 40 | 3 | 27.3 | 11 | 2 | AAR36917 | Aar36917 Insulin-1 |
| 41 | 3 | 27.3 | 11 | 2 | AAR36874 | Aar36874 Insulin-1 |
| 42 | 3 | 27.3 | 11 | 2 | AAR36914 | Aar36914 Insulin-1 |
| 43 | 3 | 27.3 | 11 | 2 | AAR42959 | Aar42959 Beta chai |
| 44 | 3 | 27.3 | 11 | 2 | AAR42956 | Aar42956 Beta chai |
| 45 | 3 | 27.3 | 11 | 2 | AAR32352 | Aar32352 Human Fac |
| 46 | 3 | 27.3 | 11 | 2 | AAR43594 | Aar43594 Peptide d |
| 47 | 3 | 27.3 | 11 | 2 | AAR43598 | Aar43598 Peptide d |
| 48 | 3 | 27.3 | 11 | 2 | AAR43618 | Aar43618 Peptide d |
| 49 | 3 | 27.3 | 11 | 2 | AAR43599 | Aar43599 Peptide d |
| 50 | 3 | 27.3 | 11 | 2 | AAR43638 | Aar43638 Peptide d |
| 51 | 3 | 27.3 | 11 | 2 | AAR37430 | Aar37430 Promega p |
| 52 | 3 | 27.3 | 11 | 2 | AAR44560 | Aar44560 Encoded b |
| 53 | 3 | 27.3 | 11 | 2 | AAR53641 | Aar53641 Mutant tr |
| 54 | 3 | 27.3 | 11 | 2 | AAR52885 | Aar52885 TK-SH2 as |
| 55 | 3 | 27.3 | 11 | 2 | AAR52886 | Aar52886 TK-SH2 as |
| 56 | 3 | 27.3 | 11 | 2 | AAR68593 | Aar68593 Rat NDF p |
| 57 | 3 | 27.3 | 11 | 2 | AAR78518 | Aar78518 Synthetic |
| 58 | 3 | 27.3 | 11 | 2 | AAW21497 | Aaw21497 Hepatitis |
| 59 | 3 | 27.3 | 11 | 2 | AAW21210 | Aaw21210 Farnesyl  |
| 60 | 3 | 27.3 | 11 | 2 | AAR98482 | Aar98482 Anti-IL-5 |
| 61 | 3 | 27.3 | 11 | 2 | AAW05770 | Aaw05770 Presenili |
| 62 | 3 | 27.3 | 11 | 2 | AAR89702 | Aar89702 Prostate  |
| 63 | 3 | 27.3 | 11 | 2 | AAR89705 | Aar89705 Prostate  |
| 64 | 3 | 27.3 | 11 | 2 | AAR98513 | Aar98513 CD8 antag |
| 65 | 3 | 27.3 | 11 | 2 | AAW06895 | Aaw06895 Anti-CD18 |
| 66 | 3 | 27.3 | 11 | 2 | AAR91286 | Aar91286 Anti-idio |

|     |   |      |    |   |          |          |           |
|-----|---|------|----|---|----------|----------|-----------|
| 67  | 3 | 27.3 | 11 | 2 | AAW09653 | Aaw09653 | Labelled  |
| 68  | 3 | 27.3 | 11 | 2 | AAE22529 | Aae22529 | Human Fcg |
| 69  | 3 | 27.3 | 11 | 2 | AAW11502 | Aaw11502 | Humanised |
| 70  | 3 | 27.3 | 11 | 2 | AAW44188 | Aaw44188 | H-2Kd-res |
| 71  | 3 | 27.3 | 11 | 2 | AAW11511 | Aaw11511 | Humanised |
| 72  | 3 | 27.3 | 11 | 2 | AAW30194 | Aaw30194 | Salvage r |
| 73  | 3 | 27.3 | 11 | 2 | AAW15672 | Aaw15672 | Platelet  |
| 74  | 3 | 27.3 | 11 | 2 | AAW25009 | Aaw25009 | Oncoimmun |
| 75  | 3 | 27.3 | 11 | 2 | AAW28862 | Aaw28862 | HTLV-1a,c |
| 76  | 3 | 27.3 | 11 | 2 | AAW24059 | Aaw24059 | Salvage r |
| 77  | 3 | 27.3 | 11 | 2 | AAW15948 | Aaw15948 | Interleuk |
| 78  | 3 | 27.3 | 11 | 2 | AAW27332 | Aaw27332 | Salvage r |
| 79  | 3 | 27.3 | 11 | 2 | AAW33597 | Aaw33597 | Oligopept |
| 80  | 3 | 27.3 | 11 | 2 | AAW33539 | Aaw33539 | Oligopept |
| 81  | 3 | 27.3 | 11 | 2 | AAW33536 | Aaw33536 | Oligopept |
| 82  | 3 | 27.3 | 11 | 2 | AAW33583 | Aaw33583 | Oligopept |
| 83  | 3 | 27.3 | 11 | 2 | AAW41012 | Aaw41012 | Anti-glut |
| 84  | 3 | 27.3 | 11 | 2 | AAW34507 | Aaw34507 | Salvage r |
| 85  | 3 | 27.3 | 11 | 2 | AAW65652 | Aaw65652 | Peptide # |
| 86  | 3 | 27.3 | 11 | 2 | AAW62364 | Aaw62364 | Antithrom |
| 87  | 3 | 27.3 | 11 | 2 | AAW42459 | Aaw42459 | Mouse ant |
| 88  | 3 | 27.3 | 11 | 2 | AAW57427 | Aaw57427 | Amino aci |
| 89  | 3 | 27.3 | 11 | 2 | AAW68880 | Aaw68880 | Peptide b |
| 90  | 3 | 27.3 | 11 | 2 | AAW59349 | Aaw59349 | Human Fab |
| 91  | 3 | 27.3 | 11 | 2 | AAW72876 | Aaw72876 | Bacillus  |
| 92  | 3 | 27.3 | 11 | 2 | AAW40511 | Aaw40511 | Mouse ner |
| 93  | 3 | 27.3 | 11 | 2 | AAW40510 | Aaw40510 | Human ner |
| 94  | 3 | 27.3 | 11 | 2 | AAW62020 | Aaw62020 | Salvage r |
| 95  | 3 | 27.3 | 11 | 2 | AAW20426 | Aay20426 | Human mic |
| 96  | 3 | 27.3 | 11 | 2 | AAW54632 | Aaw54632 | Peptide f |
| 97  | 3 | 27.3 | 11 | 2 | AAW70627 | Aaw70627 | Salvage r |
| 98  | 3 | 27.3 | 11 | 2 | AAW37137 | Aaw37137 | Cyclic pi |
| 99  | 3 | 27.3 | 11 | 2 | AAW40573 | Aaw40573 | Human IgG |
| 100 | 3 | 27.3 | 11 | 2 | AAW44819 | Aaw44819 | Salvage r |

# ALIGNMENTS

## RESULT 1

AAW88549

ID AAW88549 standard; peptide; 11 AA.

XX

AC AAW88549;

XX

DT 07-AUG-2000 (first entry)

XX

DE NCAM Igl binding peptide #21.

XX

KW NCAM; neural cell adhesion molecule; Igl; immunoglobulin domain 1;

KW neurite outgrowth promoter; proliferation; nerve damage; sclerosis;

KW impaired myelination; stroke; Parkinson's disease; memory; schizophrenia;

KW Alzheimer's disease; diabetes mellitus; circadian clock; nephrosis;

KW treatment; prosthetic nerve guide; treatment; nervous system.

XX

OS Synthetic.

XX

PN WO200018801-A2.  
XX  
PD 06-APR-2000.  
XX  
PF 23-SEP-1999; 99WO-DK000500.  
XX  
PR 29-SEP-1998; 98DK-00001232.  
PR 29-APR-1999; 99DK-00000592.  
XX  
PA (RONN/) RONN L C B.  
PA (BOCK/) BOCK E.  
PA (HOLM/) HOLM A.  
PA (OLSE/) OLSEN M.  
PA (OSTE/) OSTERGAARD S.  
PA (JENS/) JENSEN P H.  
PA (POUL/) POULSEN F M.  
PA (SORO/) SOROKA V.  
PA (RALE/) RALETS I.  
PA (BERE/) BEREZIN V.  
XX  
PI Ronn LCB, Bock E, Holm A, Olsen M, Ostergaard S, Jensen PH;  
PI Poulsen FM, Soroka V, Ralets I, Berezin V;  
XX  
DR WPI; 2000-293111/25.  
XX  
PT Compositions that bind neural cell adhesion molecules useful for treating  
PT disorders of the nervous system and muscles e.g. Alzheimer's and  
PT Parkinson's diseases.  
XX  
PS Example 4; Page 25; 119pp; English.  
XX  
CC Neural cell adhesion molecule (NCAM) is a cellular adhesion molecule.  
CC NCAM is found in three forms, two of which are transmembrane forms, while  
CC the third is attached via a lipid anchor to the cell membrane. All three  
CC NCAM forms have an extracellular structure consisting five immunoglobulin  
CC domains (Ig domains). The Ig domains are numbered 1 to 5 from the N-  
CC terminal. The present sequence represents a peptide which binds to the  
CC NCAM Ig1 domain. The peptide can be used in a compound which binds to  
CC NCAM-Ig1/Ig2 domains, and is capable of stimulating or promoting neurite  
CC outgrowth from NCAM presenting cells, and is also capable of promoting  
CC the proliferation of NCAM presenting cells. The compound may be used in  
CC the treatment of normal, degenerated or damaged NCAM presenting cells.  
CC The compound may in particular be used to treat diseases of the central  
CC and peripheral nervous systems such as post-operative nerve damage,  
CC traumatic nerve damage, impaired myelination of nerve fibres, conditions  
CC resulting from a stroke, Parkinson's disease, Alzheimer's disease,  
CC dementias, sclerosis, nerve degeneration associated with diabetes  
CC mellitus, disorders affecting the circadian clock or neuro-muscular  
CC transmission and schizophrenia. Conditions affecting the muscles may also  
CC be treated with the compound, such as conditions associated with impaired  
CC function of neuromuscular connections (e.g. genetic or traumatic shock or  
CC traumatic atrophic muscle disorders). Conditions of the gonads, pancreas  
CC (e.g. diabetes mellitus types I and II), kidney (e.g. nephrosis), heart,  
CC liver and bowel may also be treated using the compound. The compound is  
CC used in a prosthetic nerve guide, and also to stimulate the ability to  
CC learn, and to stimulate the memory of a subject  
XX



SQ Sequence 11 AA;

Query Match 100.0%; Score 11; DB 3; Length 11;  
Best Local Similarity 100.0%; Pred. No. 6.4e-05;  
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AKSRKGNSSLM 11  
| | | | | | | | | |  
Db 1 AKSRKGNSSLM 11

RESULT 2

ABG69349

ID ABG69349 standard; peptide; 11 AA.

XX

AC ABG69349;

XX

DT 21-OCT-2002 (first entry)

XX

DE Human neural cell adhesion molecule (NCAM) peptide #21.

XX

KW Human; neural cell adhesion molecule; NCAM; heart muscle cell survival;

KW acute myocardial infarction; central nervous system disorder; stroke;

KW peripheral nervous system disorder; postoperative nerve damage;

KW traumatic nerve damage; spinal cord injury; nerve fibre; schizophrenia;

KW postischaemic damage; multiinfarct dementia; multiple sclerosis;

KW nerve degeneration; diabetes mellitus; neuro-muscular degeneration;

KW Alzheimer's disease; Parkinson's disease;

KW Huntington's disease. atrophic muscle disorder; gonad degeneration;

KW nephrosis.

XX

OS Homo sapiens.

XX

PN WO200247719-A2.

XX

PD 20-JUN-2002.

XX

PF 12-DEC-2001; 2001WO-DK000822.

XX

PR 12-DEC-2000; 2000DK-00001863.

XX

PA (ENKA-) ENKAM PHARM AS.

XX

PI Bock-E, Berezin V, Kohler LB;

XX

DR WPI; 2002-583473/62.

XX

PT Use of a compound comprising a peptide of neural cell adhesion molecule,  
PT in the preparation of medicament for preventing death of cells presenting  
PT NCAM or NCAM ligand and treating central nervous system diseases.

XX

PS Disclosure; Page 16; 57pp; English.

XX

CC The invention relates to use of a compound (I) comprising a peptide which  
CC comprises at least 5 contiguous amino acid residues of a sequence of the  
CC neural cell adhesion molecule (NCAM), its fragment, variant or its mimic,  
CC for the preparation of a medicament for preventing death of cells

CC presenting the NCAM or an NCAM ligand. (I) is useful in the preparation  
 CC of a medicament for preventing death of cells presenting the NCAM or an  
 CC NCAM ligand. The medicament is for the stimulation of the survival of  
 CC heart muscle cells, such as survival after acute myocardial infarction.  
 CC The medicament is for the treatment of diseases or conditions of the  
 CC central and peripheral nervous system, such as postoperative nerve  
 CC damage, traumatic nerve damage, e.g. resulting from spinal cord injury,  
 CC impaired myelination of nerve fibres, postischaemic damage, e.g.  
 CC resulting from a stroke, multiinfarct dementia, multiple sclerosis, nerve  
 CC degeneration associated with diabetes mellitus, neuro-muscular  
 CC degeneration, schizophrenia, Alzheimer's disease, Parkinson's disease and  
 CC Huntington's disease. The medicament is for the treatment of diseases or  
 CC conditions of the muscles including conditions with impaired function of  
 CC neuro-muscular connections, such as genetic or traumatic atrophic muscle  
 CC disorders, and for the treatment of diseases or conditions of various  
 CC organs, such as degenerative conditions of the gonads, pancreas (e.g.  
 CC diabetes mellitus type I and II) and kidney (e.g. nephrosis). ABG69329-  
 CC ABG69352 represent human NCAM peptides of the invention  
 XX  
 SQ Sequence 11 AA;

Query Match 100.0%; Score 11; DB 5; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 6.4e-05;  
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AKSRKGNSSLM 11  
 |||||  
 Db 1 AKSRKGNSSLM 11

# RESULT 3

AAR04739

ID AAR04739 standard; protein; 11 AA.

XX

AC AAR04739;

XX

DT 31-OCT-2002 (revised)

DT 05-AUG-1990 (first entry)

XX

DE Deduced sequence at fusion point of E. coli lacZ and Cellulomonas fimi  
 DE endoglucanase (CenA) in expression plasmid pUCEC2.

XX

KW LacZ-endoglucanase expression plasmid pUCEC2; CenA;

~~KW Cellulomonas fimi-endoglucanase.~~

XX

OS Cellulomonas fimi.

XX

| Key | Location/Qualifiers |
|-----|---------------------|
|-----|---------------------|

|            |       |
|------------|-------|
| FT Protein | 1. .6 |
|------------|-------|

|    |               |
|----|---------------|
| FT | /note= "lacZ" |
|----|---------------|

|            |        |
|------------|--------|
| FT Protein | 7. .11 |
|------------|--------|

|    |               |
|----|---------------|
| FT | /note= "CenA" |
|----|---------------|

XX

PN WO9000609-A.

XX

PD 25-JAN-1990.

XX

PF 28-JUN-1989; 89WO-GB000718.  
 XX  
 PR 08-JUL-1988; 88US-00216794.  
 XX  
 PA (UYBR-) UNIV BRIT COLUMBIA.  
 XX  
 PI Kilburn DG, Miller RC, Warren RA, Gilkes NR;  
 XX  
 DR WPI; 1990-051713/07.  
 DR N-PSDB; AAQ02961.  
 XX  
 PT Polysaccharide matrix bonded with fusion protein - contg.  
 PT polysaccharidase binding region and specific polypeptide, useful for  
 PT affinity purificn. and immobilisation, e.g. for drug delivery.  
 XX  
 PS Example 2; Fig 4B; 47pp; English.  
 XX  
 CC A 1.6 kb fragment from the 6.0 kb insert of C. fimi DBA in pCEC2 was  
 CC purified and sub-cloned into the SstI site of pUC18 to form pUCEC2. It is  
 CC constructed to illustrate method of preparation of a polysaccharide  
 CC matrix bonded to a hybrid protein and a substrate binding region (SBR) of  
 CC a polysaccharidase. The binding of the hybrid protein to the matrix is a  
 CC rapid and inexpensive method of purifying it. (Updated on 31-OCT-2002 to  
 CC add missing OS field.)  
 XX  
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.2e+03;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSLM 11  
 ||||  
 Db 7 SSLM 10

RESULT 4  
 AAY07532

ID AAY07532 standard; peptide; 11 AA.

XX

AC AAY07532;

XX

DT 17-AUG-1999 (first entry)

XX

DE Laminin-derived peptide linked to metal-binding domain.

XX

KW Laminin; diagnostic; metal-binding; polyvalent; linked; branched; repeat;  
 KW platelet accumulation.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Domain 1. .5

FT /label= Biological\_function

FT /note= "Laminin-derived peptide"

FT Modified-site 1

FT /note= "N-acetyl-Tyr"

FT Modified-site 6  
 FT /note= "The epsilon-amino group of this residue has  
 FT another biological function domain of formula Ac-YIGSR-  
 FT attached to it"  
 FT Domain 7. .11  
 FT /label= Metal\_ion-binding  
 FT Misc-difference 10  
 FT /note= "D-form residue"  
 FT Modified-site 11  
 FT /note= "Gly-NH2"  
 XX  
 PN WO9501188-A1.  
 XX  
 PD 12-JAN-1995.  
 XX  
 PF 01-JUL-1994; 94WO-US007462.  
 XX  
 PR 02-JUL-1993; 93US-00087219.  
 PR 30-JUN-1994; 94US-00269929.  
 XX  
 PA (RHOM-) RHOMED INC.  
 XX  
 PI Rhodes BA, Zamora PO, Freer RJ, Sharma SD;  
 XX  
 DR WPI; 1995-060818/08.  
 XX  
 PT New high affinity peptide-based compsns. for diagnosis and therapy - in  
 PT which peptide has at least two biological-functional domains and a metal  
 PT ion binding domain.  
 XX  
 PS Disclosure; Page 42; 60pp; English.  
 XX  
 CC The patent discloses a high affinity peptide-based pharmaceutical  
 CC composition which comprises (a) at least two linear repeat, linked or  
 CC branched amino acid sequence biological-function domains and (b) one or  
 CC more medically useful metal ion-binding domains. When bound with a  
 CC medically useful metal (e.g. an isotope of Tc, Re, In, Au, Ag, Hg or Cu),  
 CC the composition can be used for detection and treatment of pathological  
 CC conditions and for diagnostic imaging. The composition allows direct  
 CC binding with a metal without the necessity of conjugation to bifunctional  
 CC chelators. Metals can be bound while retaining the high activity of the  
 CC biological function domains. The present sequence represents a laminin-  
 CC derived peptide (a preferred example of a biological function domain)  
 CC joined to a metal-ion binding domain via a Lys-residue which has another  
 CC laminin-derived peptide attached to its side chain amino group. Metal-  
 CC bound compositions containing the sequence can be used for detection of  
 CC sites of platelet accumulation in e.g. thrombosis, pulmonary embolism,  
 CC inflammatory response secondary to myocardial infarction, endocarditis,  
 CC bypass graft occlusion, aneurysms, prosthetic arterial graft platelet  
 CC accumulation, prosthetic arterial graft platelet occlusion, cerebral  
 CC embolism, cerebral haemorrhage, traumatic injury with haemorrhage,  
 CC gastrointestinal haemorrhage and thrombosis secondary to catheters and  
 CC other implanted devices, or for detection of carcinomas including primary  
 CC carcinomas and metastatic carcinomas  
 XX  
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.2e+03;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SRKG 6  
||||  
Db 4 SRKG 7

RESULT 5

AAY07531

ID AAY07531 standard; peptide; 11 AA.

XX

AC AAY07531;

XX

DT 17-AUG-1999 (first entry)

XX

DE Laminin-derived peptide linked to metal-binding domain.

XX

KW Laminin; diagnostic; metal-binding; polyvalent; linked; branched; repeat;  
KW platelet accumulation.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Domain 1. .5

FT /label= Biological\_function

FT /note= "Laminin-derived peptide"

FT Modified-site 1

FT /note= "N-acetyl-Tyr"

FT Modified-site 6

FT /note= "The epsilon-amino group of this residue has  
another biological function domain of formula Ac-YIGSR-  
attached to it"

FT Domain 7. .11

FT /label= Metal\_ion-binding

FT Modified-site 11

FT /note= "Ala-NH2"

XX

PN WO9501188-A1.

XX

PD 12-JAN-1995.

XX

PF 01-JUL-1994; 94WO-US007462.

XX

PR 02-JUL-1993; 93US-00087219.

PR 30-JUN-1994; 94US-00269929.

XX

PA (RHOM-) RHOMED INC.

XX

PI Rhodes BA, Zamora PO, Freer RJ, Sharma SD;

XX

DR WPI; 1995-060818/08.

XX

PT New high affinity peptide-based compsns. for diagnosis and therapy - in  
PT which peptide has at least two biological-functional domains and a metal  
PT ion binding domain.

XX  
 PS Disclosure; Page 42; 60pp; English.  
 XX  
 CC The patent discloses a high affinity peptide-based pharmaceutical  
 CC composition which comprises (a) at least two linear repeat, linked or  
 CC branched amino acid sequence biological-function domains and (b) one or  
 CC more medically useful metal ion-binding domains. When bound with a  
 CC medically useful metal (e.g. an isotope of Tc, Re, In, Au, Ag, Hg or Cu),  
 CC the composition can be used for detection and treatment of pathological  
 CC conditions and for diagnostic imaging. The composition allows direct  
 CC binding with a metal without the necessity of conjugation to bifunctional  
 CC chelators. Metals can be bound while retaining the high activity of the  
 CC biological function domains. The present sequence represents a laminin-  
 CC derived peptide (a preferred example of a biological function domain)  
 CC joined to a metal ion binding domain via a Lys residue which has another  
 CC laminin-derived peptide attached to its side chain amino group. Metal-  
 CC bound compositions containing the sequence can be used for detection of  
 CC sites of platelet accumulation in e.g. thrombosis, pulmonary embolism,  
 CC inflammatory response secondary to myocardial infarction, endocarditis,  
 CC bypass graft occlusion, aneurysms, prosthetic arterial graft platelet  
 CC accumulation, prosthetic arterial graft platelet occlusion, cerebral  
 CC embolism, cerebral haemorrhage, traumatic injury with haemorrhage,  
 CC gastrointestinal haemorrhage and thrombosis secondary to catheters and  
 CC other implanted devices, or for detection of carcinomas including primary  
 CC carcinomas and metastatic carcinomas  
 XX  
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.2e+03;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 SRKG 6  
 ||||  
 Db 4 SRKG 7

RESULT 6  
 AAW76689

ID AAW76689 standard; protein; 11 AA.

XX

AC AAW76689;

XX

DT 05-JAN-1999 (first entry)

XX

DE Plasmid pGEX-3X protein fragment.

XX

KW Dendroaspin; snake venom; clotting cascade; anticoagulant; platelet;  
 KW integrin binding; injury; blood; cell migration; thrombosis; inhibitor;  
 KW proliferation; signal transduction; regulator; coagulation; treatment;  
 KW prophylactic; artery; vein; wall thickening; myocardial infarction;  
 KW retinal neovascularisation; dysregulated apoptosis; tumorigenesis;  
 KW leukocyte recruitment, immune system; tissue fibrosis.

XX

OS Synthetic.

XX

PN WO9842834-A1.

XX  
 PD 01-OCT-1998.  
 XX  
 PF 20-MAR-1998; 98WO-GB000848.  
 XX  
 PR 20-MAR-1997; 97GB-00005787.  
 XX  
 PA (THRO-) THROMBOSIS RES INST.  
 XX  
 PI Lu X, Scully MF, Kakkar V, Authi K;  
 XX  
 DR WPI; 1998-542278/46.  
 DR N-PSDB; AAV61951.  
 XX  
 PT New hybrid dendroaspin polypeptide(s) - used for treating, e.g.  
 PT thrombosis, myocardial infarction, dysregulated apoptosis, abnormal cell  
 PT migration and immune system activation.  
 XX  
 PS Example 2; Fig 4; 59pp; English.  
 XX  
 CC This sequence represents a fragment of the plasmid pGEX-3X which is used  
 CC in the isolation of a snake venom dendroaspin fragment. When dendroaspin  
 CC is modified to incorporate further functional amino acid sequence, e.g.  
 CC active portions or motifs of agonists, antagonists or inhibitors of  
 CC factors in the clotting cascade, the resulting molecules are particularly  
 CC useful as anticoagulants. The molecules have an integrin binding activity  
 CC which when administered in vivo results in the binding of the molecules  
 CC to platelets thereby inhibiting the aggregation of the platelets at sites  
 CC of injury. Non-wild type dendroaspin domains provide secondary,  
 CC optionally further functionality, e.g. antithrombotic action, inhibiting  
 CC cell migration and proliferation and regulating signal transduction. Such  
 CC variants have bi- or multifunctional activities against blood  
 CC coagulation, particularly thrombus formation and arterial/venous wall  
 CC thickening at the sites of injury. The variants may have activities  
 CC against leukocyte recruitment, immune system activation, tissue fibrosis  
 CC and tumourigenesis. The polypeptides can be used for the treatment or  
 CC prophylaxis of a disease associated with thrombosis, e.g. myocardial  
 CC infarction, retinal neovascularisation, endothelial injury, dysregulated  
 CC apoptosis, abnormal cell migration, leukocyte recruitment, immune system  
 CC activation, tissue fibrosis or tumorigenesis  
 XX  
 SQ Sequence 11 AA;

---

Query-Match 36.4%; Score 4; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.2e+03;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 GNSS 9  
 ||||  
 Db 8 GNSS 11

RESULT 7  
 AAM98749  
 ID AAM98749 standard; peptide; 11 AA.  
 XX  
 AC AAM98749;

XX  
 DT 24-JAN-2002 (first entry)  
 XX  
 DE Human peptide #2024 encoded by a SNP oligonucleotide.  
 XX  
 KW Immunosuppressive; immunostimulatory; antiinflammatory; cytostatic;  
 KW neuroprotective; antimicrobial; gene therapy; vaccine; amylase; cancer;  
 KW amyloid protein; angiopoietin; apoptosis related protein; cadherin;  
 KW cyclin; polymerase; oncogene; histone; kinase; colony stimulating factor;  
 KW complement related protein; cytochrome; kinesin; cytokine; interferon;  
 KW interleukin; G-protein coupled receptor; thioesterase; inflammation;  
 KW multifactorial disease; autoimmune disease; infection;  
 KW nervous system disease.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200147944-A2.  
 XX  
 PD 05-JUL-2001.  
 XX  
 PF 28-DEC-2000; 2000WO-US035498.  
 XX  
 PR 28-DEC-1999; 99US-0173419P.  
 PR 27-DEC-2000; 2000US-00173419.  
 XX  
 PA (CURA-) CURAGEN CORP.  
 XX  
 PI Shimkets RA, Leach M;  
 XX  
 DR WPI; 2001-465210/50.  
 XX  
 PT Polymorphic nucleic acids encoding e.g. amylases, cyclins, polymerases,  
 PT oncogenes and histones, useful for diagnosing and treating, e.g. cancer,  
 PT autoimmune diseases and infections.  
 XX  
 PS Disclosure; Page 4112; 4143pp; English.  
 XX  
 CC The present invention relates to oligonucleotides (see AAL26793-AAL34659)  
 CC encoding polymorphic variants of proteins related to amylases, amyloid  
 CC proteins, angiopoietin, apoptosis related proteins, cadherin, cyclin,  
 CC polymerase, oncogenes, histones, kinases, colony stimulating factors,  
 CC complement related proteins, cytochromes, kinesins, cytokines,  
 CC interferons, interleukins, G-protein coupled receptors and thioesterases.  
 CC ~~The present sequence is a peptide encoded by one such oligonucleotide.~~  
 CC The oligonucleotides and the peptides encoded by them may be used in the  
 CC prevention, diagnosis and treatment of diseases associated with  
 CC inappropriate expression of the proteins listed above. Disorders that may  
 CC be prevented, diagnosed and/or treated include multifactorial diseases  
 CC with a genetic component, such as autoimmune diseases (e.g. rheumatoid  
 CC arthritis, multiple sclerosis, diabetes, systemic lupus erythromatosus  
 CC and Grave's disease), inflammation, cancer (e.g. cancers of the bladder,  
 CC brain, breast, colon and kidney, leukaemia), diseases of the nervous  
 CC system and an infection of pathogenic organisms  
 XX  
 SQ Sequence 11 AA;

Query Match

36.4%; Score 4; DB 4; Length 11;



Best Local Similarity 100.0%; Pred. No. 1.2e+03;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSIM 11  
||||  
Db 7 SSIM 10

RESULT 8

AAB68771

ID AAB68771 standard; peptide; 11 AA.

XX

AC AAB68771;

XX

DT 18-APR-2001 (first entry)

XX

DE Human FAS peptide #1.

XX

KW Human; fatty acid synthase; FAS; polyketide synthase;

KW ketoacyl synthase domain; decarboxylation; polyketide synthase priming.

XX

OS Homo sapiens.

XX

PN WO200104274-A2.

XX

PD 18-JAN-2001.

XX

PF 06-JUL-2000; 2000WO-US018494.

XX

PR 07-JUL-1999; 99US-00348974.

XX

PA (CHIL-) CHILDREN'S HOSPITAL OAKLAND RES INST.

XX

PI Smith S, Joshi A, Rangan V, Witkowski A;

XX

DR WPI; 2001-138335/14.

XX

PT Novel polyketide synthase with improved and enhanced priming, generated

PT by incorporating a ketoacyl synthase domain with increased

PT decarboxylative activity into loading module of polyketide synthase.

XX

PS Disclosure; Fig 1A; 39pp; English.

XX

~~CC The present sequence is given in a specification relating to a novel~~  
CC polyketide synthase with improved and enhanced priming. The polyketide  
CC synthase was generated by incorporating a ketoacyl synthase domain with  
CC increased decarboxylative activity into a loading module of polyketide  
CC synthase. The loading module comprises an acyl carrier protein, an acyl  
CC transferase domain and a ketoacyl synthase domain variant with a non-  
CC nucleophilic residue at the position corresponding to residue 161 in the  
CC rat fatty acid synthase. The ketoacyl synthase domain has increased  
CC decarboxylase activity by mutation of a conserved active site cysteine  
CC residue corresponding to residue 161 in rat fatty acid synthase. The  
CC ketoacyl synthase domains with enhanced decarboxylation activity improve  
CC priming or loading of polyketide synthases

XX

SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 4; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.2e+03;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSIM 11  
| | | |  
Db 7 SSIM 10

RESULT 9

ABP17604

ID ABP17604 standard; peptide; 11 AA.

XX

AC ABP17604;

XX

DT 11-SEP-2003 (revised)

DT 15-JUL-2002 (first entry)

XX

DE HIV B58 super motif env peptide #5.

XX

KW HIV; HIV-1; human immunodeficiency virus; env; pol; gag; nef; vpr; vpu;

KW vif; tat; cytotoxic T lymphocyte; CTL; immune response; epitope; antigen;

KW vaccine; HIV infection; immunisation; virucide.

XX

OS Human immunodeficiency virus 1.

XX

PN WO200124810-A1.

XX

PD 12-APR-2001.

XX

PF 05-OCT-2000; 2000WO-US027766.

XX

PR 05-OCT-1999; 99US-00412863.

XX

PA (EPIM-) EPIMMUNE INC.

XX

PI Sette A, Sidney J, Southwood S, Livingston BD, Chesnut R;

PI Baker DM, Celis E, Kubo RT, Grey HM;

XX

DR WPI; 2001-354887/37.

XX

PT Vaccine compositions comprising human immunodeficiency virus-1 (HIV-1)

PT peptide groups, useful for vaccinating against HIV-1.

XX

PS Claim 32; Page 230; 448pp; English.

XX

CC The present invention describes a composition (I) comprising a prepared  
CC human immunodeficiency virus-1 (HIV-1) group comprising an amino acid  
CC sequence selected from 51 defined amino acid sequences (ABL25347 to  
CC ABP25397). (I) has virucide activity and can be used in vaccines. (I) may  
CC be used for immunising subjects against HIV-1 infections. The use of  
CC group-based vaccines has several advantages over traditional vaccines,  
CC particularly when compared to the use of whole antigens in vaccine  
CC compositions. There is evidence that the immune response to whole  
CC antigens is directed largely toward variable regions of the antigen,  
CC allowing for immune escape due to mutations. The groups for inclusion in

CC an group-based vaccine may be selected from conserved regions of viral or  
CC tumour-associated antigens, which therefore reduces the likelihood of  
CC escape mutants. Furthermore, immunosuppressive groups that may be present  
CC in whole antigens can be avoided with the use of group-based vaccines. An  
CC additional advantage of an group-based vaccine approach is the ability to  
CC combine selected groups (CTL and HTL), and further, to modify the  
CC composition of the groups, achieving, for example, enhanced  
CC immunogenicity. Accordingly, the immune response can be modulated, as  
CC appropriate, for the target disease. Similar engineering of the response  
CC is not possible with traditional approaches. ABP11501 to ABP25412  
CC represent peptide sequences used in the exemplification of the present  
CC invention. (Updated on 11-SEP-2003 to standardise OS field)

XX

SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 4; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.2e+03;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 GNSS 9

||||

Db 4 GNSS 7

RESULT 10

ABB74319

ID ABB74319 standard; peptide; 11 AA.

XX

AC ABB74319;

XX

DT 18-APR-2002 (first entry)

XX

DE Simple nuclear localisation signal peptide SEQ ID NO:83.

XX

KW Fusogenic; nuclear localisation signal; NLS; encapsulation; lipogene;

KW liposome; micelle; karyophilic; cytostatic; antitumour; solid tumour;

KW peptide-lipid-polynucleotide complex; neoplastic disease; gene therapy;

KW breast carcinoma; prostate carcinoma.

XX

OS Synthetic.

XX

PN WO200193836-A2.

XX

PD 13-DEC-2001.

XX

PF 08-JUN-2001; 2001WO-US018657.

XX

PR 09-JUN-2000; 2000US-0210925P.

XX

PA (BOUL/) BOULIKAS T.

XX

PI Boulikas T;

XX

DR WPI; 2002-164295/21.

XX

PT Encapsulation of plasmid DNA (Lipogenes) and therapeutic agents with

PT nuclear localization signal/fusogenic peptide conjugates into targeted

PT liposome complexes.

XX

PS Claim 14; Page 57; 107pp; English.

XX

CC The present invention describes a method for producing micelles with  
CC entrapped therapeutic agents. The method comprises: (1) combining  
CC negatively charged agent with a cationic lipid in a ratio where 30-90 %  
CC of the negatively charged atoms are neutralised by positive charges on  
CC lipid molecules to form an electrostatic micelle complex in 20-80 %  
CC ethanol; and (2) combining the micelle complex of (a) with fusogenic-  
CC karyophilic peptide conjugates in a 0.0-0.3 ratio, therefore producing  
CC micelles with entrapped therapeutic agents. Also described is a method  
CC for delivering a therapeutic agent in vivo, comprising the administration  
CC of the micelle. ABB74256 to ABB74858 represent specifically claimed  
CC nuclear localisation signal (NLS) peptides for use in the method as the  
CC fusogenic-karyophilic peptides. The micelles produced can have cytostatic  
CC and antitumour activities. The peptide-lipid-polynucleotide complexes  
CC produced are useful for inhibiting the progression of neoplastic  
CC diseases. The invention relates to the field of gene therapy and is  
CC directed toward methods for producing peptide-lipid-polynucleotide  
CC complexes suitable for delivery of polynucleotides. The encapsulated  
CC molecules display therapeutic efficacy in eradicating solid tumours  
CC including but not limited to breast carcinoma or prostate carcinoma.  
CC ABB74235 to ABB74255 are used in the exemplification of the present  
CC invention

XX

SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 5; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.2e+03;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SRKG 6

||||

Db 4 SRKG 7

RESULT 11

ABP99717

ID ABP99717 standard; protein; 11 AA.

XX

AC ABP99717;

XX

DT 26-MAR-2003 (first entry)

XX

DE Human secreted protein SEQ ID NO 661.

XX

KW Human; secreted protein; nootropic; neuroprotective; cytostatic;  
KW virucide; dermatological; immunosuppressive; antiinflammatory; anti-HIV;  
KW vulnerary; antibacterial; antiparkinsonian; antisickling; antianaemic;  
KW antiarthritic; cancer; antirheumatic; hepatotropic; cerebroprotective;  
KW antiinflammatory; antiallergic; antidiabetic; antiulcer; anticonvulsant;  
KW antifungal; antiparasitic; cardiant; immune disorder; infection; vaccine;  
KW cardiovascular disorder; neurological disease; nephrotropic;  
KW gene therapy.

XX

OS Homo sapiens.

XX  
 PN WO200277186-A2.  
 XX  
 PD 03-OCT-2002.  
 XX  
 PF 26-MAR-2002; 2002WO-US009188.  
 XX  
 PR 27-MAR-2001; 2001US-0278650P.  
 PR 12-SEP-2001; 2001US-00950082.  
 PR 12-SEP-2001; 2001US-00950083.  
 XX  
 PA (HUMA-) HUMAN GENOME SCI INC.  
 XX  
 PI Rosen CA, Ruben SM;  
 XX  
 DR WPI; 2003-040583/03.  
 DR N-PSDB; ABZ67138.  
 XX  
 PT New human secreted proteins encoded by genes contained in cDNA clones  
 PT (e.g. HGCAC19), useful for preventing, treating or diagnosing e.g. AIDS,  
 PT multiple sclerosis, herpes virus, leukemia, tick-borne encephalitis or  
 PT West Nile fever.  
 XX  
 PS Claim 1; Page 1462; 2423pp; English.  
 XX  
 CC The invention relates to novel human genes (ABZ66891-ABZ68209) and the  
 CC encoded secreted proteins (ABP99470-ABP99872) useful for preventing,  
 CC treating or ameliorating medical conditions e.g. by protein or gene  
 CC therapy. The genes are isolated from a range of human tissues disclosed  
 CC in the specification. The nucleic acids, proteins, antibodies and  
 CC (ant)agonists are useful in the diagnosis, treatment and prevention of:  
 CC (a) cancer, e.g. breast and ovarian cancer and other cancers of the  
 CC adrenal gland, bone, bone marrow, breast, gastrointestinal tract, liver,  
 CC lung or urogenital; (b) immune disorders e.g. Addison's disease,  
 CC allergies, autoimmune haemolytic anaemia, autoimmune thyroiditis,  
 CC diabetes mellitus, Crohn's disease, multiple sclerosis, rheumatoid  
 CC arthritis and ulcerative colitis; (c) cardiovascular disorders such as  
 CC myocardial ischaemias; (d) wound healing; (e) neurological diseases e.g.  
 CC cerebral anoxia and epilepsy; and (f) infectious diseases such as viral,  
 CC bacterial, fungal and parasitic infections  
 XX  
 SQ Sequence 11 AA;

---

Query Match 36.4%; Score 4; DB 6; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.2e+03;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSLM 11  
 ||||  
 Db 3 SSLM 6

RESULT 12  
 ABP72546  
 ID ABP72546 standard; peptide; 11 AA.  
 XX  
 AC ABP72546;

XX  
 DT 29-MAY-2003 (first entry)  
 XX  
 DE Peptide encoded by cloning region of vector pGEX-3X.  
 XX  
 KW Vector; pGEX-3X; vasoactive intestinal peptide; bombesin; substance P;  
 KW epidermal growth factor; human; cancer; vaccine.  
 XX  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT Cleavage-site 1. .4  
 FT /note= "Factor Xa cleavage site"  
 XX  
 PN WO2003013426-A2.  
 XX  
 PD 20-FEB-2003.  
 XX  
 PF 02-AUG-2002; 2002WO-US024561.  
 XX  
 PR 03-AUG-2001; 2001US-0309975P.  
 XX  
 PA (DABU-) DABUR RES FOUND.  
 PA (CORD/) CORD J I.  
 XX  
 PI Mukherjee R, Rao MRS, Burman AC, Thomas B, Prasad S, Sengupta P;  
 XX  
 DR WPI; 2003-256477/25.  
 DR N-PSDB; ABZ81613.  
 XX  
 PT New multivalent vaccine comprising vasoactive intestinal peptide,  
 PT Bombesin, Substance P and epidermal growth factor peptides, useful for  
 PT preventing or treating cancer.  
 XX  
 PS Example 2; Fig 5; 6lpp; English.  
 XX  
 CC The present sequence is the peptide encoded by the cloning/expression  
 CC region of vector plasmid pGEX-3X. This prokaryotic expression vector  
 CC provides protein expression as a C-terminal fusion with glutathione  
 CC transferase, which enables purification of the protein on a glutathione-  
 CC Sepharose column. In the present invention, the target gene for cloning  
 CC was a synthetic gene (see ABZ70689) encoding a multivalent polypeptide  
 CC (see ABP72533) comprising vasoactive intestinal peptide, bombesin,  
 CC substance P and epidermal growth factor joined via glycine-glycine  
 CC linkers. This is useful as a multivalent vaccine for the prevention and  
 CC treatment of e.g. colon, rectum, lung, breast, brain, pancreas, prostate,  
 CC liver, gastrointestinal, thyroid, ovary, head and neck, and kidney  
 CC cancers, melanoma, neuroblastoma, glioblastoma, leukaemia and lymphoma  
 XX  
 SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 6; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.2e+03;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 GNSS 9  
 ||||

## RESULT 13

ABR01199

ID ABR01199 standard; peptide; 11 AA.

XX

AC ABR01199;

XX

DT 12-MAY-2003 (first entry)

XX

DE Human gene 253-encoded secreted protein HOUED72, SEQ ID NO:680.

XX

KW Human; secreted protein; cancer; tumour; hyperproliferative disorder;  
KW autoimmune disorder; inflammation; angiogenic diseases; AIDS;  
KW acquired immunodeficiency syndrome; hepatitis; anaemia; wound healing;  
KW drug screening; chromosome identification; chromosome mapping;  
KW cytostatic; gene therapy; antiinflammatory; immunomodulator; anti-HIV;  
KW antianaemic; vulnerary.

XX

OS Homo sapiens.

XX

PN WO200277013-A2.

XX

PD 03-OCT-2002.

XX

PF 26-MAR-2002; 2002WO-US009370.

XX

PR 27-MAR-2001; 2001US-0278650P.

PR 12-SEP-2001; 2001US-00950082.

PR 12-SEP-2001; 2001US-00950083.

XX

PA (HUMA-) HUMAN GENOME SCI INC.

XX

PI Rosen CA, Ruben SM;

XX

DR WPI; 2003-040578/03.

DR N-PSDB; ABZ73533.

XX

PT New human secreted proteins and nucleic acids, useful for detecting or  
PT treating cancer or other hyperproliferative disorders, autoimmune  
PT disorders, inflammatory disorders, HIV disease, hepatitis or anemia.

XX

PS ~~Claim 13; Page 1460; 2474pp; English.~~

XX

CC ABZ73281-ABZ73697 represent cDNAs corresponding to 391 human secreted  
CC protein genes, and ABP00947-ABP01363 represent the proteins they encode.  
CC ABZ73698-ABZ74687 represent human secreted protein genomic fragments. The  
CC invention also encompasses antibodies specific for the secreted proteins,  
CC the use of the secreted proteins in drug screening and recombinant  
CC vectors and host cells comprising a nucleic acid of the invention. The  
CC secreted proteins are thought to be involved in biological activities  
CC associated with cellular signalling, cellular differentiation, cell  
CC migration, prohormone activation and neurotransmitter activity. The  
CC secreted proteins, nucleic acids encoding them, antibodies or antibody  
CC fragments specific for the secreted proteins, and modulators of protein  
CC activity are useful for diagnosing or treating cancers or other

CC hyperproliferative disorders. Additionally, the secreted proteins and  
CC their nucleic acids may also be used in the treatment of autoimmune  
CC disorders, inflammatory disorders, diseases involving angiogenesis, AIDS  
CC (acquired immunodeficiency syndrome), hepatitis, anaemia, and to promote  
CC wound healing. Nucleic acids of the invention may be used for chromosome  
CC identification, chromosome mapping, in gene therapy, for identifying  
CC individuals from minute biological samples, as hybridisation probes, and  
CC as molecular weight markers. The present sequence represents a human  
CC secreted protein of the invention

XX

SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 6; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.2e+03;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSLM 11

||||

Db 3 SSLM 6

#### RESULT 14

ADC22397

ID ADC22397 standard; peptide; 11 AA.

XX

AC ADC22397;

XX

DT 18-DEC-2003 (first entry)

XX

DE Nuclear localisation signal motif amino acid sequence SEQ ID NO:246.

XX

KW recombinant fusion protein; fusion protein; binding; detection;

KW localisation domain; binding domain;

KW subcellular compartment localisation.

XX

OS Unidentified.

XX

PN WO2003012068-A2.

XX

PD 13-FEB-2003.

XX

PF 01-AUG-2002; 2002WO-US024572.

XX

PR 01-AUG-2001; 2001US-0309395P.

PR 13-DEC-2001; 2001US-0341589P.

XX

PA (CELL-) CELLOMICS INC.

XX

PI Bright G, Premkumar DR, Chen Y;

XX

DR WPI; 2003-248174/24.

XX

PT New recombinant fusion protein comprising detection and first

PT localization domains and a binding domain for the molecule of interest,

PT useful for detecting binding of a molecule of interest.

XX

PS Claim 20; SEQ ID NO 246; 101pp; English.



XX  
CC The present invention describes a recombinant fusion protein (I) for  
CC detecting binding of a molecule of interest. (I) comprises: (a) a  
CC detection domain; (b) a first localisation domain; and (c) a binding  
CC domain for the molecule of interest. The detection domain, the first  
CC localisation domain and the binding domain for the molecule of interest  
CC constituting the recombinant fusion protein for detecting binding of a  
CC molecule of interest are operably linked. The binding domain for the  
CC molecule of interest is separated from the first localisation domain by 0  
CC -20 amino acid residues. The first localisation domain and the binding  
CC domain for the molecule of interest both do not occur in a single non-  
CC recombinant protein with the same spacing as in the recombinant fusion  
CC protein for detecting binding of a molecule of interest. Also described:  
CC (1) a recombinant nucleic acid encoding the recombinant fusion protein;  
CC (2) a recombinant expression vector comprising the nucleic acid control  
CC sequences operably linked to the recombinant nucleic acid molecule; (3) a  
CC genetically engineered host cell transfected with the recombinant  
CC expression vector; (4) a kit for detecting binding of the molecule of  
CC interest; and (5) a method for identifying compounds that alter the  
CC binding of the molecule of interest. The recombinant fusion protein is  
CC useful for detecting binding of a molecule of interest. The recombinant  
CC fusion protein eliminates the need to construct two or more chimeric  
CC proteins and enables the monitoring of biochemical events in live, intact  
CC or fixed cells. The present sequence is used in the exemplification of  
CC the present invention.  
XX  
SQ Sequence 11 AA;

Query Match 36.4%; Score 4; DB 7; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.2e+03;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SRKG 6  
| | | |  
Db 4 SRKG 7

RESULT 15  
AAP50987  
ID AAP50987 standard; peptide; 11 AA.  
XX  
AC AAP50987;  
XX  
DT 25-MAR-2003 (revised)  
DT 08-MAR-1992 (first entry)  
XX  
DE FTS-derived peptide.  
XX  
KW Serum thymus factor; FTS.  
XX  
OS Synthetic.  
XX  
PN JP60089499-A.  
XX  
PD 20-MAY-1985.  
XX  
PF 21-OCT-1983; 83JP-00196079.

XX  
 PR 21-OCT-1983; 83JP-00196079.  
 XX  
 PA (MITH ) MITSUI PHARM INC.  
 XX  
 DR WPI; 1985-156917/26.  
 XX  
 PT New peptide for use in analysis - derived from lysine, tyrosine, glycine,  
 PT alanine, serine and asparagine units.  
 XX  
 PS Claim 1; Page 1; 12pp; Japanese.  
 XX  
 CC The peptide is derived from FTS (Pyr-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn). It  
 CC has similar activity to FTS and can be easily labelled with radioactive  
 CC iodide for use in RIA. See also AAP50412 and AAP50413. (Updated on 25-MAR  
 CC -2003 to correct PR field.)  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AKS 3  
 |||  
 Db 4 AKS 6

# RESULT 16

AAP50941

ID AAP50941 standard; peptide; 11 AA.

XX

AC AAP50941;

XX

DT 25-MAR-2003 (revised)

DT 06-OCT-1991 (first entry)

XX

DE Hepatitis B virus (HBV) envelope protein pre-S gene peptide fragment.

XX

KW Immunogen; vaccine; antigen; epitope; diagnosis.

XX

OS Hepatitis B virus.

XX

PN EP154902-A.

XX

PD 18-SEP-1985.

XX

PF 28-FEB-1985; 85EP-00102250.

XX

PR 07-MAR-1984; 84US-00587090.

PR 05-FEB-1985; 85US-00698499.

PR 28-APR-1986; 86US-00856522.

XX

PA (CALY ) CALIFORNIA INST OF TECHN.

PA (NYBL-) NEW YORK BLOOD CENTER INC.

XX

PI Neurath AR, Kent SBH;

XX  
 DR WPI; 1985-237979/39.  
 XX  
 PT Pre-s gene coded hepatitis B immunogens - useful in in vaccines for  
 PT protection and as diagnostics for detection of antigens and antigens.  
 XX  
 PS Claim 30; Page 101; 140pp; English.  
 XX  
 CC The peptides of the invention are immunogens which, esp. when linked to  
 CC carriers, may be used in vaccines for conferring protection against HBV,  
 CC and in the diagnosis of viral conditions in man and animals and in the  
 CC detection of the antigens and antibodies. More specifically, the chain of  
 CC AAs is between sequence posn. pre-S 120-174. (Updated on 25-MAR-2003 to  
 CC correct PA field.)  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 RKG 6  
 |||  
 Db 9 RKG 11

# RESULT 17

AAP82901

ID AAP82901 standard; protein; 11 AA.

XX

AC AAP82901;

XX

DT 25-MAR-2003 (revised)

DT 10-MAR-2003 (revised)

DT 17-DEC-2001 (revised)

DT 23-NOV-1990 (first entry)

XX

DE Activated metalloproteinase CNBr cleavage product #2.

XX

KW metalloproteinase marker; basement membrane type IV collagen;

KW cancer metastases.

XX

OS Homo sapiens.

XX

PN USN7196242-N.

XX

PD 01-NOV-1988.

XX

PF 20-MAY-1988; 88US-00196242.

XX

PR 20-MAY-1988; 88US-00196242.

XX

PA (USSH ) US DEPT HEALTH & HUMAN SERVICE.

XX

PI Liotta LA, Stetlerste W, Kruttsch HC;

XX

DR WPI; 1988-360971/50.

XX  
PT Metallo:proteinase marker for cancer metastases - which cleaves basement  
PT membrane type IV collagen but does not cleave types I, II or III  
PT collagen.  
XX  
PS Disclosure; Page ?; 31pp; English.  
XX  
CC Recipient cells (e.g. rat embryo cell lines) transfected with the ras  
CC oncogene secrete a metalloproteinase of mol wt 60-75kD. This enzyme  
CC cleaves the pepsin resistant domain of basement membrane type IV collagen  
CC but does not cleave native types I, II or III. This sequence is a  
CC cyanogen bromide cleavage product of the activated form of the enzyme.  
CC Metastatic cancer cells can be identified by the level of secretion of  
CC the metalloproteinase. Affinity purified antibodies which recognise the N  
CC -terminal 30 amino acid residues can distinguish the latent from the  
CC activated proteinase. See also AAP82899-P82900 and AAP82902-P82903.  
CC (Note: Revised entry submitted to correct the patent number format of US  
CC Government-owned NTIS applications to prevent clashes with ongoing US  
CC granted patent numbers. For further information please visit the Derwent  
CC web site at [www.derwent.com/dwpi/updates/ntis\\_us.html](http://www.derwent.com/dwpi/updates/ntis_us.html).) (Updated on 10-  
CC MAR-2003 to add missing OS field.) (Updated on 25-MAR-2003 to correct PA  
CC field.)  
XX  
SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 1; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 GNS 8  
|||  
Db 6 GNS 8

# RESULT 18

AAP80854

ID AAP80854 standard; protein; 11 AA.

XX

AC AAP80854;

XX

DT 15-JAN-1991 (first entry)

XX

DE Sequence of N-terminal methionyl-porcine growth hormone encoded on

DE plasmid pGHX.1.

XX

KW Transgenic animal; somatotrophin.

XX

OS Sus scrofa.

XX

PN WO8808026-A.

XX

PD 20-OCT-1988.

XX

PF 14-APR-1988; 88WO-AU000109.

XX

PR 14-APR-1987; 87AU-00001427.

PR 17-APR-1987; 88AU-00017004.

PR 10-NOV-1987; 87AU-00005326.  
 XX  
 PA (LUMI-) LUMINIS PTY LTD.  
 XX  
 PI Seamark RF, Wells JR;  
 XX  
 DR WPI; 1988-307564/43.  
 DR N-PSDB; AAN80882, AAN80885, AAN80886, AAN80887, AAN80888.  
 XX  
 PT Creating new breed(s) of animals - by introducing a gene sample of a  
 PT hormone homologous with the ovum into the male nucleus of a fertilised  
 PT ovum.  
 XX  
 PS Example; Fig 6; 35pp; English.  
 XX  
 CC A method for creating new breeds of animals comprises (a) obtaining a  
 CC recently fertilised ovum, (b) isolating a gene sample of a characterising  
 CC hormone homologous with the ovum, (c) introducing the gene sample into  
 CC the male nucleus of the ovum prior to fusion with the female nucleus to  
 CC form a single cell embryo and (d) subsequently implanting the ovum into a  
 CC suitably prepd. female animal. Also claimed is a plasmid expression  
 CC vector comprising a plasmid cloning vector including a first cloned  
 CC sequence of DNA encoding a non-porcine promoter region and a second  
 CC cloned sequence encoding porcine growth hormone activity  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
 |||  
 Db 8 SSL 10

# RESULT 19

AAP81302

ID AAP81302 standard; protein; 11 AA.

XX

AC AAP81302;

XX

DT 10-MAR-2003 (revised)

DT 23-NOV-1990 (first entry)

XX

DE Atrial natriuretic polypeptide binding polypeptide T51.

XX

KW Diuretic; atrium cardis; atrial natriuretic peptide binding; T51;  
 KW hypotensive action.

XX

OS Mammalia.

XX

PN JP63079598-A.

XX

PD 09-APR-1988.

XX

PF 22-SEP-1986; 86JP-00222192.

XX  
 PR 22-SEP-1986; 86JP-00222192.  
 XX  
 PA (SUNR ) SUNTORY LTD.  
 XX  
 DR WPI; 1988-137132/20.  
 XX  
 PT Novel polypeptide, with diuretic action - is obtd. from atrium cardis of  
 PT mammals showing specific bond to atrial natriuretic polypeptide and gene  
 PT coding it.  
 XX  
 PS Claim 1; Page 2; 23pp; Japanese.  
 XX  
 CC Peptide binds to atrial natriuretic polypeptide (ANP) and has diuretic  
 CC (partic. natriuretic) and hypotensive action. See also AAN81690-93 and  
 CC AAP81282-P81309. (Updated on 10-MAR-2003 to add missing OS field.)  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
 |||  
 Db 7 SSL 9

# RESULT 20

AAAY07371

ID AAY07371 standard; peptide; 11 AA.

XX

AC AAY07371;

XX

DT 25-MAR-2003 (revised)

DT 16-JUL-1999 (first entry)

XX

DE Matrix metalloprotease antigenic peptide #8.

XX

KW Matrix metalloprotease; inhibitor; tissue damage; angiogenesis; antibody;

KW arthritis; tumour growth; granulomatous inflammatory condition; enzyme;

KW metastasis; sarcoidosis; antigen.

XX

OS Synthetic.

OS Homo sapiens.

XX

PN WO9010228-A.

XX

PD 07-SEP-1990.

XX

PF 01-MAR-1989; 89US-00317407.

XX

PR 01-MAR-1989; 89US-00317407.

PR 26-FEB-1990; 90US-00488460.

XX

PA (USDC ) US SEC OF COMMERCE.

PA (USSH ) NAT INST OF HEALTH.

XX  
 PI Liotta LA, Stetlerste W, Krutzsh H;  
 XX  
 DR WPI; 1990-290458/38.  
 XX  
 PT Matrix metallo:proteinase peptide(s) - used to inhibit enzyme in treating  
 PT tissue damage caused by activated enzyme.  
 XX  
 PS Example 3; Page 34; 6lpp; English.  
 XX  
 CC This sequence represents an antigenic peptide derived from a human type  
 CC IV matrix metalloprotease (MMP) protein. The invention relates to MMP  
 CC inhibitor peptides which can be used to treat tissue damage caused by  
 CC activated MMPs, e.g. for treating inappropriate angiogenesis, arthritis,  
 CC tumour growth, invasion and metastasis and granulomatous inflammatory  
 CC conditions such as sarcoidosis. Also antibodies to the peptides can be  
 CC used to detect the MMPs and can distinguish activated from latent enzyme.  
 CC (Updated on 25-MAR-2003 to correct PR field.) (Updated on 25-MAR-2003 to  
 CC correct PA field.) (Updated on 25-MAR-2003 to correct PI field.)  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 GNS 8  
 |||  
 Db 6 GNS 8

# RESULT 21

AAR07165

ID AAR07165 standard; protein; 11 AA.

XX

AC AAR07165;

XX

DT 24-JAN-1991 (first entry)

XX

DE Synthetic Nerve growth factor (NGF) peptide fragment.

XX

KW Nervous disorders; Alzheimer's disease; Parkinson's disease; stroke.

XX

OS Synthetic.

XX

PN WO9010644-A.

XX

PD 20-SEP-1990.

XX

PF 14-MAR-1989; 89SE-00000899.

XX

PR 14-MAR-1989; 89SE-00000899.

XX

PA (LOPE-) LOPE MED AB.

XX

PI Olson L, Persson H, Ebendal T;

XX

DR WPI; 1990-304983/40.  
 XX  
 PT New peptide fragments of nerve growth factor or its precursor - used to  
 PT raise specific antibodies for immunoassay, esp. for brain tissue.  
 XX  
 PS Disclosure; Page 11; 24pp; English.  
 XX  
 CC Peptides are Abs raised to them are useful in detecting the presence of  
 CC NGF and precursors, allowing early diagnosis and treatment of nervous  
 CC disorders eg. Alzheimer's and Parkinson's disease, spinal cord injury,  
 CC stroke etc. Peptide corresponds to AAs 111 to 120 of rat NGF  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SRK 5  
 |||  
 Db 4 SRK 6

RESULT 22

AAR10045

ID AAR10045 standard; protein; 11 AA.

XX

AC AAR10045;

XX

DT 27-AUG-2003 (revised)

DT 25-MAR-2003 (revised)

DT 09-JAN-2003 (revised)

DT 14-MAR-1991 (first entry)

XX

DE N-terminal fusion of VP2 to hexapeptide.

XX

KW VP2 protein; infectious bursal disease virus; poultry vaccine.

XX

OS Infectious bursal disease virus.

XX

FH Key Location/Qualifiers

FT Peptide 7. .11

FT /label= VP2 peptide

XX

PN WO9015140-A.

XX

PD 13-DEC-1990.

XX

PF 30-MAY-1989; 89AU-00004469.

XX

PR 30-MAY-1989; 89AU-00004469.

XX

PA (CSIR ) COMMONWEALTH SCI & IND RES ORG.

XX

PI Azad AA, Macreadie JG, Mckern NM, Vaughan PR, Jagadish MN;

PI Fahey KJ, Chapman JJ, Heine HG;

XX



DR WPI; 1991-007210/01.  
 DR N-PSDB; AAQ10155.  
 XX  
 PT Highly immunogenic VP2 protein - of infectious bursal disease virus,  
 PT useful in vaccine compsn. for immunisation against the disease in  
 PT poultry.  
 XX  
 PS Disclosure; Page 31; 70pp; English.  
 XX  
 CC This sequence comprises the region encompassing the N-terminal fusion of  
 CC a vector (pIP201) hexapeptide prod. and the N-terminal Met and residues -  
 CC 1(Thr) - 5(Asp) of the VP2 protein. The resultant prod. constitutes a  
 CC highly immunogenic form of VP2. A hybrid VP2 can also be constructed,  
 CC having an N-terminal from one strain of IBDV and a C- terminal from  
 CC another strain of IBDV. The proteins can be used in vaccines against IBDV  
 CC disease in poultry. See also AAQ10373. (Updated on 09-JAN-2003 to add  
 CC missing OS field.) (Updated on 25-MAR-2003 to correct PA field.) (Updated  
 CC on 25-MAR-2003 to correct PI field.) (Updated on 27-AUG-2003 to correct  
 CC OS field.)  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 NSS 9  
 |||  
 Db 2 NSS 4

# RESULT 23

AAR14094

ID AAR14094 standard; protein; 11 AA.

XX

AC AAR14094;

XX

DT 25-MAR-2003 (revised)

DT 04-DEC-1991 (first entry)

XX

DE Pre-S(1-11) immunogenic peptide based on HBV subtype adw2.

XX

KW hepatitis B virus; vaccine; liposome-peptide complex.

XX

OS Synthetic.

XX

PN EP448126-A.

XX

PD 25-SEP-1991.

XX

PF 28-FEB-1985; 91EP-00105948.

XX

PR 07-MAR-1984; 84US-00587090.

PR 05-FEB-1985; 85US-00698499.

XX

PA (NYBL-) NEW YORK BLOOD CENTER INC.

PA (CALY ) CALIFORNIA INST OF TECHN.

XX  
 PI Neurath AR, Kent SBH;  
 XX  
 DR WPI; 1991-283144/39.  
 XX  
 PT Synthetic lipid vesicle carrier linked to pre-S gene coded peptide - the  
 PT peptide is a hepatitis B immunogen, vaccine or diagnostic.  
 XX  
 PS Disclosure; Page 13; 54pp; English.  
 XX  
 CC This peptide is one of ten preferred HBV antigenic sequences which are  
 CC suitable for attachment to lipid vesicles for use as vaccines. The lipid  
 CC vesicle carrier is stabilised by cross-linking and has covalently bonded  
 CC sites on its outer surface to bind the peptide. See AAR14086-R14095.  
 CC (Updated on 25-MAR-2003 to correct PF field.) (Updated on 25-MAR-2003 to  
 CC correct PA field.)  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 RKG 6  
 |||  
 Db 9 RKG 11

#### RESULT 24

AAR44308

ID AAR44308 standard; protein; 11 AA.

XX

AC AAR44308;

XX

DT 20-DEC-1993 (first entry)

XX

DE Ballast constituent in pINT90d pro-insulin fusion protein.

XX

KW Fusion protein; ballast constituent; monkey pro-insulin; increased;

KW recombinant protein production; HMG CoA reductase;

KW human 3-hydroxy-3-methylglutaryl-coenzyme A-reductase.

XX

OS Synthetic.

XX

PN US5227293-A.

XX

PD 13-JUL-1993.

XX

PF 23-APR-1992; 92US-00838221.

XX

PR 29-AUG-1989; 89US-00399874.

PR 28-AUG-1990; 90WO-US004840.

XX

PA (GEHO ) GEN HOSPITAL CORP.

PA (FARH ) HOECHST AG.

XX

PI Stengelin S, Ulmer W, Habermann P, Uhlmann E, Seed B;

XX  
 DR WPI; 1991-102070/14.  
 DR N-PSDB; AAQ51807.  
 XX  
 PT Prepn. of fusion proteins contg. ballast constituent and protein - giving  
 PT prods. which are protease resistant or insoluble.  
 XX  
 PS Example 17; Col 7-8; 22pp; English.  
 XX  
 CC Sequence AAR44308 is an example of a specific ballast constituent peptide  
 CC which corresponds to a preferred generic coding sequence. The invention  
 CC covers fusion proteins in which a short ballast constituent is fused to a  
 CC desired protein, esp. to modified pro- insulin, to increase recombinant  
 CC production of the protein. See AAR44301-R44312  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 GNS 8  
 III  
 Db 7 GNS 9

# RESULT 25

AAR31358

ID AAR31358 standard; peptide; 11 AA.

XX

AC AAR31358;

XX

DT 25-MAR-2003 (revised)

DT 20-MAY-1998 (first entry)

XX

DE Antimicrobial peptide #12 derived from bovine lactoferrin.

XX

KW antimicrobial agent; iron-binding protein; athlete's foot; mastitis;

KW antibacterial agent.

XX

OS Synthetic.

XX

PN EP503939-A1.

XX

PD 16-SEP-1992.

XX

PF 12-MAR-1992; 92EP-00302125.

XX

PR 13-MAR-1991; 91JP-00048196.

PR 24-APR-1991; 91JP-00094492.

PR 24-APR-1991; 91JP-00094493.

XX

PA (MORG ) MORINAGA MILK IND CO LTD.

XX

PI Tomita M, Kawase K, Takase M, Bellamy WR, Yamauchi K;

PI Wakabayashi H, Tokita Y;

XX

DR WPI; 1992-310006/38.  
 XX  
 PT New antimicrobial peptide(s) - active against e.g. *Listeria*  
 PT *monocytogenes*, *Staphylococcus aureus*, *Pseudomonas aeruginosa* and  
 PT *Klebsiella pneumoniae*, for treating e.g. diarrhoea, mastitis, etc.  
 XX  
 PS Claim 8; Page 17; 19pp; English.  
 XX  
 CC This synthetic peptide has a sequence derived from bovine lactoferrin.  
 CC The peptide has stronger antimicrobial activity than unhydrolysed  
 CC lactoferrin and improved heat resistance. The peptide had a minimum  
 CC inhibitory concentration (microM) of 1.5, 3, 6 and 25 against *Listeria*  
 CC *monocytogenes*, *Staphylococcus aureus*, *Pseudomonas aeruginosa* and  
 CC *Klebsiella pneumoniae*, respectively. This and other peptides derived from  
 CC hydrolysed lactoferrin can be incorporated into foods, human or  
 CC veterinary compositions (e.g. for treating mastitis and athlete's foot),  
 CC toiletries, cosmetics, cleaning agents, etc. See AAR31350-R31361.  
 CC (Updated on 25-MAR-2003 to correct PN field.)  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 KSR 4  
 |||  
 Db 1 KSR 3

# RESULT 26

AAR24850

ID AAR24850 standard; protein; 11 AA.

XX

AC AAR24850;

XX

DT 25-MAR-2003 (revised)

DT 08-DEC-1992 (first entry)

XX

DE Weight regulating peptide 33.

XX

KW Amphetamine; appetite suppressor.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Misc-difference 2

FT /label= GLY, ALA, VAL, LEU, SER, THR, CYS, MET, ASP, GLU,

FT ASN, GLN, LYS, HIS, ARG, PHE, TYR, TRP, PRO, OTHER

FT /note= "cystine, hydroxylysine, hydroxyproline"

FT Misc-difference 3

FT /label= GLY, ALA, VAL, LEU, SER, THR, CYS, MET, ASP, GLU,

FT ASN, GLN, LYS, HIS, ARG, PHE, TYR, TRP, PRO, OTHER

FT /note= "cystine, hydroxylysine, hydroxyproline"

XX

PN WO9209296-A1.

XX

PD 11-JUN-1992.  
 XX  
 PF 20-NOV-1991; 91WO-US008497.  
 XX  
 PR 21-NOV-1990; 90US-00616910.  
 XX  
 PA (GEOU ) UNIV GEORGETOWN.  
 XX  
 PI Fleming PJ, Kent UM;  
 XX  
 DR WPI; 1992-216791/26.  
 XX  
 PT New dodeca:peptide cpds. - used for regulating wt. gain in mammals or for  
 PT producing antibodies for attenuating such effects.  
 XX  
 PS Disclosure; Page 10; 34pp; English.  
 XX  
 CC The sequences given in AAR24818-61 are new peptides which comprise at  
 CC least 6 amino acids from the sequence given in AAR24814. The remaining  
 CC amino acids are each Gly, Ala, Val, Leu, Ser, Thr, Cys, cystine, Met,  
 CC Asp, Glu, Asn, Gln, Lys, hydroxylysine, His, Arg, Phe, Tyr, Trp, Pro or  
 CC hydroxyproline. These peptides used for the regulation of weight gain in  
 CC mammals and can be used instead of amphetamine, which is largely used as  
 CC an appetite suppressor. These peptides can also be used to prepare  
 CC antibodies. Such antibodies can be used to attenuate the effect of the  
 CC peptides in a host or to detect, quantify or purify the peptides.  
 CC (Updated on 25-MAR-2003 to correct PN field.)  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 RKG 6  
 |||  
 Db 4 RKG 6

# RESULT 27

AAR28088

ID AAR28088 standard; protein; 11 AA.

XX

AC AAR28088;

XX

DT 25-MAR-2003 (revised)

DT 27-NOV-1992 (first entry)

XX

DE Cell-to-cell binding inhibiting peptide subunit (13).

XX

KW Adhesion; integrin; multimer.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Cross-links 6. .11

FT /note= "sequence linked by interchain amide bond at Lys

FT position to Glu residue on Arg5-Glu-Ser-Arg-Gly-Asp-Val  
FT sequence (see AAR28087)"

XX

PN WO9208476-A1.

XX

PD 29-MAY-1992.

XX

PF 07-NOV-1991; 91WO-US008328.

XX

PR 07-NOV-1990; 90US-00610363.

XX

PA (SCRI ) SCRIPPS RES INST.

XX

PI Ruggeri ZM, Houghten RA;

XX

DR WPI; 1992-199940/24.

XX

PT Peptides inhibiting binding of adhesion mols. to cells expressing  
PT integrins - for treating and preventing thrombus formation and diseases  
PT associated with platelet aggregation.

XX

PS Disclosure; Page 37-38; 70pp; English.

XX

CC A peptide which inhibits binding of adhesion mols. to cells expressing  
CC integrins comprises two subunits having the sequences given in AAR28087-  
CC 88, held together by an interchain stable bond. The sequence RGD is in  
CC each of the subunits. (Updated on 25-MAR-2003 to correct PN field.)

XX

SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 KSR 4

|||

Db 6 KSR 8

RESULT 28

AAR25763

ID AAR25763 standard; protein; 11 AA.

XX

AC AAR25763;

XX

DT 25-MAR-2003 (revised)

DT 15-JAN-1993 (first entry)

XX

DE Histone H2B peptide - N-Ac-[Lupus 2'(2-12)]-CONH2.

XX

KW Autoimmune; systemic lupus erythematosus; SLE; antibody; domain.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Modified-site 1

FT /note= "N-terminal is acetylated"

FT Modified-site 11  
 FT /note= "C-terminal is amidated"  
 XX  
 PN WO9211029-A1.  
 XX  
 PD 09-JUL-1992.  
 XX  
 PF 17-DEC-1991; 91WO-US009176.  
 XX  
 PR 17-DEC-1990; 90US-00628858.  
 XX  
 PA (UYJO ) UNIV JOHNS HOPKINS.  
 XX  
 PI Dintzis HM, Dintzis RZ, Blodgett JK, Cheronis JC;  
 PI Kirschenheuter G;  
 XX  
 DR WPI; 1992-249851/30.  
 XX  
 PT Suppression of undesired immune responses using an antigenic construct -  
 PT for treating pollen allergies and auto:immune diseases e.g. multiple  
 PT sclerosis, Myasthenia Gravis.  
 XX  
 PS Example 3; Page 71; 230pp; English.  
 XX  
 CC In order to suppress the autoimmune response to histone H2B that occurs  
 CC in the (NZBxNZW) F, murine model of systemic lupus erythematosus (SLE),  
 CC the antibody binding domain(s) of histone H2B had to be identified. It is  
 CC known that removal of the H2B N-terminal region with trypsin results in a  
 CC loss of antigenicity (Portanova, J.P., et al., J. Immunol. 38, 446-457,  
 CC (1987)). Attention was therefore, focussed on the synthesis of peptides  
 CC derived from this region of histone H2B. The peptides synthesised  
 CC together with their respective designations are represented in AAR25751-  
 CC 65. The antigen recognised by (NZBxNZW) F, mice was assigned as being  
 CC within H2B residues 3-12. (Updated on 25-MAR-2003 to correct PN field.)  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AKS 3  
 |||  
 Db 3 AKS 5

# RESULT 29

AAR27520

ID AAR27520 standard; peptide; 11 AA.

XX

AC AAR27520;

XX

DT 25-MAR-2003 (revised)

DT 10-MAR-1993 (first entry)

XX

DE Effector cell protease receptor-1 derived peptide.

XX

KW EPR-1; antibodies; chronic lymphocytic leukaemia; hairy cell leukaemia.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO9216558-A1.  
 XX  
 PD 01-OCT-1992.  
 XX  
 PF 12-MAR-1992; 92WO-US002109.  
 XX  
 PR 12-MAR-1991; 91US-00667957.  
 XX  
 PA (SCRI ) SCRIPPS RES INST.  
 XX  
 PI Altieri DC, Edgington TS;  
 XX  
 DR WPI; 1992-349160/42.  
 XX  
 PT Cell surface receptors homologous to coagulation factors V and VIII - for  
 PT monitoring the response to treatment of chronic lymphocytic leukaemia.  
 XX  
 PS Claim 1; Page 71; 83pp; English.  
 XX  
 CC The peptide is derived from effector cell protease receptor-1 (EPR-1)  
 CC Antibodies raised against it can be used for monitoring treatment of  
 CC patients afflicted with chronic lymphocytic leukaemia, hairy cell  
 CC leukaemia and other diseases in which expression of receptors homologous  
 CC to coagulation factors V and VIII is correlated with the disease state.  
 CC The antibodies can also be used for detecting EPR-1 cell surface  
 CC receptors. See also AAR27515-R27521. (Updated on 25-MAR-2003 to correct  
 CC PN field.)  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 GNS 8  
 |||  
 Db 1 GNS 3

---

RESULT-30

AAR26085  
 ID AAR26085 standard; peptide; 11 AA.  
 XX  
 AC AAR26085;  
 XX  
 DT 25-MAR-2003 (revised)  
 DT 01-FEB-1993 (first entry)  
 XX  
 DE Immunising peptide fragment #5 of T cell receptor.  
 XX  
 KW TCR; beta chain; rheumatoid arthritis; multiple sclerosis;  
 KW autoimmune disease; diabetes; T-cell lymphoma; vaccination; immunisation.  
 XX



OS Synthetic.  
 XX  
 PN WO9212996-A2.  
 XX  
 PD 06-AUG-1992.  
 XX  
 PF 21-JAN-1992; 92WO-US000482.  
 XX  
 PR 22-JAN-1991; 91US-00644611.  
 XX  
 PA (IMMU-) IMMUNE RESPONSE CORP.  
 XX  
 PI Howell MD, Brostoff SW, Carlo DJ;  
 XX  
 DR WPI; 1992-284600/34.  
 XX  
 PT Treatment of auto:immune diseases e.g. rheumatoid arthritis - using  
 PT vaccine contg. T-cell receptors from surface of T-cells which mediate the  
 PT diseases.  
 XX  
 PS Disclosure; Page 15; 87pp; English.  
 XX  
 CC This peptide fragment of the T-cell receptor is used as an immunising  
 CC peptide as part of a vaccine used to control rheumatoid arthritis or  
 CC multiple sclerosis, but can also be used against other autoimmune  
 CC diseases (eg. diabetes) or T-cell lymphoma. The sequence is part of a  
 CC beta chain VDJ region. (Updated on 25-MAR-2003 to correct PN field.)  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
 |||  
 Db 2 SSL 4

# RESULT 31

AAR26084

ID AAR26084 standard; peptide; 11 AA.

XX

AC AAR26084;

XX

DT 25-MAR-2003 (revised)

DT 01-FEB-1993 (first entry)

XX

DE Immunising peptide fragment #4 of T cell receptor.

XX

KW TCR; beta chain; rheumatoid arthritis; multiple sclerosis;

KW autoimmune disease; diabetes; T-cell lymphoma; vaccination; immunisation.

XX

OS Synthetic.

XX

PN WO9212996-A2.

XX

PD 06-AUG-1992.  
 XX  
 PF 21-JAN-1992; 92WO-US000482.  
 XX  
 PR 22-JAN-1991; 91US-00644611.  
 XX  
 PA (IMMU-) IMMUNE RESPONSE CORP.  
 XX  
 PI Howell MD, Brostoff SW, Carlo DJ;  
 XX  
 DR WPI; 1992-284600/34.  
 XX  
 PT Treatment of auto:immune diseases e.g. rheumatoid arthritis - using  
 PT vaccine contg. T-cell receptors from surface of T-cells which mediate the  
 PT diseases.  
 XX  
 PS Disclosure; Page 15; 87pp; English.  
 XX  
 CC This peptide fragment of the T-cell receptor is used as an immunising  
 CC peptide as part of a vaccine used to control rheumatoid arthritis or  
 CC multiple sclerosis, but can also be used against other autoimmune  
 CC diseases (eg. diabetes) or T-cell lymphoma. The sequence is part of a  
 CC beta chain VDJ region. (Updated on 25-MAR-2003 to correct PN field.)  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
 |||  
 Db 2 SSL 4

# RESULT 32

AAR26832

ID AAR26832 standard; peptide; 11 AA.

XX

AC AAR26832;

XX

DT 20-MAY-1998 (first entry)

XX

DE ~~TY-11(6)-FGF-analogue.~~

XX

KW Fibroblast growth factor; DMSO oxidation; disulphide peptides;  
 KW oxidative folding; dimethyl sulphoxide.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT disulfide\_bond 2. .7

FT /note= "bridge formed by DMSO oxidation"

XX

PN US5144006-A.

XX

PD 01-SEP-1992.

XX  
 PF 13-JUN-1991; 91US-00714659.  
 XX  
 PR 13-JUN-1991; 91US-00714659.  
 XX  
 PA (UYRQ ) UNIV ROCKEFELLER.  
 XX  
 PI Tam JP;  
 XX  
 DR WPI; 1992-315567/38.  
 XX  
 PT Oxidative folding of peptide and protein substrates - using hydrocarbon  
 PT sulphoxide(s), e.g. DMSO, with wide pH and temp. range, for synthesis of  
 PT e.g. endothelin.  
 XX  
 PS Disclosure; Fig 1; 14pp; English.  
 XX  
 CC This peptide is one of a series of basic peptides derived from the  
 CC receptor-recognition site comprised of residues 100-115 of human basic  
 CC fibroblast growth factor. This highly basic and hydrophobic sequence  
 CC contained no cysteine but was converted to cysteinyl- containing  
 CC sequences so that the peptides could be used as models to show the  
 CC effectiveness of DMSO as an oxidising agent in the novel method. Using  
 CC 20% DMSO in aq.soln. as the oxidative folding reagent, the disulphide  
 CC formation by DMSO oxidation was rapid in all the model peptides. The  
 CC optimal pH range for disulphide formation is 3-8, although this can be  
 CC extended to 2-10 with some substrates. The method can be used in the  
 CC synthesis of defensins (anti-microbials), endothelin and its precursor  
 CC big endothelin. See also AAR26833-R26840  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SRK 5  
 |||  
 Db 4 SRK 6

# RESULT 33

AAR26834

ID AAR26834-standard; peptide; 11-AA.

XX

AC AAR26834;

XX

DT 20-MAY-1998 (first entry)

XX

DE CY-11(8) FGF analogue.

XX

KW Fibroblast growth factor; DMSO oxidation; disulphide peptides;

KW oxidative folding; dimethyl sulphoxide.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT disulfide\_bond 1. .8  
 FT /note= "bridge formed by DMSO oxidation"  
 XX  
 PN US5144006-A.  
 XX  
 PD 01-SEP-1992.  
 XX  
 PF 13-JUN-1991; 91US-00714659.  
 XX  
 PR 13-JUN-1991; 91US-00714659.  
 XX  
 PA (UYRQ ) UNIV ROCKEFELLER.  
 XX  
 PI Tam JP;  
 XX  
 DR WPI; 1992-315567/38.  
 XX  
 PT Oxidative folding of peptide and protein substrates - using hydrocarbon  
 PT sulphoxide(s), e.g. DMSO, with wide pH and temp. range, for synthesis of  
 PT e.g. endothelin.  
 XX  
 PS Disclosure; Fig 1; 14pp; English.  
 XX  
 CC This peptide is one of a series of basic peptides derived from the  
 CC receptor-recognition site comprised of residues 100-115 of human basic  
 CC fibroblast growth factor. This highly basic and hydrophobic sequence  
 CC contained no cysteine but was converted to cysteinyl- containing  
 CC sequences so that the peptides could be used as models to show the  
 CC effectiveness of DMSO as an oxidising agent in the novel method. Using  
 CC 20% DMSO in aq.soln. as the oxidative folding reagent, the disulphide  
 CC formation by DMSO oxidation was rapid in all the model peptides. The  
 CC optimal pH range for disulphide formation is 3-8, although this can be  
 CC extended to 2-10 with some substrates. The method can be used in the  
 CC synthesis of defensins (anti-microbials), endothelin and its precursor  
 CC big endothelin. See AAR26832-R26840  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SRK 5  
 |||  
 Db 4 SRK 6

RESULT 34  
 AAR26833  
 ID AAR26833 standard; peptide; 11 AA.  
 XX  
 AC AAR26833;  
 XX  
 DT 20-MAY-1998 (first entry)  
 XX  
 DE CY-11(7) FGF analogue.  
 XX

KW Fibroblast growth factor; DMSO oxidation; disulphide peptides;  
 KW oxidative folding; dimethyl sulphoxide.  
 XX  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT disulfide\_bond 1. .7  
 FT /note= "bridge formed by DMSO oxidation"  
 XX  
 PN US5144006-A.  
 XX  
 PD 01-SEP-1992.  
 XX  
 PF 13-JUN-1991; 91US-00714659.  
 XX  
 PR 13-JUN-1991; 91US-00714659.  
 XX  
 PA (UYRQ ) UNIV ROCKEFELLER.  
 XX  
 PI Tam JP;  
 XX  
 DR WPI; 1992-315567/38.  
 XX  
 PT Oxidative folding of peptide and protein substrates - using hydrocarbon  
 PT sulphoxide(s), e.g. DMSO, with wide pH and temp. range, for synthesis of  
 PT e.g. endothelin.  
 XX  
 PS Disclosure; Fig 1; 14pp; English.  
 XX  
 CC This peptide is one of a series of basic peptides derived from the  
 CC receptor-recognition site comprised of residues 100-115 of human basic  
 CC fibroblast growth factor. This highly basic and hydrophobic sequence  
 CC contained no cysteine but was converted to cysteinyl- containing  
 CC sequences so that the peptides could be used as models to show the  
 CC effectiveness of DMSO as an oxidising agent in the novel method. Using  
 CC 20% DMSO in aq.soln. as the oxidative folding reagent, the disulphide  
 CC formation by DMSO oxidation was rapid in all the model peptides. The  
 CC optimal pH range for disulphide formation is 3-8, although this can be  
 CC extended to 2-10 with some substrates. The method can be used in the  
 CC synthesis of defensins (anti-microbials), endothelin and its precursor  
 CC big endothelin. See also AAR26833-R26840  
 XX  
 SQ Sequence 11 AA;

---

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SRK 5  
 |||  
 Db 4 SRK 6

RESULT 35  
 AAR26835  
 ID AAR26835 standard; peptide; 11 AA.  
 XX

AC AAR26835;  
XX  
DT 20-MAY-1998 (first entry)  
XX  
DE CY-11(9) FGF analogue.  
XX  
KW Fibroblast growth factor; DMSO oxidation; disulphide peptides;  
KW oxidative folding; dimethyl sulphoxide.  
XX  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT disulfide\_bond 1. .9  
FT /note= "bridge formed by DMSO oxidation"  
XX  
PN US5144006-A.  
XX  
PD 01-SEP-1992.  
XX  
PF 13-JUN-1991; 91US-00714659.  
XX  
PR 13-JUN-1991; 91US-00714659.  
XX  
PA (UYRQ ) UNIV ROCKEFELLER.  
XX  
PI Tam JP;  
XX  
DR WPI; 1992-315567/38.  
XX  
PT Oxidative folding of peptide and protein substrates - using hydrocarbon  
PT sulphoxide(s), e.g. DMSO, with wide pH and temp. range, for synthesis of  
PT e.g. endothelin.  
XX  
PS Disclosure; Fig 1; 14pp; English.  
XX  
CC This peptide is one of a series of basic peptides derived from the  
CC receptor-recognition site comprised of residues 100-115 of human basic  
CC fibroblast growth factor. This highly basic and hydrophobic sequence  
CC contained no cysteine but was converted to cysteinyl- containing  
CC sequences so that the peptides could be used as models to show the  
CC effectiveness of DMSO as an oxidising agent in the novel method. Using  
CC 20% DMSO in aq.soln. as the oxidative folding reagent, the disulphide  
CC formation by DMSO oxidation was rapid in all the model peptides. The  
CC optimal pH-range for disulphide formation is 3-8, although this can be  
CC extended to 2-10 with some substrates. The method can be used in the  
CC synthesis of defensins (anti-microbials), endothelin and its precursor  
CC big endothelin. See AAR26832-R26840  
XX  
SQ Sequence 11 AA;  
  
Query Match 27.3%; Score 3; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
Qy 3 SRK 5  
| | |  
Db 4 SRK 6

RESULT 36

AAR36904

ID AAR36904 standard; peptide; 11 AA.

XX

AC AAR36904;

XX

DT 25-MAR-2003 (revised)

DT 02-SEP-1993 (first entry)

XX

DE Insulin-like growth factor-II functional derivative.

XX

KW IGF-II; disorder; treatment; survival; retinal neuronal cells; promotion;

KW injury; ageing; disease; photodegeneration; trauma; axotomy;

KW neurotoxic-excitatory degeneration; diabetic retinopathy;

KW ischemic neuronal degeneration; inherited retinal dystrophy;

KW Alzheimer's disease; infantile malignant osteopetrosis; cholestasis;

KW ceroid-lipofuscosis; cyclic.

XX

OS Homo sapiens.

XX

FH Key Location/Qualifiers

FT Disulfide-bond 1. .11

XX

PN WO9308826-A1.

XX

PD 13-MAY-1993.

XX

PF 03-NOV-1992; 92WO-US009443.

XX

PR 08-NOV-1991; 91US-00790690.

PR 15-OCT-1992; 92US-00963329.

XX

PA (CEPH-) CEPHALON INC.

XX

PI Bozyczko-Coyne D, Neff N, Lewis ME, Iqbal M;

XX

DR WPI; 1993-167389/20.

XX

PT Use of IGF-I or IGF-II or their functional derivs. - for treating

PT disorders characterised by death and/or dysfunction of retinal cells.

XX

PS ~~Example; Page 69; 97pp; English.~~

XX

CC The sequence is that of a functional derivative of human insulin-like  
 CC growth factor (IGF)-II which promotes the survival of retinal neuronal  
 CC cells. It can be used for the treatment of retinal neuronal tissues which  
 CC are suffering from the effects of injury, ageing and/or disease such as  
 CC photodegeneration, trauma, axotomy, neurotoxic-excitatory degeneration,  
 CC ischemic neuronal degeneration, inherited retinal dystrophy, diabetic  
 CC retinopathy, Alzheimer's disease, infantile malignant osteopetrosis,  
 CC ceroid lipofuscosis or cholestasis. (Updated on 25-MAR-2003 to correct PN  
 CC field.)

XX

SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AKS 3  
|||  
Db 7 AKS 9

RESULT 37

AAR36924

ID AAR36924 standard; peptide; 11 AA.

XX

AC AAR36924;

XX

DT 25-MAR-2003 (revised)

DT 02-SEP-1993 (first entry)

XX

DE Insulin-like growth factor-II functional derivative.

XX

KW IGF-II; disorder; treatment; survival; retinal neuronal cells; promotion;

KW injury; ageing; disease; photodegeneration; trauma; axotomy;

KW neurotoxic-excitatory degeneration; diabetic retinopathy;

KW ischemic neuronal degeneration; inherited retinal dystrophy;

KW Alzheimer's disease; infantile malignant osteopetrosis; cholestasis;

KW ceroid-lipofuscosis; cyclic.

XX

OS Synthetic.

XX

PN WO9308826-A1.

XX

PD 13-MAY-1993.

XX

PF 03-NOV-1992; 92WO-US009443.

XX

PR 08-NOV-1991; 91US-00790690.

PR 15-OCT-1992; 92US-00963329.

XX

PA (CEPH-) CEPHALON INC.

XX

PI Bozyczko-Coyne D, Neff N, Lewis ME, Iqbal M;

XX

DR WPI; 1993-167389/20.

XX

PT Use of IGF-I or IGF-II or their functional derivs. - for treating  
PT disorders characterised by death and/or dysfunction of retinal cells.

XX

PS Example; Page 76; 97pp; English.

XX

CC The sequence is that of a functional derivative of human insulin-like  
CC growth factor (IGF)-II which promotes the survival of retinal neuronal  
CC cells. It can be used for the treatment of retinal neuronal tissues which  
CC are suffering from the effects of injury, ageing and/or disease such as  
CC photodegeneration, trauma, axotomy, neurotoxic-excitatory degeneration,  
CC ischemic neuronal degeneration, inherited retinal dystrophy, diabetic  
CC retinopathy, Alzheimer's disease, infantile malignant osteopetrosis,  
CC ceroid lipofuscosis or cholestasis. (Updated on 25-MAR-2003 to correct PN



CC field.)  
XX  
SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AKS 3  
|||  
Db 8 AKS 10

RESULT 38

AAR36905

ID AAR36905 standard; peptide; 11 AA.

XX

AC AAR36905;

XX

DT 25-MAR-2003 (revised)

DT 02-SEP-1993 (first entry)

XX

DE Insulin-like growth factor-II functional derivative.

XX

KW IGF-II; disorder; treatment; survival; retinal neuronal cells; promotion;

KW injury; ageing; disease; photodegeneration; trauma; axotomy;

KW neurotoxic-excitatory degeneration; diabetic retinopathy;

KW ischemic neuronal degeneration; inherited retinal dystrophy;

KW Alzheimer's disease; infantile malignant osteopetrosis; cholestasis;

KW ceroid-lipofuscosis; cyclic.

XX

OS Homo sapiens.

XX

FH Key Location/Qualifiers

FT Disulfide-bond 1. .11

XX

PN WO9308826-A1.

XX

PD 13-MAY-1993.

XX

PF 03-NOV-1992; 92WO-US009443.

XX

PR 08-NOV-1991; 91US-00790690.

PR 15-OCT-1992; 92US-00963329.

XX

PA (CEPH-) CEPHALON INC.

XX

PI Bozyczko-Coyne D, Neff N, Lewis ME, Iqbal M;

XX

DR WPI; 1993-167389/20.

XX

PT Use of IGF-I or IGF-II or their functional derivs. - for treating  
PT disorders characterised by death and/or dysfunction of retinal cells.

XX

PS Example; Page 70; 97pp; English.

XX

CC The sequence is that of a functional derivative of human insulin-like

CC growth factor (IGF)-II which promotes the survival of retinal neuronal  
CC cells. It can be used for the treatment of retinal neuronal tissues which  
CC are suffering from the effects of injury, ageing and/or disease such as  
CC photodegeneration, trauma, axotomy, neurotoxic-excitatory degeneration,  
CC ischemic neuronal degeneration, inherited retinal dystrophy, diabetic  
CC retinopathy, Alzheimer's disease, infantile malignant osteopetrosis,  
CC ceroid lipofuscosis or cholestasis. (Updated on 25-MAR-2003 to correct PN  
CC field.)

XX

SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AKS 3

|||

Db 7 AKS 9

# RESULT 39

AAR36894

ID AAR36894 standard; peptide; 11 AA.

XX

AC AAR36894;

XX

DT 25-MAR-2003 (revised)

DT 02-SEP-1993 (first entry)

XX

DE Insulin-like growth factor-II functional derivative.

XX

KW IGF-II; disorder; treatment; survival; retinal neuronal cells; promotion;

KW injury; ageing; disease; photodegeneration; trauma; axotomy;

KW neurotoxic-excitatory degeneration; diabetic retinopathy;

KW ischemic neuronal degeneration; inherited retinal dystrophy;

KW Alzheimer's disease; infantile malignant osteopetrosis; cholestasis;

KW ceroid-lipofuscosis; cyclic.

XX

OS Homo sapiens.

XX

FH Key Location/Qualifiers

FT Disulfide-bond 1. .11

FT Misc-difference 3

FT /note="D-form"

XX

PN WO9308826-A1.

XX

PD 13-MAY-1993.

XX

PF 03-NOV-1992; 92WO-US009443.

XX

PR 08-NOV-1991; 91US-00790690.

PR 15-OCT-1992; 92US-00963329.

XX

PA (CEPH-) CEPHALON INC.

XX

PI Bozyczko-Coyne D, Neff N, Lewis ME, Iqbal M;

XX  
 DR WPI; 1993-167389/20.  
 XX  
 PT Use of IGF-I or IGF-II or their functional derivs. - for treating  
 PT disorders characterised by death and/or dysfunction of retinal cells.  
 XX  
 PS Example; Page 66; 97pp; English.  
 XX  
 CC The sequence is that of a functional derivative of human insulin-like  
 CC growth factor (IGF)-II which promotes the survival of retinal neuronal  
 CC cells. It can be used for the treatment of retinal neuronal tissues which  
 CC are suffering from the effects of injury, ageing and/or disease such as  
 CC photodegeneration, trauma, axotomy, neurotoxic-excitatory degeneration,  
 CC ischemic neuronal degeneration, inherited retinal dystrophy, diabetic  
 CC retinopathy, Alzheimer's disease, infantile malignant osteopetrosis,  
 CC ceroid lipofuscosiis or cholestasis. (Updated on 25-MAR-2003 to correct PN  
 CC field.)  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AKS 3  
 |||  
 Db 7 AKS 9

RESULT 40  
 AAR36917  
 ID AAR36917 standard; peptide; 11 AA.  
 XX  
 AC AAR36917;  
 XX  
 DT 25-MAR-2003 (revised)  
 DT 02-SEP-1993 (first entry)  
 XX  
 DE Insulin-like growth factor-II functional derivative.  
 XX  
 KW IGF-II; disorder; treatment; survival; retinal neuronal cells; promotion;  
 KW injury; ageing; disease; photodegeneration; trauma; axotomy;  
 KW neurotoxic-excitatory degeneration; diabetic retinopathy;  
 KW ~~ischemic neuronal degeneration; inherited retinal dystrophy;~~  
 KW Alzheimer's disease; infantile malignant osteopetrosis; cholestasis;  
 KW ceroid-lipofuscosiis; cyclic.  
 XX  
 OS Synthetic.  
 XX  
 PN WO9308826-A1.  
 XX  
 PD 13-MAY-1993.  
 XX  
 PF 03-NOV-1992; 92WO-US009443.  
 XX  
 PR 08-NOV-1991; 91US-00790690.  
 PR 15-OCT-1992; 92US-00963329.

XX  
PA (CEPH-) CEPHALON INC.  
XX  
PI Bozyczko-Coyne D, Neff N, Lewis ME, Iqbal M;  
XX  
DR WPI; 1993-167389/20.  
XX  
PT Use of IGF-I or IGF-II or their functional derivs. - for treating  
PT disorders characterised by death and/or dysfunction of retinal cells.  
XX  
PS Example; Page 74; 97pp; English.  
XX  
CC The sequence is that of a functional derivative of human insulin-like  
CC growth factor (IGF)-II which promotes the survival of retinal neuronal  
CC cells. It can be used for the treatment of retinal neuronal tissues which  
CC are suffering from the effects of injury, ageing and/or disease such as  
CC photodegeneration, trauma, axotomy, neurotoxic-excitatory degeneration,  
CC ischemic neuronal degeneration, inherited retinal dystrophy, diabetic  
CC retinopathy, Alzheimer's disease, infantile malignant osteopetrosis,  
CC ceroid lipofuscosis or cholestasis. (Updated on 25-MAR-2003 to correct PN  
CC field.)  
XX  
SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AKS 3  
| | |  
Db 8 AKS 10

# RESULT 41

AAR36874

ID AAR36874 standard; peptide; 11 AA.

XX

AC AAR36874;

XX

DT 25-MAR-2003 (revised)

DT 02-SEP-1993 (first entry)

XX

DE Insulin-like growth factor-I functional derivative.

XX

KW IGF-I; disorder; treatment; survival; retinal neuronal cells; promotion;  
KW injury; ageing; disease; photodegeneration; trauma; axotomy;  
KW neurotoxic-excitatory degeneration; diabetic retinopathy;  
KW ischemic neuronal degeneration; inherited retinal dystrophy;  
KW Alzheimer's disease; infantile malignant osteopetrosis; cholestasis;  
KW ceroid-lipofuscosis; loop peptide.

XX

OS Homo sapiens.

XX

PN W09308826-A1.

XX

PD 13-MAY-1993.

XX

PF 03-NOV-1992; 92WO-US009443.  
 XX  
 PR 08-NOV-1991; 91US-00790690.  
 PR 15-OCT-1992; 92US-00963329.  
 XX  
 PA (CEPH-) CEPHALON INC.  
 XX  
 PI Bozyczko-Coyne D, Neff N, Lewis ME, Iqbal M;  
 XX  
 DR WPI; 1993-167389/20.  
 XX  
 PT Use of IGF-I or IGF-II or their functional derivs. - for treating  
 PT disorders characterised by death and/or dysfunction of retinal cells.  
 XX  
 PS Example; Page 60; 97pp; English.  
 XX  
 CC The sequence is that of a functional derivative of human insulin-like  
 CC growth factor (IGF)-I which promotes the survival of retinal neuronal  
 CC cells. It can be used for the treatment of retinal neuronal tissues which  
 CC are suffering from the effects of injury, ageing and/or disease such as  
 CC photodegeneration, trauma, axotomy, neurotoxic-excitatory degeneration,  
 CC ischemic neuronal degeneration, inherited retinal dystrophy, diabetic  
 CC retinopathy, Alzheimer's disease, infantile malignant osteopetrosis,  
 CC ceroid lipofuscosis or cholestasis. (Updated on 25-MAR-2003 to correct PN  
 CC field.)  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AKS 3  
 |||  
 Db 7 AKS 9

# RESULT 42

AAR36914

ID AAR36914 standard; peptide; 11 AA.

XX

AC AAR36914;

XX

DT 25-MAR-2003 (revised)

DT 02-SEP-1993 (first entry)

XX

DE Insulin-like growth factor-II functional derivative.

XX

KW IGF-II; disorder; treatment; survival; retinal neuronal cells; promotion;

KW injury; ageing; disease; photodegeneration; trauma; axotomy;

KW neurotoxic-excitatory degeneration; diabetic retinopathy;

KW ischemic neuronal degeneration; inherited retinal dystrophy;

KW Alzheimer's disease; infantile malignant osteopetrosis; cholestasis;

KW ceroid-lipofuscosis; cyclic.

XX

OS Synthetic.

XX

PN WO9308826-A1.  
 XX  
 PD 13-MAY-1993.  
 XX  
 PF 03-NOV-1992; 92WO-US009443.  
 XX  
 PR 08-NOV-1991; 91US-00790690.  
 PR 15-OCT-1992; 92US-00963329.  
 XX  
 PA (CEPH-) CEPHALON INC.  
 XX  
 PI Bozyczko-Coyne D, Neff N, Lewis ME, Iqbal M;  
 XX  
 DR WPI; 1993-167389/20.  
 XX  
 PT Use of IGF-I or IGF-II or their functional derivs. - for treating  
 PT disorders characterised by death and/or dysfunction of retinal cells.  
 XX  
 PS Example; Page 73; 97pp; English.  
 XX  
 CC The sequence is that of a functional derivative of human insulin-like  
 CC growth factor (IGF)-II which promotes the survival of retinal neuronal  
 CC cells. It can be used for the treatment of retinal neuronal tissues which  
 CC are suffering from the effects of injury, ageing and/or disease such as  
 CC photodegeneration, trauma, axotomy, neurotoxic-excitatory degeneration,  
 CC ischemic neuronal degeneration, inherited retinal dystrophy, diabetic  
 CC retinopathy, Alzheimer's disease, infantile malignant osteopetrosis,  
 CC ceroid lipofuscosin or cholestasis. (Updated on 25-MAR-2003 to correct PN  
 CC field.)  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AKS 3  
 |||  
 Db 8 AKS 10

# RESULT 43

AAR42959

ID AAR42959-standard; peptide; 11-AA.

XX

AC AAR42959;

XX

DT 14-MAY-2003 (revised)

DT 25-MAR-2003 (revised)

DT 08-DEC-1993 (first entry)

XX

DE Beta chain VDJ region (Vbeta3-Jbeta1.1).

XX

KW CDR; T-cell receptor; TCR; vaccine.

XX

OS Synthetic.

XX

PN WO9312814-A2.  
 XX  
 PD 08-JUL-1993.  
 XX  
 PF 21-DEC-1992; 92WO-US011159.  
 XX  
 PR 24-DEC-1991; 91US-00813867.  
 XX  
 PA (IMMU-) IMMUNE RESPONSE CORP.  
 XX  
 PI Howell MD, Brostoff SW, Carlo DJ;  
 XX  
 DR WPI; 1993-227059/28.  
 XX  
 PT Vaccine comprising T cell receptor from T cells which mediate pathology -  
 PT for treating and preventing T cell lymphoma, rheumatoid arthritis,  
 PT auto:immune diseases etc.  
 XX  
 PS Claim 13; Page 73; 79pp; English.  
 XX  
 CC A vaccine for preventing or treating a T-cell mediated pathology in a  
 CC vertebrate comprises a medium and a pure T-cell receptor (TCR) or  
 CC immunogenic fragment corresp. to a TCR present on the surface of T- cells  
 CC mediating the pathology. The immunogenic fragment may comprise the amino  
 CC acid sequence of a beta-chain variable region, pref. the CD2 region (see  
 CC Features Table of AAR38720-22). Alternatively the fragment may comprise  
 CC the amino acid sequence of a beta-chain VDJ region of the TCR. The beta-  
 CC chain VDJ region may comprise the sequences given in AAR42956-61.  
 CC (Updated on 25-MAR-2003 to correct PN field.) (Updated on 14-MAY-2003 to  
 CC correct PS field.)  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
 |||  
 Db 2 SSL 4

#### RESULT 44

AAR42956-  
 ID AAR42956 standard; peptide; 11 AA.  
 XX  
 AC AAR42956;  
 XX  
 DT 14-MAY-2003 (revised)  
 DT 25-MAR-2003 (revised)  
 DT 08-DEC-1993 (first entry)  
 XX  
 DE Beta chain VDJ region (Vbeta14-Jbeta2.1).  
 XX  
 KW CDR; T-cell receptor; TCR; vaccine.  
 XX  
 OS Synthetic.

XX  
 PN WO9312814-A2.  
 XX  
 PD 08-JUL-1993.  
 XX  
 PF 21-DEC-1992; 92WO-US011159.  
 XX  
 PR 24-DEC-1991; 91US-00813867.  
 XX  
 PA (IMMU-) IMMUNE RESPONSE CORP.  
 XX  
 PI Howell MD, Brostoff SW, Carlo DJ;  
 XX  
 DR WPI; 1993-227059/28.  
 XX  
 PT Vaccine comprising T cell receptor from T cells which mediate pathology -  
 PT for treating and preventing T cell lymphoma, rheumatoid arthritis,  
 PT auto:immune diseases etc.  
 XX  
 PS Claim 12; Page 73; 79pp; English.  
 XX  
 CC A vaccine for preventing or treating a T-cell mediated pathology in a  
 CC vertebrate comprises a medium and a pure T-cell receptor (TCR) or  
 CC immunogenic fragment corresp. to a TCR present on the surface of T- cells  
 CC mediating the pathology. The immunogenic fragment may comprise the amino  
 CC acid sequence of a beta-chain variable region, pref. the CD2 region (see  
 CC Features Table of AAR38720-22). Alternatively the fragment may comprise  
 CC the amino acid sequence of a beta-chain VDJ region of the TCR. The beta-  
 CC chain VDJ region may comprise the sequences given in AAR42956-61.  
 CC (Updated on 25-MAR-2003 to correct PN field.) (Updated on 14-MAY-2003 to  
 CC correct PS field.)  
 XX  
 SQ Sequence 11 AA;  
  
 Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
 Qy 8 SSL 10  
 |||  
 Db 2 SSL 4

---

RESULT-45

AAR32352

ID AAR32352 standard; peptide; 11 AA.

XX

AC AAR32352;

XX

DT 05-JUL-1993 (first entry)

XX

DE Human Factor X peptide.

XX

KW Anticoagulant; intrinsic; extrinsic; prothrombin activation; thrombin;  
 KW formation; Factor Xa; pathway mediated activation; inhibition.

XX

OS Synthetic.



XX  
 PN US5187155-A.  
 XX  
 PD 16-FEB-1993.  
 XX  
 PF 23-JUN-1989; 89US-00371561.  
 XX  
 PR 23-JUN-1989; 89US-00371561.  
 XX  
 PA (TEXA ) UNIV TEXAS SYSTEM.  
 XX  
 PI Fair DS;  
 XX  
 DR WPI; 1993-075751/09.  
 XX  
 PT Compsns. comprising peptide(s) of 10-50 aminoacid residues - inhibit  
 PT factor X activation and/or Factor Xa function, useful for preventing  
 PT blood clot formation and treating deep vein thrombosis, pulmonary  
 PT embolism, etc.  
 XX  
 PS Example; Page 6; 23pp; English.  
 XX  
 CC The sequence is that of a peptide corresponding to amino acids 404-414 of  
 CC the human factor X molecule which was tested for its effect, (as a % of  
 CC the control rate), on the rate of Factor Xa formation and on the rate of  
 CC thrombin formation. The results obt'd. were for activation of Factor X by  
 CC the extrinsic activation complex 78%, by the intrinsic activation complex  
 CC 98%, and activation by RVV-X, 76%. For the rate of thrombin formation the  
 CC rate was 88% as compared to the control rate  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 RKG 6  
 |||  
 Db 2 RKG 4

#### RESULT 46

AAR43594

ID AAR43594-standard; peptide; 11 AA.

XX

AC AAR43594;

XX

DT 25-MAR-2003 (revised)

DT 10-MAY-1994 (first entry)

XX

DE Peptide derived from insulin-like growth factor.

XX

KW IGF; IGF-II; neuronal cell survival; neurite regeneration; stroke;

KW epilepsy; Parkinson's disease; head injury; spinal cord injury;

KW age-related neuronal loss; amyotrophic lateral sclerosis.

XX

OS Synthetic.

XX  
 PN WO9320836-A1.  
 XX  
 PD 28-OCT-1993.  
 XX  
 PF 14-APR-1993; 93WO-US003515.  
 XX  
 PR 15-APR-1992; 92US-00869913.  
 PR 07-OCT-1992; 92US-00958903.  
 XX  
 PA (CEPH-) CEPHALON INC.  
 XX  
 PI Lewis ME, Kauer JC, Smith KR, Callison KV, Baldino F, Neff N;  
 PI Iqbal M;  
 XX  
 DR WPI; 1993-351361/44.  
 XX  
 PT Peptide(s) derived from insulin-like growth factor - used for promoting  
 PT neuronal cell survival and neurite regeneration, partic. in treating  
 PT diseases e.g. stroke, epilepsy, Parkinson's, etc.  
 XX  
 PS Claim 12; Page 77; 119pp; English.  
 XX  
 CC The sequence is that of a fragment of insulin-like growth factor II (IGF-  
 CC II). The synthetic peptide can be used to enhance the survival of  
 CC neuronal cells in a mammal that are at risk of dying or to treat a head  
 CC or spinal cord injury, or to enhance neurite regeneration in a mammal, or  
 CC to treat stroke, epilepsy, age-related neuronal loss, amyotrophic lateral  
 CC sclerosis and Parkinson's disease. See also AAR43590-645. (Updated on 25-  
 CC MAR-2003 to correct PN field.)  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AKS 3  
 |||  
 Db 8 AKS 10

# RESULT 47

AAR43598

ID AAR43598 standard; peptide; 11 AA.  
 XX  
 AC AAR43598;  
 XX  
 DT 25-MAR-2003 (revised)  
 DT 10-MAY-1994 (first entry)  
 XX  
 DE Peptide derived from insulin-like growth factor.  
 XX  
 KW IGF; IGF-II; neuronal cell survival; neurite regeneration; stroke;  
 KW epilepsy; Parkinson's disease; head injury; spinal cord injury;  
 KW age- related neuronal loss; amyotrophic lateral sclerosis; cyclic.  
 XX

OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT Disulfide-bond 1. .11  
 XX  
 PN WO9320836-A1.  
 XX  
 PD 28-OCT-1993.  
 XX  
 PF 14-APR-1993; 93WO-US003515.  
 XX  
 PR 15-APR-1992; 92US-00869913.  
 PR 07-OCT-1992; 92US-00958903.  
 XX  
 PA (CEPH-) CEPHALON INC.  
 XX  
 PI Lewis ME, Kauer JC, Smith KR, Callison KV, Baldino F, Neff N;  
 PI Iqbal M;  
 XX  
 DR WPI; 1993-351361/44.  
 XX  
 PT Peptide(s) derived from insulin-like growth factor - used for promoting  
 PT neuronal cell survival and neurite regeneration, partic. in treating  
 PT diseases e.g. stroke, epilepsy, Parkinson's, etc.  
 XX  
 PS Claim 15; Page 79; 119pp; English.  
 XX  
 CC The sequence is that of a fragment of insulin-like growth factor II (IGF-  
 CC II). The synthetic peptide can be used to enhance the survival of  
 CC neuronal cells in a mammal that are at risk of dying or to treat a head  
 CC or spinal cord injury, or to enhance neurite regeneration in a mammal, or  
 CC to treat stroke, epilepsy, age-related neuronal loss, amyotrophic lateral  
 CC sclerosis and Parkinson's disease. See also AAR43590-645. (Updated on 25-  
 CC MAR-2003 to correct PN field.)  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AKS 3  
 |||  
 Db 7-AKS-9

# RESULT 48

AAR43618

ID AAR43618 standard; peptide; 11 AA.

XX

AC AAR43618;

XX

DT 25-MAR-2003 (revised)

DT 10-MAY-1994 (first entry)

XX

DE Peptide derived from insulin-like growth factor.

XX

KW IGF; IGF-II; neuronal cell survival; neurite regeneration; stroke;  
 KW epilepsy; Parkinson's disease; head injury; spinal cord injury;  
 KW age- related neuronal loss; amyotrophic lateral sclerosis; cyclic.  
 XX  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT Disulfide-bond 1. .11  
 XX  
 PN WO9320836-A1.  
 XX  
 PD 28-OCT-1993.  
 XX  
 PF 14-APR-1993; 93WO-US003515.  
 XX  
 PR 15-APR-1992; 92US-00869913.  
 PR 07-OCT-1992; 92US-00958903.  
 XX  
 PA (CEPH-) CEPHALON INC.  
 XX  
 PI Lewis ME, Kauer JC, Smith KR, Callison KV, Baldino F, Neff N;  
 PI Iqbal M;  
 XX  
 DR WPI; 1993-351361/44.  
 XX  
 PT Peptide(s) derived from insulin-like growth factor - used for promoting  
 PT neuronal cell survival and neurite regeneration, partic. in treating  
 PT diseases e.g. stroke, epilepsy, Parkinson's, etc.  
 XX  
 PS Claim 20; Page 86; 119pp; English.  
 XX  
 CC The sequence is that of a fragment of insulin-like growth factor II (IGF-  
 CC II). The synthetic peptide can be used to enhance the survival of  
 CC neuronal cells in a mammal that are at risk of dying or to treat a head  
 CC or spinal cord injury, or to enhance neurite regeneration in a mammal, or  
 CC to treat stroke, epilepsy, age-related neuronal loss, amyotrophic lateral  
 CC sclerosis and Parkinson's disease. See also AAR43590-645. (Updated on 25-  
 CC MAR-2003 to correct PN field.)  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AKS 3  
 |||  
 Db 7 AKS 9

RESULT 49  
 AAR43599  
 ID AAR43599 standard; peptide; 11 AA.  
 XX  
 AC AAR43599;  
 XX  
 DT 25-MAR-2003 (revised)

DT 10-MAY-1994 (first entry)  
 XX  
 DE Peptide derived from insulin-like growth factor.  
 XX  
 KW IGF; IGF-II; neuronal cell survival; neurite regeneration; stroke;  
 KW epilepsy; Parkinson's disease; head injury; spinal cord injury;  
 KW age- related neuronal loss; amyotrophic lateral sclerosis; cyclic.  
 XX  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT Disulfide-bond 1. .11  
 XX  
 PN WO9320836-A1.  
 XX  
 PD 28-OCT-1993.  
 XX  
 PF 14-APR-1993; 93WO-US003515.  
 XX  
 PR 15-APR-1992; 92US-00869913.  
 PR 07-OCT-1992; 92US-00958903.  
 XX  
 PA (CEPH-) CEPHALON INC.  
 XX  
 PI Lewis ME, Kauer JC, Smith KR, Callison KV, Baldino F, Neff N;  
 PI Iqbal M;  
 XX  
 DR WPI; 1993-351361/44.  
 XX  
 PT Peptide(s) derived from insulin-like growth factor - used for promoting  
 PT neuronal cell survival and neurite regeneration, partic. in treating  
 PT diseases e.g. stroke, epilepsy, Parkinson's, etc.  
 XX  
 PS Claim 17; Page 79; 119pp; English.  
 XX  
 CC The sequence is that of a fragment of insulin-like growth factor II (IGF-  
 CC II). The synthetic peptide can be used to enhance the survival of  
 CC neuronal cells in a mammal that are at risk of dying or to treat a head  
 CC or spinal cord injury, or to enhance neurite regeneration in a mammal, or  
 CC to treat stroke, epilepsy, age-related neuronal loss, amyotrophic lateral  
 CC sclerosis and Parkinson's disease. See also AAR43590-645. (Updated on 25-  
 CC MAR-2003 to correct PN field.)  
 XX  
 SQ Sequence-11-AA;

---

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AKS 3  
 |||  
 Db 7 AKS 9

RESULT 50  
 AAR43638  
 ID AAR43638 standard; peptide; 11 AA.

XX  
 AC AAR43638;  
 XX  
 DT 25-MAR-2003 (revised)  
 DT 10-MAY-1994 (first entry)  
 XX  
 DE Peptide derived from insulin-like growth factor.  
 XX  
 KW IGF; IGF-II; neuronal cell survival; neurite regeneration; stroke;  
 KW epilepsy; Parkinson's disease; head injury; spinal cord injury;  
 KW age- related neuronal loss; amyotrophic lateral sclerosis; cyclic.  
 XX  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT Disulfide-bond 1. .11  
 FT Modified-site 3  
 FT /note= "D form"  
 XX  
 PN WO9320836-A1.  
 XX  
 PD 28-OCT-1993.  
 XX  
 PF 14-APR-1993; 93WO-US003515.  
 XX  
 PR 15-APR-1992; 92US-00869913.  
 PR 07-OCT-1992; 92US-00958903.  
 XX  
 PA (CEPH-) CEPHALON INC.  
 XX  
 PI Lewis ME, Kauer JC, Smith KR, Callison KV, Baldino F, Neff N;  
 PI Iqbal M;  
 XX  
 DR WPI; 1993-351361/44.  
 XX  
 PT Peptide(s) derived from insulin-like growth factor - used for promoting  
 PT neuronal cell survival and neurite regeneration, partic. in treating  
 PT diseases e.g. stroke, epilepsy, Parkinson's, etc.  
 XX  
 PS Claim 16; Page 93; 119pp; English.  
 XX  
 CC The sequence is that of a fragment of insulin-like growth factor II (IGF-  
 CC II). The synthetic peptide can be used to enhance the survival of  
 CC ~~neuronal cells in a mammal that are at risk of dying or to treat a head~~  
 CC or spinal cord injury, or to enhance neurite regeneration in a mammal, or  
 CC to treat stroke, epilepsy, age-related neuronal loss, amyotrophic lateral  
 CC sclerosis and Parkinson's disease. See also AAR43590-645. (Updated on 25-  
 CC MAR-2003 to correct PN field.)  
 XX  
 SQ Sequence 11 AA;  
  
 Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
 Qy 1 AKS 3  
 |||

## RESULT 51

AAR37430

ID AAR37430 standard; peptide; 11 AA.

XX

AC AAR37430;

XX

DT 25-MAR-2003 (revised)

DT 08-SEP-1993 (first entry)

XX

DE Promega peptide 5.

XX

KW Modified peptide substrate; non-radioactive; detection; dansyl;  
KW sulphorhodamine 101; lissamine; rhodamine; enzymes; phosphatases;  
KW protein kinases; proteases.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Modified-site 1

FT /note= "detection tag= lissamine, Rhodamine"

XX

PN WO9310461-A1.

XX

PD 27-MAY-1993.

XX

PF 12-NOV-1992; 92WO-US009595.

XX

PR 12-NOV-1991; 91US-00791928.

XX

PA (PROM-) PROMEGA CORP.

XX

PI Shultz JW, White DH;

XX

DR WPI; 1993-182698/22.

XX

PT Quantitating presence or activity of enzyme - by incubating with modified  
PT peptide substrate and measuring the modified peptide prod.

XX

PS Claim 24; Page 27; 103pp; English.

XX

~~CC Promega peptide 5 is tagged with dansyl at residue 1 and may be used in a~~  
CC novel non-radioactive method of quantitating the presence or activity of  
CC an enzyme. The method can be used for rapid, specific and highly  
CC sensitive detection of enzymes such as protein kinases, phosphatases and  
CC proteases, esp. in this case protein kinase C. They can be used to study  
CC enzyme function in metabolism and in diagnosis of disease. They also  
CC allow quantitative determ. of the enzyme's activity. See also AAR37426-  
CC 36. (Updated on 25-MAR-2003 to correct PN field.)

XX

SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;

Best Local Similarity 100.0%; Pred. No. 1.3e+04;

Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 KSR 4  
   | | |  
Db 6 KSR 8

RESULT 52

AAR44560

ID AAR44560 standard; protein; 11 AA.

XX

AC AAR44560;

XX

DT 25-MAR-2003 (revised)

DT 26-MAY-1994 (first entry)

XX

DE Encoded by human Ews exon7/Hum-Fli-1 exon 5 fusion.

XX

KW chromosomal translocation; chimeric; chimaeric; Ewing sarcoma; Ews gene;

KW malignant melanoma; hum-fli-1;

KW primitive peripheral neuroectodermal tumour; human chromosome 11;

KW human chromosome 22.

XX

OS Homo sapiens.

XX

FH Key Location/Qualifiers

FT Region 1. .5

FT /note= "encoded by 3'-end of Ews exon 7"

FT Region 6. .11

FT /note= "encoded by 5'-end of Hum-Fli-1 exon 5"

XX

PN WO9323549-A2.

XX

PD 25-NOV-1993.

XX

PF 19-MAY-1993; 93WO-FR000494.

XX

PR 20-MAY-1992; 92FR-00006123.

XX

PA (CNRS ) CNRS CENT NAT RECH SCI.

XX

PI Aurias A, Delattre O, Desmaze C, Melot T, Peter M, Plougastel B;

PI Thomas G, Zucman J;

XX

DR WPI; 1993-386580/48.

DR N-PSDB; AAQ50673.

XX

PT New nucleic acid of EWS gene and its hybrid(s) - contg. gene sequence

PT involved in chromosomal trans-location, also derived mRNA, probes, fusion

PT proteins etc., for diagnosis and treatment of Ewing sarcoma and melanoma.

XX

PS Disclosure; Fig 14; 123pp; French.

XX

CC The intron-exon junctions of the human Ews gene and the Hum-Fli-1 gene

CC have been sequenced (see AAQ50646 and AAQ50662, respectively). The

CC different fusion products which could be formed by fusing exons from the

CC two genes, as happens after specific chromosomal translocations, can be

CC predicted. See AAR44558-R44565 for the amino acid sequences resulting



CC from the different fusion events. (Updated on 25-MAR-2003 to correct PN  
CC field.)

XX

SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10

|||

Db 6 SSL 8

# RESULT 53

AAR53641

ID AAR53641 standard; protein; 11 AA.

XX

AC AAR53641;

XX

DT 25-MAR-2003 (revised)

DT 19-JAN-1995 (first entry)

XX

DE Mutant transaminase tyrB fragment from pIF200.

XX

KW improved method; transaminases; conversion; D-amino acids; L-amino acids;

KW tyr B; tyrosine aminotransferase; amino acid synthesis.

XX

OS Escherichia coli.

XX

PN US5316943-A.

XX

PD 31-MAY-1994.

XX

PF 19-JUN-1989; 89US-00368480.

XX

PR 14-JUN-1988; 88US-00206622.

XX

PA (SCOL/) SCOLLAR M P.

PA (KIDM/) KIDMAN G E.

PA (ROBI/) ROBINSON L E.

PA (ROBI/) ROBINSON L E.

XX

PI Fotheringham IG, Kidman GE, Robinson LE, Scollar MP;

XX

DR WPI; 1994-176276/21.

DR N-PSDB; AAQ63803.

XX

PT Prodn. of optically pure L-aminoacid from D,L racemic mixt. - by  
PT fermentation with microorganism producing recombinant amino:transferase  
PT to convert D to L isomer, for use in prodn. of L-phenylalanine for prepn.  
PT of aspartame sweetener.

XX

PS Disclosure; Fig 4; 9pp; English.

XX

CC The method of the invention is particularly useful in the prepn. of  
CC aspartame, the low calorie sweetener. It is preferred to separate the two

CC isomers or convert a racemic mixture of the two to obtain one of the  
CC enantiomers that is relatively free of contamination by the other.  
CC Aspartame is a dipeptide comprising aspartic acid and phenylalanine  
CC (Phe), in the L-L form. Methods of production of Phe typically result in  
CC racemic mixtures of D and L isomers which must either be separated or  
CC resolved, to yield pure L-Phe. L-amino acids can be produced by  
CC transamination. The enzymes used are expensive and often inactivated by  
CC hydrogen peroxide (a byproduct of the reaction). This invention provides  
CC a transaminase that produces optically pure L-Phe from a D,L racemic  
CC mixture without the problems of previous methods. More specifically the  
CC enzyme of interest is a mutant of the tyrosine transaminase (AAR53641 and  
CC AAR53642, encoded by the tyrB gene - AAQ63803-4). (Updated on 25-MAR-2003  
CC to correct PF field.)

XX

SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 NSS 9

|||

Db 2 NSS 4

#### RESULT 54

AAR52885

ID AAR52885 standard; peptide; 11 AA.

XX

AC AAR52885;

XX

DT 25-MAR-2003 (revised)

DT 07-NOV-1994 (first entry)

XX

DE TK-SH2 association inhibitory peptide.

XX

KW Tyrosine kinase; SH2 domains; inhibition of association; abl;

KW Epidermal Growth Factor Receptor; phosphotyrosine residue;

KW control proliferative disease; control cancer; TK; EGFR;

KW Src-homology domains.

XX

OS Synthetic.

XX

| FH | Key           | Location/Qualifiers      |
|----|---------------|--------------------------|
| FT | Modified-site | 4                        |
| FT |               | /label= other            |
| FT |               | /note= "phosphotyrosine" |

XX

PN W09407913-A1.

XX

PD 14-APR-1994.

XX

PF 22-SEP-1993; 93WO-US008996.

XX

PR 25-SEP-1992; 92US-00951241.

PR 15-SEP-1993; 93US-00122028.

XX

PA (WARN ) WARNER LAMBERT CO.  
 XX  
 PI Dobrusin EM, Mcnamara DJ, Soltiel AR, Maclean D, Thieme-Sefler A;  
 XX  
 DR WPI; 1994-135508/16.  
 XX  
 PT New peptide(s) with a tyrosine auto-phosphorylation site - inhibit  
 PT tyrosine kinase association with regulatory proteins, used for treating,  
 PT e.g., hyper-proliferative, viral, allergic inflammatory, auto-immune and  
 PT cardiovascular diseases.  
 XX  
 PS Example 7; Page 11; 50pp; English.  
 XX  
 CC The peptide inhibits the association of a tyrosine kinase with its  
 CC cellular substrates and effectively uncouples the tyrosine kinase from  
 CC specific signal transduction pathways. The peptide inhibition is probably  
 CC the result of competition between the phosphorylated peptide and the  
 CC phosphorylated receptor for the same binding site on the SH2 domains. The  
 CC inventors claim the peptides can be used for the control of several  
 CC proliferative diseases, eg. cancer. (Updated on 25-MAR-2003 to correct PN  
 CC field.)  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 NSS 9  
 |||  
 Db 9 NSS 11

# RESULT 55

AAR52886

ID AAR52886 standard; peptide; 11 AA.

XX

AC AAR52886;

XX

DT 25-MAR-2003 (revised)

DT 07-NOV-1994 (first entry)

XX

DE TK-SH2 association inhibitory peptide.

XX

KW Tyrosine kinase; SH2 domains; inhibition of association; abl;

KW Epidermal Growth Factor Receptor; phosphotyrosine residue;

KW control proliferative disease; control cancer; TK; EGFR;

KW Src-homology domains.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Modified-site 5

FT /label= other

FT /note= "phosphotyrosine"

XX

PN WO9407913-A1.

XX  
PD 14-APR-1994.  
XX  
PF 22-SEP-1993; 93WO-US008996.  
XX  
PR 25-SEP-1992; 92US-00951241.  
PR 15-SEP-1993; 93US-00122028.  
XX  
PA (WARN ) WARNER LAMBERT CO.  
XX  
PI Dobrusin EM, Mcnamara DJ, Soltiel AR, Maclean D, Thieme-Seffler A;  
XX  
DR WPI; 1994-135508/16.  
XX  
PT New peptide(s) with a tyrosine auto-phosphorylation site - inhibit  
PT tyrosine kinase association with regulatory proteins, used for treating,  
PT e.g., hyper-proliferative, viral, allergic inflammatory, auto-immune and  
PT cardiovascular diseases.  
XX  
PS Example 8; Page 11; 50pp; English.  
XX  
CC The peptide inhibits the association of a tyrosine kinase with its  
CC cellular substrates and effectively uncouples the tyrosine kinase from  
CC specific signal transduction pathways. The peptide inhibition is probably  
CC the result of competition between the phosphorylated peptide and the  
CC phosphorylated receptor for the same binding site on the SH2 domains. The  
CC inventors claim the peptides can be used for the control of several  
CC proliferative diseases, eg. cancer. (Updated on 25-MAR-2003 to correct PN  
CC field.)  
XX  
SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 NSS 9  
| | |  
Db 9 NSS 11

# RESULT 56

AAR68593

ID ~~AAR68593-standard; peptide; 11-AA.~~

XX

AC AAR68593;

XX

DT 25-MAR-2003 (revised)

DT 01-SEP-1995 (first entry)

XX

DE Rat NDF peptide fragment #3.

XX

KW Alpha; beta; neu differentiation factor; NDF; human; rat; p185-neu;  
KW tyrosine phosphorylation; differentiation; phenotype; proliferation;  
KW wound; tumour; epithelial tissue; breast; stomach; PCR; amplify;  
KW gastrointestinal disease; Barrett's oesophagus; primer;  
KW (non-)cystic kidney disease; inflammatory bowel disease.

XX  
 OS Rattus rattus.  
 XX  
 PN WO9428133-A1.  
 XX  
 PD 08-DEC-1994.  
 XX  
 PF 23-MAY-1994; 94WO-US005769.  
 XX  
 PR 21-MAY-1993; 93US-00066384.  
 XX  
 PA (AMGE-) AMGEN INC.  
 XX  
 PI Wen D, Koski RA, Pierce GF, Hu S, Sugarman BJ, Liu N;  
 XX  
 DR WPI; 1995-022805/03.  
 XX  
 PT New recombinant neu differentiation factors and corresp. DNA - are used  
 PT in the treatment of tumours, dermal wounds, and gastrointestinal, kidney  
 PT and inflammatory bowel diseases.  
 XX  
 PS Example 1; Page 226; 34lpp; English.  
 XX  
 CC The sequences given in AAR68591-95 represent fragments of rat neu  
 CC differentiation factor (NDF). NDF peptides possess the ability to  
 CC stimulate p185-neu tyrosine phosphorylation. These peptides have the  
 CC ability to induce a differentiated phenotype in certain cell lines and  
 CC can stimulate or inhibit proliferation of certain cell lines. NDF's can  
 CC be used to treat wounds, tumours derived from epithelial tissue of the  
 CC breast, stomach etc., gastrointestinal disease, Barrett's oesophagus,  
 CC (non-)cystic kidney disease or inflammatory bowel disease. DNA sequences  
 CC derived from these peptides may be used as primers and probes in the  
 CC isolation sequences from human cDNA libraries which encode human NDF's.  
 CC (Updated on 25-MAR-2003 to correct PN field.)  
 XX  
 SQ Sequence 11 AA;  
  
 Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
 Qy 8 SSL 10  
 |||  
 Db 8-SSL-10

---

RESULT 57

AAR78518

ID AAR78518 standard; peptide; 11 AA.

XX

AC AAR78518;

XX

DT 25-JAN-1996 (first entry)

XX

DE Synthetic HTLV peptide #50 binds to HLA-B35 antigen.

XX

KW Human T-cell leukaemia virus; HTLV; cytotoxic; HLA-B35 antigen; vaccine;

KW prophylaxis; HTLV-1 associated myelopathy; HAM.  
 XX  
 OS Synthetic.  
 XX  
 PN JP07126290-A.  
 XX  
 PD 16-MAY-1995.  
 XX  
 PF 29-OCT-1993; 93JP-00294472.  
 XX  
 PR 29-OCT-1993; 93JP-00294472.  
 XX  
 PA (KENB/) KENBARA K.  
 PA (TAKI/) TAKIGUCHI M.  
 XX  
 DR WPI; 1995-212957/28.  
 XX  
 PT Synthetic peptide(s) derived from human T cell leukaemia virus (HTLV) -  
 PT bind to HLA-B35 antigen, useful in a vaccine against HTLV-1 associated  
 PT myelopathy and human T cell leukaemia.  
 XX  
 PS Claim 1; Page 2; 13pp; Japanese.  
 XX  
 CC Peptides AAR78469-R78518 are synthetic peptides derived from the sequence  
 CC of the human T-cell leukaemia virus (HTLV) which are capable of inducing  
 CC cytotoxic T cells by binding to the HLA-B35 antigen. The peptides can be  
 CC used as a vaccine in prophylaxis of human T cell leukaemia and HTLV-1  
 CC associated myelopathy (HAM), both caused by HTLV. This sequence  
 CC corresponds to amino acids 97-107 of the HTLV-1a and c strains pol  
 CC protein  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
 |||  
 Db 5 SSL 7

# RESULT 58

AAW21497

ID AAW21497 standard; peptide; 11 AA.  
 XX  
 AC AAW21497;  
 XX  
 DT 16-OCT-2003 (revised)  
 DT 30-JUL-1997 (first entry)  
 XX  
 DE Hepatitis delta antigen derived signal oligopeptide #2.  
 XX  
 KW Hydrophilic; signal oligopeptide; hydrophilicity maxima; vaccine; SIV;  
 KW competitive inhibitor; feedback regulator; synthesis; gastrin precursor;  
 KW charge; polarity; farnesyl synthetase; plasminogen activator inhibitor 1;  
 KW hydroxymethylglutaryl coenzyme A reductase; glucagon precursor; rhesus;

KW gonadoliberin precursor; plasminogen activator inhibitor 2; prorenin;  
 KW Alzheimer amyloid A4; corticotropin releasing factor binding protein;  
 KW apolipoprotein E; herpes virus 1 glycoprotein B; HSV1; human; OMVVS;  
 KW herpes virus 2 glycoprotein B; HSV2; collagenase; apolipoprotein A;  
 KW Treponema pallidum membrane protein; TMPA; islet amyloid polypeptide;  
 KW fibroblast MMP1; schistosoma elastase precursor; schistosomin;  
 KW hepatitis delta antigen; rev protein; HIV; VILV; angiotensinogen.  
 XX  
 OS Hepatitis D virus.  
 XX  
 PN WO9519568-A1.  
 XX  
 PD 20-JUL-1995.  
 XX  
 PF 12-JAN-1995; 95WO-US000575.  
 XX  
 PR 14-JAN-1994; 94US-00182248.  
 XX  
 PA (RATH/) RATH M.  
 XX  
 PI Rath M;  
 XX  
 DR WPI; 1995-263953/34.  
 XX  
 PT Identifying signal oligopeptide(s) in protein sequence(s) - shown as  
 PT regions of max. hydrophilicity, used in modulating communication between  
 PT protein(s).  
 XX  
 PS Claim 5; Page 72; 88pp; English.  
 XX  
 CC The sequences given in AAW21201-560 represent hydrophilic signal oligo-  
 CC peptides. These signal oligopeptides are localised on the surface of the  
 CC protein and are represented by the hydrophilicity maxima of the protein.  
 CC These peptides are enriched in charged amino acids arranged with neutral  
 CC spacer amino acids. The specific signal character of these oligopeptides  
 CC is determined by a characteristic combination of conformation and charge  
 CC within the signal sequence. These oligopeptides may be used as vaccines  
 CC in the treatment of human disease, as competitive inhibitors to prevent  
 CC or reduce the metabolic action or interaction of a selected protein by  
 CC blocking its specific signal sequences, or as therapeutic agents to  
 CC function as feedback regulators to reduce synthesis rate of a selected  
 CC protein. These peptides may be modified by omitting one or more amino  
 CC acids at the N- and/or C-terminal, by substituting one or more amino  
 CC ~~acids without consideration of charge and polarity, by substituting one~~  
 CC or more amino acids with amino acid residues with similar charge and/or  
 CC polarity, by omitting one or more amino acids or a combination of these.  
 CC (Updated on 16-OCT-2003 to standardise OS field)  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SRK 5  
 |||  
 Db 2 SRK 4

RESULT 59

AAW21210

ID AAW21210 standard; peptide; 11 AA.

XX

AC AAW21210;

XX

DT 29-JUL-1997 (first entry)

XX

DE Farnesyl synthetase derived signal oligopeptide #10.

XX

KW Hydrophilic; signal oligopeptide; hydrophilicity maxima; vaccine; SIV;  
 KW competitive inhibitor; feedback regulator; synthesis; gastrin precursor;  
 KW charge; polarity; farnesyl synthetase; plasminogen activator inhibitor 1;  
 KW hydroxymethylglutaryl coenzyme A reductase; glucagon precursor; rhesus;  
 KW gonadoliberin precursor; plasminogen activator inhibitor 2; prorenin;  
 KW Alzheimer amyloid A4; corticotropin releasing factor binding protein;  
 KW apolipoprotein E; herpes virus 1 glycoprotein B; HSV1; human; OMVVS;  
 KW herpes virus 2 glycoprotein B; HSV2; collagenase; apolipoprotein A;  
 KW Treponema pallidum membrane protein; TMPA; islet amyloid polypeptide;  
 KW fibroblast MMP1; schistosoma elastase precursor; schistosomin;  
 KW hepatitis delta antigen; rev protein; HIV; VILV; angiotensinogen.

XX

OS Homo sapiens.

XX

PN WO9519568-A1.

XX

PD 20-JUL-1995.

XX

PF 12-JAN-1995; 95WO-US000575.

XX

PR 14-JAN-1994; 94US-00182248.

XX

PA (RATH/) RATH M.

XX

PI Rath M;

XX

DR WPI; 1995-263953/34.

XX

PT Identifying signal oligopeptide(s) in protein sequence(s) - shown as  
 PT regions of max. hydrophilicity, used in modulating communication between  
 PT protein(s).

XX

PS Claim 5; Page 24; 88pp; English.

XX

CC The sequences given in AAW21201-560 represent hydrophilic signal oligo-  
 CC peptides. These signal oligopeptides are localised on the surface of the  
 CC protein and are represented by the hydrophilicity maxima of the protein.  
 CC These peptides are enriched in charged amino acids arranged with neutral  
 CC spacer amino acids. The specific signal character of these oligopeptides  
 CC is determined by a characteristic combination of conformation and charge  
 CC within the signal sequence. These oligopeptides may be used as vaccines  
 CC in the treatment of human disease, as competitive inhibitors to prevent  
 CC or reduce the metabolic action or interaction of a selected protein by  
 CC blocking its specific signal sequences, or as therapeutic agents to  
 CC function as feedback regulators to reduce synthesis rate of a selected



CC protein. These peptides may be modified by omitting one or more amino  
CC acids at the N- and/or C-terminal, by substituting one or more amino  
CC acids without consideration of charge and polarity, by substituting one  
CC or more amino acids with amino acid residues with similar charge and/or  
CC polarity, by omitting one or more amino acids or a combination of these  
XX  
SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 SSL 10  
|||  
Db 6 SSL 8

RESULT 60

AAR98482

ID AAR98482 standard; peptide; 11 AA.

XX

AC AAR98482;

XX

DT 12-OCT-1996 (first entry)

XX

DE Anti-IL-5 MAb heavy chain variable region CDR3.

XX

KW Antibody engineering; humanised antibody; chimeric antibody; Fab;

KW interleukin-5; IL-5; eosinophil; asthma; therapy; diagnosis;

KW complementarity determining region; CDR; heavy chain; VH;

KW monoclonal antibody; MAb.

XX

OS Mus sp.

XX

PN W09621000-A2.

XX

PD 11-JUL-1996.

XX

PF 22-DEC-1995; 95WO-US017082.

XX

PR 23-DEC-1994; 94US-00363131.

PR 06-JUN-1995; 95US-00467420.

PR 06-JUN-1995; 95US-00470110.

XX

PA (SMIK ) SMITHKLINE BEECHAM CORP.

PA (SMIK ) SMITHKLINE BEECHAM PLC.

XX

PI Ames RS, Appelbaum ER, Chaiken IM, Cook RM, Gross MS, Holmes SD;

PI Mcmillan LJ, Theisen TW;

XX

DR WPI; 1996-333976/33.

XX

PT New monoclonal antibody to human interleukin-5 - used to produce products

PT for the treatment and diagnosis of conditions associated with excess

PT eosinophil prodn., e.g asthma etc.

XX

PS Claim 11; Page 48; 120pp; English.

XX  
 CC The complementarity determining regions (CDRs) for the VH region of  
 CC monoclonal antibody (MAb) 2B6 (see also AAR98478) are given in AAR98480-  
 CC 82. MAb 2F2 VH (see also AAR98478) had identical CDRs. For MAb 2E3 VH  
 CC (see also AAR98496), CDR1 and CDR2 are identical to those of 2B6 and 2F2,  
 CC but CDR3 has a different amino acid sequence (AAR98483). The CDRs for the  
 CC 2B6 VL region (see also AAR98479) are given in AAR98484-86. For 2F2 VL  
 CC (see also AAR98495) and 2E3 VL (see also AAR98497), CDR1 and CDR2 are  
 CC identical to CDR1 and CDR2 of 2B6, but CDR3 is different (AAR98487). 2B6,  
 CC 2F2 and 2E3 are murine anti-human interleukin-5 MAb's. The CDRs can be  
 CC used in the construction of humanised antibodies (see also AAR98488-89)  
 CC and AAR98492-93) useful in the treatment of IL-5-mediated conditions,  
 CC e.g. asthma  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
 |||  
 Db 4 SSL 6

# RESULT 61

AAW05770

ID AAW05770 standard; peptide; 11 AA.

XX

AC AAW05770;

XX

DT 25-MAR-2003 (revised)

DT 28-JUL-1997 (first entry)

XX

DE Presenilin-1-1 residues 50-60.

XX

KW Presenilin-1; human; hPS1-1; hPS1-2; PS-2; integral membrane protein; AD;

KW familial Alzheimer's disease; cerebral haemorrhage; schizophrenia;

KW depression; antibody; gene expression modulator; therapy; mutagen.

XX

OS Homo sapiens.

XX

PN W09634099-A2.

XX

PD 31-OCT-1996.

XX

PF 29-APR-1996; 96WO-CA000263.

XX

PR 28-APR-1995; 95US-00431048.

PR 28-JUN-1995; 95US-00496841.

PR 31-JUL-1995; 95US-00509359.

XX

PA (HSCR-) HSC RES & DEV LP.

PA (UTOR ) UNIV TORONTO GOVERNING COUNCIL.

XX

PI St George's Hospital, Fraser PE, Rommens JM;

XX

DR WPI; 1996-497631/49.  
 XX  
 PT New presenilin genes - useful for diagnosis, therapy and drug screening  
 PT of familial Alzheimer's disease, cerebral disorders, etc.  
 XX  
 PS Claim 71; Page; 178pp; English.  
 XX  
 CC AAW05768-W05788 represent antigenic fragments of the human presenilin-1-1  
 CC protein (see AAW05733 for wild type sequence). AAW05734 represents a  
 CC different wild type form of presenilin-1 that results from alternate  
 CC splicing of the genomic DNA sequence. The presenilins are a family of  
 CC highly conserved integral membrane proteins with a common structural  
 CC motif, common alternate splicing patterns, and common mutational hot spot  
 CC regions. Mutations in PS genes are implicated in familial Alzheimer's  
 CC disease (AD) and possibly other diseases such as cerebral haemorrhage,  
 CC schizophrenia, depression etc., so detection of mutations in the DNA  
 CC encoding the wild type sequences can be used for diagnosis of these  
 CC diseases. The wild type proteins, or vectors that express them or  
 CC containing antisense sequences, antibodies selective for these mutant  
 CC forms of the proteins and modulators of PS gene expression are  
 CC potentially useful for treatment of AD etc. Transgenic animals are useful  
 CC as models for drug screening. The antibodies can also be used e.g. for  
 CC affinity purification and in immunoassays. (Updated on 25-MAR-2003 to  
 CC correct PI field.)  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 GNS 8  
 |||  
 Db 8 GNS 10

# RESULT 62

AAR89702

ID AAR89702 standard; peptide; 11 AA.

XX

AC AAR89702;

XX

DT 25-MAR-2003 (revised)

DT 02-SEP-1996 (first entry)

XX

DE Prostate specific antigen, semenogelin derived, cleavage substrate.

XX

KW Human; semenogelin I; sperm entrapping gel; ejaculation; protease;  
 KW gel structure; dissolution; prostate specific antigen; proteolysis;  
 KW chymotrypsin like specificity; peptide substrate; cleavage site; assay;  
 KW determination; proteolytic activity; identification; inhibitor;  
 KW cytotoxic agent; conjugated; treatment; prostate cancer.

XX

OS Homo sapiens.

XX

FH Key Location/Qualifiers

FT Modified-site 1

FT /note= "acylated"  
 FT Cleavage-site 7. .8  
 FT /note= "prostate specific antigen proteolytic cleavage  
 FT site"  
 FT Modified-site 11  
 FT /note= "C-terminally conjugated to the amino of the sugar  
 FT moiety of doxorubicin"  
 XX  
 PN WO9600503-A1.  
 XX  
 PD 11-JAN-1996.  
 XX  
 PF 07-JUN-1995; 95WO-US008156.  
 XX  
 PR 28-JUN-1994; 94US-00267092.  
 PR 15-MAR-1995; 95US-00404833.  
 XX  
 PA (MERI ) MERCK & CO INC.  
 XX  
 PI DefeoJones D, Feng D, Garsky VM, Jones RE, Oliff AI;  
 XX  
 DR WPI; 1996-077275/08.  
 XX  
 PT New peptide substrates cleaved by prostate-specific antigen - also  
 PT cytotoxic conjugates for treating prostate cancer, and assay for  
 PT determination of PSA activity.  
 XX  
 PS Claim 19; Page 104; 142pp; English.  
 XX  
 CC Human semenogelin I (hSI) is one of the major proteins, including hSII  
 CC and fibronectin, in the sperm entrapping gel formed at ejaculation. This  
 CC gel structure undergoes dissolution via the action of prostate specific  
 CC antigen (PSA), a protease with chymotrypsin like specificity, which  
 CC proteolyses the above major proteins. New substrates, including the  
 CC present peptide, cleaved by PSA, i.e. peptides contg. a hSI PSA cleavage  
 CC site, can be used in assays to determine the proteolytic activity of free  
 CC PSA in a sample, and to identify cpds. which inhibit the proteolytic  
 CC activity of PSA, they may also be conjugated, via a covalent bond or  
 CC peptide linker, to a cytotoxic agent and used to treat prostate cancer.  
 CC In a PSA hydrolysis assay, the percentage of the present peptide cleaved  
 CC by YORK PSA after 3 hrs. was 100 %. (Updated on 25-MAR-2003 to correct PI  
 CC field.)  
 XX  
 SQ Sequence 11 AA;

---

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
 |||  
 Db 9 SSL 11

RESULT 63  
 AAR89705  
 ID AAR89705 standard; peptide; 11 AA.

XX  
 AC AAR89705;  
 XX  
 DT 25-MAR-2003 (revised)  
 DT 03-SEP-1996 (first entry)  
 XX  
 DE Prostate specific antigen, semenogelin derived, cleavage substrate.  
 XX  
 KW Human; semenogelin I; sperm entrapping gel; ejaculation; protease;  
 KW gel structure; dissolution; prostate specific antigen; proteolysis;  
 KW chymotrypsin like specificity; peptide substrate; cleavage site; assay;  
 KW determination; proteolytic activity; identification; inhibitor;  
 KW cytotoxic agent; conjugated; treatment; prostate cancer.  
 XX  
 OS Homo sapiens.  
 XX  
 FH Key Location/Qualifiers  
 FT Modified-site 1  
 FT /note= "acylated"  
 FT Cleavage-site 7. .8  
 FT /note= "prostate specific antigen proteolytic cleavage  
 FT site"  
 FT Modified-site 11  
 FT /note= "C-terminally conjugated to the amino of the sugar  
 FT moiety of doxorubicin"  
 XX  
 PN WO9600503-A1.  
 XX  
 PD 11-JAN-1996.  
 XX  
 PF 07-JUN-1995; 95WO-US008156.  
 XX  
 PR 28-JUN-1994; 94US-00267092.  
 PR 15-MAR-1995; 95US-00404833.  
 XX  
 PA (MERI ) MERCK & CO INC.  
 XX  
 PI DefeoJones D, Feng D, Garsky VM, Jones RE, Oliff AI;  
 XX  
 DR WPI; 1996-077275/08.  
 XX  
 PT New peptide substrates cleaved by prostate-specific antigen - also  
 PT cytotoxic conjugates for treating prostate cancer, and assay for  
 PT determination of PSA activity.  
 XX  
 PS Example 3; Page 105; 142pp; English.  
 XX  
 CC Human semenogelin I (hSI) is one of the major proteins, including hSII  
 CC and fibronectin, in the sperm entrapping gel formed at ejaculation. This  
 CC gel structure undergoes dissolution via the action of prostate specific  
 CC antigen (PSA), a protease with chymotrypsin like specificity, which  
 CC proteolyses the above major proteins. New substrates, including the  
 CC present peptide, cleaved by PSA, i.e. peptides contg. a hSI PSA cleavage  
 CC site, can be used in assays to determine the proteolytic activity of free  
 CC PSA in a sample, and to identify cpds. which inhibit the proteolytic  
 CC activity of PSA, they may also be conjugated, via a covalent bond or  
 CC peptide linker, to a cytotoxic agent and used to treat prostate cancer.

CC In a PSA hydrolysis assay, the percentage of the present peptide cleaved  
CC by YORK PSA after 4 hrs. was 0 %. (Updated on 25-MAR-2003 to correct PI  
CC field.)  
XX  
SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
| | |  
Db 9 SSL 11

RESULT 64

AAR98513

ID AAR98513 standard; peptide; 11 AA.

XX

AC AAR98513;

XX

DT 04-MAR-1997 (first entry)

XX

DE CD8 antagonist #8.

XX

KW CD8 antagonist; inhibitor; T-cell activation; human; CD8 alpha chain;

KW thymic differentiation; transplantation; bone marrow; liver; heart; lung;

KW kidney; cornea; skin graft; graft versus host disease; therapy.

XX

OS Synthetic.

XX

PN WO9622106-A1.

XX

PD 25-JUL-1996.

XX

PF 17-JAN-1996; 96WO-US000310.

XX

PR 17-JAN-1995; 95US-00372952.

XX

PA (UYJE-) UNIV JEFFERSON THOMAS.

XX

PI Jameson BA, Choksi S, Korngold R, Huang Z;

XX

DR WPI; 1996-354307/35.

XX

PT CD8 antagonist peptide(s) - used for inhibiting T cell activation,  
PT partic. for treating transplant rejection or graft versus host disease.

XX

PS Example 1; Page 23; 44pp; English.

XX

CC AAR98506-R98513 represent CD8 antagonists of the invention. CD8 plays a  
CC major role in the activation of mature T-cells, and in the thymic  
CC differentiation process that leads to CD8 expression. CD8 is expressed  
CC either as a homodimer (containing two alpha chains) or as a heterodimer  
CC (an alpha and a beta chain). The CD8 CDR2-like region is involved in  
CC regulating T-cell activation. The antagonists of the invention comprise a  
CC molecular surface similar to at least a portion of human CD8 molecular

CC surface around the site of one of these peptides. The compounds of the  
CC invention compete with CD8 so as to inhibit T-cell activation. They can  
CC also be used to treat an individual who is about to undergo, is  
CC undergoing, or has undergone a transplantation procedure such as bone  
CC marrow, liver, heart, kidney, lung, islets, or cornea transplantation, or  
CC skin grafts. The compounds can also be used to treat an individual  
CC suspected of suffering from, or susceptible to graft versus host disease

XX

SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 NSS 9

|||

Db 6 NSS 8

# RESULT 65

AAW06895

ID AAW06895 standard; peptide; 11 AA.

XX

AC AAW06895;

XX

DT 19-JUN-1997 (first entry)

XX

DE Anti-CD18 Fab epitope.

XX

KW Anti-CD18; salvage receptor binding epitope; immunoglobulin G; IgG;

KW variant; kidney; in vivo half-life; effector; antigenic function;

KW LFA-1 antagonist; psoriasis; transplant rejection; asthma; wound repair;

KW meningitis; multiple sclerosis; B-cell lymphoma.

XX

OS Synthetic.

XX

PN WO9632478-A1.

XX

PD 17-OCT-1996.

XX

PF 28-MAR-1996; 96WO-US004316.

XX

PR 14-APR-1995; 95US-00422093.

XX

PA (GETH ) GENENTECH INC.

XX

PI Presta LG, Snedecor BR;

XX

DR WPI; 1996-477129/47.

XX

PT Polypeptide variants, esp. LFA-1 antagonists, comprising a salvage

PT receptor binding epitope of an Fc region of an IgG - have increased in

PT vivo half-life and are useful to treat e.g. psoriasis, transplant

PT rejection, asthma, etc.

XX

PS Claim 13; Page 63; 72pp; English.

XX

CC This peptide sequence is that of an anti-CD18 Fab epitope, in particular  
CC a salvage receptor binding epitope of an immunoglobulin G (IgG) molecule.  
CC Polypeptide variants of a protein which is cleared from the kidney (and  
CC which does not contain a Fc region of a IgG) comprise the present  
CC sequence and possibly also one of AAW06896-99. The variant has a longer  
CC in vivo half-life and is useful for providing in vivo effector or  
CC antigenic function or activity. In partic. LFA-1 antagonist variants can  
CC be obtd. for treating LFA-1-mediated disorders (claimed), e.g. psoriasis,  
CC transplant rejection, asthma, wound repair, meningitis, multiple  
CC sclerosis or B-cell lymphomas  
XX  
SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 NSS 9  
|||  
Db 3 NSS 5

RESULT 66

AAR91286

ID AAR91286 standard; peptide; 11 AA.

XX

AC AAR91286;

XX

DT 14-OCT-1996 (first entry)

XX

DE Anti-idiotypic T-cell modulating peptide.

XX

KW Peptide; VDJ; anti-idiotypic T cell; vaccine; detection; diagnosis;  
KW insulin dependent diabetes mellitus; IDDM; assay; proliferation;  
KW cytokine.

XX

OS Synthetic.

XX

PN WO9611214-A1.

XX

PD 18-APR-1996.

XX

PF 10-OCT-1995; 95WO-US012686.

XX

PR 07-OCT-1994; 94IL-00111196.

XX

PA (YEDA ) YEDA RES & DEV CO LTD.

XX

PI Cohen IR, Elias D;

XX

DR WPI; 1996-209811/21.

XX

PT Novel VDJ peptide and corresponding DNA - used in treatment and  
PT prevention of insulin dependent diabetes mellitus.

XX

PS Claim 3; Page 41; 60pp; English.

XX



CC Peptides having a VDJ region where V includes the dipeptide sequence A-S,  
CC D preferably has 2-5 amino acids and includes the dipeptide L-G and J  
CC includes the tripeptide N-Q-D, may be used as agents for the detection of  
CC anti-idiotypic T-cells and in a vaccine against insulin dependent  
CC diabetes mellitus (IDDM). The peptides may also be used in the prevention  
CC and treatment of IDDM by activating autologous T- cells against the  
CC peptides and then re-administering them to the patient. The peptides may  
CC also be used in the diagnosis or staging of IDDM or for monitoring the  
CC course of treatment of IDDM by assaying T-cells of the subject being  
CC tested for proliferation or cytokine production upon in vitro contact  
CC with the peptides

XX

SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10

|||

Db 2 SSL 4

#### RESULT 67

AAW09653

ID AAW09653 standard; peptide; 11 AA.

XX

AC AAW09653;

XX

DT 25-MAR-2003 (revised)

DT 20-MAY-1997 (first entry)

XX

DE Labelled peptide substrate used in enzyme activity assay.

XX

KW Enzyme activity; assay; measurement; label; rhodamine; dansyl;

KW non-radioactive; electrophoretic separation; protein kinase; protease;

KW phosphatase.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Modified-site 1

FT /note= "labelled with rhodamine B detection tag"

XX

PN US5580747-A.

XX

PD 03-DEC-1996.

XX

PF 21-JAN-1994; 94US-00185448.

XX

PR 12-NOV-1991; 91US-00791928.

XX

PA (PROM-) PROMEGA CORP.

XX

PI White DH, Shultz JW;

XX

DR WPI; 1997-033568/03.

XX  
PT Non:radioactive assay for measuring enzyme activity - involving  
PT electrophoretic sepn. of labelled cleavage prod. from labelled peptide  
PT substrate.  
XX  
PS Claim 5; Col 39-40; 35pp; English.  
XX  
CC AAW09653 is a peptide substrate used in a non-radioactive assay for  
CC measuring enzyme activity. The assay comprises incubating the enzyme with  
CC the labelled peptide substrate to form a labelled peptide product;  
CC separating the product from the substrate by agarose gel electrophoresis  
CC and measuring the amount of product by detecting the label by  
CC fluorescence or chemiluminescence. The assay can be performed rapidly and  
CC with great sensitivity. This peptide is especially for determining  
CC protein kinase C activity, e.g. to study its function in metabolism or to  
CC screen for potential inhibitors. (Updated on 25-MAR-2003 to correct PF  
CC field.)  
XX  
SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 KSR 4  
| | |  
Db 6 KSR 8

# RESULT 68

AAE22529

ID AAE22529 standard; peptide; 11 AA.

XX

AC AAE22529;

XX

DT 26-JUL-2002 (first entry)

XX

DE Human Fcgamma RI antibody (H22) hinge region fragment #3.

XX

KW Human; multispecific multivalent molecule; anti-Fc receptor; cytostatic;

KW anti-enhancement factor protein; breast; ovarian cancer; systemic lupus;

KW autoimmune disease; toxoplasma gondii; fungal infection; dermatological;

KW Fcgamma RI antibody hinge region; immunosuppressive; antimicrobial;

KW therapy.

XX

OS Homo sapiens.

XX

PN US2002032312-A1.

XX

PD 14-MAR-2002.

XX

PF 07-JUN-1995; 95US-00484172.

XX

PR 07-JUN-1995; 95US-00484172.

XX

PA (MEDA-) MEDAREX INC.

XX

PI Deo YM, Goldstein J, Graziano R, Somasundaram C;  
 XX  
 DR WPI; 1997-052242/05.  
 DR N-PSDB; AAD35553.  
 XX  
 PT Recombinant, multi-specific anti-Fc receptor antibody molecules - also  
 PT comprise an anti-target portion, used for the treatment of cancer,  
 PT autoimmune disease and pathogenic infection.  
 XX  
 PS Example 2; Fig 1; 34pp; English.  
 XX  
 CC The invention relates to new multispecific multivalent molecules which  
 CC comprise: a recombinant multispecific molecule comprising an anti-Fc  
 CC receptor portion and an anti-target portion; a multivalent molecule  
 CC comprising at least one anti-Fc receptor portion and at least one anti-  
 CC target portion; or a multispecific molecule having one anti-FcR, one anti-  
 CC -target portion and one anti-enhancement factor protein. The  
 CC multispecific, multivalent molecules are useful for treating cancer or  
 CC autoimmune disease, or for removing unwanted pathogens. These diseases  
 CC include breast or ovarian cancer, toxoplasma gondii, fungal infection or  
 CC systemic lupus. The present sequence is human Fcgamma RI antibody (H22)  
 CC hinge region fragment  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
 |||  
 Db 5 SSL 7

# RESULT 69

AAW11502

ID AAW11502 standard; peptide; 11 AA.

XX

AC AAW11502;

XX

DT 24-SEP-1997 (first entry)

XX

DE Humanised anti-Fc gamma RI monoclonal antibody modified H-chain hinge.

XX

KW Humanised antibody; anti-Fc receptor; H22; bifunctional; bispecific;  
 KW fusion protein; chimera; breast cancer; ovarian cancer; HER2/neu;  
 KW small cell lung carcinoma; HIV; human immunodeficiency virus;  
 KW Toxoplasma gondii; candidiasis; autoimmune disease; vaccine;  
 KW immune thrombocytopenia purpura; systemic lupus erythematosus;  
 KW heavy chain.

XX

OS Homo sapiens.

OS Mus musculus.

OS Synthetic.

OS Chimeric.

XX

FH Key Location/Qualifiers

FT Region 5. .11  
FT /note= "New C-terminus; encoded by inserted sequence  
FT which introduces XhoI and NotI restriction sites upstream  
FT of a stop codon and a BamHI site downstream of the stop  
FT codon"

XX

PN WO9640789-A1.

XX

PD 19-DEC-1996.

XX

PF 07-JUN-1996; 96WO-US009988.

XX

PR 07-JUN-1995; 95US-00484172.

XX

PA (MEDA-) MEDAREX INC.

XX

PI Deo YM, Goldstein J, Graziano R, Somasundaram C;

XX

DR WPI; 1997-052242/05.

DR N-PSDB; AAT58126.

XX

PT Recombinant, multi-specific anti-Fc receptor antibody molecules - also  
PT comprise an anti-target portion, used for the treatment of cancer,  
PT autoimmune disease and pathogenic infection.

XX

PS Example 2; Fig 1C; 115pp; English.

XX

CC New multispecific polypeptides comprise one portion that specifically  
CC binds to Fc-gamma receptor 1 (Fc gamma RI), one portion that binds  
CC specifically to one epitope of a target antigen and one portion that  
CC binds specifically to a different site on the same target cell. The  
CC multispecific molecules can be used to treat a number of diseases and  
CC conditions dependent upon the identity of their anti-target portion. In  
CC particular, they can be targetted against cancers (e.g. breast cancer,  
CC ovarian cancer expressing HER2/neu, small cell carcinoma of the lung),  
CC pathogenic infection (e.g. viral (HIV), protozoan (Toxoplasma gondii),  
CC fungal (candidiasis)), and autoimmune disease (e.g. immune  
CC thrombocytopenia purpura and systemic lupus erythematosus). They are also  
CC useful for removing unwanted pathogens and in vaccines. In specific  
CC examples, a humanised version of a mouse anti-Fc gamma RI monoclonal  
CC antibody, designated H22, was used as part of a multispecific fusion  
CC construct. To produce suitable fusion genes, the heavy chain of H22 had  
CC to be modified; the CH2 and CH3 domains were removed and replaced by  
CC ~~ligand coding sequences. PCR was used to engineer the sequence coding for~~  
CC the new C-terminus of the heavy chain fragment having the present  
CC sequence

XX

SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;

Best Local Similarity 100.0%; Pred. No. 1.3e+04;

Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10

|||

Db 5 SSL 7

RESULT 70

AAW44188

ID AAW44188 standard; peptide; 11 AA.

XX

AC AAW44188;

XX

DT 12-MAY-1998 (first entry)

XX

DE H-2Kd-restricted cytotoxic T cell epitope HA2.

XX

KW H-2Kd-restricted cytotoxic T cell; CTL; epitope; nuclear protein;

KW influenza haemagglutinin; protection; influenza virus; immunisation.

XX

OS Synthetic.

OS Influenza virus.

XX

PN WO9741891-A1.

XX

PD 13-NOV-1997.

XX

PF 02-MAY-1997; 97WO-CA000296.

XX

PR 03-MAY-1996; 96CA-02175719.

XX

PA (CONN-) CONNAUGHT LAB LTD.

XX

PI Burt D, Sambhara S, Underdown B, Morein B, Klein MH;

XX

DR WPI; 1997-558696/51.

XX

PT Protecting against disease caused by influenza virus infection - by  
PT immunising with solubilised influenza virus comprising haemagglutinin and  
PT an immunostimulating complex also gives cross-protection.

XX

PS Example 4; Page 13; 39pp; English.

XX

CC A new method has been developed of protecting a host against disease  
CC caused by infection with an influenza virus. The method comprises  
CC administering a complex of solubilized influenza virus comprising  
CC haemagglutinin (HA) (or fragment(s)) and an immunostimulating complex  
CC (ISCOM) (flu-ISCOMs) to produce cytotoxic T cells specific for influenza  
CC virus HA of H1 HA and H2 HA subtypes. A second method has been developed  
CC which comprises administering substantially purified HA (or fragment(s))  
CC retaining the immunological properties of HA incorporated into ISCOMs.  
CC The present sequence represents a peptide used in an example of the  
CC present invention. N.B. ISCOMs are known adjuvanted particulate vaccine  
CC systems comprising cholesterol, phospholipid, antigen and Quil A (a  
CC purified mixture of saponins from Quillaja saponaria). The methods can be  
CC used to manufacture medicines (including vaccines) to stimulate cytotoxic  
CC T cells specific for HA of both H1 HA and H2 HA subtypes of influenza  
CC virus in a host, so protecting the host against disease caused by these  
CC subtypes

XX

SQ Sequence 11 AA;

Query Match

27.3%; Score 3; DB 2; Length 11;

Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
|||  
Db 7 SSL 9

RESULT 71

AAW11511

ID AAW11511 standard; peptide; 11 AA.

XX

AC AAW11511;

XX

DT 24-SEP-1997 (first entry)

XX

DE Humanised anti-Fc gamma RI monoclonal antibody modified H-chain hinge.

XX

KW Humanised antibody; anti-Fc receptor; H22; bifunctional; bispecific;

KW fusion protein; chimera; immunoglobulin E; IgE; allergen; allergy;

KW Fc epsilon; heavy chain.

XX

OS Homo sapiens.

OS Mus musculus.

OS Synthetic.

OS Chimeric.

XX

FH Key Location/Qualifiers

FT Region 5. .11

FT /note= "New C-terminus; encoded by inserted sequence

FT which introduces XhoI and NotI restriction sites upstream

FT of a stop codon and a BamHI site downstream of the stop

FT codon"

XX

PN W09640788-A1.

XX

PD 19-DEC-1996.

XX

PF 05-JUN-1996; 96WO-US009071.

XX

PR 07-JUN-1995; 95US-00479902.

XX

PA (MEDA-) MEDAREX INC.

XX

PI Guyre PM, Fanger M;

XX

DR WPI; 1997-052241/05.

DR N-PSDB; AAT58133.

XX

PT New bi-specific mol. with anti-effector cell and anti-IgE portions -

PT useful for preventing allergic reactions by reducing IgE antibody prodn.

PT and increasing IgG prodn.

XX

PS Example 1; Fig 1C; 18pp; English.

XX

CC New bispecific polypeptides comprise an anti-effector cell portion and an

CC anti-immunoglobulin E portion. In a specific example, a bispecific

CC protein was constructed by fusing a humanised version of a mouse anti-Fc  
CC gamma RI monoclonal antibody, designated H22, and an IgE receptor. The  
CC resulting polypeptide was able to bind to circulating IgE or to allergen  
CC bound to IgE. To produce a suitable fusion gene, the heavy chain of H22  
CC had to be modified; the CH2 and CH3 domains were removed and replaced by  
CC ligand coding sequences. PCR was used to engineer the sequence coding for  
CC the new C-terminus of the heavy chain fragment having the present  
CC sequence  
XX  
SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
|||  
Db 5 SSL 7

RESULT 72

AAW30194

ID AAW30194 standard; peptide; 11 AA.

XX

AC AAW30194;

XX

DT 15-APR-1998 (first entry)

XX

DE Salvage receptor binding epitope.

XX

KW Salvage receptor binding epitope; antibody; ErbB3 protein; heregulin;  
KW HRG; ErbB2-ErbB3 complex; inhibitor; tumour detection; therapy; lymphoma;  
KW leukaemia; blastoma; carcinoma; sarcoma; inflammatory disorder;  
KW angiogenic disease; immunological disease.

XX

OS Mammalia.

XX

PN WO9735885-A1.

XX

PD 02-OCT-1997.

XX

PF 07-MAR-1997; 97WO-US003546.

XX

PR 27-MAR-1996; 96US-00624036.

XX

PA (GETH ) GENENTECH INC.

XX

PI Akita R, Sliwkowski M;

XX

DR WPI; 1997-489570/45.

XX

PT Antibody that binds to the ErbB3 receptor - used for diagnosis and  
PT treatment of tumours, inflammation, angiogenesis and immunological  
PT disease.

XX

PS Disclosure; Page 19; 44pp; English.

XX

CC This sequence represents a salvage receptor binding epitope that can be  
 CC used in the antibody (AB) of the invention. The Ab of the invention is an  
 CC Ab that binds to ErbB3 protein and reduces heregulin (HRG)-induced  
 CC formation of an ErbB2-ErbB3 complex in cells producing both these  
 CC proteins. The Ab are used for in vivo and in vitro detection of ErbB3 in  
 CC binding assays, particularly for detection of tumours characterised by  
 CC elevated ErbB3 expression. The Ab are also used for treatment and  
 CC prevention of diseases associated with excessive activation of the ErbB2-  
 CC ErbB3 complex, particularly benign or malignant tumours (e.g. leukaemia,  
 CC lymphoma, blastoma, carcinoma or sarcoma), but also inflammation,  
 CC angiogenic and immunological diseases. Also, the Ab can be used as  
 CC affinity purification reagents

XX

SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 NSS 9

|||

Db 3 NSS 5

# RESULT 73

AAW15672

ID AAW15672 standard; peptide; 11 AA.

XX

AC AAW15672;

XX

DT 25-MAR-2003 (revised)

DT 11-JUN-1997 (first entry)

XX

DE Platelet aggregation inhibitor #97.

XX

KW Platelet aggregation inhibitor; RGD analogue; cyclic peptide; fibrinogen;

KW hydrophobically enhanced analogue; blood platelet; endothelial surface;

KW blood vessel; serum protein; GP IIb/IIIa glycoprotein complex; integrin;

KW plasma membrane; thrombosis; cell adhesion receptor; fibronectin;

KW vitronectin receptor; vascular graft occlusion; therapy.

XX

OS Synthetic.

XX

| Key              | Location/Qualifiers                                  |
|------------------|--|
| FT Modified-site | 1: .10   |
| FT               | /note= "forms peptide bond to create cyclic peptide" |
| PN               | US5612311-A.   |
| PD               | 18-MAR-1997.   |
| PF               | 22-DEC-1994; 94US-00363963.                          |
| PR               | 06-APR-1990; 90US-00506444.                          |
| PR               | 05-APR-1991; 91US-00681119.                          |
| PR               | 14-APR-1993; 93US-00050736.                          |
| PR               | 02-MAR-1994; 94US-00204817.                          |



XX  
PA (LJOL-) LA JOLLA CANCER RES FOUND.  
XX  
PI Craig WS, Lukeman DS, Cheng S, Tschopp JF, Pierschbacher MD;  
XX  
DR WPI; 1997-192139/17.  
XX  
PT RGD-contg. peptide(s) that inhibit platelet aggregation - useful for  
PT treating thrombosis.  
XX  
PS Example 5; Col 77; 50pp; English.  
XX  
CC AAW15576-W15695 represent platelet aggregation inhibitors. All of these  
CC sequences are hydrophobically enhanced RGD peptide analogues. The  
CC interaction of blood platelets with the endothelial surface of injured  
CC blood vessels and with other platelets (platelet aggregation) is a major  
CC factor in the course of development of thrombi. Thrombosis is a serious  
CC condition which can cause tissue damage and eventually death (if  
CC untreated). Platelet aggregation is dependent upon the binding of  
CC fibrinogen and other serum proteins to the GP IIb/IIIa glycoprotein  
CC complex on the platelet plasma membrane. GP IIb/IIIa is a member of the  
CC integrin family of cell adhesion receptors, which are known to recognise  
CC a RGD tripeptide recognition sequence. The peptides inhibit platelet  
CC aggregation without prolonging bleeding time. These sequences have high  
CC affinity for the IIb/IIIa receptor and low affinity for the fibronectin  
CC and vitronectin receptors. The peptides are used as platelet aggregation  
CC inhibitors for treating thrombosis and vascular graft occlusion. (Updated  
CC on 25-MAR-2003 to correct PF field.)  
XX  
SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 RKG 6  
| | |  
Db 1 RKG 3

#### RESULT 74

AAW25009

ID AAW25009 standard; peptide; 11 AA.

XX

AC AAW25009;

XX

DT 25-MAR-2003 (revised)

DT 07-OCT-1997 (first entry)

XX

DE Oncoimmunin lymphoid factor peptide used for antibody production.

XX

KW Oncoimmunin myeloid factor; lymphoid factor; OI-M; OI-L; antibody;  
KW tumour; cancer diagnosis; neoplasia; monoclonal; prognosis; melanoma.

XX

OS Homo sapiens.

XX

PN US5635356-A.

XX  
 PD 03-JUN-1997.  
 XX  
 PF 22-MAR-1994; 94US-00218023.  
 XX  
 PR 31-MAY-1991; 91US-00707136.  
 PR 23-SEP-1991; 91US-00764695.  
 XX  
 PA (USSH ) US DEPT HEALTH & HUMAN SERVICES.  
 XX  
 PI Komoriya A, Packard B;  
 XX  
 DR WPI; 1997-309823/28.  
 XX  
 PT Antibody to onco:immunin-myeloid factor - for detection of onco:immunin-  
 PT myeloid factor especially in tumour cell.  
 XX  
 PS Example 15; Col 43-44; 49pp; English.  
 XX  
 CC AAW25003-W25009 are peptides derived from an oncoimmunin-lymphoid (OI-L)  
 CC factor derived from a melanoma cell line. The peptides were used for  
 CC immunisation to produce monoclonal antibodies specific for the OI-L  
 CC factor. Antibodies specific for an oncoimmunin-myeloid (OI-M) factor were  
 CC also produced. Antibodies specific for OI-M or OI-L factors are used for  
 CC detecting the factors in a sample, to screen tumour cells for production  
 CC of the factors and hence identify cells as being of tumour origin. The  
 CC antibodies are also useful to determine serum OI-M and OI-L levels for  
 CC tumour diagnosis or for prognosis evaluation after tumour therapy.  
 CC (Updated on 25-MAR-2003 to correct PF field.)  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 NSS 9  
 |||  
 Db 8 NSS 10

# RESULT 75

AAW28862

ID AAW28862-standard; peptide; 11-AA.

XX

AC AAW28862;

XX

DT 27-AUG-2003 (revised)

DT 25-MAR-2003 (revised)

DT 21-NOV-1997 (first entry)

XX

DE HTLV-1a,c derived peptide 50, recognised by HLA-B35.

XX

KW Human adult leukaemia; vaccine; prevention; therapy; epitope;

KW human leukocyte antigen; HLA-B35; cytotoxic T lymphocyte; diagnosis.

XX

OS Human T-lymphotropic virus type 1.

OS Human adult leukaemia virus 1c.  
 XX  
 PN JP09188696-A.  
 XX  
 PD 22-JUL-1997.  
 XX  
 PF 29-OCT-1993; 96JP-00220326.  
 XX  
 PR 29-OCT-1993; 93JP-00294472.  
 XX  
 PA (NOKI/) NOKIHARA K.  
 PA (TAKI/) TAKIGUCHI M.  
 XX  
 DR WPI; 1997-420580/39.  
 XX  
 PT Synthetic peptide derived from human T cell leukaemia virus - is able to  
 PT bind to HLA-B35 and is useful in a vaccine for prevention or treatment of  
 PT human adult leukaemia.  
 XX  
 PS Claim 10; Page 2; 14pp; Japanese.  
 XX  
 CC The present sequence corresponds to amino acids 97-107 of pol from human  
 CC adult leukaemia virus HTLV-1a,c. The synthetic peptide having this  
 CC sequence is shown in cytotoxic T cells by combining with HLA-B35 antigen.  
 CC The peptide can be used in a preventive vaccine and a therapeutic agent  
 CC for human adult leukaemia caused by human T cell leukaemia virus.  
 CC (Updated on 25-MAR-2003 to correct PF field.) (Updated on 27-AUG-2003 to  
 CC correct OS field.)  
 XX  
 SQ Sequence 11 AA;

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.3e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
 |||  
 Db 5 SSL 7

Search completed: April 8, 2004, 15:40:12  
 Job time : 45.3077 secs

---

OM protein - protein search, using sw model

Run on: April 8, 2004, 15:30:08 ; Search time 11.3077 Seconds  
 (without alignments)  
 50.221 Million cell updates/sec

Title: US-09-787-443A-21  
 Perfect score: 11  
 Sequence: 1 AKSRKGNSSLM 11

Scoring table: OLIGO  
 Gapop 60.0 , Gapext 60.0

Searched: 389414 seqs, 51625971 residues

Word size : 0

Total number of hits satisfying chosen parameters: 8542

Minimum DB seq length: 11  
 Maximum DB seq length: 11

Post-processing: Listing first 100 summaries

Database : Issued\_Patents\_AA:\*  
 1: /cgn2\_6/ptodata/2/iaa/5A\_COMB.pep:\*  
 2: /cgn2\_6/ptodata/2/iaa/5B\_COMB.pep:\*  
 3: /cgn2\_6/ptodata/2/iaa/6A\_COMB.pep:\*  
 4: /cgn2\_6/ptodata/2/iaa/6B\_COMB.pep:\*  
 5: /cgn2\_6/ptodata/2/iaa/PCTUS\_COMB.pep:\*  
 6: /cgn2\_6/ptodata/2/iaa/backfiles1.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

| Result No. | Score | Query |        | DB | ID                 | Description       |
|------------|-------|-------|--------|----|--------------------|-------------------|
|            |       | Match | Length |    |                    |                   |
| 1          | 4     | 36.4  | 11     | 4  | US-09-381-546-48   | Sequence 48, Appl |
| 2          | 3     | 27.3  | 11     | 1  | US-07-696-551B-10  | Sequence 10, Appl |
| 3          | 3     | 27.3  | 11     | 1  | US-08-030-731A-20  | Sequence 20, Appl |
| 4          | 3     | 27.3  | 11     | 1  | US-07-851-941-12   | Sequence 12, Appl |
| 5          | 3     | 27.3  | 11     | 1  | US-08-167-336A-11  | Sequence 11, Appl |
| 6          | 3     | 27.3  | 11     | 1  | US-08-269-441A-14  | Sequence 14, Appl |
| 7          | 3     | 27.3  | 11     | 1  | US-08-185-448-5    | Sequence 5, Appli |
| 8          | 3     | 27.3  | 11     | 1  | US-08-190-788A-280 | Sequence 280, App |
| 9          | 3     | 27.3  | 11     | 1  | US-08-167-035-38   | Sequence 38, Appl |
| 10         | 3     | 27.3  | 11     | 1  | US-08-179-481-44   | Sequence 44, Appl |
| 11         | 3     | 27.3  | 11     | 1  | US-08-218-023-9    | Sequence 9, Appli |

|    |   |      |    |   |                     |                   |
|----|---|------|----|---|---------------------|-------------------|
| 12 | 3 | 27.3 | 11 | 1 | US-08-372-952-8     | Sequence 8, Appli |
| 13 | 3 | 27.3 | 11 | 1 | US-07-958-903A-5    | Sequence 5, Appli |
| 14 | 3 | 27.3 | 11 | 1 | US-07-958-903A-9    | Sequence 9, Appli |
| 15 | 3 | 27.3 | 11 | 1 | US-07-958-903A-10   | Sequence 10, Appl |
| 16 | 3 | 27.3 | 11 | 1 | US-07-958-903A-29   | Sequence 29, Appl |
| 17 | 3 | 27.3 | 11 | 1 | US-07-958-903A-49   | Sequence 49, Appl |
| 18 | 3 | 27.3 | 11 | 1 | US-08-416-962-11    | Sequence 11, Appl |
| 19 | 3 | 27.3 | 11 | 1 | US-08-445-745-119   | Sequence 119, App |
| 20 | 3 | 27.3 | 11 | 1 | US-08-208-887A-38   | Sequence 38, Appl |
| 21 | 3 | 27.3 | 11 | 1 | US-08-467-420A-9    | Sequence 9, Appli |
| 22 | 3 | 27.3 | 11 | 1 | US-08-470-110A-9    | Sequence 9, Appli |
| 23 | 3 | 27.3 | 11 | 1 | US-08-462-018-5     | Sequence 5, Appli |
| 24 | 3 | 27.3 | 11 | 1 | US-08-462-018-9     | Sequence 9, Appli |
| 25 | 3 | 27.3 | 11 | 1 | US-08-462-018-10    | Sequence 10, Appl |
| 26 | 3 | 27.3 | 11 | 1 | US-08-462-018-29    | Sequence 29, Appl |
| 27 | 3 | 27.3 | 11 | 1 | US-08-462-018-49    | Sequence 49, Appl |
| 28 | 3 | 27.3 | 11 | 1 | US-08-596-864-9     | Sequence 9, Appli |
| 29 | 3 | 27.3 | 11 | 1 | US-08-422-101-3     | Sequence 3, Appli |
| 30 | 3 | 27.3 | 11 | 1 | US-08-589-011-11    | Sequence 11, Appl |
| 31 | 3 | 27.3 | 11 | 1 | US-08-422-091-3     | Sequence 3, Appli |
| 32 | 3 | 27.3 | 11 | 1 | US-08-040-548-43    | Sequence 43, Appl |
| 33 | 3 | 27.3 | 11 | 1 | US-08-466-344-43    | Sequence 43, Appl |
| 34 | 3 | 27.3 | 11 | 1 | US-08-823-245-5     | Sequence 5, Appli |
| 35 | 3 | 27.3 | 11 | 1 | US-08-823-245-9     | Sequence 9, Appli |
| 36 | 3 | 27.3 | 11 | 1 | US-08-823-245-10    | Sequence 10, Appl |
| 37 | 3 | 27.3 | 11 | 1 | US-08-823-245-29    | Sequence 29, Appl |
| 38 | 3 | 27.3 | 11 | 1 | US-08-823-245-49    | Sequence 49, Appl |
| 39 | 3 | 27.3 | 11 | 1 | US-08-667-769A-9    | Sequence 9, Appli |
| 40 | 3 | 27.3 | 11 | 1 | US-08-465-391A-280  | Sequence 280, App |
| 41 | 3 | 27.3 | 11 | 2 | US-08-452-724A-44   | Sequence 44, Appl |
| 42 | 3 | 27.3 | 11 | 2 | US-08-940-371-9     | Sequence 9, Appli |
| 43 | 3 | 27.3 | 11 | 2 | US-08-948-762-11    | Sequence 11, Appl |
| 44 | 3 | 27.3 | 11 | 2 | US-08-539-005-38    | Sequence 38, Appl |
| 45 | 3 | 27.3 | 11 | 2 | US-08-464-538B-280  | Sequence 280, App |
| 46 | 3 | 27.3 | 11 | 2 | US-08-540-412-120   | Sequence 120, App |
| 47 | 3 | 27.3 | 11 | 2 | US-08-540-412-123   | Sequence 123, App |
| 48 | 3 | 27.3 | 11 | 2 | US-08-540-412-184   | Sequence 184, App |
| 49 | 3 | 27.3 | 11 | 2 | US-08-540-412-191   | Sequence 191, App |
| 50 | 3 | 27.3 | 11 | 2 | US-08-422-092-3     | Sequence 3, Appli |
| 51 | 3 | 27.3 | 11 | 2 | US-08-468-819-14    | Sequence 14, Appl |
| 52 | 3 | 27.3 | 11 | 2 | US-08-559-524A-11   | Sequence 11, Appl |
| 53 | 3 | 27.3 | 11 | 2 | US-08-637-759B-76   | Sequence 76, Appl |
| 54 | 3 | 27.3 | 11 | 2 | US-08-463-076E-370  | Sequence 370, App |
| 55 | 3 | 27.3 | 11 | 2 | US-08-788-800-8     | Sequence 8, Appli |
| 56 | 3 | 27.3 | 11 | 2 | US-08-982-597A-6    | Sequence 6, Appli |
| 57 | 3 | 27.3 | 11 | 2 | US-08-747-137-63    | Sequence 63, Appl |
| 58 | 3 | 27.3 | 11 | 2 | US-08-989-667-9     | Sequence 9, Appli |
| 59 | 3 | 27.3 | 11 | 2 | US-09-121-527-4     | Sequence 4, Appli |
| 60 | 3 | 27.3 | 11 | 2 | US-08-350-260A-485  | Sequence 485, App |
| 61 | 3 | 27.3 | 11 | 2 | US-08-827-009-1     | Sequence 1, Appli |
| 62 | 3 | 27.3 | 11 | 2 | US-08-343-443B-68   | Sequence 68, Appl |
| 63 | 3 | 27.3 | 11 | 2 | US-08-466-860-3     | Sequence 3, Appli |
| 64 | 3 | 27.3 | 11 | 2 | US-08-466-860-6     | Sequence 6, Appli |
| 65 | 3 | 27.3 | 11 | 3 | US-08-871-355A-76   | Sequence 76, Appl |
| 66 | 3 | 27.3 | 11 | 3 | US-08-904-446A-6    | Sequence 6, Appli |
| 67 | 3 | 27.3 | 11 | 3 | US-08-904-446A-7    | Sequence 7, Appli |
| 68 | 3 | 27.3 | 11 | 3 | US-08-159-339A-1131 | Sequence 1131, Ap |

|     |   |      |    |   |                   |                   |
|-----|---|------|----|---|-------------------|-------------------|
| 69  | 3 | 27.3 | 11 | 3 | US-08-974-899-16  | Sequence 16, Appl |
| 70  | 3 | 27.3 | 11 | 3 | US-08-749-707-11  | Sequence 11, Appl |
| 71  | 3 | 27.3 | 11 | 3 | US-09-136-218-6   | Sequence 6, Appli |
| 72  | 3 | 27.3 | 11 | 3 | US-08-472-040A-3  | Sequence 3, Appli |
| 73  | 3 | 27.3 | 11 | 3 | US-08-472-040A-6  | Sequence 6, Appli |
| 74  | 3 | 27.3 | 11 | 3 | US-08-817-177-4   | Sequence 4, Appli |
| 75  | 3 | 27.3 | 11 | 3 | US-08-491-954-93  | Sequence 93, Appl |
| 76  | 3 | 27.3 | 11 | 3 | US-08-422-093-3   | Sequence 3, Appli |
| 77  | 3 | 27.3 | 11 | 3 | US-08-891-845-5   | Sequence 5, Appli |
| 78  | 3 | 27.3 | 11 | 3 | US-08-422-112-3   | Sequence 3, Appli |
| 79  | 3 | 27.3 | 11 | 3 | US-08-637-647-9   | Sequence 9, Appli |
| 80  | 3 | 27.3 | 11 | 3 | US-09-051-342-120 | Sequence 120, App |
| 81  | 3 | 27.3 | 11 | 3 | US-09-051-342-123 | Sequence 123, App |
| 82  | 3 | 27.3 | 11 | 3 | US-09-051-342-184 | Sequence 184, App |
| 83  | 3 | 27.3 | 11 | 3 | US-09-051-342-191 | Sequence 191, App |
| 84  | 3 | 27.3 | 11 | 3 | US-08-855-958-4   | Sequence 4, Appli |
| 85  | 3 | 27.3 | 11 | 3 | US-08-855-958-9   | Sequence 9, Appli |
| 86  | 3 | 27.3 | 11 | 3 | US-08-468-161-120 | Sequence 120, App |
| 87  | 3 | 27.3 | 11 | 3 | US-08-468-161-123 | Sequence 123, App |
| 88  | 3 | 27.3 | 11 | 3 | US-09-097-171A-4  | Sequence 4, Appli |
| 89  | 3 | 27.3 | 11 | 3 | US-09-051-759-120 | Sequence 120, App |
| 90  | 3 | 27.3 | 11 | 3 | US-09-051-759-123 | Sequence 123, App |
| 91  | 3 | 27.3 | 11 | 3 | US-09-051-759-184 | Sequence 184, App |
| 92  | 3 | 27.3 | 11 | 3 | US-09-051-759-191 | Sequence 191, App |
| 93  | 3 | 27.3 | 11 | 3 | US-08-875-309-8   | Sequence 8, Appli |
| 94  | 3 | 27.3 | 11 | 3 | US-08-652-877-51  | Sequence 51, Appl |
| 95  | 3 | 27.3 | 11 | 3 | US-08-276-776-3   | Sequence 3, Appli |
| 96  | 3 | 27.3 | 11 | 3 | US-08-276-776-6   | Sequence 6, Appli |
| 97  | 3 | 27.3 | 11 | 3 | US-08-471-209-3   | Sequence 3, Appli |
| 98  | 3 | 27.3 | 11 | 3 | US-08-471-209-6   | Sequence 6, Appli |
| 99  | 3 | 27.3 | 11 | 3 | US-08-861-423A-11 | Sequence 11, Appl |
| 100 | 3 | 27.3 | 11 | 3 | US-09-177-249-286 | Sequence 286, App |

#### ALIGNMENTS

##### RESULT 1

US-09-381-546-48

; Sequence 48, Application US/09381546

; Patent No. 6451976

; GENERAL INFORMATION:

; APPLICANT: Trigen Limited

; TITLE OF INVENTION: BI- OR MULTIFUNCTIONAL MOLECULES BASED ON A DENDROASPIN

; TITLE OF INVENTION: SCAFFOLD

; FILE REFERENCE: P41007WO

; CURRENT APPLICATION NUMBER: US/09/381,546

; CURRENT FILING DATE: 1999-09-20

; PRIOR APPLICATION NUMBER: PCT/GB98/00848

; PRIOR FILING DATE: 1998-09-20

; PRIOR APPLICATION NUMBER: GB9705787.1

; PRIOR FILING DATE: 1997-03-20

; NUMBER OF SEQ ID NOS: 48

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 48

; LENGTH: 11

; TYPE: PRT

; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: amino acids  
; OTHER INFORMATION: encoded by bases 921-956 of pGEX-3X  
US-09-381-546-48

Query Match 36.4%; Score 4; DB 4; Length 11;  
Best Local Similarity 100.0%; Pred. No. 2.4e+02;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 GNSS 9  
| | | |  
Db 8 GNSS 11

RESULT 2

US-07-696-551B-10  
; Sequence 10, Application US/07696551B  
; Patent No. 5232841  
; GENERAL INFORMATION:  
; APPLICANT: Hashimoto, Tamotsu  
; APPLICANT: Tsujimura, Atsushi  
; APPLICANT: Udaka, Shigezo  
; TITLE OF INVENTION: Process for Preparing Peptide  
; NUMBER OF SEQUENCES: 12  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &  
; ADDRESSEE: Dunner  
; STREET: 1300 I Street, N.W., Suite 700  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20005-3315  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: MS-DOS/PC-DOS  
; SOFTWARE: Patentin Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/07/696,551B  
; FILING DATE: 19910509  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: JP 2-122166  
; FILING DATE: 11-MAY-1990  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: JP 2-334575  
; FILING DATE: 30-NOV-1990  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Lawrence M. Lavin, Jr.  
; REGISTRATION NUMBER: 30,768  
; REFERENCE/DOCKET NUMBER: 2481-1070  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (202) 408-4000  
; TELEFAX: (202) 408-4400  
; INFORMATION FOR SEQ ID NO: 10:  
; SEQUENCE CHARACTERISTICS:

; LENGTH: 11 amino acids  
; TYPE: AMINO ACID  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-07-696-551B-10

Query Match 27.3%; Score 3; DB 1; Length 11;  
Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 GNS 8  
| | |  
Db 7 GNS 9

RESULT 3

US-08-030-731A-20

; Sequence 20, Application US/08030731A  
; Patent No. 5426036  
; GENERAL INFORMATION:  
; APPLICANT: Koller, Klaus-Peter  
; APPLICANT: Riess, Guenther Johannes  
; APPLICANT: Uhlmann, Eugen  
; APPLICANT: Wallmeier, Holger  
; TITLE OF INVENTION: Processes for the Preparation of Foreign  
; TITLE OF INVENTION: Proteins in Streptomyces  
; NUMBER OF SEQUENCES: 48  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &  
; ADDRESSEE: Dunner  
; STREET: 1300 I Street, N.W., Suite 700  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20005-3315  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/030,731A  
; FILING DATE: 12-MAR-1993  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/189,840  
; FILING DATE: 03-MAY-1988  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/430,622  
; FILING DATE: 01-NOV-1989  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/687,610  
; FILING DATE: 19-APR-1991  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/735,757  
; FILING DATE: 29-JUL-1991



```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: DE P 37 14 866.4
; FILING DATE: 05-MAY-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: DE P 38 37 273.8
; FILING DATE: 03-NOV-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: DE P 39 27 449.7
; FILING DATE: 19-AUG-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: DE P 40 12 818.0
; FILING DATE: 21-APR-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Kirschner Michael K.
; REGISTRATION NUMBER: 34,851
; REFERENCE/DOCKET NUMBER: 02481-0593-02000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-408-4000
; TELEFAX: 202-408-4400
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; TOPOLOGY: unknown
; MOLECULE TYPE: peptide
US-08-030-731A-20

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      6 GNS 8
      |||
Db      7 GNS 9

```

#### RESULT 4

US-07-851-941-12

```

; Sequence 12, Application US/07851941
; Patent No. 5428016
; GENERAL INFORMATION:
; APPLICANT: Mamoru TOMITA et al.
; TITLE OF INVENTION: Antimicrobial Peptide and an
; TITLE OF INVENTION: Antimicrobial Agent
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Wenderoth, Lind & Ponack
; STREET: 805 Fifteenth Street, N.W., #700
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 5.25 inch, 500 kb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: DisplayWrite

```

; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/07/851,941  
; FILING DATE: 19920313  
; CLASSIFICATION: 530  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 07/851,941  
; FILING DATE: March 13, 1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warren M. Cheek, Jr.  
; REGISTRATION NUMBER: 33,367  
; REFERENCE/DOCKET NUMBER:  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202-371-8850  
; TELEFAX:  
; TELEX:  
; INFORMATION FOR SEQ ID NO: 12:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 11 amino acid residues  
; TYPE: AMINO ACID  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; HYPOTHETICAL:  
; ANTI-SENSE:  
; FRAGMENT TYPE:  
; ORIGINAL SOURCE:  
; ORGANISM:  
; STRAIN:  
; INDIVIDUAL ISOLATE:  
; DEVELOPMENTAL STAGE:  
; HAPLOTYPE:  
; TISSUE TYPE:  
; CELL TYPE:  
; CELL LINE:  
; ORGANELLE:  
; IMMEDIATE SOURCE:  
; LIBRARY:  
; CLONE:  
; POSITION IN GENOME:  
; CHROMOSOME/SEGMENT:  
; MAP POSITION:  
; UNITS:  
; FEATURE:  
; NAME/KEY:  
; LOCATION:  
; IDENTIFICATION METHOD:  
; OTHER INFORMATION:  
; PUBLICATION INFORMATION:  
; AUTHORS:  
; TITLE:  
; JOURNAL:  
; VOLUME:  
; ISSUE:  
; PAGES:  
; DATE:  
; DOCUMENT NUMBER:  
; FILING DATE:

; PUBLICATION DATE:  
; RELEVANT RESIDUES IN SEQ ID NO:  
US-07-851-941-12

Query Match 27.3%; Score 3; DB 1; Length 11;  
Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 KSR 4  
|||  
Db 1 KSR 3

RESULT 5

US-08-167-336A-11

; Sequence 11, Application US/08167336A  
; Patent No. 5531990  
; GENERAL INFORMATION:  
; APPLICANT: THANAVALA, YASMIN  
; APPLICANT: THAKUR, ARVIND  
; APPLICANT: ROITT, IVAN  
; APPLICANT: PRIDE, MICHAEL  
; TITLE OF INVENTION: ANTI-IDIOTYPIC ANTIBODY  
; TITLE OF INVENTION: HAVING CORRESPONDENCE WITH HUMAN HEPATITIS  
; TITLE OF INVENTION: B SURFACE ANTIGEN  
; NUMBER OF SEQUENCES: 12  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: DUNN & ASSOCIATES, P.C.  
; STREET: P.O. BOX 96  
; CITY: NEWFANE  
; STATE: NEW YORK  
; COUNTRY: USA  
; ZIP: 14108  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB  
; COMPUTER: VICTOR 300 SX/25  
; OPERATING SYSTEM: MS-DOS VERSION 5.0  
; SOFTWARE: WORDSTAR PROFESSIONAL RELEASE 4  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/167,336A  
; FILING DATE: 15-DEC-1993  
; CLASSIFICATION: 530  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER:  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DUNN, MICHAEL L.  
; REGISTRATION NUMBER: 25,330  
; REFERENCE/DOCKET NUMBER: RPP:138 US  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (716) 433-1661  
; TELEFAX: (716) 433-1665  
; INFORMATION FOR SEQ ID NO: 11:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 11  
; TYPE: AMINO ACID  
; STRANDEDNESS: UNKNOWN

```

;      TOPOLOGY:  UNKNOWN
;      MOLECULE TYPE:  PEPTIDE
;      HYPOTHETICAL:
;      ANTI-SENSE:
;      FRAGMENT TYPE:
;      ORIGINAL SOURCE:
;      ORGANISM:
;      STRAIN:
;      INDIVIDUAL ISOLATE:
;      DEVELOPMENTAL STAGE:
;      HAPLOTYPE:
;      TISSUE TYPE:
;      CELL TYPE:
;      CELL LINE:
;      ORGANELLE:
;      IMMEDIATE SOURCE:
;      LIBRARY:
;      CLONE:
;      POSITION IN GENOME:
;      CHROMOSOME/SEGMENT:
;      MAP POSITION:
;      UNITS:
;      FEATURE:
;      NAME/KEY:
;      LOCATION:
;      IDENTIFICATION METHOD:
;      OTHER INFORMATION:
;      PUBLICATION INFORMATION:
;      AUTHORS:
;      TITLE:
;      JOURNAL:
;      VOLUME:
;      ISSUE:
;      PAGES:
;      DATE:
;      DOCUMENT NUMBER:
;      FILING DATE:
;      PUBLICATION DATE:
;      RELEVANT RESIDUES IN SEQ ID NO:
US-08-167-336A-11

```

```

Query Match          27.3%;  Score 3;  DB 1;  Length 11;
Best Local Similarity 100.0%;  Pred. No. 2.7e+03;
Matches      3;  Conservative      0;  Mismatches      0;  Indels      0;  Gaps      0;

```

```

Qy          6 GNS 8
            |||
Db          7 GNS 9

```

# RESULT 6

US-08-269-441A-14

; Sequence 14, Application US/08269441A

; Patent No. 5552529

; GENERAL INFORMATION:

; APPLICANT: Rearden, Ann

; TITLE OF INVENTION: A NOVEL AUTOANTIGEN, PINCH

; NUMBER OF SEQUENCES: 17  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Fish & Richardson P.C.  
 ; STREET: 4225 Executive Square, Suite 1400  
 ; CITY: Los Angeles  
 ; STATE: California  
 ; COUNTRY: USA  
 ; ZIP: 92037  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: PatentIn Release #1.0, Version #1.25  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/269,441A  
 ; FILING DATE: 30-JUN-1994  
 ; CLASSIFICATION: 435  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Haile Ph.D., Lisa A.  
 ; REGISTRATION NUMBER: 38,347  
 ; REFERENCE/DOCKET NUMBER: 07257/009001  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: (619) 678-5070  
 ; TELEFAX: (619) 678-5099  
 ; INFORMATION FOR SEQ ID NO: 14:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 11 amino acids  
 ; TYPE: amino acid  
 ; STRANDEDNESS: single  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: peptide  
 ; FEATURE:  
 ; NAME/KEY: Peptide  
 ; LOCATION: 1..11  
 US-08-269-441A-14

Query Match 27.3%; Score 3; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 NSS 9  
 |||  
 Db 3 NSS 5

# RESULT 7

US-08-185-448-5

; Sequence 5, Application US/08185448

; Patent No. 5580747

; GENERAL INFORMATION:

; APPLICANT: SHULTZ, JOHN W.

; APPLICANT: WHITE, DOUGLAS H.

; TITLE OF INVENTION: NON-RADIOACTIVE KINASE,

; TITLE OF INVENTION: PHOSPHATASE AND PROTEASE ASSAY

; NUMBER OF SEQUENCES: 11

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: ANDRUS, SCEALES, STARKE & SAWALL

```

; STREET: 100 E. WISCONSIN AVENUE, SUITE 1100
; CITY: MILWAUKEE
; STATE: WISCONSIN
; COUNTRY: USA
; ZIP: 53202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version
; SOFTWARE: #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/185,448
; FILING DATE: 21-JAN-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/791,928
; FILING DATE: 12-NOV-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: SARA, CHARLES S
; REGISTRATION NUMBER: 30492
; REFERENCE/DOCKET NUMBER: F.3347-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (608) 255-2022
; TELEFAX: (608) 255-2182
; TELEX: 26832 ANDSTARK
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; FEATURE:
; NAME/KEY: Binding-site
; LOCATION: 1
; OTHER INFORMATION: /label= LABEL
; OTHER INFORMATION: /note= "LOCATION OF LISSAMINE RHODAMINE
; OTHER INFORMATION: DETECTION TAG"
US-08-185-448-5

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches      3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      2 KSR 4
      |||
Db      6 KSR 8

```

# RESULT 8

US-08-190-788A-280

; Sequence 280, Application US/08190788A

; Patent No. 5608035

## ; GENERAL INFORMATION:

; APPLICANT: Yanofsky, Stephen D.

; APPLICANT: Barrett, Ronald W.

; APPLICANT: Baldwin, David N.

```

; APPLICANT: Jacobs, Jeff W.
; TITLE OF INVENTION: Peptides and Compounds That Bind to the
; TITLE OF INVENTION: IL-1 Receptor
; NUMBER OF SEQUENCES: 312
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Affymax Technologies N.V.
; STREET: 4001 Miranda Avenue
; CITY: Palo Alto
; STATE: California
; COUNTRY: USA
; ZIP: 94304
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/190,788A
; FILING DATE: 02-FEB-1994
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/847,567
; FILING DATE: 05-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Stevens, Lauren L.
; REGISTRATION NUMBER: 36,691
; REFERENCE/DOCKET NUMBER: 1019.1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-496-2300
; TELEFAX: 415-424-0832
; INFORMATION FOR SEQ ID NO: 280:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-190-788A-280

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches      3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      7 NSS 9
      |||
Db      2 NSS 4

```

# RESULT 9

US-08-167-035-38

; Sequence 38, Application US/08167035

; Patent No. 5618691

; GENERAL INFORMATION:

; APPLICANT: Schlessinger, Joseph

; APPLICANT: Skolnick, Edward Y.

; APPLICANT: Margolis, Benjamin L.

; TITLE OF INVENTION: NOVEL EXPRESSION CLONING METHOD FOR

```

; TITLE OF INVENTION:  IDENTIFYING TARGET PROTEINS FOR EUKARYOTIC TYROSINE
; TITLE OF INVENTION:  KINASES AND NOVEL TARGET PROTEINS
; NUMBER OF SEQUENCES:  50
; CORRESPONDENCE ADDRESS:
;   ADDRESSEE:  PENNIE & EDMONDS
;   STREET:  1155 Avenue of the Americas
;   CITY:  New York
;   STATE:  New York
;   COUNTRY:  10036-2711
;   ZIP:  10036-2711
; COMPUTER READABLE FORM:
;   MEDIUM TYPE:  Floppy disk
;   COMPUTER:  IBM PC compatible
;   OPERATING SYSTEM:  PC-DOS/MS-DOS
;   SOFTWARE:  PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
;   APPLICATION NUMBER:  US/08/167,035
;   FILING DATE:  16-DEC-1993
;   CLASSIFICATION:  435
; ATTORNEY/AGENT INFORMATION:
;   NAME:  Coruzzi, Laura A.
;   REGISTRATION NUMBER:  30,742
;   REFERENCE/DOCKET NUMBER:  7683-062
; TELECOMMUNICATION INFORMATION:
;   TELEPHONE:  (212) 790-9090
;   TELEFAX:  (212) 869-9741/8864
;   TELEX:  66141 PENNIE
; INFORMATION FOR SEQ ID NO:  38:
;   SEQUENCE CHARACTERISTICS:
;     LENGTH:  11 amino acids
;     TYPE:  amino acid
;     TOPOLOGY:  unknown
;   MOLECULE TYPE:  peptide
US-08-167-035-38

```

```

Query Match          27.3%;  Score 3;  DB 1;  Length 11;
Best Local Similarity 100.0%;  Pred. No. 2.7e+03;
Matches      3;  Conservative      0;  Mismatches      0;  Indels      0;  Gaps      0;

```

```

Qy          7 NSS 9
            |||
Db          3 NSS 5

```

# RESULT 10

```

US-08-179-481-44
; Sequence 44, Application US/08179481
; Patent No. 5624816
; GENERAL INFORMATION:
;   APPLICANT:  CARRAWAY, KERMIT L.
;   APPLICANT:  CAROTHERS CARRAWAY, CORALIE A.
;   APPLICANT:  FREGIEN, NEVIS L.
;   TITLE OF INVENTION:  ONCOGENE PRODUCT LIGAND
;   NUMBER OF SEQUENCES:  125
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE:  CUSHMAN, DARBY & CUSHMAN
;     STREET:  1100 NEW YORK AVENUE, N.W.

```



```

; CITY: WASHINGTON
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20005-3918
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/179,481
; FILING DATE: 28-DEC-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/922,521
; FILING DATE: 30-JUL-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: KOKULIS, PAUL N.
; REGISTRATION NUMBER: 16,773
; REFERENCE/DOCKET NUMBER: 200702/UM92-08CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 861-3000
; TELEFAX: (202) 822-0944
; TELEX: 6714627 CUSH
; INFORMATION FOR SEQ ID NO: 44:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-179-481-44

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      8 SSL 10
      |||
Db      2 SSL 4

```

```

RESULT 11
US-08-218-023-9
; Sequence 9, Application US/08218023
; Patent No. 5635356
; GENERAL INFORMATION:
; APPLICANT: Packard, Beverly
; APPLICANT: Komoriya, Akira
; TITLE OF INVENTION: ONCOIMMUNINS
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend Khourie and Crew
; STREET: Steuart Street Tower, One Market Plaza
; CITY: San Francisco
; STATE: California
; COUNTRY: US

```

```

; ZIP: 94105-1493
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/218,023
; FILING DATE:
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Dow, Karen B.
; REGISTRATION NUMBER: 29,684
; REFERENCE/DOCKET NUMBER: 15280-132-1,E12691/2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 543-9600
; TELEFAX: (415) 543-5043
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; TOPOLOGY: unknown
; MOLECULE TYPE: peptide
US-08-218-023-9

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      7 NSS 9
        |||
Db      8 NSS 10

```

# RESULT 12

US-08-372-952-8

```

; Sequence 8, Application US/08372952
; Patent No. 5645837
; GENERAL INFORMATION:
; APPLICANT: Jameson, Bradford A.
; APPLICANT: Choksi, Swati
; APPLICANT: Korngold, Robert
; TITLE OF INVENTION: CD8 Antagonists
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz &
; ADDRESSEE: No. 5645837ris
; STREET: One Liberty Place, 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Wordperfect

```

```

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/372,952
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: DeLuca, Mark
; REGISTRATION NUMBER: 33,229
; REFERENCE/DOCKET NUMBER: TJU-1440
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-372-952-8

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches      3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      7 NSS 9
        |||
Db      6 NSS 8

```

# RESULT 13

US-07-958-903A-5

```

; Sequence 5, Application US/07958903A
; Patent No. 5652214
; GENERAL INFORMATION:
; APPLICANT: Lewis, Michael E.
; APPLICANT: Kauer, James C.
; APPLICANT: Smith, Kevin R.
; APPLICANT: Callison, Kathleen V.
; APPLICANT: Baldino, Frank
; APPLICANT: Neff, Nicola
; APPLICANT: Iqbal, Mohamed
; TITLE OF INVENTION: TREATING DISORDERS BY APPLICATION
; TITLE OF INVENTION: OF INSULIN-LIKE GROWTH FACTORS AND
; TITLE OF INVENTION: ANALOGS
; NUMBER OF SEQUENCES: 56
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

```

```

;   COMPUTER:  IBM PS/2 Model 50Z or 55SX
;   OPERATING SYSTEM:  MS-DOS (Version 5.0)
;   SOFTWARE:  WordPerfect (Version 5.1)
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER:  US/07/958,903A
;     FILING DATE:  October 7, 1992
;     CLASSIFICATION:  514
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER:  07/361,595
;     FILING DATE:  June 5, 1989
;     APPLICATION NUMBER:  07/534,139
;     FILING DATE:  June 5, 1990
;     APPLICATION NUMBER:  07/869,913
;     FILING DATE:  April 15, 1992
;   ATTORNEY/AGENT INFORMATION:
;     NAME:  Clark, Paul T.
;     REGISTRATION NUMBER:  30,162
;     REFERENCE/DOCKET NUMBER:  02655/003004
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE:  (617) 542-5070
;     TELEFAX:  (617) 542-8906
;     TELEX:  200154
;   INFORMATION FOR SEQ ID NO:  5:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  11
;       TYPE:  amino acid
;       STRANDEDNESS:
;       TOPOLOGY:  linear
US-07-958-903A-5

```

```

Query Match          27.3%;  Score 3;  DB 1;  Length 11;
Best Local Similarity 100.0%;  Pred. No. 2.7e+03;
Matches      3;  Conservative      0;  Mismatches      0;  Indels      0;  Gaps      0;

```

```

Qy      1 AKS 3
      |||
Db      8 AKS 10

```

# RESULT 14

US-07-958-903A-9

```

; Sequence 9, Application US/07958903A
; Patent No. 5652214

```

## GENERAL INFORMATION:

```

;   APPLICANT:  Lewis, Michael E.
;   APPLICANT:  Kauer, James C.
;   APPLICANT:  Smith, Kevin R.
;   APPLICANT:  Callison, Kathleen V.
;   APPLICANT:  Baldino, Frank
;   APPLICANT:  Neff, Nicola
;   APPLICANT:  Iqbal, Mohamed
;   TITLE OF INVENTION:  TREATING DISORDERS BY APPLICATION
;   TITLE OF INVENTION:  OF INSULIN-LIKE GROWTH FACTORS AND
;   TITLE OF INVENTION:  ANALOGS
;   NUMBER OF SEQUENCES:  56
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE:  Fish & Richardson

```

```

; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM PS/2 Model 50Z or 55SX
; OPERATING SYSTEM: MS-DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/958,903A
; FILING DATE: October 7, 1992
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/361,595
; FILING DATE: June 5, 1989
; APPLICATION NUMBER: 07/534,139
; FILING DATE: June 5, 1990
; APPLICATION NUMBER: 07/869,913
; FILING DATE: April 15, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 02655/003004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
US-07-958-903A-9

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      1 AKS 3
      |||
Db      7 AKS 9

```

```

RESULT 15
US-07-958-903A-10
; Sequence 10, Application US/07958903A
; Patent No. 5652214
; GENERAL INFORMATION:
; APPLICANT: Lewis, Michael E.
; APPLICANT: Kauer, James C.
; APPLICANT: Smith, Kevin R.
; APPLICANT: Callison, Kathleen V.
; APPLICANT: Baldino, Frank
; APPLICANT: Neff, Nicola

```

```

; APPLICANT: Iqbal, Mohamed
; TITLE OF INVENTION: TREATING DISORDERS BY APPLICATION
; TITLE OF INVENTION: OF INSULIN-LIKE GROWTH FACTORS AND
; TITLE OF INVENTION: ANALOGS
; NUMBER OF SEQUENCES: 56
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM PS/2 Model 50Z or 55SX
; OPERATING SYSTEM: MS-DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/958,903A
; FILING DATE: October 7, 1992
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/361,595
; FILING DATE: June 5, 1989
; APPLICATION NUMBER: 07/534,139
; FILING DATE: June 5, 1990
; APPLICATION NUMBER: 07/869,913
; FILING DATE: April 15, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 02655/003004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
US-07-958-903A-10

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      1 AKS 3
      |||
Db      7 AKS 9

```

```

RESULT 16
US-07-958-903A-29
; Sequence 29, Application US/07958903A
; Patent No. 5652214

```

```

; GENERAL INFORMATION:
; APPLICANT: Lewis, Michael E.
; APPLICANT: Kauer, James C.
; APPLICANT: Smith, Kevin R.
; APPLICANT: Callison, Kathleen V.
; APPLICANT: Baldino, Frank
; APPLICANT: Neff, Nicola
; APPLICANT: Iqbal, Mohamed
; TITLE OF INVENTION: TREATING DISORDERS BY APPLICATION
; TITLE OF INVENTION: OF INSULIN-LIKE GROWTH FACTORS AND
; TITLE OF INVENTION: ANALOGS
; NUMBER OF SEQUENCES: 56
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM PS/2 Model 50Z or 55SX
; OPERATING SYSTEM: MS-DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/958,903A
; FILING DATE: October 7, 1992
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/361,595
; FILING DATE: June 5, 1989
; APPLICATION NUMBER: 07/534,139
; FILING DATE: June 5, 1990
; APPLICATION NUMBER: 07/869,913
; FILING DATE: April 15, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 02655/003004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 29:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
US-07-958-903A-29

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      1 AKS 3
      |||

```

## RESULT 17

US-07-958-903A-49

; Sequence 49, Application US/07958903A

; Patent No. 5652214

## ; GENERAL INFORMATION:

; APPLICANT: Lewis, Michael E.

; APPLICANT: Kauer, James C.

; APPLICANT: Smith, Kevin R.

; APPLICANT: Callison, Kathleen V.

; APPLICANT: Baldino, Frank

; APPLICANT: Neff, Nicola

; APPLICANT: Iqbal, Mohamed

; TITLE OF INVENTION: TREATING DISORDERS BY APPLICATION

; TITLE OF INVENTION: OF INSULIN-LIKE GROWTH FACTORS AND

; TITLE OF INVENTION: ANALOGS

; NUMBER OF SEQUENCES: 56

## ; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Fish &amp; Richardson

; STREET: 225 Franklin Street

; CITY: Boston

; STATE: Massachusetts

; COUNTRY: U.S.A.

; ZIP: 02110-2804

## ; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

; COMPUTER: IBM PS/2 Model 50Z or 55SX

; OPERATING SYSTEM: MS-DOS (Version 5.0)

; SOFTWARE: WordPerfect (Version 5.1)

## ; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/07/958,903A

; FILING DATE: October 7, 1992

; CLASSIFICATION: 514

## ; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 07/361,595

; FILING DATE: June 5, 1989

; APPLICATION NUMBER: 07/534,139

; FILING DATE: June 5, 1990

; APPLICATION NUMBER: 07/869,913

; FILING DATE: April 15, 1992

## ; ATTORNEY/AGENT INFORMATION:

; NAME: Clark, Paul T.

; REGISTRATION NUMBER: 30,162

; REFERENCE/DOCKET NUMBER: 02655/003004

## ; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (617) 542-5070

; TELEFAX: (617) 542-8906

; TELEX: 200154

## ; INFORMATION FOR SEQ ID NO: 49:

## ; SEQUENCE CHARACTERISTICS:

; LENGTH: 11

; TYPE: amino acid

; STRANDEDNESS:

; TOPOLOGY: linear

; FEATURE:



; OTHER INFORMATION: Xaa represents the D-isomer of tyrosine.  
US-07-958-903A-49

Query Match 27.3%; Score 3; DB 1; Length 11;  
Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AKS 3  
|||  
Db 7 AKS 9

RESULT 18

US-08-416-962-11

; Sequence 11, Application US/08416962

; Patent No. 5668253

; GENERAL INFORMATION:

; APPLICANT: THANAVALA, YASMIN

; APPLICANT: THAKUR, ARVIND

; APPLICANT: ROITT, IVAN

; APPLICANT: PRIDE, MICHAEL

; TITLE OF INVENTION: ANTI-IDIOTYPIC ANTIBODY

; TITLE OF INVENTION: HAVING CORRESPONDENCE WITH HUMAN HEPATITIS

; TITLE OF INVENTION: B SURFACE ANTIGEN

; NUMBER OF SEQUENCES: 12

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: DUNN & ASSOCIATES, P.C.

; STREET: P.O. BOX 96

; CITY: NEWFANE

; STATE: NEW YORK

; COUNTRY: USA

; ZIP: 14108

; COMPUTER READABLE FORM:

; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB

; COMPUTER: VICTOR 300 SX/25

; OPERATING SYSTEM: MS-DOS VERSION 5.0

; SOFTWARE: WORDSTAR PROFESSIONAL RELEASE 4

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/416,962

; FILING DATE: 05-APR-1995

; CLASSIFICATION: 530

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/167,336

; FILING DATE: 15-DEC-1993

; ATTORNEY/AGENT INFORMATION:

; NAME: DUNN, MICHAEL L.

; REGISTRATION NUMBER: 25,330

; REFERENCE/DOCKET NUMBER: RPP:138 US

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (716) 433-1661

; TELEFAX: (716) 433-1665

; INFORMATION FOR SEQ ID NO: 11:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 11

; TYPE: AMINO ACID

; STRANDEDNESS: UNKNOWN

; TOPOLOGY: UNKNOWN

```

; MOLECULE TYPE: PEPTIDE
; HYPOTHETICAL:
; ANTI-SENSE:
; FRAGMENT TYPE:
; ORIGINAL SOURCE:
; ORGANISM:
; STRAIN:
; INDIVIDUAL ISOLATE:
; DEVELOPMENTAL STAGE:
; HAPLOTYPE:
; TISSUE TYPE:
; CELL TYPE:
; CELL LINE:
; ORGANELLE:
; IMMEDIATE SOURCE:
; LIBRARY:
; CLONE:
; POSITION IN GENOME:
; CHROMOSOME/SEGMENT:
; MAP POSITION:
; UNITS:
; FEATURE:
; NAME/KEY:
; LOCATION:
; IDENTIFICATION METHOD:
; OTHER INFORMATION:
; PUBLICATION INFORMATION:
; AUTHORS:
; TITLE:
; JOURNAL:
; VOLUME:
; ISSUE:
; PAGES:
; DATE:
; DOCUMENT NUMBER:
; FILING DATE:
; PUBLICATION DATE:
; RELEVANT RESIDUES IN SEQ ID NO:
US-08-416-962-11

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches      3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      6 GNS 8
      |||
Db      7 GNS 9

```

```

RESULT 19
US-08-445-745-119
; Sequence 119, Application US/08445745
; Patent No. 5672585
; GENERAL INFORMATION:
; APPLICANT: Pierschbacher, Michael D.
; APPLICANT: Cheng, Soan
; APPLICANT: Craig, William S.

```

```

; APPLICANT: Tschopp, Juerg F.
; TITLE OF INVENTION: Methods and Composition for Treating
; TITLE OF INVENTION: Thrombosis
; NUMBER OF SEQUENCES: 168
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Campbell and Flores
; STREET: 4370 La Jolla Village Drive, Suite 700
; CITY: San Diego
; STATE: California
; COUNTRY: USA
; ZIP: 92122
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/445,745
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/171,068
; FILING DATE: 20-DEC-1993
; APPLICATION NUMBER: US 08/079,441
; FILING DATE: 18-JUN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/050,73614
; FILING DATE: 14-APR-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/681,119
; FILING DATE: 05-APR-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/506,444
; FILING DATE: 06-APR-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Campbell, Cathryn A.
; REGISTRATION NUMBER: 31,815
; REFERENCE/DOCKET NUMBER: P-LA 9829
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 535-9001
; TELEFAX: (619) 535-8949
; INFORMATION FOR SEQ ID NO: 119:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; TOPOLOGY: circular
US-08-445-745-119

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches      3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      4 RKG 6
        |||
Db      1 RKG 3

```

RESULT 20

US-08-208-887A-38

; Sequence 38, Application US/08208887A

; Patent No. 5677421

; GENERAL INFORMATION:

; APPLICANT: Schlessinger, Joseph

; APPLICANT: Skolnick, Edward Y.

; APPLICANT: Margolis, Benjamin L.

; TITLE OF INVENTION: NOVEL EXPRESSION CLONING METHOD FOR

; TITLE OF INVENTION: IDENTIFYING TARGET PROTEINS FOR EUKARYOTIC TYROSINE

; TITLE OF INVENTION: KINASES AND NOVEL TARGET PROTEINS

; NUMBER OF SEQUENCES: 51

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: PENNIE & EDMONDS

; STREET: 1155 Avenue of the Americas

; CITY: New York

; STATE: New York

; COUNTRY: 10036-2711

; ZIP: 10036-2711

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.30

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/208,887A

; FILING DATE: 11-MAR-1994

; CLASSIFICATION: 435

; ATTORNEY/AGENT INFORMATION:

; NAME: Coruzzi, Laura A.

; REGISTRATION NUMBER: 30,742

; REFERENCE/DOCKET NUMBER: 7683-063

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (212) 790-9090

; TELEFAX: (212) 869-9741/8864

; TELEX: 66141 PENNIE

; INFORMATION FOR SEQ ID NO: 38:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 11 amino acids

; TYPE: amino acid

; TOPOLOGY: unknown

; MOLECULE TYPE: peptide

US-08-208-887A-38

Query Match 27.3%; Score 3; DB 1; Length 11;

Best Local Similarity 100.0%; Pred. No. 2.7e+03;

Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 NSS 9

|||

Db 3 NSS 5

RESULT 21

US-08-467-420A-9

; Sequence 9, Application US/08467420A

; Patent No. 5683892

```

; GENERAL INFORMATION:
; APPLICANT: Ames, Robert S.
; APPLICANT: Appelbaum, Edward R.
; APPLICANT: Chaiken, Irwin M.
; APPLICANT: Cook, Richard M.
; APPLICANT: Gross, Mitchell S.
; APPLICANT: Holmes, Stephen D.
; APPLICANT: McMillan, Lynette J.
; APPLICANT: Theisen, Timothy W.
; TITLE OF INVENTION: Recombinant IL5 Antagonists Useful in
; TITLE OF INVENTION: Treatment of IL5 Mediated Disorders
; NUMBER OF SEQUENCES: 74
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SmithKline Beecham Corp./Corporate
; ADDRESSEE: Intellectual Property
; STREET: P. O. Box 1539-UW2220
; CITY: King of Prussia
; STATE: Pennsylvania
; COUNTRY: USA
; ZIP: 19406-0939
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/467,420A
; FILING DATE:
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/363131
; FILING DATE: 23-DEC-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Sutton, Jeffrey A.
; REGISTRATION NUMBER: 34,028
; REFERENCE/DOCKET NUMBER: P50282
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 610 270-5024
; TELEFAX: 610 270-5090
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-467-420A-9

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      8 SSL 10
      |||
Db      4 SSL 6

```

RESULT 22  
 US-08-470-110A-9  
 ; Sequence 9, Application US/08470110A  
 ; Patent No. 5693323  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Ames, Robert S.  
 ; APPLICANT: Appelbaum, Edward R.  
 ; APPLICANT: Chaiken, Irwin M.  
 ; APPLICANT: Cook, Richard M.  
 ; APPLICANT: Gross, Mitchell S.  
 ; APPLICANT: Holmes, Stephen D.  
 ; APPLICANT: McMillan, Lynette J.  
 ; APPLICANT: Theisen, Timothy W.  
 ; TITLE OF INVENTION: Recombinant IL5 Antagonists Useful in  
 ; TITLE OF INVENTION: Treatment of IL5 Mediated Disorders  
 ; NUMBER OF SEQUENCES: 74  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: SmithKline Beecham Corp./Corporate  
 ; ADDRESSEE: Intellectual Property  
 ; STREET: P. O. Box 1539-UW2220  
 ; CITY: King of Prussia  
 ; STATE: Pennsylvania  
 ; COUNTRY: USA  
 ; ZIP: 19406-0939  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: PatentIn Release #1.0, Version #1.25  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/470,110A  
 ; FILING DATE:  
 ; CLASSIFICATION: 426  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: US 08/363131  
 ; FILING DATE: 23-DEC-1994  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Sutton, Jeffrey A.  
 ; REGISTRATION NUMBER: 34,028  
 ; REFERENCE/DOCKET NUMBER: P50282  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: 610 270-5024  
 ; TELEFAX: 610 270-5090  
 ; INFORMATION FOR SEQ ID NO: 9:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 11 amino acids  
 ; TYPE: amino acid  
 ; STRANDEDNESS: single  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: protein  
 US-08-470-110A-9

Query Match 27.3%; Score 3; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10

Db                    III  
                      4 SSL 6

RESULT 23

US-08-462-018-5

; Sequence 5, Application US/08462018

; Patent No. 5703045

; GENERAL INFORMATION:

; APPLICANT: Lewis, Michael E.

; APPLICANT: Kauer, James C.

; APPLICANT: Smith, Kevin R.

; APPLICANT: Callison, Kathleen V.

; APPLICANT: Baldino, Frank

; APPLICANT: Neff, Nicola

; APPLICANT: Iqbal, Mohamed

; TITLE OF INVENTION: TREATING DISORDERS BY APPLICATION

; TITLE OF INVENTION: OF INSULIN-LIKE GROWTH FACTORS AND

; TITLE OF INVENTION: ANALOGS

; NUMBER OF SEQUENCES: 56

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Fish & Richardson P.C.

; STREET: 225 Franklin Street

; CITY: Boston

; STATE: Massachusetts

; COUNTRY: U.S.A.

; ZIP: 02110-2804

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

; COMPUTER: IBM PS/2 Model 50Z or 55SX

; OPERATING SYSTEM: MS-DOS (Version 5.0)

; SOFTWARE: WordPerfect (Version 5.1)

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/462,018

; FILING DATE:

; CLASSIFICATION: 435

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 07/958,903

; FILING DATE: October 7, 1992

; APPLICATION NUMBER: 07/361,595

; FILING DATE: June 5, 1989

; APPLICATION NUMBER: 07/534,139

; FILING DATE: June 5, 1990

; APPLICATION NUMBER: 07/869,913

; FILING DATE: April 15, 1992

; ATTORNEY/AGENT INFORMATION:

; NAME: Clark, Paul T.

; REGISTRATION NUMBER: 30,162

; REFERENCE/DOCKET NUMBER: 02655/003005

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (617) 542-5070

; TELEFAX: (617) 542-8906

; TELEX: 200154

; INFORMATION FOR SEQ ID NO: 5:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 11

; TYPE: amino acid

; STRANDEDNESS:  
; TOPOLOGY: linear  
US-08-462-018-5

Query Match 27.3%; Score 3; DB 1; Length 11;  
Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AKS 3  
|||  
Db 8 AKS 10

RESULT 24

US-08-462-018-9

; Sequence 9, Application US/08462018  
; Patent No. 5703045

; GENERAL INFORMATION:

; APPLICANT: Lewis, Michael E.  
; APPLICANT: Kauer, James C.  
; APPLICANT: Smith, Kevin R.  
; APPLICANT: Callison, Kathleen V.  
; APPLICANT: Baldino, Frank  
; APPLICANT: Neff, Nicola  
; APPLICANT: Iqbal, Mohamed  
; TITLE OF INVENTION: TREATING DISORDERS BY APPLICATION  
; TITLE OF INVENTION: OF INSULIN-LIKE GROWTH FACTORS AND  
; TITLE OF INVENTION: ANALOGS  
; NUMBER OF SEQUENCES: 56  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fish & Richardson P.C.  
; STREET: 225 Franklin Street  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: U.S.A.  
; ZIP: 02110-2804

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; COMPUTER: IBM PS/2 Model 50Z or 55SX  
; OPERATING SYSTEM: MS-DOS (Version 5.0)  
; SOFTWARE: WordPerfect (Version 5.1)

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/462,018  
; FILING DATE:  
; CLASSIFICATION: 435

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 07/958,903  
; FILING DATE: October 7, 1992  
; APPLICATION NUMBER: 07/361,595  
; FILING DATE: June 5, 1989  
; APPLICATION NUMBER: 07/534,139  
; FILING DATE: June 5, 1990  
; APPLICATION NUMBER: 07/869,913  
; FILING DATE: April 15, 1992

; ATTORNEY/AGENT INFORMATION:

; NAME: Clark, Paul T.  
; REGISTRATION NUMBER: 30,162



; REFERENCE/DOCKET NUMBER: 02655/003005  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (617) 542-5070  
; TELEFAX: (617) 542-8906  
; TELEX: 200154  
; INFORMATION FOR SEQ ID NO: 9:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 11  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
US-08-462-018-9

Query Match 27.3%; Score 3; DB 1; Length 11;  
Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AKS 3  
|||  
Db 7 AKS 9

RESULT 25

US-08-462-018-10

; Sequence 10, Application US/08462018  
; Patent No. 5703045

; GENERAL INFORMATION:

; APPLICANT: Lewis, Michael E.  
; APPLICANT: Kauer, James C.  
; APPLICANT: Smith, Kevin R.  
; APPLICANT: Callison, Kathleen V.  
; APPLICANT: Baldino, Frank  
; APPLICANT: Neff, Nicola  
; APPLICANT: Iqbal, Mohamed  
; TITLE OF INVENTION: TREATING DISORDERS BY APPLICATION  
; TITLE OF INVENTION: OF INSULIN-LIKE GROWTH FACTORS AND  
; TITLE OF INVENTION: ANALOGS  
; NUMBER OF SEQUENCES: 56  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fish & Richardson P.C.  
; STREET: 225 Franklin Street  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: U.S.A.  
; ZIP: 02110-2804

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; COMPUTER: IBM PS/2 Model 50Z or 55SX  
; OPERATING SYSTEM: MS-DOS (Version 5.0)  
; SOFTWARE: WordPerfect (Version 5.1)

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/462,018  
; FILING DATE:  
; CLASSIFICATION: 435

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 07/958,903  
; FILING DATE: October 7, 1992

```

; APPLICATION NUMBER: 07/361,595
; FILING DATE: June 5, 1989
; APPLICATION NUMBER: 07/534,139
; FILING DATE: June 5, 1990
; APPLICATION NUMBER: 07/869,913
; FILING DATE: April 15, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
; REFERENCE/DOCKET NUMBER: 02655/003005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: linear
US-08-462-018-10

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      1 AKS 3
      |||
Db      7 AKS 9

```

# RESULT 26

US-08-462-018-29

; Sequence 29, Application US/08462018

; Patent No. 5703045

; GENERAL INFORMATION:

; APPLICANT: Lewis, Michael E.

; APPLICANT: Kauer, James C.

; APPLICANT: Smith, Kevin R.

; APPLICANT: Callison, Kathleen V.

; APPLICANT: Baldino, Frank

; APPLICANT: Neff, Nicola

; APPLICANT: Iqbal, Mohamed

; TITLE OF INVENTION: TREATING DISORDERS BY APPLICATION

; TITLE OF INVENTION: OF INSULIN-LIKE GROWTH FACTORS AND

; TITLE OF INVENTION: ANALOGS

; NUMBER OF SEQUENCES: 56

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Fish & Richardson P.C.

; STREET: 225 Franklin Street

; CITY: Boston

; STATE: Massachusetts

; COUNTRY: U.S.A.

; ZIP: 02110-2804

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

; COMPUTER: IBM PS/2 Model 50Z or 55SX

```

;   OPERATING SYSTEM:  MS-DOS (Version 5.0)
;   SOFTWARE:  WordPerfect (Version 5.1)
;   CURRENT APPLICATION DATA:
;   APPLICATION NUMBER:  US/08/462,018
;   FILING DATE:
;   CLASSIFICATION:  435
;   PRIOR APPLICATION DATA:
;   APPLICATION NUMBER:  07/958,903
;   FILING DATE:  October 7, 1992
;   APPLICATION NUMBER:  07/361,595
;   FILING DATE:  June 5, 1989
;   APPLICATION NUMBER:  07/534,139
;   FILING DATE:  June 5, 1990
;   APPLICATION NUMBER:  07/869,913
;   FILING DATE:  April 15, 1992
;   ATTORNEY/AGENT INFORMATION:
;   NAME:  Clark, Paul T.
;   REGISTRATION NUMBER:  30,162
;   REFERENCE/DOCKET NUMBER:  02655/003005
;   TELECOMMUNICATION INFORMATION:
;   TELEPHONE:  (617) 542-5070
;   TELEFAX:  (617) 542-8906
;   TELEX:  200154
;   INFORMATION FOR SEQ ID NO:  29:
;   SEQUENCE CHARACTERISTICS:
;   LENGTH:  11
;   TYPE:  amino acid
;   STRANDEDNESS:
;   TOPOLOGY:  linear
US-08-462-018-29

```

```

Query Match          27.3%;  Score 3;  DB 1;  Length 11;
Best Local Similarity 100.0%;  Pred. No. 2.7e+03;
Matches      3;  Conservative    0;  Mismatches    0;  Indels      0;  Gaps      0;

```

```

Qy      1 AKS 3
      |||
Db      7 AKS 9

```

# RESULT 27

US-08-462-018-49

```

; Sequence 49, Application US/08462018
; Patent No. 5703045
; GENERAL INFORMATION:
;   APPLICANT:  Lewis, Michael E.
;   APPLICANT:  Kauer, James C.
;   APPLICANT:  Smith, Kevin R.
;   APPLICANT:  Callison, Kathleen V.
;   APPLICANT:  Baldino, Frank
;   APPLICANT:  Neff, Nicola
;   APPLICANT:  Iqbal, Mohamed
;   TITLE OF INVENTION:  TREATING DISORDERS BY APPLICATION
;   TITLE OF INVENTION:  OF INSULIN-LIKE GROWTH FACTORS AND
;   TITLE OF INVENTION:  ANALOGS
;   NUMBER OF SEQUENCES:  56
;   CORRESPONDENCE ADDRESS:

```

; ADDRESSEE: Fish & Richardson P.C.  
 ; STREET: 225 Franklin Street  
 ; CITY: Boston  
 ; STATE: Massachusetts  
 ; COUNTRY: U.S.A.  
 ; ZIP: 02110-2804  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
 ; COMPUTER: IBM PS/2 Model 50Z or 55SX  
 ; OPERATING SYSTEM: MS-DOS (Version 5.0)  
 ; SOFTWARE: WordPerfect (Version 5.1)  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/462,018  
 ; FILING DATE:  
 ; CLASSIFICATION: 435  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: 07/958,903  
 ; FILING DATE: October 7, 1992  
 ; APPLICATION NUMBER: 07/361,595  
 ; FILING DATE: June 5, 1989  
 ; APPLICATION NUMBER: 07/534,139  
 ; FILING DATE: June 5, 1990  
 ; APPLICATION NUMBER: 07/869,913  
 ; FILING DATE: April 15, 1992  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Clark, Paul T.  
 ; REGISTRATION NUMBER: 30,162  
 ; REFERENCE/DOCKET NUMBER: 02655/003005  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: (617) 542-5070  
 ; TELEFAX: (617) 542-8906  
 ; TELEX: 200154  
 ; INFORMATION FOR SEQ ID NO: 49:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 11  
 ; TYPE: amino acid  
 ; STRANDEDNESS:  
 ; TOPOLOGY: linear  
 ; FEATURE:  
 ; OTHER INFORMATION: Xaa represents the D-isomer of tyrosine.  
 US-08-462-018-49

Query Match 27.3%; Score 3; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AKS 3  
 |||  
 Db 7 AKS 9

RESULT 28  
 US-08-596-864-9  
 ; Sequence 9, Application US/08596864  
 ; Patent No. 5731183  
 ; GENERAL INFORMATION:  
 ; APPLICANT: KOBAYASHI, KATSUNORI

```

; APPLICANT: YAMANAKA, SHIGERU
; APPLICANT: MIWA, KIYOSHI
; APPLICANT: SUZUKI, SHUNICHI
; APPLICANT: ETO, YUZURU
; APPLICANT: TANITA, YUKO
; APPLICANT: YOKOZEKI, KENZO
; APPLICANT: HASHIGUCHI, KENICHI
; TITLE OF INVENTION: BACILLUS-DERIVED TRANSGLUTAMINASE
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OBLON, SPIVAK, MCCLELLEAND, MAIER & NEUSTADT,
; ADDRESSEE: P.C.
; STREET: 1755 S. JEFFERSON DAVIS HIGHWAY, SUITE 400
; CITY: ARLINGTON
; STATE: VA
; COUNTRY: USA
; ZIP: 22202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/596,864
; FILING DATE: 09-FEB-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 021963/1995
; FILING DATE: 09-FEB-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 226316/1995
; FILING DATE: 04-SEP-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 013072/1996
; FILING DATE: 29-JAN-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: OBLON, NORMAN F.
; REGISTRATION NUMBER: 24,618
; REFERENCE/DOCKET NUMBER: 10-786-0
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-413-3000
; TELEFAX: 703-413-2220
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-596-864-9

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy          7 NSS 9
          |||

```

Db

6 NSS 8

RESULT 29

US-08-422-101-3

; Sequence 3, Application US/08422101

; Patent No. 5739277

; GENERAL INFORMATION:

; APPLICANT: Leonard Presta

; APPLICANT: Brad Snedecor

; TITLE OF INVENTION: Altered Polypeptides with Increased

; TITLE OF INVENTION: Half-Life

; NUMBER OF SEQUENCES: 31

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Genentech, Inc.

; STREET: 460 Point San Bruno Blvd

; CITY: South San Francisco

; STATE: California

; COUNTRY: USA

; ZIP: 94080

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: patin (Genentech)

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/422,101

; FILING DATE: 14-APR-1995

; CLASSIFICATION: 530

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER:

; FILING DATE:

; ATTORNEY/AGENT INFORMATION:

; NAME: Lee, Wendy M.

; REGISTRATION NUMBER:

; REFERENCE/DOCKET NUMBER: 932-3

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 415/225-1994

; TELEFAX: 415/952-9881

; TELEX: 910/371-7168

; INFORMATION FOR SEQ ID NO: 3:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 11 amino acids

; TYPE: amino acid

; TOPOLOGY: linear

US-08-422-101-3

Query Match 27.3%; Score 3; DB 1; Length 11;

Best Local Similarity 100.0%; Pred. No. 2.7e+03;

Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 NSS 9

|||

Db 3 NSS 5

RESULT 30

US-08-589-011-11  
; Sequence 11, Application US/08589011  
; Patent No. 5744135  
; GENERAL INFORMATION:  
; APPLICANT: THANAVALA, YASMIN  
; APPLICANT: THAKUR, ARVIND  
; APPLICANT: ROITT, IVAN  
; APPLICANT: PRIDE, MICHAEL  
; TITLE OF INVENTION: ANTI-IDIOTYPIC ANTIBODY  
; TITLE OF INVENTION: HAVING CORRESPONDENCE WITH HUMAN HEPATITIS  
; TITLE OF INVENTION: B SURFACE ANTIGEN  
; NUMBER OF SEQUENCES: 12  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: DUNN & ASSOCIATES, P.C.  
; STREET: P.O. BOX 96  
; CITY: NEWFANE  
; STATE: NEW YORK  
; COUNTRY: USA  
; ZIP: 14108  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB  
; COMPUTER: VICTOR 300 SX/25  
; OPERATING SYSTEM: MS-DOS VERSION 5.0  
; SOFTWARE: WORDSTAR PROFESSIONAL RELEASE 4  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/589,011  
; FILING DATE: 19-JAN-1996  
; CLASSIFICATION: 424  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/167,336  
; FILING DATE: 15-DEC-1993  
; ATTORNEY/AGENT INFORMATION:  
; NAME: DUNN, MICHAEL L.  
; REGISTRATION NUMBER: 25,330  
; REFERENCE/DOCKET NUMBER: RPP:138 US  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (716) 433-1661  
; TELEFAX: (716) 433-1665  
; INFORMATION FOR SEQ ID NO: 11:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 11  
; TYPE: AMINO ACID  
; STRANDEDNESS: UNKNOWN  
; TOPOLOGY: UNKNOWN  
; MOLECULE TYPE: PEPTIDE  
; HYPOTHETICAL:  
; ANTI-SENSE:  
; FRAGMENT TYPE:  
; ORIGINAL SOURCE:  
; ORGANISM:  
; STRAIN:  
; INDIVIDUAL ISOLATE:  
; DEVELOPMENTAL STAGE:  
; HAPLOTYPE:  
; TISSUE TYPE:  
; CELL TYPE:  
; CELL LINE:

```

; ORGANELLE:
; IMMEDIATE SOURCE:
; LIBRARY:
; CLONE:
; POSITION IN GENOME:
; CHROMOSOME/SEGMENT:
; MAP POSITION:
; UNITS:
; FEATURE:
; NAME/KEY:
; LOCATION:
; IDENTIFICATION METHOD:
; OTHER INFORMATION:
; PUBLICATION INFORMATION:
; AUTHORS:
; TITLE:
; JOURNAL:
; VOLUME:
; ISSUE:
; PAGES:
; DATE:
; DOCUMENT NUMBER:
; FILING DATE:
; PUBLICATION DATE:
; RELEVANT RESIDUES IN SEQ ID NO:
US-08-589-011-11

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      6 GNS 8
      |||
Db      7 GNS 9

```

# RESULT 31

US-08-422-091-3

```

; Sequence 3, Application US/08422091
; Patent No. 5747035
; GENERAL INFORMATION:
; APPLICANT: Leonard Presta
; APPLICANT: Brad Snedecor
; TITLE OF INVENTION: Altered Polypeptides with Increased
; TITLE OF INVENTION: Half-Life
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 460 Point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS

```



```

; SOFTWARE: patin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/422,091
; FILING DATE: 14-APR-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Lee, Wendy M.
; REGISTRATION NUMBER:
; REFERENCE/DOCKET NUMBER: 932-6
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415/225-1994
; TELEFAX: 415/952-9881
; TELEX: 910/371-7168
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; TOPOLOGY: linear
US-08-422-091-3

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches      3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      7 NSS 9
        |||
Db      3 NSS 5

```

RESULT 32

US-08-040-548-43

```

; Sequence 43, Application US/08040548
; Patent No. 5763209
; GENERAL INFORMATION:
; APPLICANT: Sukhatme, Vikas P.
; TITLE OF INVENTION: METHODS AND MATERIALS RELATING TO THE
; TITLE OF INVENTION: FUNCTIONAL DOMAINS OF DNA BINDING PROTEINS
; NUMBER OF SEQUENCES: 67
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: 321 No. 5763209th Clark Street, Suite 800
; CITY: Chicago
; STATE: Illinois
; COUNTRY: U.S.A.
; ZIP: 60610
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/040,548
; FILING DATE:
; CLASSIFICATION: 514

```

; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Coughlin, Daniel F.  
 ; REGISTRATION NUMBER: 36,111  
 ; REFERENCE/DOCKET NUMBER: arcd067  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: (312) 744-0090  
 ; TELEFAX: (312) 245-4961  
 ; INFORMATION FOR SEQ ID NO: 43:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 11 amino acids  
 ; TYPE: amino acid  
 ; STRANDEDNESS: single  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: peptide  
 US-08-040-548-43

Query Match 27.3%; Score 3; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 7 NSS 9  
 |||  
 Db 2 NSS 4

# RESULT 33

US-08-466-344-43

; Sequence 43, Application US/08466344  
 ; Patent No. 5773583

## ; GENERAL INFORMATION:

; APPLICANT: Sukhatme, Vikas P.  
 ; TITLE OF INVENTION: METHODS AND MATERIALS RELATING TO THE  
 ; TITLE OF INVENTION: FUNCTIONAL DOMAINS OF DNA BINDING PROTEINS  
 ; NUMBER OF SEQUENCES: 67  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Arnold, White & Durkee  
 ; STREET: 321 No. 5773583th Clark Street, Suite 800  
 ; CITY: Chicago  
 ; STATE: Illinois  
 ; COUNTRY: U.S.A.  
 ; ZIP: 60610

## ; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: PatentIn Release #1.0, Version #1.25

## ; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/466,344  
 ; FILING DATE: 06-JUN-1995  
 ; CLASSIFICATION: 514

## ; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/040,548  
 ; FILING DATE: 31-MAR-1993

## ; ATTORNEY/AGENT INFORMATION:

; NAME: Coughlin, Daniel F.  
 ; REGISTRATION NUMBER: 36,111  
 ; REFERENCE/DOCKET NUMBER: arcd067

; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (312) 744-0090  
; TELEFAX: (312) 245-4961  
; INFORMATION FOR SEQ ID NO: 43:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 11 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-466-344-43

Query Match 27.3%; Score 3; DB 1; Length 11;  
Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 NSS 9  
|||  
Db 2 NSS 4

RESULT 34

US-08-823-245-5

; Sequence 5, Application US/08823245  
; Patent No. 5776897  
; GENERAL INFORMATION:  
; APPLICANT: Lewis, Michael  
; APPLICANT: Kauer, James C.  
; APPLICANT: Smith, Kevin R.  
; APPLICANT: Callison, Kathleen V.  
; APPLICANT: Baldino, Frank  
; APPLICANT: Neff, Nicola  
; APPLICANT: Iqbal, Mohamed  
; TITLE OF INVENTION: TREATING DISORDERS BY  
; TITLE OF INVENTION: APPLICATION  
; TITLE OF INVENTION: OF INSULIN-LIKE GROWTH  
; TITLE OF INVENTION: FACTORS AND  
; TITLE OF INVENTION: ANALOGS  
; NUMBER OF SEQUENCES: 56  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fish & Richardson  
; STREET: 225 Franklin Street  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: U.S.A.  
; ZIP: 02110-2804  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; COMPUTER: IBM PS/2 Model 50Z or  
; COMPUTER: 55SX  
; OPERATING SYSTEM: MS-DOS (Version 5.0)  
; SOFTWARE: WordPerfect (Version  
; SOFTWARE: 5.1)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/823,245  
; FILING DATE: March 24, 1997  
; CLASSIFICATION: 514

```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/361,595
; FILING DATE: June 6, 1989
; APPLICATION NUMBER: 07/534,139
; FILING DATE: June 5, 1990
; APPLICATION NUMBER: 07/869,913
; FILING DATE: April 15, 1992
; APPLICATION NUMBER: 07/958,903
; FILING DATE: October 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Creeson, Gary L.
; REGISTRATION NUMBER: 34,310
; REFERENCE/DOCKET NUMBER: 02655/003008
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11
; TYPE: amino acid
; STRANDEDNESS: N/A
; TOPOLOGY: N/A
US-08-823-245-5

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      1 AKS 3
        |||
Db      8 AKS 10

```

# RESULT 35

US-08-823-245-9

```

; Sequence 9, Application US/08823245
; Patent No. 5776897
; GENERAL INFORMATION:
; APPLICANT: Lewis, Michael
; APPLICANT: Kauer, James C.
; APPLICANT: Smith, Kevin R.
; APPLICANT: Callison, Kathleen V.
; APPLICANT: Baldino, Frank
; APPLICANT: Neff, Nicola
; APPLICANT: Iqbal, Mohamed
; TITLE OF INVENTION: TREATING DISORDERS BY
; TITLE OF INVENTION: APPLICATION
; TITLE OF INVENTION: OF INSULIN-LIKE GROWTH
; TITLE OF INVENTION: FACTORS AND
; TITLE OF INVENTION: ANALOGS
; NUMBER OF SEQUENCES: 56
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts

```

```

; COUNTRY: U.S.A.
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM PS/2 Model 50Z or
; COMPUTER: 55SX
; OPERATING SYSTEM: MS-DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version
; SOFTWARE: 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/823,245
; FILING DATE: March 24, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/361,595
; FILING DATE: June 6, 1989
; APPLICATION NUMBER: 07/534,139
; FILING DATE: June 5, 1990
; APPLICATION NUMBER: 07/869,913
; FILING DATE: April 15, 1992
; APPLICATION NUMBER: 07/958,903
; FILING DATE: October 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Creeson, Gary L.
; REGISTRATION NUMBER: 34,310
; REFERENCE/DOCKET NUMBER: 02655/003008
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11
; TYPE: amino acid
; STRANDEDNESS: N/A
; TOPOLOGY: N/A
US-08-823-245-9

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      1 AKS 3
      |||
Db      7 AKS 9

```

```

RESULT 36
US-08-823-245-10
; Sequence 10, Application US/08823245
; Patent No. 5776897
; GENERAL INFORMATION:
; APPLICANT: Lewis, Michael
; APPLICANT: Kauer, James C.
; APPLICANT: Smith, Kevin R.
; APPLICANT: Callison, Kathleen V.
; APPLICANT: Baldino, Frank

```

; APPLICANT: Neff, Nicola  
 ; APPLICANT: Iqbal, Mohamed  
 ; TITLE OF INVENTION: TREATING DISORDERS BY  
 ; TITLE OF INVENTION: APPLICATION  
 ; TITLE OF INVENTION: OF INSULIN-LIKE GROWTH  
 ; TITLE OF INVENTION: FACTORS AND  
 ; TITLE OF INVENTION: ANALOGS  
 ; NUMBER OF SEQUENCES: 56  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Fish & Richardson  
 ; STREET: 225 Franklin Street  
 ; CITY: Boston  
 ; STATE: Massachusetts  
 ; COUNTRY: U.S.A.  
 ; ZIP: 02110-2804  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
 ; COMPUTER: IBM PS/2 Model 50Z or  
 ; COMPUTER: 55SX  
 ; OPERATING SYSTEM: MS-DOS (Version 5.0)  
 ; SOFTWARE: WordPerfect (Version  
 ; SOFTWARE: 5.1)  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/823,245  
 ; FILING DATE: March 24, 1997  
 ; CLASSIFICATION: 514  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: 07/361,595  
 ; FILING DATE: June 6, 1989  
 ; APPLICATION NUMBER: 07/534,139  
 ; FILING DATE: June 5, 1990  
 ; APPLICATION NUMBER: 07/869,913  
 ; FILING DATE: April 15, 1992  
 ; APPLICATION NUMBER: 07/958,903  
 ; FILING DATE: October 7, 1992  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Creeson, Gary L.  
 ; REGISTRATION NUMBER: 34,310  
 ; REFERENCE/DOCKET NUMBER: 02655/003008  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: (617) 542-5070  
 ; TELEFAX: (617) 542-8906  
 ; TELEX: 200154  
 ; INFORMATION FOR SEQ ID NO: 10:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 11  
 ; TYPE: amino acid  
 ; STRANDEDNESS: N/A  
 ; TOPOLOGY: N/A  
 US-08-823-245-10

Query Match 27.3%; Score 3; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AKS 3  
 |||

## RESULT 37

US-08-823-245-29

; Sequence 29, Application US/08823245

; Patent No. 5776897

## ; GENERAL INFORMATION:

; APPLICANT: Lewis, Michael

; APPLICANT: Kauer, James C.

; APPLICANT: Smith, Kevin R.

; APPLICANT: Callison, Kathleen V.

; APPLICANT: Baldino, Frank

; APPLICANT: Neff, Nicola

; APPLICANT: Iqbal, Mohamed

; TITLE OF INVENTION: TREATING DISORDERS BY

; TITLE OF INVENTION: APPLICATION

; TITLE OF INVENTION: OF INSULIN-LIKE GROWTH

; TITLE OF INVENTION: FACTORS AND

; TITLE OF INVENTION: ANALOGS

; NUMBER OF SEQUENCES: 56

## ; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Fish &amp; Richardson

; STREET: 225 Franklin Street

; CITY: Boston

; STATE: Massachusetts

; COUNTRY: U.S.A.

; ZIP: 02110-2804

## ; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

; COMPUTER: IBM PS/2 Model 50Z or

; COMPUTER: 55SX

; OPERATING SYSTEM: MS-DOS (Version 5.0)

; SOFTWARE: WordPerfect (Version

; SOFTWARE: 5.1)

## ; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/823,245

; FILING DATE: March 24, 1997

; CLASSIFICATION: 514

## ; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 07/361,595

; FILING DATE: June 6, 1989

; APPLICATION NUMBER: 07/534,139

; FILING DATE: June 5, 1990

; APPLICATION NUMBER: 07/869,913

; FILING DATE: April 15, 1992

; APPLICATION NUMBER: 07/958,903

; FILING DATE: October 7, 1992

## ; ATTORNEY/AGENT INFORMATION:

; NAME: Creeson, Gary L.

; REGISTRATION NUMBER: 34,310

; REFERENCE/DOCKET NUMBER: 02655/003008

## ; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (617) 542-5070

; TELEFAX: (617) 542-8906

; TELEX: 200154

; INFORMATION FOR SEQ ID NO: 29:

; SEQUENCE CHARACTERISTICS:  
; LENGTH: 11  
; TYPE: amino acid  
; STRANDEDNESS: N/A  
; TOPOLOGY: N/A  
US-08-823-245-29

Query Match 27.3%; Score 3; DB 1; Length 11;  
Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AKS 3  
|||  
Db 7 AKS 9

RESULT 38

US-08-823-245-49

; Sequence 49, Application US/08823245  
; Patent No. 5776897

; GENERAL INFORMATION:

; APPLICANT: Lewis, Michael  
; APPLICANT: Kauer, James C.  
; APPLICANT: Smith, Kevin R.  
; APPLICANT: Callison, Kathleen V.  
; APPLICANT: Baldino, Frank  
; APPLICANT: Neff, Nicola  
; APPLICANT: Iqbal, Mohamed  
; TITLE OF INVENTION: TREATING DISORDERS BY  
; TITLE OF INVENTION: APPLICATION  
; TITLE OF INVENTION: OF INSULIN-LIKE GROWTH  
; TITLE OF INVENTION: FACTORS AND  
; TITLE OF INVENTION: ANALOGS  
; NUMBER OF SEQUENCES: 56  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fish & Richardson  
; STREET: 225 Franklin Street  
; CITY: Boston  
; STATE: Massachusetts  
; COUNTRY: U.S.A.  
; ZIP: 02110-2804

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; COMPUTER: IBM PS/2 Model 50Z or  
; COMPUTER: 55SX  
; OPERATING SYSTEM: MS-DOS (Version 5.0)  
; SOFTWARE: WordPerfect (Version  
; SOFTWARE: 5.1)

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/823,245  
; FILING DATE: March 24, 1997  
; CLASSIFICATION: 514

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 07/361,595  
; FILING DATE: June 6, 1989  
; APPLICATION NUMBER: 07/534,139  
; FILING DATE: June 5, 1990



```

; APPLICATION NUMBER: 07/869,913
; FILING DATE: April 15, 1992
; APPLICATION NUMBER: 07/958,903
; FILING DATE: October 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Creeson, Gary L.
; REGISTRATION NUMBER: 34,310
; REFERENCE/DOCKET NUMBER: 02655/003008
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 542-5070
; TELEFAX: (617) 542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 49:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11
; TYPE: amino acid
; STRANDEDNESS: N/A
; TOPOLOGY: N/A
; FEATURE:
; OTHER INFORMATION: Xaa represents the D-isomer of
; OTHER INFORMATION: tyrosine.
US-08-823-245-49

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      1 AKS 3
      |||
Db      7 AKS 9

```

# RESULT 39

US-08-667-769A-9

```

; Sequence 9, Application US/08667769A
; Patent No. 5783184

```

## GENERAL INFORMATION:

```

; APPLICANT: Ames, Robert S.
; APPLICANT: Appelbaum, Edward R.
; APPLICANT: Chaiken, Irwin M.
; APPLICANT: Cook, Richard M.
; APPLICANT: Gross, Mitchell S.
; APPLICANT: Holmes, Stephen D.
; APPLICANT: McMillan, Lynette J.
; APPLICANT: Theisen, Timothy W.
; TITLE OF INVENTION: Recombinant IL5 Antagonists Useful in
; TITLE OF INVENTION: Treatment of IL5 Mediated Disorders
; NUMBER OF SEQUENCES: 76
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SmithKline Beecham Corp./Corporate
; STREET: P.O. Box 1539-UW2220
; CITY: King of Prussia
; STATE: Pennsylvania
; COUNTRY: USA
; ZIP: 19406-0939
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk

```

```

;   COMPUTER:  IBM PC compatible
;   OPERATING SYSTEM:  PC-DOS/MS-DOS
;   SOFTWARE:  PatentIn Release #1.0, Version #1.30
;   CURRENT APPLICATION DATA:
;   APPLICATION NUMBER:  US/08/667,769A
;   FILING DATE:
;   CLASSIFICATION:  424
;   PRIOR APPLICATION DATA:
;   APPLICATION NUMBER:  PCT/US95/17082
;   FILING DATE:  22-DEC-1995
;   PRIOR APPLICATION DATA:
;   APPLICATION NUMBER:  US 08/470110
;   FILING DATE:  06-JUN-1995
;   PRIOR APPLICATION DATA:
;   APPLICATION NUMBER:  US 08/467420
;   FILING DATE:  06-JUN-1995
;   PRIOR APPLICATION DATA:
;   APPLICATION NUMBER:  US 08/363131
;   FILING DATE:  23-DEC-1994
;   ATTORNEY/AGENT INFORMATION:
;   NAME:  Sutton, Jeffrey A.
;   REGISTRATION NUMBER:  34,028
;   REFERENCE/DOCKET NUMBER:  P50503
;   TELECOMMUNICATION INFORMATION:
;   TELEPHONE:  610-270-5024
;   TELEFAX:  610-270-5090
;   INFORMATION FOR SEQ ID NO:  9:
;   SEQUENCE CHARACTERISTICS:
;   LENGTH:  11 amino acids
;   TYPE:  amino acid
;   STRANDEDNESS:  single
;   TOPOLOGY:  linear
;   MOLECULE TYPE:  protein
US-08-667-769A-9

```

```

Query Match          27.3%;  Score 3;  DB 1;  Length 11;
Best Local Similarity 100.0%;  Pred. No. 2.7e+03;
Matches      3;  Conservative      0;  Mismatches      0;  Indels      0;  Gaps      0;

```

```

Qy      8 SSL 10
      |||
Db      4 SSL 6

```

```

RESULT 40
US-08-465-391A-280
; Sequence 280, Application US/08465391A
; Patent No. 5786331
; GENERAL INFORMATION:
;   APPLICANT:  Barrett, Ronald W.
;   APPLICANT:  Yanofsky, Stephen D.
;   APPLICANT:  Baldwin, David
;   APPLICANT:  Jacobs, Jeff W.
;   APPLICANT:  Bovy, Phillipe R.
;   APPLICANT:  Leahy, Ellen M.
;   APPLICANT:  Pottorf, Richard S.
;   TITLE OF INVENTION:  Peptides and Compounds That Bind to the

```

```

; TITLE OF INVENTION: IL-1 Receptor
; NUMBER OF SEQUENCES: 405
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew
; STREET: One Market Plaza, Steuart Tower, Suite 2000
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/465,391A
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/373,474
; FILING DATE: 01-FEB-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/190,788
; FILING DATE: 02-FEB-1994
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 5786331viel, Vern
; REGISTRATION NUMBER: 32,483
; REFERENCE/DOCKET NUMBER: 16528A-001840/1019.2A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-326-2400
; TELEFAX: 415-326-2422
; INFORMATION FOR SEQ ID NO: 280:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-465-391A-280

```

```

Query Match          27.3%; Score 3; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      7 NSS 9
      |||
Db      2 NSS 4

```

```

RESULT 41
US-08-452-724A-44
; Sequence 44, Application US/08452724A
; Patent No. 5830650
; GENERAL INFORMATION:
; APPLICANT: Crea, Roberto

```

```

; TITLE OF INVENTION: Walk-Through Mutagenesis
; NUMBER OF SEQUENCES: 59
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
; STREET: 2 Militia Drive
; CITY: Lexington
; STATE: MA
; COUNTRY: USA
; ZIP: 02173
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/452,724A
; FILING DATE: 30-MAY-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/930,600
; FILING DATE: 05-APR-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/02362
; FILING DATE: 05-APR-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/505,314
; FILING DATE: 05-APR-1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Brook Esq., David E.
; REGISTRATION NUMBER: 22,592
; REFERENCE/DOCKET NUMBER: RC90-01AZ
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 861-6240
; TELEFAX: (617) 861-9540
; INFORMATION FOR SEQ ID NO: 44:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS:
; TOPOLOGY: unknown
US-08-452-724A-44

```

```

Query Match          27.3%; Score 3; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      5 KGN 7
      |||
Db      5 KGN 7

```

```

RESULT 42
US-08-940-371-9
; Sequence 9, Application US/08940371
; Patent No. 5851525
; GENERAL INFORMATION:
; APPLICANT: Ames, Robert S.

```

```

; APPLICANT: Appelbaum, Edward R.
; APPLICANT: Chaiken, Irwin M.
; APPLICANT: Cook, Richard M.
; APPLICANT: Gross, Mitchell S.
; APPLICANT: Holmes, Stephen D.
; APPLICANT: McMillan, Lynette J.
; APPLICANT: Theisen, Timothy W.
; TITLE OF INVENTION: Recombinant IL5 Antagonists Useful in
; TITLE OF INVENTION: Treatment of IL5 Mediated Disorders
; NUMBER OF SEQUENCES: 74
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SmithKline Beecham Corp./Corporate
; ADDRESSEE: Intellectual Property
; STREET: P. O. Box 1539-UW2220
; CITY: King of Prussia
; STATE: Pennsylvania
; COUNTRY: USA
; ZIP: 19406-0939
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/940,371
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/470,110
; FILING DATE:
; APPLICATION NUMBER: US 08/363131
; FILING DATE: 23-DEC-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Sutton, Jeffrey A.
; REGISTRATION NUMBER: 34,028
; REFERENCE/DOCKET NUMBER: P50282
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 610 270-5024
; TELEFAX: 610 270-5090
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-940-371-9

```

```

Query Match          27.3%; Score 3; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      8 SSL 10
        |||
Db      4 SSL 6

```

RESULT 43

US-08-948-762-11

; Sequence 11, Application US/08948762

; Patent No. 5856087

; GENERAL INFORMATION:

; APPLICANT: THANAVALA, YASMIN

; APPLICANT: THAKUR, ARVIND

; APPLICANT: ROITT, IVAN

; APPLICANT: PRIDE, MICHAEL

; TITLE OF INVENTION: ANTI-IDIOTYPIC ANTIBODY

; TITLE OF INVENTION: HAVING CORRESPONDENCE WITH HUMAN HEPATITIS

; TITLE OF INVENTION: B SURFACE ANTIGEN

; NUMBER OF SEQUENCES: 12

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: DUNN & ASSOCIATES, P.C.

; STREET: P.O. BOX 96

; CITY: NEWFANE

; STATE: NEW YORK

; COUNTRY: USA

; ZIP: 14108

; COMPUTER READABLE FORM:

; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB

; COMPUTER: VICTOR 300 SX/25

; OPERATING SYSTEM: MS-DOS VERSION 5.0

; SOFTWARE: WORDSTAR PROFESSIONAL RELEASE 4

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/948,762

; FILING DATE:

; CLASSIFICATION:

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/589,011

; FILING DATE: 19-JAN-1996

; APPLICATION NUMBER: 08/167,336

; FILING DATE: 15-DEC-1993

; ATTORNEY/AGENT INFORMATION:

; NAME: DUNN, MICHAEL L.

; REGISTRATION NUMBER: 25,330

; REFERENCE/DOCKET NUMBER: RPP:138 US

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (716) 433-1661

; TELEFAX: (716) 433-1665

; INFORMATION FOR SEQ ID NO: 11:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 11

; TYPE: AMINO ACID

; STRANDEDNESS: UNKNOWN

; TOPOLOGY: UNKNOWN

; MOLECULE TYPE: PEPTIDE

; HYPOTHETICAL:

; ANTI-SENSE:

; FRAGMENT TYPE:

; ORIGINAL SOURCE:

; ORGANISM:

; STRAIN:

; INDIVIDUAL ISOLATE:

; DEVELOPMENTAL STAGE:

; HAPLOTYPE:

```

; TISSUE TYPE:
; CELL TYPE:
; CELL LINE:
; ORGANELLE:
; IMMEDIATE SOURCE:
; LIBRARY:
; CLONE:
; POSITION IN GENOME:
; CHROMOSOME/SEGMENT:
; MAP POSITION:
; UNITS:
; FEATURE:
; NAME/KEY:
; LOCATION:
; IDENTIFICATION METHOD:
; OTHER INFORMATION:
; PUBLICATION INFORMATION:
; AUTHORS:
; TITLE:
; JOURNAL:
; VOLUME:
; ISSUE:
; PAGES:
; DATE:
; DOCUMENT NUMBER:
; FILING DATE:
; PUBLICATION DATE:
; RELEVANT RESIDUES IN SEQ ID NO:
US-08-948-762-11

```

```

Query Match          27.3%; Score 3; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches      3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      6 GNS 8
      |||
Db      7 GNS 9

```

RESULT 44

US-08-539-005-38

```

; Sequence 38, Application US/08539005
; Patent No. 5858686

```

; GENERAL INFORMATION:

```

; APPLICANT: Schlessinger, Joseph
; APPLICANT: Skolnick, Edward Y.
; APPLICANT: Margolis, Benjamin L.
; TITLE OF INVENTION: NOVEL EXPRESSION CLONING METHOD FOR
; TITLE OF INVENTION: IDENTIFYING TARGET PROTEINS FOR EUKARYOTIC TYROSINE
; TITLE OF INVENTION: KINASES AND NOVEL TARGET PROTEINS
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PENNIE & EDMONDS
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: 10036-2711

```

```

; ZIP: 10036-2711
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/539,005
; FILING DATE: 4-OCT-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/167,035
; FILING DATE: 16-DEC-1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A.
; REGISTRATION NUMBER: 30,742
; REFERENCE/DOCKET NUMBER: 7683-062
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 790-9090
; TELEFAX: (212) 869-9741/8864
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 38:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; TOPOLOGY: unknown
; MOLECULE TYPE: peptide
US-08-539-005-38

```

```

Query Match          27.3%; Score 3; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches      3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      7 NSS 9
      |||
Db      3 NSS 5

```

# RESULT 45

```

US-08-464-538B-280
; Sequence 280, Application US/08464538B
; Patent No. 5861476
; GENERAL INFORMATION:
; APPLICANT: Barrett, Ronald W.
; APPLICANT: Yanofsky, Stephen D.
; APPLICANT: Baldwin, David
; APPLICANT: Jacobs, Jeff W.
; APPLICANT: Bovy, Phillipe R.
; APPLICANT: Leahy, Ellen M.
; APPLICANT: Pottorf, Richard S.
; TITLE OF INVENTION: Peptides and Compounds That Bind to the
; TITLE OF INVENTION: IL-1 Receptor
; NUMBER OF SEQUENCES: 402
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, 8th Floor

```



```

;   CITY:  San Francisco
;   STATE:  California
;   COUNTRY:  USA
;   ZIP:  94111
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE:  Floppy disk
;     COMPUTER:  IBM PC compatible
;     OPERATING SYSTEM:  PC-DOS/MS-DOS
;     SOFTWARE:  PatentIn Release #1.0, Version #1.25
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER:  US/08/464,538B
;     FILING DATE:  05-JUN-1995
;     CLASSIFICATION:  514
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER:  US 08/373,474
;     FILING DATE:  01-FEB-1995
;     CLASSIFICATION:  514
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER:  US 08/190,788
;     FILING DATE:  02-FEB-1994
;     CLASSIFICATION:  514
;   ATTORNEY/AGENT INFORMATION:
;     NAME:  Smith, William M.
;     REGISTRATION NUMBER:  30,223
;     REFERENCE/DOCKET NUMBER:  16528A-001810
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE:  415-326-2400
;     TELEFAX:  415-326-2422
;   INFORMATION FOR SEQ ID NO:  280:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  11 amino acids
;       TYPE:  amino acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  peptide
US-08-464-538B-280

```

```

Query Match          27.3%;  Score 3;  DB 2;  Length 11;
Best Local Similarity 100.0%;  Pred. No. 2.7e+03;
Matches      3;  Conservative    0;  Mismatches    0;  Indels      0;  Gaps      0;

```

```

Qy          7 NSS 9
            |||
Db          2 NSS 4

```

```

RESULT 46
US-08-540-412-120
; Sequence 120, Application US/08540412
; Patent No. 5866679
;   GENERAL INFORMATION:
;     APPLICANT:  DeFeo-Jones, Deborah
;     APPLICANT:  Feng, Dong-Mei
;     APPLICANT:  Garsky, Victor M.
;     APPLICANT:  Jones, Raymond E.
;     APPLICANT:  Oliff, Allen I.
;   TITLE OF INVENTION:  NOVEL PEPTIDES

```

```

; NUMBER OF SEQUENCES: 194
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: DAVID A. MUTHARD
; STREET: 126 E. Lincoln Avenue, P.O. BOX 2000
; CITY: RAHWAY
; STATE: NEW JERSEY
; COUNTRY: U.S.A.
; ZIP: 07065
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/540,412
; FILING DATE:
; CLASSIFICATION: 530
; ATTORNEY/AGENT INFORMATION:
; NAME: Muthard, David A.
; REGISTRATION NUMBER: 35,297
; REFERENCE/DOCKET NUMBER: 19253IC
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (908)594-3903
; TELEFAX: (908)594-4720
; INFORMATION FOR SEQ ID NO: 120:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: internal
US-08-540-412-120

```

```

Query Match          27.3%; Score 3; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      8 SSL 10
        |||
Db      9 SSL 11

```

#### RESULT 47

US-08-540-412-123

; Sequence 123, Application US/08540412

; Patent No. 5866679

; GENERAL INFORMATION:

; APPLICANT: DeFeo-Jones, Deborah

; APPLICANT: Feng, Dong-Mei

; APPLICANT: Garsky, Victor M.

; APPLICANT: Jones, Raymond E.

; APPLICANT: Oliff, Allen I.

; TITLE OF INVENTION: NOVEL PEPTIDES

; NUMBER OF SEQUENCES: 194

```

;   CORRESPONDENCE ADDRESS:
;   ADDRESSEE:  DAVID A. MUTHARD
;   STREET:  126 E. Lincoln Avenue, P.O. BOX 2000
;   CITY:  RAHWAY
;   STATE:  NEW JERSEY
;   COUNTRY:  U.S.A.
;   ZIP:  07065
;   COMPUTER READABLE FORM:
;   MEDIUM TYPE:  Floppy disk
;   COMPUTER:  IBM PC compatible
;   OPERATING SYSTEM:  PC-DOS/MS-DOS
;   SOFTWARE:  PatentIn Release #1.0, Version #1.30
;   CURRENT APPLICATION DATA:
;   APPLICATION NUMBER:  US/08/540,412
;   FILING DATE:
;   CLASSIFICATION:  530
;   ATTORNEY/AGENT INFORMATION:
;   NAME:  Muthard, David A.
;   REGISTRATION NUMBER:  35,297
;   REFERENCE/DOCKET NUMBER:  19253IC
;   TELECOMMUNICATION INFORMATION:
;   TELEPHONE:  (908)594-3903
;   TELEFAX:  (908)594-4720
;   INFORMATION FOR SEQ ID NO:  123:
;   SEQUENCE CHARACTERISTICS:
;   LENGTH:  11 amino acids
;   TYPE:  amino acid
;   STRANDEDNESS:  single
;   TOPOLOGY:  linear
;   MOLECULE TYPE:  peptide
;   HYPOTHETICAL:  NO
;   ANTI-SENSE:  NO
;   FRAGMENT TYPE:  internal
US-08-540-412-123

```

```

Query Match          27.3%;  Score 3;  DB 2;  Length 11;
Best Local Similarity 100.0%;  Pred. No. 2.7e+03;
Matches      3;  Conservative      0;  Mismatches      0;  Indels      0;  Gaps      0;

```

```

Qy      8 SSL 10
      |||
Db      9 SSL 11

```

```

RESULT 48
US-08-540-412-184
; Sequence 184, Application US/08540412
; Patent No. 5866679
;   GENERAL INFORMATION:
;   APPLICANT:  DeFeo-Jones, Deborah
;   APPLICANT:  Feng, Dong-Mei
;   APPLICANT:  Garsky, Victor M.
;   APPLICANT:  Jones, Raymond E.
;   APPLICANT:  Oliff, Allen I.
;   TITLE OF INVENTION:  NOVEL PEPTIDES
;   NUMBER OF SEQUENCES:  194
;   CORRESPONDENCE ADDRESS:

```

; ADDRESSEE: DAVID A. MUTHARD  
 ; STREET: 126 E. Lincoln Avenue, P.O. BOX 2000  
 ; CITY: RAHWAY  
 ; STATE: NEW JERSEY  
 ; COUNTRY: U.S.A.  
 ; ZIP: 07065  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: PatentIn Release #1.0, Version #1.30  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/540,412  
 ; FILING DATE:  
 ; CLASSIFICATION: 530  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Muthard, David A.  
 ; REGISTRATION NUMBER: 35,297  
 ; REFERENCE/DOCKET NUMBER: 19253IC  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: (908)594-3903  
 ; TELEFAX: (908)594-4720  
 ; INFORMATION FOR SEQ ID NO: 184:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 11 amino acids  
 ; TYPE: amino acid  
 ; STRANDEDNESS: single  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: peptide  
 US-08-540-412-184

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
 |||  
 Db 9 SSL 11

# RESULT 49

US-08-540-412-191

; Sequence 191, Application US/08540412

; Patent No. 5866679

## ; GENERAL INFORMATION:

; APPLICANT: DeFeo-Jones, Deborah

; APPLICANT: Feng, Dong-Mei

; APPLICANT: Garsky, Victor M.

; APPLICANT: Jones, Raymond E.

; APPLICANT: Oliff, Allen I.

; TITLE OF INVENTION: NOVEL PEPTIDES

; NUMBER OF SEQUENCES: 194

## ; CORRESPONDENCE ADDRESS:

; ADDRESSEE: DAVID A. MUTHARD

; STREET: 126 E. Lincoln Avenue, P.O. BOX 2000

; CITY: RAHWAY

; STATE: NEW JERSEY

```

; COUNTRY: U.S.A.
; ZIP: 07065
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/540,412
; FILING DATE:
; CLASSIFICATION: 530
; ATTORNEY/AGENT INFORMATION:
; NAME: Muthard, David A.
; REGISTRATION NUMBER: 35,297
; REFERENCE/DOCKET NUMBER: 19253IC
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (908)594-3903
; TELEFAX: (908)594-4720
; INFORMATION FOR SEQ ID NO: 191:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-540-412-191

```

```

Query Match          27.3%; Score 3; DB 2; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      8 SSL 10
      |||
Db      9 SSL 11

```

# RESULT 50

US-08-422-092-3

```

; Sequence 3, Application US/08422092
; Patent No. 5869046
; GENERAL INFORMATION:
; APPLICANT: Leonard Presta
; APPLICANT: Brad Snedecor
; TITLE OF INVENTION: Altered Polypeptides with Increased
; TITLE OF INVENTION: Half-Life
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 460 Point San Bruno Blvd
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch, 360 Kb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS

```

```

;   SOFTWARE:  patin (Genentech)
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER:  US/08/422,092
;     FILING DATE:  14-APR-1995
;     CLASSIFICATION:  530
;   PRIOR APPLICATION DATA:
;     APPLICATION NUMBER:
;     FILING DATE:
;   ATTORNEY/AGENT INFORMATION:
;     NAME:  Lee, Wendy M.
;     REGISTRATION NUMBER:
;     REFERENCE/DOCKET NUMBER:  932-4
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE:  415/225-1994
;     TELEFAX:  415/952-9881
;     TELEX:  910/371-7168
;   INFORMATION FOR SEQ ID NO:  3:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  11 amino acids
;       TYPE:  amino acid
;       TOPOLOGY:  linear
US-08-422-092-3

```

```

Query Match          27.3%;  Score 3;  DB 2;  Length 11;
Best Local Similarity 100.0%;  Pred. No. 2.7e+03;
Matches      3;  Conservative    0;  Mismatches    0;  Indels      0;  Gaps      0;

```

```

Qy      7 NSS 9
        |||
Db      3 NSS 5

```

RESULT 51

US-08-468-819-14

```

; Sequence 14, Application US/08468819
; Patent No. 5871723
; GENERAL INFORMATION:
;   APPLICANT:  Strieter, Robert M.
;   APPLICANT:  Polverini, Peter J.
;   APPLICANT:  Kunkel, Steven L.
;   TITLE OF INVENTION:  CXC Chemokines as Regulators of
;   TITLE OF INVENTION:  Angiogenesis
;   NUMBER OF SEQUENCES:  93
;   CORRESPONDENCE ADDRESS:
;     ADDRESSEE:  Arnold, White & Durkee
;     STREET:  P.O. Box 4433
;     CITY:  Houston
;     STATE:  TX
;     COUNTRY:  US
;     ZIP:  77210
;   COMPUTER READABLE FORM:
;     MEDIUM TYPE:  Floppy disk
;     COMPUTER:  IBM PC compatible
;     OPERATING SYSTEM:  PC-DOS/MS-DOS
;     SOFTWARE:  PatentIn Release #1.0, Version #1.30
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER:  US/08/468,819

```

; FILING DATE: Concurrently herewith  
 ; CLASSIFICATION: 424  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Highlander, Steven L.  
 ; REGISTRATION NUMBER: 37,642  
 ; REFERENCE/DOCKET NUMBER: UMIC:003/HYL  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: 512/418-3000  
 ; TELEFAX: 512/474-7477  
 ; TELEX: N/A  
 ; INFORMATION FOR SEQ ID NO: 14:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 11 amino acids  
 ; TYPE: amino acid  
 ; STRANDEDNESS: single  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: peptide  
 US-08-468-819-14

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 RKG 6  
 |||  
 Db 5 RKG 7

RESULT 52

US-08-559-524A-11

; Sequence 11, Application US/08559524A  
 ; Patent No. 5871963  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Conley, Pamela B.  
 ; APPLICANT: Jantzen, Hans-Michael  
 ; TITLE OF INVENTION: NOVEL PURINERGIC RECEPTOR  
 ; NUMBER OF SEQUENCES: 14  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: MORGAN, LEWIS & BOCKIUS LLP  
 ; STREET: 1800 M Street, N.W.  
 ; CITY: Washington  
 ; STATE: D.C.  
 ; COUNTRY: USA  
 ; ZIP: 20036-5869  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: PatentIn Release #1.0, Version #1.30  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/559,524A  
 ; FILING DATE: 15-NOV-1995  
 ; CLASSIFICATION: 435  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Adler, Reid G.  
 ; REGISTRATION NUMBER: 30,988  
 ; REFERENCE/DOCKET NUMBER: 044481-5010-00-US

; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202-467-7000  
; TELEFAX: 202-467-7176  
; INFORMATION FOR SEQ ID NO: 11:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 11 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-559-524A-11

Query Match 27.3%; Score 3; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 NSS 9  
|||  
Db 7 NSS 9

RESULT 53

US-08-637-759B-76

; Sequence 76, Application US/08637759B  
; Patent No. 5876931  
; GENERAL INFORMATION:  
; APPLICANT: David William Holden  
; TITLE OF INVENTION: Identification of Genes  
; NUMBER OF SEQUENCES: 501  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Patrea L. Pabst  
; STREET: 2800 One Atlantic Center  
; STREET: 1201 West Peachtree Street  
; CITY: Atlanta  
; STATE: Georgia  
; COUNTRY: USA  
; ZIP: 30309-3450  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/637,759B  
; FILING DATE: 03-MAY-1996  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: PCT/GB95/02875  
; FILING DATE: 11-DEC-1995  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Pabst, Patrea L.  
; REGISTRATION NUMBER: 31,284  
; REFERENCE/DOCKET NUMBER: RPMS 101  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (404) 873-8794  
; TELEFAX: (404) 873-8795



; INFORMATION FOR SEQ ID NO: 76:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 11 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; HYPOTHETICAL: NO  
US-08-637-759B-76

Query Match 27.3%; Score 3; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AKS 3  
|||  
Db 6 AKS 8

RESULT 54

US-08-463-076E-370

; Sequence 370, Application US/08463076E  
; Patent No. 5880096  
; GENERAL INFORMATION:  
; APPLICANT: Barrett, Ronald W.  
; APPLICANT: Yanofsky, Stephen D.  
; TITLE OF INVENTION: Peptides and Compounds That Bind to the  
; TITLE OF INVENTION: IL-1 Receptor  
; NUMBER OF SEQUENCES: 392  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Townsend and Townsend and Crew LLP  
; STREET: Two Embarcadero Center, Eighth Floor  
; CITY: San Francisco  
; STATE: California  
; COUNTRY: USA  
; ZIP: 94111-3834  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/463,076E  
; FILING DATE: 05-JUN-1995  
; CLASSIFICATION: 514  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Snyder, Joseph R.  
; REGISTRATION NUMBER: 39,381  
; REFERENCE/DOCKET NUMBER: 16528A-001850US  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (415) 576-0200  
; TELEFAX: (415) 576-0300  
; INFORMATION FOR SEQ ID NO: 370:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 11 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:

; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-463-076E-370

Query Match 27.3%; Score 3; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 NSS 9  
|||  
Db 2 NSS 4

RESULT 55

US-08-788-800-8

; Sequence 8, Application US/08788800  
; Patent No. 5914112  
; GENERAL INFORMATION:  
; APPLICANT: Bednar, Martin M.  
; APPLICANT: Thomas, G. Roger  
; APPLICANT: Gross, Cordell E.  
; TITLE OF INVENTION: ANTI-CD18 ANTIBODIES IN STROKE  
; NUMBER OF SEQUENCES: 15  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Genentech, Inc.  
; STREET: 460 Point San Bruno Blvd  
; CITY: South San Francisco  
; STATE: California  
; COUNTRY: USA  
; ZIP: 94080  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: WinPatin (Genentech)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/788,800  
; FILING DATE: 22-Jan-1997  
; CLASSIFICATION: 424  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Lee, Wendy M.  
; REGISTRATION NUMBER: 40,378  
; REFERENCE/DOCKET NUMBER: P0987r1  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 415/225-1994  
; TELEFAX: 415/952-9881  
; TELEX: 910/371-7168  
; INFORMATION FOR SEQ ID NO: 8:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 11 amino acids  
; TYPE: Amino Acid  
; TOPOLOGY: Linear

US-08-788-800-8

Query Match 27.3%; Score 3; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 NSS 9  
|||  
Db 3 NSS 5

RESULT 56

US-08-982-597A-6

; Sequence 6, Application US/08982597A  
; Patent No. 5932693  
; GENERAL INFORMATION:  
; APPLICANT: Santoro, Samuel A.  
; APPLICANT: Staatz, William D.  
; TITLE OF INVENTION: Antithrombotic Peptides  
; NUMBER OF SEQUENCES: 26  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Scott J. Meyer  
; STREET: 800 No. 5932693th Lindbergh Blvd.  
; CITY: St. Louis  
; STATE: MO  
; COUNTRY: USA  
; ZIP: 63167  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Word Perfect 5.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/982,597A  
; FILING DATE:  
; CLASSIFICATION: 530  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/032,542  
; FILING DATE: 10-DEC-1996  
; CLASSIFICATION: 530  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Meyer, Scott J.  
; REGISTRATION NUMBER: 25,275  
; REFERENCE/DOCKET NUMBER: WU-3002  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 314-694-3117  
; INFORMATION FOR SEQ ID NO: 6:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 11 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide

US-08-982-597A-6

Query Match 27.3%; Score 3; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 GNS 8  
|||  
Db 9 GNS 11

RESULT 57  
 US-08-747-137-63  
 ; Sequence 63, Application US/08747137  
 ; Patent No. 5945033  
 ; GENERAL INFORMATION:  
 ; APPLICANT: YEN, Richard C.K.  
 ; TITLE OF INVENTION: NON-CROSSLINKED PROTEIN PARTICLES FOR  
 ; TITLE OF INVENTION: THERAPEUTIC AND DIAGNOSTIC USE  
 ; NUMBER OF SEQUENCES: 184  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Townsend and Townsend and Crew LLP  
 ; STREET: Two Embarcadero Center, 8th Floor  
 ; CITY: San Francisco  
 ; STATE: CA  
 ; COUNTRY: USA  
 ; ZIP: 94111  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: PatentIn Release #1.0, Version #1.30  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/747,137  
 ; FILING DATE: 12-NOV-1996  
 ; CLASSIFICATION: 424  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: US 08/212,546  
 ; FILING DATE: 14-MAR-1994  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: US 08/069,831  
 ; FILING DATE: 01-JUN-1993  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: US 07/959,560  
 ; FILING DATE: 13-OCT-1992  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: US 07/641,720  
 ; FILING DATE: 15-JAN-1991  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Apple, Randolph T.  
 ; REGISTRATION NUMBER: 36,429  
 ; REFERENCE/DOCKET NUMBER: 016197-000840US  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: 415-576-0200  
 ; INFORMATION FOR SEQ ID NO: 63:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 11 amino acids  
 ; TYPE: amino acid  
 ; STRANDEDNESS: not relevant  
 ; TOPOLOGY: not relevant  
 US-08-747-137-63

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 KSR 4

## RESULT 58

US-08-989-667-9

; Sequence 9, Application US/08989667

; Patent No. 5948662

## ; GENERAL INFORMATION:

; APPLICANT: KOBAYASHI, KATSUNORI

; APPLICANT: YAMANAKA, SHIGERU

; APPLICANT: MIWA, KIYOSHI

; APPLICANT: SUZUKI, SHUNICHI

; APPLICANT: ETO, YUZURU

; APPLICANT: TANITA, YUKO

; APPLICANT: YOKOZEKI, KENZO

; APPLICANT: HASHIGUCHI, KENICHI

; TITLE OF INVENTION: BACILLUS-DERIVED TRANSGLUTAMINASE

; NUMBER OF SEQUENCES: 9

## ; CORRESPONDENCE ADDRESS:

; ADDRESSEE: OBLON, SPIVAK, MCCLELLEAND, MAIER &amp; NEUSTADT,

; ADDRESSEE: P.C.

; STREET: 1755 S. JEFFERSON DAVIS HIGHWAY, SUITE 400

; CITY: ARLINGTON

; STATE: VA

; COUNTRY: USA

; ZIP: 22202

## ; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.30

## ; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/989,667

; FILING DATE:

; CLASSIFICATION:

## ; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 08/596,864

; FILING DATE: 09-FEB-1996

; APPLICATION NUMBER: JP 021963/1995

; FILING DATE: 09-FEB-1995

## ; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: JP 226316/1995

; FILING DATE: 04-SEP-1995

## ; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: JP 013072/1996

; FILING DATE: 29-JAN-1996

## ; ATTORNEY/AGENT INFORMATION:

; NAME: OBLON, NORMAN F.

; REGISTRATION NUMBER: 24,618

; REFERENCE/DOCKET NUMBER: 10-786-0

## ; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 703-413-3000

; TELEFAX: 703-413-2220

; INFORMATION FOR SEQ ID NO: 9:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 11 amino acids

; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-989-667-9

Query Match 27.3%; Score 3; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 NSS 9  
|||  
Db 6 NSS 8

RESULT 59

US-09-121-527-4  
; Sequence 4, Application US/09121527  
; Patent No. 5958775  
; GENERAL INFORMATION:  
; APPLICANT: WICKSTROM, ERIC  
; APPLICANT: CLEAVER, STEPHEN  
; TITLE OF INVENTION: COMPOSITION AND METHOD FOR TARGETED INTEGRATION INTO  
; TITLE OF INVENTION: CELLS  
; FILE REFERENCE: JEFF-0251  
; CURRENT APPLICATION NUMBER: US/09/121,527  
; CURRENT FILING DATE: 1998-07-23  
; EARLIER APPLICATION NUMBER: 60/054,146  
; EARLIER FILING DATE: 1997-07-25  
; NUMBER OF SEQ ID NOS: 4  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 4  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-121-527-4

Query Match 27.3%; Score 3; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AKS 3  
|||  
Db 5 AKS 7

RESULT 60

US-08-350-260A-485  
; Sequence 485, Application US/08350260A  
; Patent No. 5962255  
; GENERAL INFORMATION:  
; APPLICANT: Winter, Gregory Paul  
; APPLICANT: Griffiths, Andrew David  
; APPLICANT: Williams, Samuel Cameron  
; APPLICANT: Waterhouse, Peter  
; APPLICANT: Nissim, Ahuva  
; APPLICANT: Johnson, Kevin Stuart

```

; APPLICANT: Smith, Andrew John Hammond
; TITLE OF INVENTION: Methods for producing members of specific
; TITLE OF INVENTION: binding pairs
; NUMBER OF SEQUENCES: 602
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: David W. Clough
; STREET: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/350,260A
; FILING DATE: 05-DEC-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9110549.4
; FILING DATE: 15-MAY-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9206318.9
; FILING DATE: 24-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/GB91/01134
; FILING DATE: 10-JUL-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/GB92/00883
; FILING DATE: 15-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/GB93/00605
; FILING DATE: 24-MAR-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/150,002
; FILING DATE: 31-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/307,619
; FILING DATE: 16-SEP-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Clough, David W
; REGISTRATION NUMBER: 36,107
; REFERENCE/DOCKET NUMBER: 28111/32372
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312-474-6300
; INFORMATION FOR SEQ ID NO: 485:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-350-260A-485

```

Query Match 27.3%; Score 3; DB 2; Length 11;

Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SRK 5  
|||  
Db 5 SRK 7

RESULT 61

US-08-827-009-1

; Sequence 1, Application US/08827009

; Patent No. 5968511

; GENERAL INFORMATION:

; APPLICANT: Akita, Robert

; APPLICANT: Sliwowski, Mark

; TITLE OF INVENTION: ErbB3 Antibodies

; NUMBER OF SEQUENCES: 5

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Genentech, Inc.

; STREET: 1 DNA Way

; CITY: South San Francisco

; STATE: California

; COUNTRY: USA

; ZIP: 94080

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: WinPatin (Genentech)

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/827,009

; FILING DATE:

; CLASSIFICATION: 424

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 60/046850

; FILING DATE: 27-MAR-1996

; ATTORNEY/AGENT INFORMATION:

; NAME: Lee, Wendy M.

; REGISTRATION NUMBER: 40,378

; REFERENCE/DOCKET NUMBER: P1003R1

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 650/225-1994

; TELEFAX: 650/952-9881

; INFORMATION FOR SEQ ID NO: 1:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 11 amino acids

; TYPE: Amino Acid

; TOPOLOGY: Linear

US-08-827-009-1

Query Match 27.3%; Score 3; DB 2; Length 11;

Best Local Similarity 100.0%; Pred. No. 2.7e+03;

Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 NSS 9  
|||  
Db 3 NSS 5



RESULT 62

US-08-343-443B-68

; Sequence 68, Application US/08343443B

; Patent No. 5968734

; GENERAL INFORMATION:

; APPLICANT: Aurias, Alain

; APPLICANT: Delattre, Olivier

; APPLICANT: Desmaze, Chantal

; APPLICANT: Melot, Thomas

; APPLICANT: Peter, Martine

; APPLICANT: Ploougastel, Beatrice

; APPLICANT: Thomas, Gilles

; APPLICANT: Zucman, Jessica

; TITLE OF INVENTION: NUCLEIC ACID CORRESPONDING TO A GENE OF

; TITLE OF INVENTION: CHROMOSOME 22 INVOLVED IN RECURRENT CHROMOSOMAL

; TITLE OF INVENTION: TRANSLATIONS ASSOCIATED WITH THE DEVELOPMENT OF

CANCEROUS

; TITLE OF INVENTION: TUMORS, AND NUCLEIC ACIDS OF FUSION RESULTING FROM

SAID

; TITLE OF INVENTION: TRANSLOCATIONS

; NUMBER OF SEQUENCES: 129

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Weiser & Associates

; STREET: 230 South Fifteenth Street

; CITY: Philadelphia

; STATE: PA

; COUNTRY: USA

; ZIP: 19102

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: AEDIT 1.0 DOS text editor

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/343,443B

; FILING DATE: 18-NOV-1994

; CLASSIFICATION: 514

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: PCT/FR93/00494

; FILING DATE: 19-MAY-1993

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: FR 92/06123

; FILING DATE: 20-MAY-1992

; ATTORNEY/AGENT INFORMATION:

; NAME: Weiser, Gerard J.

; REGISTRATION NUMBER: 19,763

; REFERENCE/DOCKET NUMBER: 989.6121P

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 215-875-8383

; TELEFAX: 215-875-8394

; INFORMATION FOR SEQ ID NO: 68:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 11 amino acids

; TYPE: amino acid

; TOPOLOGY: linear

; MOLECULE TYPE: protein  
US-08-343-443B-68

Query Match 27.3%; Score 3; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 SSL 10  
|||  
Db 6 SSL 8

RESULT 63

US-08-466-860-3

; Sequence 3, Application US/08466860  
; Patent No. 5985552

; GENERAL INFORMATION:

; APPLICANT: HOWELL, MARK D.  
; APPLICANT: BROSTOFF, STEVEN W.  
; APPLICANT: CARLO, DENNIS J.  
; TITLE OF INVENTION: VACCINATION AND METHODS AGAINST DISEASES  
; TITLE OF INVENTION: RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL  
; TITLE OF INVENTION: POPULATIONS  
; NUMBER OF SEQUENCES: 75  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: CAMPBELL AND FLORES  
; STREET: 4370 LA JOLLA VILLAGE DRIVE, SUITE 700  
; CITY: SAN DIEGO  
; STATE: CALIFORNIA  
; COUNTRY: UNITED STATES  
; ZIP: 92122

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/466,860  
; FILING DATE:  
; CLASSIFICATION: 424

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 07/813,867  
; FILING DATE: 24-DEC-1991

; ATTORNEY/AGENT INFORMATION:

; NAME: CAMPBELL, CATHRYN  
; REGISTRATION NUMBER: 31,815  
; REFERENCE/DOCKET NUMBER: P-IM 9107

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 619-535-9001  
; TELEFAX: 619-535-8949

; INFORMATION FOR SEQ ID NO: 3:

; SEQUENCE CHARACTERISTICS:  
; LENGTH: 11 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; FRAGMENT TYPE: N-terminal

US-08-466-860-3

Query Match 27.3%; Score 3; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
|||  
Db 2 SSL 4

RESULT 64

US-08-466-860-6

; Sequence 6, Application US/08466860  
; Patent No. 5985552  
; GENERAL INFORMATION:  
; APPLICANT: HOWELL, MARK D.  
; APPLICANT: BROSTOFF, STEVEN W.  
; APPLICANT: CARLO, DENNIS J.  
; TITLE OF INVENTION: VACCINATION AND METHODS AGAINST DISEASES  
; TITLE OF INVENTION: RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL  
; TITLE OF INVENTION: POPULATIONS  
; NUMBER OF SEQUENCES: 75  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: CAMPBELL AND FLORES  
; STREET: 4370 LA JOLLA VILLAGE DRIVE, SUITE 700  
; CITY: SAN DIEGO  
; STATE: CALIFORNIA  
; COUNTRY: UNITED STATES  
; ZIP: 92122  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/466,860  
; FILING DATE:  
; CLASSIFICATION: 424  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/813,867  
; FILING DATE: 24-DEC-1991  
; ATTORNEY/AGENT INFORMATION:  
; NAME: CAMPBELL, CATHRYN  
; REGISTRATION NUMBER: 31,815  
; REFERENCE/DOCKET NUMBER: P-IM 9107  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 619-535-9001  
; TELEFAX: 619-535-8949  
; INFORMATION FOR SEQ ID NO: 6:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 11 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; FRAGMENT TYPE: N-terminal  
US-08-466-860-6

Query Match 27.3%; Score 3; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
|||  
Db 2 SSL 4

RESULT 65

US-08-871-355A-76

; Sequence 76, Application US/08871355A  
; Patent No. 6015669  
; GENERAL INFORMATION:  
; APPLICANT: David William Holden  
; TITLE OF INVENTION: Identification of Genes  
; NUMBER OF SEQUENCES: 501  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Patrea L. Pabst  
; STREET: 2800 One Atlantic Center  
; STREET: 1201 West Peachtree Street  
; CITY: Atlanta  
; STATE: Georgia  
; COUNTRY: USA  
; ZIP: 30309-3450  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/871,355A  
; FILING DATE: 09-JUN-1997  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: PCT/GB95/02875  
; FILING DATE: 11-DEC-1995  
; CLASSIFICATION: 435  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Pabst, Patrea L.  
; REGISTRATION NUMBER: 31,284  
; REFERENCE/DOCKET NUMBER: RPMS 101 CON  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (404) 873-8794  
; TELEFAX: (404) 873-8795  
; INFORMATION FOR SEQ ID NO: 76:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 11 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: protein  
; HYPOTHETICAL: NO  
US-08-871-355A-76

Query Match 27.3%; Score 3; DB 3; Length 11;

Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AKS 3  
|||  
Db 6 AKS 8

RESULT 66

US-08-904-446A-6

; Sequence 6, Application US/08904446A

; Patent No. 6029114

; GENERAL INFORMATION:

; APPLICANT: Shamovsky, Igor L.

; APPLICANT: Ross, Gregory M.

; APPLICANT: Riopelle, Richard J.

; APPLICANT: Weaver, Donald F.

; TITLE OF INVENTION: Molecular Modelling of Neurotrophin-Receptor

; TITLE OF INVENTION: Binding

; NUMBER OF SEQUENCES: 17

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Dowell & Dowell, P.C.

; STREET: 1215 Jefferson Davis Highway, Suite 309

; CITY: Arlington

; STATE: Virginia

; COUNTRY: United States of America

; ZIP: 22202

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/904,446A

; FILING DATE: 31-JUL-1997

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: GB 9616105.4

; FILING DATE: 31-JUL-1996

; ATTORNEY/AGENT INFORMATION:

; NAME: RALPH A. DOWELL

; REGISTRATION NUMBER: 26868

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (703) 415-2555

; TELEFAX: (703) 415-2559

; INFORMATION FOR SEQ ID NO: 6:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 11 amino acids

; TYPE: amino acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: peptide

; FEATURE:

; NAME/KEY: Peptide

; LOCATION: 1..11

; OTHER INFORMATION: /note= "C-terminal residues 108-118

; OTHER INFORMATION: of human NGF"

US-08-904-446A-6

Query Match 27.3%; Score 3; DB 3; Length 11;  
Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SRK 5  
|||  
Db 6 SRK 8

RESULT 67

US-08-904-446A-7

; Sequence 7, Application US/08904446A  
; Patent No. 6029114

; GENERAL INFORMATION:

; APPLICANT: Shamovsky, Igor L.  
; APPLICANT: Ross, Gregory M.  
; APPLICANT: Riopelle, Richard J.  
; APPLICANT: Weaver, Donald F.  
; TITLE OF INVENTION: Molecular Modelling of Neurotrophin-Receptor  
; TITLE OF INVENTION: Binding  
; NUMBER OF SEQUENCES: 17  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Dowell & Dowell, P.C.  
; STREET: 1215 Jefferson Davis Highway, Suite 309  
; CITY: Arlington  
; STATE: Virginia  
; COUNTRY: United States of America  
; ZIP: 22202

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/904,446A  
; FILING DATE: 31-JUL-1997

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: GB 9616105.4  
; FILING DATE: 31-JUL-1996

; ATTORNEY/AGENT INFORMATION:

; NAME: RALPH A. DOWELL  
; REGISTRATION NUMBER: 26868

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (703) 415-2555  
; TELEFAX: (703) 415-2559

; INFORMATION FOR SEQ ID NO: 7:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 11 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear

; MOLECULE TYPE: peptide

; FEATURE:

; NAME/KEY: Peptide  
; LOCATION: 1..11  
; OTHER INFORMATION: /note= "C-terminal residues 108-118"

; OTHER INFORMATION: of mouse NGE"  
US-08-904-446A-7

Query Match 27.3%; Score 3; DB 3; Length 11;  
Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SRK 5  
|||  
Db 6 SRK 8

RESULT 68

US-08-159-339A-1131

; Sequence 1131, Application US/08159339A

; Patent No. 6037135

; GENERAL INFORMATION:

; APPLICANT: Kubo, Ralph T.

; APPLICANT: Grey, Howard M.

; APPLICANT: Sette, Alessandro

; APPLICANT: Celis, Esteban

; TITLE OF INVENTION: HLA Binding peptides and Their

; TITLE OF INVENTION: Uses

; NUMBER OF SEQUENCES: 1254

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Townsend and Townsend and Crew LLP

; STREET: Two Embarcadero Center, Eighth Floor

; CITY: San Francisco

; STATE: CA

; COUNTRY: USA

; ZIP: 94111-3834

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Diskette

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: DOS

; SOFTWARE: FastSEQ for Windows Version 2.0

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/159,339A

; FILING DATE: 29-NOV-1993

; CLASSIFICATION: 424

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 07/926,666

; FILING DATE: 07-AUG-1992

; APPLICATION NUMBER: US 08/027,746

; FILING DATE: 05-MAR-1993

; APPLICATION NUMBER: US 08/103,396

; FILING DATE: 06-AUG-1993

; ATTORNEY/AGENT INFORMATION:

; NAME: Weber, Ellen Lauver

; REGISTRATION NUMBER: 32,762

; REFERENCE/DOCKET NUMBER: 018623-005030US

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (415) 576-0200

; TELEFAX: (415) 576-0300

; TELEX:

; INFORMATION FOR SEQ ID NO: 1131:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 11 amino acids  
; TYPE: amino acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-08-159-339A-1131

Query Match 27.3%; Score 3; DB 3; Length 11;  
Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SRK 5  
|||  
Db 9 SRK 11

RESULT 69

US-08-974-899-16

; Sequence 16, Application US/08974899  
; Patent No. 6037454  
; GENERAL INFORMATION:  
; APPLICANT: Presta, Leonard G.  
; APPLICANT: Jardieu, Paula M.  
; TITLE OF INVENTION: Humanized Anti-CD11a Antibodies  
; NUMBER OF SEQUENCES: 24  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Genentech, Inc.  
; STREET: 1 DNA Way  
; CITY: South San Francisco  
; STATE: California  
; COUNTRY: USA  
; ZIP: 94080  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: WinPatin (Genentech)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/974,899  
; FILING DATE:  
; CLASSIFICATION: 536  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/031971  
; FILING DATE: 11/27/96  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Lee, Wendy M.  
; REGISTRATION NUMBER: 40,378  
; REFERENCE/DOCKET NUMBER: P1014R1  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 650/225-1994  
; TELEFAX: 650/952-9881  
; INFORMATION FOR SEQ ID NO: 16:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 11 amino acids  
; TYPE: Amino Acid  
; TOPOLOGY: Linear  
US-08-974-899-16



Query Match 27.3%; Score 3; DB 3; Length 11;  
Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 NSS 9  
|||  
Db 3 NSS 5

RESULT 70

US-08-749-707-11

; Sequence 11, Application US/08749707  
; Patent No. 6063582  
; GENERAL INFORMATION:  
; APPLICANT: Conley, Pamela B.  
; APPLICANT: Jantzen, Hans-Michael  
; TITLE OF INVENTION: NOVEL PURINERGIC RECEPTOR  
; NUMBER OF SEQUENCES: 14  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: MORGAN, LEWIS & BOCKIUS LLP  
; STREET: 1800 M Street, N.W.  
; CITY: Washington  
; STATE: D.C.  
; COUNTRY: USA  
; ZIP: 20036-5869  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/749,707  
; FILING DATE: 15-NOV-1996  
; CLASSIFICATION: 536  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Adler, Reid G.  
; REGISTRATION NUMBER: 30,988  
; REFERENCE/DOCKET NUMBER: 044481-5010-01-US  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 202-467-7000  
; TELEFAX: 202-467-7176  
; INFORMATION FOR SEQ ID NO: 11:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 11 amino acids  
; TYPE: amino acid  
; STRANDEDNESS:  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide

US-08-749-707-11

Query Match 27.3%; Score 3; DB 3; Length 11;  
Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 NSS 9  
|||

Db 7 NSS 9

RESULT 71

US-09-136-218-6

; Sequence 6, Application US/09136218  
; Patent No. 6083914  
; GENERAL INFORMATION:  
; APPLICANT: Santoro, Samuel A.  
; APPLICANT: Staatz, William D.  
; TITLE OF INVENTION: Antithrombotic Peptides  
; NUMBER OF SEQUENCES: 26  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Scott J. Meyer  
; STREET: 800 No. 6083914th Lindbergh Blvd.  
; CITY: St. Louis  
; STATE: MO  
; COUNTRY: USA  
; ZIP: 63167  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Word Perfect 5.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/136,218  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/982,597  
; FILING DATE:  
; APPLICATION NUMBER: 60/032,542  
; FILING DATE: 10-DEC-1996  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Meyer, Scott J.  
; REGISTRATION NUMBER: 25,275  
; REFERENCE/DOCKET NUMBER: WU-3002  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 314-694-3117  
; INFORMATION FOR SEQ ID NO: 6:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 11 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
US-09-136-218-6

Query Match 27.3%; Score 3; DB 3; Length 11;  
Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 6 GNS 8  
|||  
Db 9 GNS 11

RESULT 72

US-08-472-040A-3

; Sequence 3, Application US/08472040A  
; Patent No. 6090387  
; GENERAL INFORMATION:  
; APPLICANT: HOWELL, MARK D.  
; APPLICANT: BROSTOFF, STEVEN W.  
; APPLICANT: CARLO, DENNIS J.  
; TITLE OF INVENTION: VACCINATION AND METHODS AGAINST DISEASES  
; TITLE OF INVENTION: RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL  
; TITLE OF INVENTION: POPULATIONS  
; NUMBER OF SEQUENCES: 77  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: CAMPBELL & FLORES LLP  
; STREET: 4370 LA JOLLA VILLAGE DRIVE, SUITE 700  
; CITY: SAN DIEGO  
; STATE: CALIFORNIA  
; COUNTRY: UNITED STATES  
; ZIP: 92122  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/472,040A  
; FILING DATE: 06-JUN-1995  
; CLASSIFICATION: 424  
; ATTORNEY/AGENT INFORMATION:  
; NAME: CAMPBELL, CATHRYN  
; REGISTRATION NUMBER: 31,815  
; REFERENCE/DOCKET NUMBER: P-IM 1641  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 619-535-9001  
; TELEFAX: 619-535-8949  
; INFORMATION FOR SEQ ID NO: 3:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 11 amino acids  
; TYPE: amino acid  
; TOPOLOGY: linear  
; MOLECULE TYPE: peptide  
; FRAGMENT TYPE: N-terminal

US-08-472-040A-3

Query Match 27.3%; Score 3; DB 3; Length 11;  
Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
|||  
Db 2 SSL 4

RESULT 73

US-08-472-040A-6

; Sequence 6, Application US/08472040A  
; Patent No. 6090387  
; GENERAL INFORMATION:

; APPLICANT: HOWELL, MARK D.  
 ; APPLICANT: BROSTOFF, STEVEN W.  
 ; APPLICANT: CARLO, DENNIS J.  
 ; TITLE OF INVENTION: VACCINATION AND METHODS AGAINST DISEASES  
 ; TITLE OF INVENTION: RESULTING FROM PATHOGENIC RESPONSES BY SPECIFIC T CELL  
 ; TITLE OF INVENTION: POPULATIONS  
 ; NUMBER OF SEQUENCES: 77  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: CAMPBELL & FLORES LLP  
 ; STREET: 4370 LA JOLLA VILLAGE DRIVE, SUITE 700  
 ; CITY: SAN DIEGO  
 ; STATE: CALIFORNIA  
 ; COUNTRY: UNITED STATES  
 ; ZIP: 92122  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: PatentIn Release #1.0, Version #1.25  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/472,040A  
 ; FILING DATE: 06-JUN-1995  
 ; CLASSIFICATION: 424  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: CAMPBELL, CATHRYN  
 ; REGISTRATION NUMBER: 31,815  
 ; REFERENCE/DOCKET NUMBER: P-IM 1641  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: 619-535-9001  
 ; TELEFAX: 619-535-8949  
 ; INFORMATION FOR SEQ ID NO: 6:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 11 amino acids  
 ; TYPE: amino acid  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: peptide  
 ; FRAGMENT TYPE: N-terminal  
 US-08-472-040A-6

Query Match 27.3%; Score 3; DB 3; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
 |||  
 Db 2 SSL 4

#### RESULT 74

US-08-817-177-4

; Sequence 4, Application US/08817177  
 ; Patent No. 6096314

#### GENERAL INFORMATION:

; APPLICANT: COHEN, Irun R.  
 ; APPLICANT: ELIAS, Dana  
 ; TITLE OF INVENTION: PEPTIDES AND PHARMACEUTICAL COMPOSITIONS  
 ; TITLE OF INVENTION: COMPRISING THEM

```

; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Browdy and Neimark, P.L.L.C.
; STREET: 419 Seventh Street, N. W.
; CITY: Washington
; COUNTRY: US
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/817,177
; FILING DATE:
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/12686
; FILING DATE: 10-OCTOBER-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: ISRAEL APP. NO. 111,196
; FILING DATE: 07-OCTOBER-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: BROWDY, Roger L.
; REGISTRATION NUMBER: 25,618
; REFERENCE/DOCKET NUMBER: COHEN=27
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 628-5197
; TELEFAX: (202) 737-3528
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-08-817-177-4

```

```

Query Match          27.3%; Score 3; DB 3; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.7e+03;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      8 SSL 10
      |||
Db      2 SSL 4

```

# RESULT 75

US-08-491-954-93

; Sequence 93, Application US/08491954

; Patent No. 6096321

; GENERAL INFORMATION:

; APPLICANT: Girardeau, Jean-Pierre

; APPLICANT: Martin, Christine

; APPLICANT: Mechin, Marie-Claire

; APPLICANT: Der Vartanian, Maurice

; APPLICANT: Bousquet, Francois

; TITLE OF INVENTION: SUB-UNIT OF CS31A PROTEIN CAPSULE  
 ; TITLE OF INVENTION: MODIFIED BY AT LEAST ONE HETEROLOGOUS PEPTIDE, CS31A  
 ; TITLE OF INVENTION: PROTEIN CAPSULE INCLUDING SUCH A SUB-UNIT, AND  
 ; TITLE OF INVENTION: MICROORGANISMS WHOSE OUTER MEMBRANE CARRIES SUCH  
 ; TITLE OF INVENTION: SUB-UNITS, AND PROCEDURE FOR OBTAINING AND UTILIZING  
 SUCH  
 ; TITLE OF INVENTION: SUB-UNITS  
 ; NUMBER OF SEQUENCES: 115  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: WEISER & ASSOCIATES  
 ; STREET: 230 South Fifteenth Street, Suite 500  
 ; CITY: Philadelphia  
 ; STATE: PA  
 ; COUNTRY: USA  
 ; ZIP: 19102  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: Floppy disk  
 ; COMPUTER: IBM PC compatible  
 ; OPERATING SYSTEM: PC-DOS/MS-DOS  
 ; SOFTWARE: PatentIn Release #1.0, Version #1.30  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: US/08/491,954  
 ; FILING DATE: 16-FEB-1996  
 ; CLASSIFICATION: 424  
 ; PRIOR APPLICATION DATA:  
 ; APPLICATION NUMBER: PCT/FR93/01281  
 ; FILING DATE: 21-DEC-1993  
 ; ATTORNEY/AGENT INFORMATION:  
 ; NAME: Weiser, Gerard J.  
 ; REGISTRATION NUMBER: 19,763  
 ; REFERENCE/DOCKET NUMBER: 989.6264P  
 ; TELECOMMUNICATION INFORMATION:  
 ; TELEPHONE: 215-875-8383  
 ; TELEFAX: 215-875-8394  
 ; INFORMATION FOR SEQ ID NO: 93:  
 ; SEQUENCE CHARACTERISTICS:  
 ; LENGTH: 11 amino acids  
 ; TYPE: amino acid  
 ; TOPOLOGY: linear  
 ; MOLECULE TYPE: protein  
 US-08-491-954-93

Query Match 27.3%; Score 3; DB 3; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 2.7e+03;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 NSS 9  
 |||  
 Db 1 NSS 3

Search completed: April 8, 2004, 15:52:16  
 Job time : 12.3077 secs

OM protein - protein search, using sw model

Run on: April 8, 2004, 15:30:07 ; Search time 8.61538 Seconds  
 (without alignments)  
 122.816 Million cell updates/sec

Title: US-09-787-443A-21  
 Perfect score: 11  
 Sequence: 1 AKSRKGNSSLM 11

Scoring table: OLIGO  
 Gapop 60.0 , Gapext 60.0

Searched: 283366 seqs, 96191526 residues

Word size : 0

Total number of hits satisfying chosen parameters: 226

Minimum DB seq length: 11  
 Maximum DB seq length: 11

Post-processing: Listing first 100 summaries

Database : PIR\_78:\*  
 1: pir1:\*  
 2: pir2:\*  
 3: pir3:\*  
 4: pir4:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

|            |       | % Query |        |    |        |                    |  |
|------------|-------|---------|--------|----|--------|--------------------|--|
| Result No. | Score | Match   | Length | DB | ID     | Description        |  |
| 1          | 3     | 27.3    | 11     | 2  | S66606 | quinoline 2-oxidor |  |
| 2          | 3     | 27.3    | 11     | 2  | H54346 | pyruvate synthase  |  |
| 3          | 3     | 27.3    | 11     | 2  | G61497 | seed protein ws-23 |  |
| 4          | 2     | 18.2    | 11     | 1  | ECLQ2M | tachykinin II - mi |  |
| 5          | 2     | 18.2    | 11     | 1  | SPHO   | substance P - hors |  |
| 6          | 2     | 18.2    | 11     | 1  | EOOCC  | eledoisin - curled |  |
| 7          | 2     | 18.2    | 11     | 1  | A60654 | substance P - guin |  |
| 8          | 2     | 18.2    | 11     | 1  | EOOC   | eledoisin - musky  |  |
| 9          | 2     | 18.2    | 11     | 2  | A33917 | dihydroorotase (EC |  |
| 10         | 2     | 18.2    | 11     | 2  | JN0023 | substance P - chic |  |
| 11         | 2     | 18.2    | 11     | 2  | A40693 | transgelin - sheep |  |
| 12         | 2     | 18.2    | 11     | 2  | A38841 | rhodopsin homolog  |  |
| 13         | 2     | 18.2    | 11     | 2  | S09074 | cytochrome P450-4b |  |

|    |   |      |    |   |        |                    |
|----|---|------|----|---|--------|--------------------|
| 14 | 2 | 18.2 | 11 | 2 | D60409 | kassinin-like pept |
| 15 | 2 | 18.2 | 11 | 2 | F60409 | substance P-like p |
| 16 | 2 | 18.2 | 11 | 2 | E60409 | substance P-like p |
| 17 | 2 | 18.2 | 11 | 2 | B26744 | megascalakiinin -  |
| 18 | 2 | 18.2 | 11 | 2 | S23308 | substance P - rain |
| 19 | 2 | 18.2 | 11 | 2 | S23306 | substance P - Atla |
| 20 | 2 | 18.2 | 11 | 2 | B60409 | kassinin-like pept |
| 21 | 2 | 18.2 | 11 | 2 | C60409 | kassinin-like pept |
| 22 | 2 | 18.2 | 11 | 2 | S07203 | uperolein - frog ( |
| 23 | 2 | 18.2 | 11 | 2 | S07201 | physalaemin - frog |
| 24 | 2 | 18.2 | 11 | 2 | A61033 | ranatachykinin A - |
| 25 | 2 | 18.2 | 11 | 2 | B43669 | hypothetical prote |
| 26 | 2 | 18.2 | 11 | 2 | PC2372 | 58K heat shock pro |
| 27 | 2 | 18.2 | 11 | 2 | S19775 | wound-induced prot |
| 28 | 2 | 18.2 | 11 | 2 | S71304 | amine oxidase (cop |
| 29 | 2 | 18.2 | 11 | 2 | A34135 | DNA-binding protei |
| 30 | 2 | 18.2 | 11 | 2 | A26120 | 6-phosphofructokin |
| 31 | 2 | 18.2 | 11 | 2 | A35594 | buccalin - Califor |
| 32 | 2 | 18.2 | 11 | 2 | S69349 | neuropeptide FFami |
| 33 | 2 | 18.2 | 11 | 2 | S05002 | corazonin - Americ |
| 34 | 2 | 18.2 | 11 | 2 | S33300 | probable substance |
| 35 | 2 | 18.2 | 11 | 2 | S43626 | cytochrome-c oxida |
| 36 | 2 | 18.2 | 11 | 2 | D42965 | talin - chicken (f |
| 37 | 2 | 18.2 | 11 | 2 | I65231 | CCK-B gastrin rece |
| 38 | 2 | 18.2 | 11 | 2 | E57789 | gallbladder stone  |
| 39 | 2 | 18.2 | 11 | 2 | I52980 | glucocerebrosidase |
| 40 | 2 | 18.2 | 11 | 2 | PT0273 | Ig heavy chain CRD |
| 41 | 2 | 18.2 | 11 | 2 | PT0302 | Ig heavy chain CRD |
| 42 | 2 | 18.2 | 11 | 2 | S13279 | Ile-Ser-bradykinin |
| 43 | 2 | 18.2 | 11 | 2 | I54193 | Rhesus blood group |
| 44 | 2 | 18.2 | 11 | 2 | S68649 | spermadhesin AQN-3 |
| 45 | 2 | 18.2 | 11 | 2 | S68637 | acetylcholinestera |
| 46 | 2 | 18.2 | 11 | 2 | A33571 | follistatin - bovi |
| 47 | 2 | 18.2 | 11 | 2 | S23926 | major glycoprotein |
| 48 | 2 | 18.2 | 11 | 2 | A14454 | 6-phosphofructokin |
| 49 | 2 | 18.2 | 11 | 2 | A29806 | acidic proline-ric |
| 50 | 2 | 18.2 | 11 | 2 | PH1375 | T antigen variant  |
| 51 | 2 | 18.2 | 11 | 2 | PH1376 | T antigen variant  |
| 52 | 2 | 18.2 | 11 | 2 | PT0217 | T-cell receptor be |
| 53 | 2 | 18.2 | 11 | 2 | PT0218 | T-cell receptor be |
| 54 | 2 | 18.2 | 11 | 2 | D41946 | T-cell receptor ga |
| 55 | 2 | 18.2 | 11 | 2 | B41946 | T-cell receptor ga |
| 56 | 2 | 18.2 | 11 | 2 | C38887 | T-cell receptor ga |
| 57 | 2 | 18.2 | 11 | 2 | I41946 | T-cell receptor ga |
| 58 | 2 | 18.2 | 11 | 2 | PD0441 | translation elonga |
| 59 | 2 | 18.2 | 11 | 2 | I60434 | 68kDa neurofilamen |
| 60 | 2 | 18.2 | 11 | 2 | S65377 | cytochrome-c oxida |
| 61 | 2 | 18.2 | 11 | 2 | PH0939 | T-cell receptor be |
| 62 | 2 | 18.2 | 11 | 2 | PH0940 | T-cell receptor be |
| 63 | 2 | 18.2 | 11 | 2 | PH0941 | T-cell receptor be |
| 64 | 2 | 18.2 | 11 | 2 | PH0929 | T-cell receptor be |
| 65 | 2 | 18.2 | 11 | 2 | PH0891 | T-cell receptor be |
| 66 | 2 | 18.2 | 11 | 2 | PH0938 | T-cell receptor be |
| 67 | 2 | 18.2 | 11 | 2 | PH0947 | T-cell receptor be |
| 68 | 2 | 18.2 | 11 | 2 | PH0903 | T-cell receptor be |
| 69 | 2 | 18.2 | 11 | 2 | PH0904 | T-cell receptor be |
| 70 | 2 | 18.2 | 11 | 2 | PH0924 | T-cell receptor be |



|     |   |      |    |   |        |                    |
|-----|---|------|----|---|--------|--------------------|
| 71  | 2 | 18.2 | 11 | 2 | PH0919 | T-cell receptor be |
| 72  | 2 | 18.2 | 11 | 2 | PH0914 | T-cell receptor be |
| 73  | 2 | 18.2 | 11 | 2 | PH0922 | T-cell receptor be |
| 74  | 2 | 18.2 | 11 | 2 | PH0906 | T-cell receptor be |
| 75  | 2 | 18.2 | 11 | 2 | A34243 | H-hyosophorin - Ja |
| 76  | 2 | 18.2 | 11 | 2 | S60294 | tubulin 2 beta-3 c |
| 77  | 2 | 18.2 | 11 | 4 | I52708 | ELAV-like neuronal |
| 78  | 2 | 18.2 | 11 | 4 | S19015 | hypothetical prote |
| 79  | 1 | 9.1  | 11 | 1 | XAVIBH | bradykinin-potenti |
| 80  | 1 | 9.1  | 11 | 1 | XASNBA | bradykinin-potenti |
| 81  | 1 | 9.1  | 11 | 1 | GMROL  | leucosulfakinin -  |
| 82  | 1 | 9.1  | 11 | 1 | LFTWWE | probable trpEG lea |
| 83  | 1 | 9.1  | 11 | 2 | S66196 | alcohol dehydrogen |
| 84  | 1 | 9.1  | 11 | 2 | G42762 | proteasome endopep |
| 85  | 1 | 9.1  | 11 | 2 | S68392 | H+-transporting tw |
| 86  | 1 | 9.1  | 11 | 2 | B49164 | chromogranin-B - r |
| 87  | 1 | 9.1  | 11 | 2 | S32575 | ribosomal protein  |
| 88  | 1 | 9.1  | 11 | 2 | PQ0682 | photosystem I 17.5 |
| 89  | 1 | 9.1  | 11 | 2 | S00616 | parasporal crystal |
| 90  | 1 | 9.1  | 11 | 2 | C53652 | rhlR protein - Pse |
| 91  | 1 | 9.1  | 11 | 2 | A57458 | gene Gax protein - |
| 92  | 1 | 9.1  | 11 | 2 | A26930 | ermG leader peptid |
| 93  | 1 | 9.1  | 11 | 2 | YHRT   | morphogenetic neur |
| 94  | 1 | 9.1  | 11 | 2 | YHHU   | morphogenetic neur |
| 95  | 1 | 9.1  | 11 | 2 | YHBO   | morphogenetic neur |
| 96  | 1 | 9.1  | 11 | 2 | YHXAE  | morphogenetic neur |
| 97  | 1 | 9.1  | 11 | 2 | YHJFHY | morphogenetic neur |
| 98  | 1 | 9.1  | 11 | 2 | A61365 | phyllokinin - Rohd |
| 99  | 1 | 9.1  | 11 | 2 | S07207 | Crinia-angiotensin |
| 100 | 1 | 9.1  | 11 | 2 | D61033 | ranatachykinin D - |

#### ALIGNMENTS

##### RESULT 1

S66606

quinoline 2-oxidoreductase alpha chain - Comamonas testosteroni (fragment)

C;Species: Comamonas testosteroni

C;Date: 15-Feb-1997 #sequence\_revision 13-Mar-1997 #text\_change 17-Mar-1999

C;Accession: S66606

R;Schach, S.; Tshisuaka, B.; Fetzner, S.; Lingens, F.

Eur. J. Biochem. 232, 536-544, 1995

A;Title: Quinoline 2-oxidoreductase and 2-oxo-1,2-dihydroquinoline 5,6-dioxygenase from Comamonas testosteroni 63. The first two enzymes in quinoline and 3-methylquinoline degradation.

A;Reference number: S66606; MUID:96035889; PMID:7556204

A;Accession: S66606

A;Molecule type: protein

A;Residues: 1-11 <SCH>

A;Experimental source: strain 63

Query Match 27.3%; Score 3; DB 2; Length 11;

Best Local Similarity 100.0%; Pred. No. 2.6e+03;

Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy

1 AKS 3

Db                    |||  
                      1 AKS 3

RESULT 2

H54346

pyruvate synthase (EC 1.2.7.1) alpha chain - *Pyrococcus furiosus* (fragment)

C;Species: *Pyrococcus furiosus*

C;Date: 05-Jan-1996 #sequence\_revision 05-Jan-1996 #text\_change 05-May-2000

C;Accession: H54346

R;Blamey, J.M.; Adams, M.W.

Biochemistry 33, 1000-1007, 1994

A;Title: Characterization of an ancestral type of pyruvate ferredoxin oxidoreductase from the hyperthermophilic bacterium, *Thermotoga maritima*.

A;Reference number: A54346; MUID:94137707; PMID:8305426

A;Accession: H54346

A;Status: preliminary

A;Molecule type: protein

A;Residues: 1-11 <BLA>

C;Keywords: coenzyme A; oxidoreductase

Query Match                    27.3%; Score 3; DB 2; Length 11;  
Best Local Similarity        100.0%; Pred. No. 2.6e+03;  
Matches        3; Conservative        0; Mismatches        0; Indels        0; Gaps        0;

Qy                    5 KGN 7  
                      |||  
Db                    4 KGN 6

RESULT 3

G61497

seed protein ws-23 - winged bean (fragment)

C;Species: *Psophocarpus tetragonolobus* (winged bean)

C;Date: 07-Oct-1994 #sequence\_revision 07-Oct-1994 #text\_change 07-Oct-1994

C;Accession: G61497

R;Hirano, H.

J. Protein Chem. 8, 115-130, 1989

A;Title: Microsequence analysis of winged bean seed proteins electroblotted from two-dimensional gel.

A;Reference number: A61491; MUID:89351606; PMID:2765119

A;Accession: G61497

A;Status: preliminary

A;Molecule type: protein

A;Residues: 1-11 <HIR>

C;Keywords: glycoprotein; seed

Query Match                    27.3%; Score 3; DB 2; Length 11;  
Best Local Similarity        100.0%; Pred. No. 2.6e+03;  
Matches        3; Conservative        0; Mismatches        0; Indels        0; Gaps        0;

Qy                    1 AKS 3  
                      |||  
Db                    1 AKS 3

RESULT 4

ECLQ2M

tachykinin II - migratory locust

C;Species: Locusta migratoria (migratory locust)

C;Date: 31-Dec-1991 #sequence\_revision 31-Dec-1991 #text\_change 08-Dec-1995

C;Accession: S08266

R;Schoofs, L.; Holman, G.M.; Hayes, T.K.; Nachman, R.J.; de Loof, A.  
FEBS Lett. 261, 397-401, 1990

A;Title: Locustatachykinin I and II, two novel insect neuropeptides with  
homology to peptides of the vertebrate tachykinin family.

A;Reference number: S08265; MUID:90184489; PMID:2311766

A;Accession: S08266

A;Molecule type: protein

A;Residues: 1-11 <SCH>

C;Superfamily: tachykinin

C;Keywords: amidated carboxyl end; neuropeptide; tachykinin

F;11/Modified site: amidated carboxyl end (Arg) #status experimental

Query Match 18.2%; Score 2; DB 1; Length 11;

Best Local Similarity 100.0%; Pred. No. 3e+04;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SS 9

||

Db 4 SS 5

#### RESULT 5

SPHO

substance P - horse

C;Species: Equus caballus (domestic horse)

C;Date: 23-Oct-1981 #sequence\_revision 23-Oct-1981 #text\_change 23-Aug-1996

C;Accession: A01558

R;Studer, R.O.; Trzeciak, A.; Lergier, W.  
Helv. Chim. Acta 56, 860-866, 1973

A;Title: Isolierung und Aminosaeuresequenz von Substanz P aus Pferdedarm.

A;Reference number: A01558

A;Accession: A01558

A;Molecule type: protein

A;Residues: 1-11 <STU>

C;Superfamily: substance P precursor

C;Keywords: amidated carboxyl end; hormone

F;11/Modified site: amidated carboxyl end (Met) #status experimental

Query Match 18.2%; Score 2; DB 1; Length 11;

Best Local Similarity 100.0%; Pred. No. 3e+04;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 LM 11

||

Db 10 LM 11

#### RESULT 6

EOOCC

eledoisin - curled octopus

C;Species: Eledone cirrosa, Ozaena cirrosa (curled octopus)

C;Date: 31-Dec-1991 #sequence\_revision 31-Dec-1991 #text\_change 20-Mar-1998

C;Accession: B01561; A01561  
R;Anastasi, A.; Erspamer, V.  
Arch. Biochem. Biophys. 101, 56-65, 1963  
A;Title: The isolation and amino acid sequence of eledoisin, the active  
endecapeptide of the posterior salivary glands of Eledone.  
A;Reference number: A01561  
A;Accession: B01561  
A;Molecule type: protein  
A;Residues: 1-11 <ANA>  
C;Superfamily: substance P precursor  
C;Keywords: amidated carboxyl end; hormone; pyroglutamic acid; salivary gland;  
secretagogue; vasodilator; venom  
F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental  
F;11/Modified site: amidated carboxyl end (Met) #status experimental

Query Match 18.2%; Score 2; DB 1; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 LM 11  
||  
Db 10 LM 11

#### RESULT 7

A60654  
substance P - guinea pig  
C;Species: Cavia porcellus (guinea pig)  
C;Date: 14-May-1993 #sequence\_revision 27-Jun-1994 #text\_change 08-Dec-1995  
C;Accession: A60654  
R;Murphy, R.  
Neuropeptides 14, 105-110, 1989  
A;Title: Primary amino acid sequence of guinea-pig substance P.  
A;Reference number: A60654; MUID:90044685; PMID:2478925  
A;Accession: A60654  
A;Molecule type: protein  
A;Residues: 1-11 <MUR>  
C;Superfamily: substance P precursor  
C;Keywords: amidated carboxyl end; neuropeptide; tachykinin  
F;11/Modified site: amidated carboxyl end (Met) #status experimental

Query Match 18.2%; Score 2; DB 1; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 LM 11  
||  
Db 10 LM 11

#### RESULT 8

EOOC  
eledoisin - musky octopus  
C;Species: Eledone moschata, Ozaena moschata (musky octopus)  
C;Date: 13-Jul-1981 #sequence\_revision 13-Jul-1981 #text\_change 20-Mar-1998  
C;Accession: A01561  
R;Anastasi, A.; Erspamer, V.

Arch. Biochem. Biophys. 101, 56-65, 1963

A;Title: The isolation and amino acid sequence of eledoisin, the active endecapeptide of the posterior salivary glands of Eledone.

A;Reference number: A01561

A;Accession: A01561

A;Molecule type: protein

A;Residues: 1-11 <ANA>

C;Superfamily: substance P precursor

C;Keywords: amidated carboxyl end; hormone; pyroglutamic acid; salivary gland; secretagogue; vasodilator; venom

F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental

F;11/Modified site: amidated carboxyl end (Met) #status experimental

Query Match 18.2%; Score 2; DB 1; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 LM 11  
||  
Db 10 LM 11

#### RESULT 9

A33917

dihydroorotase (EC 3.5.2.3) - Chinese hamster (fragment)

C;Species: Cricetulus griseus (Chinese hamster)

C;Date: 09-Mar-1990 #sequence\_revision 09-Mar-1990 #text\_change 07-Nov-1997

C;Accession: A33917

R;Simmer, J.P.; Kelly, R.E.; Scully, J.L.; Grayson, D.R.; Rinker Jr., A.G.; Bergh, S.T.; Evans, D.R.

Proc. Natl. Acad. Sci. U.S.A. 86, 4382-4386, 1989

A;Title: Mammalian aspartate transcarbamylase (ATCase): sequence of the ATCase domain and interdomain linker in the CAD multifunctional polypeptide and properties of the isolated domain.

A;Reference number: A33917; MUID:89282776; PMID:2543974

A;Accession: A33917

A;Status: preliminary

A;Molecule type: mRNA

A;Residues: 1-11 <SIM>

A;Cross-references: GB:M23652

C;Superfamily: rudimentary enzyme; aspartate/ornithine carbamoyltransferase homology; Bacillus dihydroorotase homology; biotin carboxylase homology; carbamoyl-phosphate synthase (ammonia) homology; carbamoyl-phosphate synthase (glutamine-hydrolyzing) large chain homology; carbamoyl-phosphate synthase (glutamine-hydrolyzing) small chain homology; trpG homology

C;Keywords: hydrolase

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 KG 6  
||  
Db 7 KG 8

#### RESULT 10

JN0023

substance P - chicken

C;Species: Gallus gallus (chicken)

C;Date: 07-Sep-1990 #sequence\_revision 07-Sep-1990 #text\_change 11-Jul-1997

C;Accession: JN0023

R;Conlon, J.M.; Katsoulis, S.; Schmidt, W.E.; Thim, L.

Regul. Pept. 20, 171-180, 1988

A;Title: [Arg3]substance P and neurokinin A from chicken small intestine.

A;Reference number: JN0023; MUID:88204263; PMID:2452461

A;Accession: JN0023

A;Molecule type: protein

A;Residues: 1-11 <CON>

C;Superfamily: substance P precursor

C;Keywords: amidated carboxyl end; tachykinin

F;11/Modified site: amidated carboxyl end (Met) #status predicted

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 LM 11  
||  
Db 10 LM 11

RESULT 11

A40693

transgelin - sheep (fragment)

C;Species: Ovis orientalis aries, Ovis ammon aries (domestic sheep)

C;Date: 03-May-1994 #sequence\_revision 03-May-1994 #text\_change 31-Oct-1997

C;Accession: A40693

R;Shapland, C.; Hsuan, J.J.; Totty, N.F.; Lawson, D.

J. Cell Biol. 121, 1065-1073, 1993

A;Title: Purification and properties of transgelin: a transformation and shape change sensitive actin-gelling protein.

A;Reference number: A40693; MUID:93273790; PMID:8501116

A;Accession: A40693

A;Molecule type: protein

A;Residues: 1-11 <SHA>

A;Experimental source: aorta

C;Comment: This protein gels actin and is down regulated by transformation or loss of cell adherence in culture.

C;Superfamily: smooth muscle protein SM22; calponin repeat homology; smooth muscle protein SM22 homology

C;Keywords: actin binding; cytoskeleton

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 KG 6  
||  
Db 1 KG 2

RESULT 12

A38841

rhodopsin homolog - squid (Watasenia scintillans) (fragment)  
 N;Alternate names: visual pigment protein  
 C;Species: Watasenia scintillans (sparkling enope)  
 C;Date: 17-Jul-1992 #sequence\_revision 17-Jul-1992 #text\_change 31-Oct-1997  
 C;Accession: A38841  
 R;Seidou, M.; Kubota, I.; Hiraki, K.; Kito, Y.  
 Biochim. Biophys. Acta 957, 318-321, 1988  
 A;Title: Amino acid sequence of the retinal binding site of squid visual pigment.  
 A;Reference number: PT0063; MUID:89051045; PMID:3191148  
 A;Accession: A38841  
 A;Molecule type: protein  
 A;Residues: 1-11 <SEI>  
 C;Superfamily: vertebrate rhodopsin  
 C;Keywords: chromoprotein; retinal  
 F;3/Binding site: retinal (Lys) (covalent) #status experimental

Query Match 18.2%; Score 2; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 3e+04;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AK 2  
 ||  
 Db 2 AK 3

#### RESULT 13

S09074

cytochrome P450-4b - rat (fragment)

N;Alternate names: cytochrome P450K-5

N;Contains: oxidoreductase (EC 1.-.-.-)

C;Species: Rattus norvegicus (Norway rat)

C;Date: 23-Apr-1993 #sequence\_revision 23-Apr-1993 #text\_change 05-Mar-1999

C;Accession: S09074

R;Imaoka, S.; Terano, Y.; Funae, Y.

Arch. Biochem. Biophys. 278, 168-178, 1990

A;Title: Changes in the amount of cytochrome P450s in rat hepatic microsomes with starvation.

A;Reference number: S09072; MUID:90210577; PMID:2321956

A;Accession: S09074

A;Molecule type: protein

A;Residues: 1-11 <IMA>

C;Superfamily: unassigned cytochrome P450; cytochrome P450 homology

C;Keywords: heme; microsome; monooxygenase; oxidoreductase; transmembrane protein

Query Match 18.2%; Score 2; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 3e+04;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 SL 10  
 ||  
 Db 7 SL 8

#### RESULT 14

D60409

kassinin-like peptide K-III - frog (Pseudophryne guentheri)  
 C;Species: Pseudophryne guentheri  
 C;Date: 30-Jan-1993 #sequence\_revision 30-Jan-1993 #text\_change 02-Sep-2000  
 C;Accession: D60409  
 R;Simmaco, M.; Severini, C.; De Biase, D.; Barra, D.; Bossa, F.; Roberts, J.D.;  
 Melchiorri, P.; Erspamer, V.  
 Peptides 11, 299-304, 1990  
 A;Title: Six novel tachykinin- and bombesin-related peptides from the skin of  
 the Australian frog Pseudophryne guentheri.  
 A;Reference number: A60409; MUID:90287814; PMID:2356157  
 A;Accession: D60409  
 A;Molecule type: protein  
 A;Residues: 1-11 <SIM>  
 C;Superfamily: unassigned animal peptides  
 C;Keywords: amidated carboxyl end; pyroglutamic acid  
 F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental  
 F;11/Modified site: amidated carboxyl end (Met) #status experimental

Query Match 18.2%; Score 2; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 3e+04;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 LM 11  
 ||  
 Db 10 LM 11

#### RESULT 15

F60409  
 substance P-like peptide II - frog (Pseudophryne guentheri)  
 C;Species: Pseudophryne guentheri  
 C;Date: 30-Jan-1993 #sequence\_revision 30-Jan-1993 #text\_change 02-Sep-2000  
 C;Accession: F60409  
 R;Simmaco, M.; Severini, C.; De Biase, D.; Barra, D.; Bossa, F.; Roberts, J.D.;  
 Melchiorri, P.; Erspamer, V.  
 Peptides 11, 299-304, 1990  
 A;Title: Six novel tachykinin- and bombesin-related peptides from the skin of  
 the Australian frog Pseudophryne guentheri.  
 A;Reference number: A60409; MUID:90287814; PMID:2356157  
 A;Accession: F60409  
 A;Molecule type: protein  
 A;Residues: 1-11 <SIM>  
 C;Superfamily: unassigned animal peptides  
 C;Keywords: amidated carboxyl end; pyroglutamic acid  
 F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental  
 F;11/Modified site: amidated carboxyl end (Met) #status experimental

Query Match 18.2%; Score 2; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 3e+04;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 LM 11  
 ||  
 Db 10 LM 11

#### RESULT 16



E60409

substance P-like peptide I - frog (*Pseudophryne guentheri*)

C;Species: *Pseudophryne guentheri*

C;Date: 30-Jan-1993 #sequence\_revision 30-Jan-1993 #text\_change 02-Sep-2000

C;Accession: E60409

R;Simmaco, M.; Severini, C.; De Biase, D.; Barra, D.; Bossa, F.; Roberts, J.D.;  
Melchiorri, P.; Erspamer, V.

Peptides 11, 299-304, 1990

A;Title: Six novel tachykinin- and bombesin-related peptides from the skin of  
the Australian frog *Pseudophryne guentheri*.

A;Reference number: A60409; MUID:90287814; PMID:2356157

A;Accession: E60409

A;Molecule type: protein

A;Residues: 1-11 <SIM>

C;Superfamily: unassigned animal peptides

C;Keywords: amidated carboxyl end; pyroglutamic acid

F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental

F;11/Modified site: amidated carboxyl end (Met) #status experimental

Query Match 18.2%; Score 2; DB 2; Length 11;

Best Local Similarity 100.0%; Pred. No. 3e+04;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 LM 11

||

Db 10 LM 11

RESULT 17

B26744

megascoliakinin - garden dagger wasp

N;Alternate names: 6-Thr-bradykinin-Lys-Ala

C;Species: *Megascolia flavifrons* (garden dagger wasp)

C;Date: 08-Mar-1989 #sequence\_revision 08-Mar-1989 #text\_change 18-Aug-2000

C;Accession: B26744; A28609

R;Yasuhara, T.; Mantel, P.; Nakajima, T.; Piek, T.

Toxicon 25, 527-535, 1987

A;Title: Two kinins isolated from an extract of the venom reservoirs of the  
solitary wasp *Megascolia flavifrons*.

A;Reference number: A94322; MUID:87293024; PMID:3617088

A;Accession: B26744

A;Molecule type: protein

A;Residues: 1-11 <YAS>

R;Nakajima, T.; Piek, T.; Yashuara, T.; Mantel, P.

Toxicon 26, 34, 1988

A;Title: Two kinins isolated from the venom of *Megascolia flavifrons*.

A;Reference number: A28609

A;Accession: A28609

A;Molecule type: protein

A;Residues: 1-11 <NAK>

C;Superfamily: unassigned animal peptides

C;Keywords: bradykinin; presynaptic neurotoxin; venom

Query Match 18.2%; Score 2; DB 2; Length 11;

Best Local Similarity 100.0%; Pred. No. 3e+04;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 RK 5  
||  
Db 9 RK 10

RESULT 18

S23308

substance P - rainbow trout

C;Species: Oncorhynchus mykiss (rainbow trout)

C;Date: 19-Mar-1997 #sequence\_revision 19-Mar-1997 #text\_change 18-Aug-2000

C;Accession: S23308

R;Jensen, J.; Conlon, J.M.

Eur. J. Biochem. 206, 659-664, 1992

A;Title: Substance-P-related and neurokinin-A-related peptides from the brain of the cod and trout.

A;Reference number: S23186; MUID:92298992; PMID:1376687

A;Accession: S23308

A;Molecule type: protein

A;Residues: 1-11 <JEN>

A;Experimental source: brain

C;Function:

A;Description: may play a physiological role in the regulation of cardiovascular and gastrointestinal functions

A;Note: substance P is derived by post-translational processing of preprotachykinin A

C;Superfamily: unassigned animal peptides

C;Keywords: neuropeptide; amidated carboxyl end; tachykinin

F;11/Modified site: amidated carboxyl end (Met) #status predicted

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 LM 11  
||  
Db 10 LM 11

RESULT 19

S23306

substance P - Atlantic cod

C;Species: Gadus morhua (Atlantic cod)

C;Date: 19-Mar-1997 #sequence\_revision 19-Mar-1997 #text\_change 18-Aug-2000

C;Accession: S23306

R;Jensen, J.; Conlon, J.M.

Eur. J. Biochem. 206, 659-664, 1992

A;Title: Substance-P-related and neurokinin-A-related peptides from the brain of the cod and trout.

A;Reference number: S23186; MUID:92298992; PMID:1376687

A;Accession: S23306

A;Molecule type: protein

A;Residues: 1-11 <JEN>

A;Experimental source: brain

C;Function:

A;Description: may play a physiological role in the regulation of cardiovascular and gastrointestinal functions

A;Note: substance P is derived by post-translational processing of preprotachykinin A

C;Superfamily: unassigned animal peptides

C;Keywords: neuropeptide; amidated carboxyl end; tachykinin

F;11/Modified site: amidated carboxyl end (Met) #status predicted

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 LM 11  
||  
Db 10 LM 11

#### RESULT 20

B60409

kassinin-like peptide K-I - frog (*Pseudophryne guentheri*)

C;Species: *Pseudophryne guentheri*

C;Date: 30-Jan-1993 #sequence\_revision 30-Jan-1993 #text\_change 18-Aug-2000

C;Accession: B60409

R;Simmaco, M.; Severini, C.; De Biase, D.; Barra, D.; Bossa, F.; Roberts, J.D.; Melchiorri, P.; Erspamer, V.

Peptides 11, 299-304, 1990

A;Title: Six novel tachykinin- and bombesin-related peptides from the skin of the Australian frog *Pseudophryne guentheri*.

A;Reference number: A60409; MUID:90287814; PMID:2356157

A;Accession: B60409

A;Molecule type: protein

A;Residues: 1-11 <SIM>

A;Note: this peptide was also found in a deamidated form

C;Superfamily: unassigned animal peptides

C;Keywords: amidated carboxyl end; pyroglutamic acid

F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental

F;11/Modified site: amidated carboxyl end (Met) (partial) #status experimental

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 LM 11  
||  
Db 10 LM 11

#### RESULT 21

C60409

kassinin-like peptide K-II - frog (*Pseudophryne guentheri*)

C;Species: *Pseudophryne guentheri*

C;Date: 30-Jan-1993 #sequence\_revision 30-Jan-1993 #text\_change 18-Aug-2000

C;Accession: C60409

R;Simmaco, M.; Severini, C.; De Biase, D.; Barra, D.; Bossa, F.; Roberts, J.D.; Melchiorri, P.; Erspamer, V.

Peptides 11, 299-304, 1990

A;Title: Six novel tachykinin- and bombesin-related peptides from the skin of the Australian frog *Pseudophryne guentheri*.

A;Reference number: A60409; MUID:90287814; PMID:2356157

A;Accession: C60409  
A;Molecule type: protein  
A;Residues: 1-11 <SIM>  
A;Note: this peptide was also found in a deamidated form  
C;Superfamily: unassigned animal peptides  
C;Keywords: amidated carboxyl end; pyroglutamic acid  
F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental  
F;11/Modified site: amidated carboxyl end (Met) (partial) #status experimental

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 LM 11  
||  
Db 10 LM 11

RESULT 22

S07203

uperolein - frog (*Uperoleia marmorata*)

C;Species: *Uperoleia marmorata*

C;Date: 12-Feb-1993 #sequence\_revision 12-Mar-1993 #text\_change 18-Aug-2000

C;Accession: S07203

R;Anastasi, A.; Erspamer, V.; Endean, R.

Experientia 31, 394-395, 1975

A;Title: Structure of uperolein, a physalaemin-like endecapeptide occurring in the skin of *Uperoleia rugosa* and *Uperoleia marmorata*.

A;Reference number: S07203; MUID:75131227; PMID:1120493

A;Accession: S07203

A;Molecule type: protein

A;Residues: 1-11 <ANA>

C;Superfamily: unassigned animal peptides

C;Keywords: amidated carboxyl end; pyroglutamic acid; skin; tachykinin

F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental

F;11/Modified site: amidated carboxyl end (Met) #status experimental

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 LM 11  
||  
Db 10 LM 11

RESULT 23

S07201

physalaemin - frog (*Physalaemus fuscumaculatus*)

C;Species: *Physalaemus fuscumaculatus*

C;Date: 12-Feb-1993 #sequence\_revision 12-Mar-1993 #text\_change 18-Aug-2000

C;Accession: S07201

R;Erspamer, V.; Anastasi, A.; Bertaccini, G.; Cei, J.M.

Experientia 20, 489-490, 1964

A;Title: Structure and pharmacological actions of physalaemin, the main active polypeptide of the skin of *Physalaemus fuscumaculatus*.

A;Reference number: S07201; MUID:66076612; PMID:5857249

A;Accession: S07201  
A;Molecule type: protein  
A;Residues: 1-11 <ERS>  
C;Superfamily: unassigned animal peptides  
C;Keywords: amidated carboxyl end; pyroglutamic acid; skin; tachykinin  
F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental  
F;11/Modified site: amidated carboxyl end (Met) #status experimental

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 LM 11  
||  
Db 10 LM 11

#### RESULT 24

A61033

ranatachykinin A - bullfrog

C;Species: Rana catesbeiana (bullfrog)

C;Date: 31-Dec-1993 #sequence\_revision 31-Dec-1993 #text\_change 18-Aug-2000

C;Accession: A61033; JE0426

R;Kangawa, K.; Kozawa, H.; Hino, J.; Minamino, N.; Matsuo, H.

Regul. Pept. 42(Suppl.1), S12, 1992

A;Title: Isolation of four novel tachykinins from frog (Rana catesbeiana) brain and intestine.

A;Reference number: A61033

A;Accession: A61033

A;Molecule type: protein

A;Residues: 1-11 <KAN>

R;Kozawa, H.; Hino, J.; Minamino, N.; Kangawa, K.; Matsuo, H.

Biochem. Biophys. Res. Commun. 177, 588-595, 1991

A;Title: Isolation of four novel tachykinins from frog (Rana catesbeiana) brain and intestine.

A;Reference number: JE0426; MUID:91254337; PMID:2043143

A;Accession: JE0426

A;Molecule type: protein

A;Residues: 1-11 <KOZ>

C;Superfamily: unassigned animal peptides

C;Keywords: amidated carboxyl end; neuropeptide

F;11/Modified site: amidated carboxyl end (Met) #status experimental

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 LM 11  
||  
Db 10 LM 11

#### RESULT 25

B43669

hypothetical protein (rhdA 5' region) - Synechococcus sp. (fragment)

C;Species: Synechococcus sp.

C;Date: 03-Mar-1993 #sequence\_revision 03-Mar-1993 #text\_change 30-Sep-1993

C;Accession: B43669  
R;Laudenbach, D.E.; Ehrhardt, D.; Green, L.; Grossman, A.  
J. Bacteriol. 173, 2751-2760, 1991  
A;Title: Isolation and characterization of a sulfur-regulated gene encoding a periplasmically localized protein with sequence similarity to rhodanese.  
A;Reference number: A43669; MUID:91210163; PMID:1708376  
A;Accession: B43669  
A;Status: preliminary  
A;Molecule type: DNA  
A;Residues: 1-11 <LAU>  
A;Cross-references: GB:M65244

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AK 2  
||  
Db 6 AK 7

RESULT 26

PC2372

58K heat shock protein groEL [similarity] - Bacillus cereus (strain ts-4)  
(fragment)

C;Species: Bacillus cereus

C;Date: 20-Apr-2000 #sequence\_revision 20-Apr-2000 #text\_change 20-Apr-2000

C;Accession: PC2372

R;Matsuno, K.; Miyamoto, T.; Yamaguchi, K.; Sayed, M.A.; Kajiwara, T.; Hatano, S.

Biosci. Biotechnol. Biochem. 59, 231-235, 1995

A;Title: Identification of DNA-binding proteins changed after induction of sporulation in Bacillus cereus.

A;Reference number: PC2369; MUID:95218265; PMID:7766022

A;Accession: PC2372

A;Status: preliminary

A;Molecule type: protein

A;Residues: 1-11 <MAS>

C;Keywords: heat shock; molecular chaperone; stress-induced protein

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AK 2  
||  
Db 1 AK 2

RESULT 27

S19775

wound-induced protein - tomato (fragment)

C;Species: Lycopersicon esculentum (tomato)

C;Date: 30-Jun-1992 #sequence\_revision 30-Jun-1992 #text\_change 09-Sep-1997

C;Accession: S19775

R;Parsons, B.L.

submitted to the EMBL Data Library, May 1991

A;Reference number: S19773  
A;Accession: S19775  
A;Molecule type: mRNA  
A;Residues: 1-11 <PAR>  
A;Cross-references: EMBL:X59884; NID:g19323; PID:g19324

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SS 9  
||  
Db 3 SS 4

RESULT 28

S71304

amine oxidase (copper-containing) (EC 1.4.3.6) II - Aspergillus niger (fragment)

C;Species: Aspergillus niger

C;Date: 12-Feb-1998 #sequence\_revision 01-May-1998 #text\_change 07-May-1999

C;Accession: S71304

R;Frebort, I.; Tamaki, H.; Ishida, H.; Pec, P.; Luhova, L.; Tsuno, H.; Halata, M.; Asano, Y.; Kato, Y.; Matsushita, K.; Toyama, H.; Kumagai, H.; Adachi, O. Eur. J. Biochem. 237, 255-265, 1996

A;Title: Two distinct quinoprotein amine oxidases are induced by n-butylamine in the mycelia of Aspergillus niger AKU 3302: purification, characterization, cDNA cloning and sequencing.

A;Reference number: S71303; MUID:96203933; PMID:8620882

A;Accession: S71304

A;Molecule type: protein

A;Residues: 1-11 <FRE>

C;Keywords: copper binding; monomer; oxidoreductase; quinoprotein; topaquinone

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 SL 10  
||  
Db 10 SL 11

RESULT 29

A34135

DNA-binding protein p - Crithidia fasciculata mitochondrion (fragment)

C;Species: mitochondrion Crithidia fasciculata

C;Date: 30-Sep-1991 #sequence\_revision 30-Sep-1991 #text\_change 07-Dec-1999

C;Accession: A34135

R;Tittawella, I.

FEBS Lett. 260, 57-61, 1990

A;Title: Kinetoplast DNA-aggregating proteins from the parasitic protozoan Crithidia fasciculata.

A;Reference number: A34135

A;Accession: A34135

A;Molecule type: protein

A;Residues: 1-11 <TIT>

C;Genetics:

A;Genome: mitochondrion  
A;Genetic code: SGC6  
C;Keywords: mitochondrion

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 RK 5  
||  
Db 8 RK 9

RESULT 30

A26120

6-phosphofructokinase (EC 2.7.1.11) - pig roundworm (fragment)

N;Alternate names: phosphofructokinase; phosphohexokinase

C;Species: Ascaris suum (pig roundworm)

C;Date: 15-Dec-1988 #sequence\_revision 15-Dec-1988 #text\_change 28-Apr-1993

C;Accession: A26120

R;Kulkarni, G.; Rao, G.S.J.; Srinivasan, N.G.; Hofer, H.W.; Yuan, P.M.; Harris, B.G.

J. Biol. Chem. 262, 32-34, 1987

A;Title: Ascaris suum phosphofructokinase. Phosphorylation by protein kinase and sequence of the phosphopeptide.

A;Reference number: A26120; MUID:87083467; PMID:3025208

A;Accession: A26120

A;Molecule type: protein

A;Residues: 1-11 <KUL>

C;Keywords: glycolysis; phosphotransferase

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AK 2  
||  
Db 1 AK 2

RESULT 31

A35594

buccalin - California sea hare

C;Species: Aplysia californica (California sea hare)

C;Date: 14-Sep-1990 #sequence\_revision 14-Sep-1990 #text\_change 24-Jun-1993

C;Accession: A35594

R;Cropper, E.C.; Miller, M.W.; Tenenbaum, R.; Kolks, M.A.G.; Kupfermann, I.; Weiss, K.R.

Proc. Natl. Acad. Sci. U.S.A. 85, 6177-6181, 1988

A;Title: Structure and action of buccalin: a modulatory neuropeptide localized to an identified small cardioactive peptide-containing cholinergic motor neuron of Aplysia californica.

A;Reference number: A35594; MUID:88320404; PMID:3413086

A;Accession: A35594

A;Status: preliminary

A;Molecule type: protein

A;Residues: 1-11 <CRO>



Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 SL 10  
||  
Db 4 SL 5

RESULT 32

S69349

neuropeptide FFamide - great pond snail

C;Species: *Lymnaea stagnalis* (great pond snail)

C;Date: 24-Jul-1998 #sequence\_revision 24-Jul-1998 #text\_change 17-Mar-1999

C;Accession: S69349

R;Li, K.W.; El Filali, Z.; van Golen, F.A.; Geraerts, W.P.M.

Eur. J. Biochem. 229, 70-72, 1995

A;Title: Identification of a novel amide peptide, GLTPNMNSLFF-NH(2), involved in the control of vas deferens motility in *Lymnaea stagnalis*.

A;Reference number: S69349; MUID:95262689; PMID:7744051

A;Accession: S69349

A;Molecule type: protein

A;Residues: 1-11 <LIK>

A;Experimental source: penis complex

C;Function:

A;Description: enhances the contraction frequency and contraction amplitude of the vas deferens

A;Note: control of male reproductive behavior

C;Keywords: amidated carboxyl end; neuropeptide

F;11/Modified site: amidated carboxyl end (Phe) #status experimental

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 NS 8  
||  
Db 7 NS 8

RESULT 33

S05002

corazonin - American cockroach

C;Species: *Periplaneta americana* (American cockroach)

C;Date: 07-Sep-1990 #sequence\_revision 09-Apr-1998 #text\_change 09-Apr-1998

C;Accession: S05002

R;Veenstra, J.A.

FEBS Lett. 250, 231-234, 1989

A;Title: Isolation and structure of corazonin, a cardioactive peptide from the american cockroach.

A;Reference number: S05002; MUID:89325572; PMID:2753132

A;Accession: S05002

A;Molecule type: protein

A;Residues: 1-11 <VEE>

C;Keywords: amidated carboxyl end; neuropeptide; pyroglutamic acid

F;1/Modified site: pyrrolidone carboxylic acid (Gln) #status experimental

F;11/Modified site: amidated carboxyl end (Asn) #status experimental

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SR 4  
||  
Db 6 SR 7

RESULT 34

S33300

probable substance P - smaller spotted catshark

C;Species: Scyliorhinus canicula (smaller spotted catshark, smaller spotted dogfish)

C;Date: 19-Mar-1997 #sequence\_revision 19-Mar-1997 #text\_change 24-Mar-1999

C;Accession: S33300

R;Waugh, D.; Wang, Y.; Hazon, N.; Balment, R.J.; Conlon, J.M.

Eur. J. Biochem. 214, 469-474, 1993

A;Title: Primary structures and biological activities of substance-P-related peptides from the brain of the dogfish, Scyliorhinus canicula.

A;Reference number: S33300; MUID:93292508; PMID:7685693

A;Accession: S33300

A;Molecule type: protein

A;Residues: 1-11 <WAW>

A;Experimental source: brain

C;Function:

A;Description: may play a physiological role in the regulation of cardiovascular and gastrointestinal functions

A;Note: substance P is derived by post-translational processing of preprotachykinin A

C;Keywords: amidated carboxyl end; neuropeptide; tachykinin

F;11/Modified site: amidated carboxyl end (Met) #status predicted

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 LM 11  
||  
Db 10 LM 11

RESULT 35

S43626

cytochrome-c oxidase (EC 1.9.3.1) chain Vb-H - trout (fragment)

C;Species: Salmo sp. (trout)

C;Date: 19-Mar-1997 #sequence\_revision 01-Aug-1997 #text\_change 02-Jul-1998

C;Accession: S43626

R;Freund, R.; Kadenbach, B.

Eur. J. Biochem. 221, 1111-1116, 1994

A;Title: Identification of tissue-specific isoforms for subunits Vb and VIIa of cytochrome c oxidase isolated from rainbow trout.

A;Reference number: S43624; MUID:94237150; PMID:8181469

A;Accession: S43626

A;Status: preliminary

A;Molecule type: protein  
A;Residues: 1-11 <FRE>  
C;Keywords: electron transfer; membrane-associated complex; oxidoreductase;  
respiratory chain; transmembrane protein

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 KG 6  
||  
Db 4 KG 5

RESULT 36

D42965

talín - chicken (fragment)

C;Species: Gallus gallus (chicken)

C;Date: 05-Jan-1996 #sequence\_revision 05-Jan-1996 #text\_change 05-Jan-1996

C;Accession: D42965

R;Hagmann, J.; Grob, M.; Burger, M.M.

J. Biol. Chem. 267, 14424-14428, 1992

A;Title: The cytoskeletal protein talin is O-glycosylated.

A;Reference number: A42965; MUID:92332560; PMID:1629228

A;Accession: D42965

A;Status: preliminary

A;Molecule type: protein

A;Residues: 1-11 <HAG>

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SS 9  
||  
Db 4 SS 5

RESULT 37

I65231

CCK-B gastrin receptor isoform - human (fragment)

C;Species: Homo sapiens (man)

C;Date: 29-May-1998 #sequence\_revision 29-May-1998 #text\_change 21-Jul-2000

C;Accession: I65231

R;Miyake, A.

Biochem. Biophys. Res. Commun. 208, 230-237, 1995

A;Title: A truncated isoform of human CCK-B/gastrin receptor generated by  
alternative usage of a novel exon.

A;Reference number: I52307; MUID:95194412; PMID:7887934

A;Accession: I65231

A;Status: preliminary; translated from GB/EMBL/DDBJ

A;Molecule type: mRNA

A;Residues: 1-11 <RES>

A;Cross-references: GB:S76072; NID:g913752; PIDN:AAB33740.1; PID:g913753

C;Genetics:

A;Gene: CCK-B

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 GN 7  
||  
Db 5 GN 6

RESULT 38

E57789

gallbladder stone matrix protein, 25K - human (fragment)

C;Species: Homo sapiens (man)

C;Date: 23-Feb-1996 #sequence\_revision 23-Feb-1996 #text\_change 23-Feb-1996

C;Accession: E57789

R;Binette, J.P.; Binette, M.B.

submitted to the Protein Sequence Database, February 1996

A;Description: The proteins of gallbladder stones.

A;Reference number: A57789

A;Accession: E57789

A;Status: preliminary

A;Molecule type: protein

A;Residues: 1-11 <BIN>

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 RK 5  
||  
Db 2 RK 3

RESULT 39

I52980

glucocerebrosidase - human (fragment)

C;Species: Homo sapiens (man)

C;Date: 02-Jul-1996 #sequence\_revision 02-Jul-1996 #text\_change 05-Nov-1999

C;Accession: I52980; I65971

R;Reiner, O.; Wigderson, M.; Horowitz, M.

DNA 7, 107-116, 1988

A;Title: Structural analysis of the human glucocerebrosidase genes.

A;Reference number: I52980; MUID:88195776; PMID:3359914

A;Accession: I52980

A;Status: preliminary; translated from GB/EMBL/DDBJ

A;Molecule type: DNA

A;Residues: 1-11 <RES>

A;Cross-references: GB:M18916; NID:g183023; PIDN:AAA35878.1; PID:g183024

A;Accession: I65971

A;Status: preliminary; translated from GB/EMBL/DDBJ

A;Molecule type: DNA

A;Residues: 1-11 <RE2>

A;Cross-references: GB:M18917; NID:g183025; PIDN:AAA35879.1; PID:g183026

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SS 9  
||  
Db 4 SS 5

RESULT 40

PT0273

Ig heavy chain CRD3 region (clone 3-109A) - human (fragment)

C;Species: Homo sapiens (man)

C;Date: 30-Sep-1993 #sequence\_revision 30-Sep-1993 #text\_change 16-Aug-1996

C;Accession: PT0273

R;Yamada, M.; Wasserman, R.; Reichard, B.A.; Shane, S.; Caton, A.J.; Rovera, G.  
J. Exp. Med. 173, 395-407, 1991

A;Title: Preferential utilization of specific immunoglobulin heavy chain  
diversity and joining segments in adult human peripheral blood B lymphocytes.

A;Reference number: PT0222; MUID:91108337; PMID:1899102

A;Accession: PT0273

A;Molecule type: DNA

A;Residues: 1-11 <YAM>

A;Experimental source: B lymphocyte

C;Keywords: heterotetramer; immunoglobulin

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SR 4  
||  
Db 2 SR 3

RESULT 41

PT0302

Ig heavy chain CRD3 region (clone 5-112) - human (fragment)

C;Species: Homo sapiens (man)

C;Date: 30-Sep-1993 #sequence\_revision 30-Sep-1993 #text\_change 16-Aug-1996

C;Accession: PT0302

R;Yamada, M.; Wasserman, R.; Reichard, B.A.; Shane, S.; Caton, A.J.; Rovera, G.  
J. Exp. Med. 173, 395-407, 1991

A;Title: Preferential utilization of specific immunoglobulin heavy chain  
diversity and joining segments in adult human peripheral blood B lymphocytes.

A;Reference number: PT0222; MUID:91108337; PMID:1899102

A;Accession: PT0302

A;Molecule type: DNA

A;Residues: 1-11 <YAM>

A;Experimental source: B lymphocyte

C;Keywords: heterotetramer; immunoglobulin

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SS 9  
||  
Db 7 SS 8

RESULT 42

S13279

Ile-Ser-bradykinin - human (fragment)

N;Alternate names: T-kinin

C;Species: Homo sapiens (man)

C;Date: 02-Dec-1993 #sequence\_revision 13-Mar-1997 #text\_change 24-Jul-1998

C;Accession: S13279

R;Wunderer, G.; Walter, I.; Eschenbacher, B.; Lang, M.; Kellermann, J.; Kindermann, G.

Biol. Chem. Hoppe-Seyler 371, 977-981, 1990

A;Title: Ile-Ser-bradykinin is an aberrant permeability factor in various human malignant effusions.

A;Reference number: S13279; MUID:91166748; PMID:2076202

A;Accession: S13279

A;Molecule type: protein

A;Residues: 1-11 <WUN>

C;Keywords: bradykinin

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SR 4  
||  
Db 2 SR 3

RESULT 43

I54193

Rhesus blood group CcEe protein - human (fragment)

C;Species: Homo sapiens (man)

C;Date: 06-Sep-1996 #sequence\_revision 06-Sep-1996 #text\_change 21-Jul-2000

C;Accession: I54193

R;Cherif-Zahar, B.; Le Van Kim, C.; Rouillac, C.; Raynal, V.; Cartron, J.P.; Colin, Y.

Genomics 19, 68-74, 1994

A;Title: Organization of the gene (RHCE) encoding the human blood group RhCcEe antigens and characterization of the promoter region.

A;Reference number: I54193; MUID:94245182; PMID:8188244

A;Accession: I54193

A;Status: preliminary; translated from GB/EMBL/DDBJ

A;Molecule type: DNA

A;Residues: 1-11 <RES>

A;Cross-references: GB:S70456; NID:g546795; PIDN:AAD14061.1; PID:g4261761

C;Genetics:

A;Gene: GDB:RHCE

A;Cross-references: GDB:229957; OMIM:111700

A;Map position: 1p36.2-1p34

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SS 9  
||  
Db 2 SS 3

RESULT 44

S68649

spermadhesin AQN-3 - pig (fragments)

C;Species: *Sus scrofa domestica* (domestic pig)

C;Date: 04-Dec-1997 #sequence\_revision 12-Dec-1997 #text\_change 17-Mar-1999

C;Accession: S68649

R;Calvete, J.J.; Dostalova, Z.; Sanz, L.; Adermann, K.; Thole, H.H.; Toepfer-Petersen, E.

FEBS Lett. 379, 207-211, 1996

A;Title: Mapping the heparin-binding domain of boar spermadhesins.

A;Reference number: S68648; MUID:96184566; PMID:8603690

A;Accession: S68649

A;Status: preliminary

A;Molecule type: protein

A;Residues: 1-6;7-11 <CAL>

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SS 9  
||  
Db 10 SS 11

RESULT 45

S68637

acetylcholinesterase (EC 3.1.1.7) P chain - bovine (fragment)

C;Species: *Bos primigenius taurus* (cattle)

C;Date: 04-Dec-1997 #sequence\_revision 04-Dec-1997 #text\_change 30-Jan-1998

C;Accession: S68637

R;Boschetti, N.; Brodbeck, U.

FEBS Lett. 380, 133-136, 1996

A;Title: The membrane anchor of mammalian brain acetylcholinesterase consists of a single glycosylated protein of 22 kDa.

A;Reference number: S68637; MUID:96181683; PMID:8603722

A;Accession: S68637

A;Molecule type: protein

A;Residues: 1-11 <BOS>

A;Experimental source: brain

C;Keywords: carboxylic ester hydrolase; glycoprotein; membrane protein

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 KS 3  
||  
Db 4 KS 5

RESULT 46

A33571

folliclistatin - bovine (fragment)

C;Species: *Bos primigenius taurus* (cattle)

C;Date: 09-Mar-1990 #sequence\_revision 09-Mar-1990 #text\_change 30-Sep-1993  
C;Accession: A33571  
R;Gospodarowicz, D.; Lau, K.  
Biochem. Biophys. Res. Commun. 165, 292-298, 1989  
A;Title: Pituitary follicular cells secrete both vascular endothelial growth factor and follistatin.  
A;Reference number: A33571; MUID:90073725; PMID:2590228  
A;Accession: A33571  
A;Status: preliminary  
A;Molecule type: protein  
A;Residues: 1-11 <GOS>

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AK 2  
||  
Db 8 AK 9

RESULT 47

S23926

major glycoprotein PAS-6 - bovine (fragment)

C;Species: Bos primigenius taurus (cattle)

C;Date: 19-Mar-1997 #sequence\_revision 01-Feb-1999 #text\_change 01-Feb-1999

C;Accession: S23926

R;Kim, D.H.; Kanno, C.; Mizokami, Y.

Biochim. Biophys. Acta 1122, 203-211, 1992

A;Title: Purification and characterization of major glycoproteins, PAS-6 and PAS-7, from bovine milk fat globule membrane.

A;Reference number: S23926; MUID:92353107; PMID:1643094

A;Accession: S23926

A;Molecule type: protein

A;Residues: 1-11 <KIM>

C;Keywords: glycoprotein; milk; blocked amino end

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 GN 7  
||  
Db 3 GN 4

RESULT 48

A14454

6-phosphofructokinase (EC 2.7.1.11) - sheep (fragment)

C;Species: Ovis orientalis aries, Ovis ammon aries (domestic sheep)

C;Date: 05-Jun-1987 #sequence\_revision 05-Jun-1987 #text\_change 28-Apr-1993

C;Accession: A14454

R;Fordyce, A.M.; Midwinter, G.G.; Moore, C.H.

Biochem. Soc. Trans. 7, 721-723, 1979

A;Title: The N-terminal amino acid sequence of sheep heart phosphofructokinase.

A;Reference number: A14454; MUID:80004524; PMID:157899

A;Accession: A14454



A;Molecule type: protein  
A;Residues: 1-11 <FOR>  
C;Keywords: glycolysis; phosphotransferase

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AK 2  
||  
Db 8 AK 9

RESULT 49

A29806

acidic proline-rich protein HP43b - golden hamster (fragment)

C;Species: Mesocricetus auratus (golden hamster)

C;Date: 19-May-1989 #sequence\_revision 19-May-1989 #text\_change 18-Jun-1993

C;Accession: A29806

R;Mehansho, H.; Ann, D.K.; Butler, L.G.; Rogler, J.; Carlson, D.M.

J. Biol. Chem. 262, 12344-12350, 1987

A;Title: Induction of proline-rich proteins in hamster salivary glands by isoproterenol treatment and an unusual growth inhibition by tannins.

A;Reference number: A92611; MUID:87308247; PMID:3040740

A;Accession: A29806

A;Molecule type: protein

A;Residues: 1-11 <MEH>

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 SL 10  
||  
Db 10 SL 11

RESULT 50

PH1375

T antigen variant K-2 - mouse (fragment)

C;Species: Mus musculus (house mouse)

C;Date: 16-Jul-1999 #sequence\_revision 16-Jul-1999 #text\_change 11-May-2000

C;Accession: PH1375

R;Lill, N.L.; Judith Tevethia, M.; Hendrickson, W.G.; Tevethia, S.S.

J. Exp. Med. 176, 449-457, 1992

A;Title: Cytotoxic T lymphocytes (CTL) against a transforming gene product select for transformed cells with point mutations within sequences encoding CTL recognition epitopes.

A;Reference number: PH1373; MUID:92364547; PMID:1380062

A;Accession: PH1375

A;Status: preliminary

A;Molecule type: mRNA

A;Residues: 1-11 <LIL>

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 KG 6  
||  
Db 2 KG 3

RESULT 51

PH1376

T antigen variant K-3 - mouse (fragment)

C;Species: Mus musculus (house mouse)

C;Date: 16-Jul-1999 #sequence\_revision 16-Jul-1999 #text\_change 11-May-2000

C;Accession: PH1376

R;Lill, N.L.; Judith Tevethia, M.; Hendrickson, W.G.; Tevethia, S.S.

J. Exp. Med. 176, 449-457, 1992

A;Title: Cytotoxic T lymphocytes (CTL) against a transforming gene product select for transformed cells with point mutations within sequences encoding CTL recognition epitopes.

A;Reference number: PH1373; MUID:92364547; PMID:1380062

A;Accession: PH1376

A;Status: preliminary

A;Molecule type: mRNA

A;Residues: 1-11 <LIL>

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 KG 6  
||  
Db 2 KG 3

RESULT 52

PT0217

T-cell receptor beta chain V-J region (4-1-E.2) - mouse (fragment)

C;Species: Mus musculus (house mouse)

C;Date: 31-Dec-1991 #sequence\_revision 31-Dec-1991 #text\_change 30-May-1997

C;Accession: PT0217

R;Nakano, N.; Kikutani, H.; Nishimoto, H.; Kishimoto, T.

J. Exp. Med. 173, 1091-1097, 1991

A;Title: T cell receptor V gene usage of islet beta cell-reactive T cells is not restricted in non-obese diabetic mice.

A;Reference number: PT0209; MUID:91217621; PMID:1902501

A;Accession: PT0217

A;Molecule type: mRNA

A;Residues: 1-11 <NAK>

C;Keywords: T-cell receptor

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SR 4  
||  
Db 3 SR 4

RESULT 53

PT0218

T-cell receptor beta chain V-J region (7-10-D.3) - mouse (fragment)

C;Species: Mus musculus (house mouse)

C;Date: 31-Dec-1991 #sequence\_revision 31-Dec-1991 #text\_change 30-May-1997

C;Accession: PT0218

R;Nakano, N.; Kikutani, H.; Nishimoto, H.; Kishimoto, T.

J. Exp. Med. 173, 1091-1097, 1991

A;Title: T cell receptor V gene usage of islet beta cell-reactive T cells is not restricted in non-obese diabetic mice.

A;Reference number: PT0209; MUID:91217621; PMID:1902501

A;Accession: PT0218

A;Molecule type: mRNA

A;Residues: 1-11 <NAK>

C;Keywords: T-cell receptor

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 GN 7  
||  
Db 7 GN 8

RESULT 54

D41946

T-cell receptor gamma chain (1a.4) - mouse (fragment)

C;Species: Mus musculus (house mouse)

C;Date: 03-Feb-1994 #sequence\_revision 03-Feb-1994 #text\_change 07-May-1999

C;Accession: D41946

R;Whetsell, M.; Mosley, R.L.; Whetsell, L.; Schaefer, F.V.; Miller, K.S.; Klein, J.R.

Mol. Cell. Biol. 11, 5902-5909, 1991

A;Title: Rearrangement and junctional-site sequence analyses of T-cell receptor gamma genes in intestinal intraepithelial lymphocytes from murine athymic chimeras.

A;Reference number: A41946; MUID:92049316; PMID:1658619

A;Accession: D41946

A;Status: preliminary; not compared with conceptual translation

A;Molecule type: DNA

A;Residues: 1-11 <WHE>

C;Keywords: T-cell receptor

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SS 9  
||  
Db 8 SS 9

RESULT 55

B41946

T-cell receptor gamma chain (1t.57) - mouse (fragment)

C;Species: Mus musculus (house mouse)

C;Date: 03-Feb-1994 #sequence\_revision 03-Feb-1994 #text\_change 07-May-1999  
C;Accession: B41946  
R;Whetsell, M.; Mosley, R.L.; Whetsell, L.; Schaefer, F.V.; Miller, K.S.; Klein, J.R.  
Mol. Cell. Biol. 11, 5902-5909, 1991  
A;Title: Rearrangement and junctional-site sequence analyses of T-cell receptor gamma genes in intestinal intraepithelial lymphocytes from murine athymic chimeras.  
A;Reference number: A41946; MUID:92049316; PMID:1658619  
A;Accession: B41946  
A;Status: preliminary; not compared with conceptual translation  
A;Molecule type: DNA  
A;Residues: 1-11 <WHE>  
C;Keywords: T-cell receptor

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SS 9  
||  
Db 8 SS 9

RESULT 56

C38887

T-cell receptor gamma chain (5a.3) - mouse (fragment)

C;Species: Mus musculus (house mouse)

C;Date: 03-Feb-1994 #sequence\_revision 03-Feb-1994 #text\_change 07-May-1999

C;Accession: C38887

R;Whetsell, M.; Mosley, R.L.; Whetsell, L.; Schaefer, F.V.; Miller, K.S.; Klein, J.R.

Mol. Cell. Biol. 11, 5902-5909, 1991

A;Title: Rearrangement and junctional-site sequence analyses of T-cell receptor gamma genes in intestinal intraepithelial lymphocytes from murine athymic chimeras.

A;Reference number: A41946; MUID:92049316; PMID:1658619

A;Accession: C38887

A;Status: preliminary; not compared with conceptual translation

A;Molecule type: DNA

A;Residues: 1-11 <WHE>

C;Keywords: T-cell receptor

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SS 9  
||  
Db 8 SS 9

RESULT 57

I41946

T-cell receptor gamma chain (5t.1) - mouse (fragment)

C;Species: Mus musculus (house mouse)

C;Date: 03-Feb-1994 #sequence\_revision 03-Feb-1994 #text\_change 07-May-1999

C;Accession: I41946  
R;Whetsell, M.; Mosley, R.L.; Whetsell, L.; Schaefer, F.V.; Miller, K.S.; Klein, J.R.  
Mol. Cell. Biol. 11, 5902-5909, 1991  
A;Title: Rearrangement and junctional-site sequence analyses of T-cell receptor gamma genes in intestinal intraepithelial lymphocytes from murine athymic chimeras.  
A;Reference number: A41946; MUID:92049316; PMID:1658619  
A;Accession: I41946  
A;Status: preliminary; not compared with conceptual translation  
A;Molecule type: DNA  
A;Residues: 1-11 <WHE>  
C;Keywords: T-cell receptor

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SS 9  
||  
Db 8 SS 9

RESULT 58

PD0441

translation elongation factor TU-like protein P43, mitochondrial - mouse (fragment)

C;Species: Mus musculus (house mouse)

C;Date: 21-Aug-1998 #sequence\_revision 21-Aug-1998 #text\_change 21-Aug-1998

C;Accession: PD0441

R;Kawakami, T.; Uchida, T.; Sakai, T.; Kamo, M.; Morimasa, T.; Tsugita, A. submitted to JIPID, August 1998

A;Description: Proteome analysis of mouse brain.

A;Reference number: PD0441

A;Accession: PD0441

A;Molecule type: protein

A;Residues: 1-11 <KAW>

A;Experimental source: striatum

C;Keywords: mitochondrion

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AK 2  
||  
Db 4 AK 5

RESULT 59

I60434

68kDa neurofilament - rat (fragment)

C;Species: Rattus norvegicus (Norway rat)

C;Date: 02-Aug-1996 #sequence\_revision 02-Aug-1996 #text\_change 05-Nov-1999

C;Accession: I60434

R;Reeben, M.; Neuman, T.; Palgi, J.; Palm, K.; Paalme, V.; Saarma, M. J. Neurosci. Res. 40, 177-188, 1995

A;Title: Characterization of the rat light neurofilament (NF-L) gene promoter and identification of NGF and cAMP responsive regions.  
A;Reference number: I60434; MUID:95264348; PMID:7745611  
A;Accession: I60434  
A;Status: preliminary; translated from GB/EMBL/DDBJ  
A;Molecule type: DNA  
A;Residues: 1-11 <RES>  
A;Cross-references: EMBL:X53981; NID:g452676; PIDN:CAA37931.1; PID:g452677  
C;Genetics:  
A;Gene: NF68

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SS 9  
||  
Db 2 SS 3

RESULT 60  
S65377

cytochrome-c oxidase (EC 1.9.3.1) chain VIa-H, cardiac - rat (fragment)  
C;Species: Rattus norvegicus (Norway rat)  
C;Date: 28-Oct-1996 #sequence\_revision 13-Mar-1997 #text\_change 16-Jul-1999  
C;Accession: S65377  
R;Schaegger, H.; Noack, H.; Halangk, W.; Brandt, U.; von Jagow, G.  
Eur. J. Biochem. 230, 235-241, 1995  
A;Title: Cytochrome-c oxidase in developing rat heart. Enzymic properties and amino-terminal sequences suggest identity of the fetal heart and the adult liver isoform.  
A;Reference number: S65372; MUID:95324529; PMID:7601105  
A;Accession: S65377  
A;Status: preliminary  
A;Molecule type: protein  
A;Residues: 1-11 <SCH>  
C;Keywords: cardiac muscle; heart; oxidoreductase

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AK 2  
||  
Db 3 AK 4

RESULT 61  
PH0939

T-cell receptor beta chain V-D-J region (clone 10) - rat (fragment)  
C;Species: Rattus norvegicus (Norway rat)  
C;Date: 09-Oct-1992 #sequence\_revision 09-Oct-1992 #text\_change 30-May-1997  
C;Accession: PH0939  
R;Gold, D.P.; Offner, H.; Sun, D.; Wiley, S.; Vandenbark, A.A.; Wilson, D.B.  
J. Exp. Med. 174, 1467-1476, 1991  
A;Title: Analysis of T cell receptor beta chains in Lewis rats with experimental allergic encephalomyelitis: conserved complementarity determining region 3.

A;Reference number: PH0891; MUID:92078857; PMID:1836012  
A;Accession: PH0939  
A;Molecule type: mRNA  
A;Residues: 1-11 <GOL>  
A;Experimental source: complete Freund's adjuvant-immunized lymph node  
C;Keywords: T-cell receptor

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SS 9  
||  
Db 3 SS 4

RESULT 62

PH0940

T-cell receptor beta chain V-D-J region (clone 11) - rat (fragment)

C;Species: Rattus norvegicus (Norway rat)

C;Date: 09-Oct-1992 #sequence\_revision 09-Oct-1992 #text\_change 30-May-1997

C;Accession: PH0940

R;Gold, D.P.; Offner, H.; Sun, D.; Wiley, S.; Vandenbark, A.A.; Wilson, D.B.  
J. Exp. Med. 174, 1467-1476, 1991

A;Title: Analysis of T cell receptor beta chains in Lewis rats with experimental  
allergic encephalomyelitis: conserved complementarity determining region 3.

A;Reference number: PH0891; MUID:92078857; PMID:1836012

A;Accession: PH0940

A;Molecule type: mRNA

A;Residues: 1-11 <GOL>

A;Experimental source: complete Freund's adjuvant-immunized lymph node

C;Keywords: T-cell receptor

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SS 9  
||  
Db 3 SS 4

RESULT 63

PH0941

T-cell receptor beta chain V-D-J region (clone 12) - rat (fragment)

C;Species: Rattus norvegicus (Norway rat)

C;Date: 09-Oct-1992 #sequence\_revision 09-Oct-1992 #text\_change 30-May-1997

C;Accession: PH0941

R;Gold, D.P.; Offner, H.; Sun, D.; Wiley, S.; Vandenbark, A.A.; Wilson, D.B.  
J. Exp. Med. 174, 1467-1476, 1991

A;Title: Analysis of T cell receptor beta chains in Lewis rats with experimental  
allergic encephalomyelitis: conserved complementarity determining region 3.

A;Reference number: PH0891; MUID:92078857; PMID:1836012

A;Accession: PH0941

A;Molecule type: mRNA

A;Residues: 1-11 <GOL>

A;Experimental source: complete Freund's adjuvant-immunized lymph node

C;Keywords: T-cell receptor

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SS 9  
||  
Db 3 SS 4

RESULT 64

PH0929

T-cell receptor beta chain V-D-J region (clone 15) - rat (fragment)

C;Species: Rattus norvegicus (Norway rat)

C;Date: 09-Oct-1992 #sequence\_revision 09-Oct-1992 #text\_change 30-May-1997

C;Accession: PH0929

R;Gold, D.P.; Offner, H.; Sun, D.; Wiley, S.; Vandembark, A.A.; Wilson, D.B.  
J. Exp. Med. 174, 1467-1476, 1991

A;Title: Analysis of T cell receptor beta chains in Lewis rats with experimental  
allergic encephalomyelitis: conserved complementarity determining region 3.

A;Reference number: PH0891; MUID:92078857; PMID:1836012

A;Accession: PH0929

A;Molecule type: mRNA

A;Residues: 1-11 <GOL>

A;Experimental source: concanavalin A-activated lymphoblast

C;Keywords: T-cell receptor

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SR 4  
||  
Db 3 SR 4

RESULT 65

PH0891

T-cell receptor beta chain V-D-J region (clone 6-1) - rat (fragment)

C;Species: Rattus norvegicus (Norway rat)

C;Date: 09-Oct-1992 #sequence\_revision 09-Oct-1992 #text\_change 30-May-1997

C;Accession: PH0891

R;Gold, D.P.; Offner, H.; Sun, D.; Wiley, S.; Vandembark, A.A.; Wilson, D.B.  
J. Exp. Med. 174, 1467-1476, 1991

A;Title: Analysis of T cell receptor beta chains in Lewis rats with experimental  
allergic encephalomyelitis: conserved complementarity determining region 3.

A;Reference number: PH0891; MUID:92078857; PMID:1836012

A;Accession: PH0891

A;Molecule type: mRNA

A;Residues: 1-11 <GOL>

A;Experimental source: myelin basic protein-immunized T-cell

C;Keywords: T-cell receptor

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;



Qy 8 SS 9  
||  
Db 3 SS 4

RESULT 66

PH0938

T-cell receptor beta chain V-D-J region (clone 9) - rat (fragment)

C;Species: Rattus norvegicus (Norway rat)

C;Date: 09-Oct-1992 #sequence\_revision 09-Oct-1992 #text\_change 30-May-1997

C;Accession: PH0938

R;Gold, D.P.; Offner, H.; Sun, D.; Wiley, S.; Vandenbark, A.A.; Wilson, D.B.  
J. Exp. Med. 174, 1467-1476, 1991

A;Title: Analysis of T cell receptor beta chains in Lewis rats with experimental allergic encephalomyelitis: conserved complementarity determining region 3.

A;Reference number: PH0891; MUID:92078857; PMID:1836012

A;Accession: PH0938

A;Molecule type: mRNA

A;Residues: 1-11 <GOL>

A;Experimental source: complete Freund's adjuvant-immunized lymph node

C;Keywords: T-cell receptor

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SS 9  
||  
Db 3 SS 4

RESULT 67

PH0947

T-cell receptor beta chain V-D-J region (clone A2) - rat (fragment)

C;Species: Rattus norvegicus (Norway rat)

C;Date: 09-Oct-1992 #sequence\_revision 09-Oct-1992 #text\_change 30-May-1997

C;Accession: PH0947

R;Gold, D.P.; Offner, H.; Sun, D.; Wiley, S.; Vandenbark, A.A.; Wilson, D.B.  
J. Exp. Med. 174, 1467-1476, 1991

A;Title: Analysis of T cell receptor beta chains in Lewis rats with experimental allergic encephalomyelitis: conserved complementarity determining region 3.

A;Reference number: PH0891; MUID:92078857; PMID:1836012

A;Accession: PH0947

A;Molecule type: mRNA

A;Residues: 1-11 <GOL>

A;Experimental source: myelin basic protein fragment-reactive T-cell, recovered from experimentally induced allergic encephalomyelitis

C;Keywords: T-cell receptor

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SR 4  
||  
Db 3 SR 4

RESULT 68

PH0903

T-cell receptor beta chain V-D-J region (hybridoma S1C2A6) - rat (fragment)

C;Species: Rattus norvegicus (Norway rat)

C;Date: 09-Oct-1992 #sequence\_revision 09-Oct-1992 #text\_change 30-May-1997

C;Accession: PH0903

R;Gold, D.P.; Offner, H.; Sun, D.; Wiley, S.; Vandenbark, A.A.; Wilson, D.B.  
J. Exp. Med. 174, 1467-1476, 1991

A;Title: Analysis of T cell receptor beta chains in Lewis rats with experimental allergic encephalomyelitis: conserved complementarity determining region 3.

A;Reference number: PH0891; MUID:92078857; PMID:1836012

A;Accession: PH0903

A;Molecule type: mRNA

A;Residues: 1-11 <GOL>

A;Experimental source: myelin basic protein-immunized T-cell

C;Keywords: T-cell receptor

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SS 9  
||  
Db 3 SS 4

RESULT 69

PH0904

T-cell receptor beta chain V-D-J region (hybridoma S22C2) - rat (fragment)

C;Species: Rattus norvegicus (Norway rat)

C;Date: 09-Oct-1992 #sequence\_revision 09-Oct-1992 #text\_change 30-May-1997

C;Accession: PH0904

R;Gold, D.P.; Offner, H.; Sun, D.; Wiley, S.; Vandenbark, A.A.; Wilson, D.B.  
J. Exp. Med. 174, 1467-1476, 1991

A;Title: Analysis of T cell receptor beta chains in Lewis rats with experimental allergic encephalomyelitis: conserved complementarity determining region 3.

A;Reference number: PH0891; MUID:92078857; PMID:1836012

A;Accession: PH0904

A;Molecule type: mRNA

A;Residues: 1-11 <GOL>

A;Experimental source: myelin basic protein-immunized T-cell

C;Keywords: T-cell receptor

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SS 9  
||  
Db 3 SS 4

RESULT 70

PH0924

T-cell receptor beta chain V-D-J region (isolate 10) - rat (fragment)

C;Species: Rattus norvegicus (Norway rat)  
 C;Date: 09-Oct-1992 #sequence\_revision 09-Oct-1992 #text\_change 30-May-1997  
 C;Accession: PH0924  
 R;Gold, D.P.; Offner, H.; Sun, D.; Wiley, S.; Vandenbark, A.A.; Wilson, D.B.  
 J. Exp. Med. 174, 1467-1476, 1991  
 A;Title: Analysis of T cell receptor beta chains in Lewis rats with experimental  
 allergic encephalomyelitis: conserved complementarity determining region 3.  
 A;Reference number: PH0891; MUID:92078857; PMID:1836012  
 A;Accession: PH0924  
 A;Molecule type: mRNA  
 A;Residues: 1-11 <GOL>  
 A;Experimental source: concanavalin A-activated lymphoblast  
 C;Keywords: T-cell receptor

Query Match 18.2%; Score 2; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 3e+04;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SS 9  
 ||  
 Db 3 SS 4

#### RESULT 71

PH0919

T-cell receptor beta chain V-D-J region (isolate 5) - rat (fragment)

C;Species: Rattus norvegicus (Norway rat)  
 C;Date: 09-Oct-1992 #sequence\_revision 09-Oct-1992 #text\_change 30-May-1997  
 C;Accession: PH0919  
 R;Gold, D.P.; Offner, H.; Sun, D.; Wiley, S.; Vandenbark, A.A.; Wilson, D.B.  
 J. Exp. Med. 174, 1467-1476, 1991  
 A;Title: Analysis of T cell receptor beta chains in Lewis rats with experimental  
 allergic encephalomyelitis: conserved complementarity determining region 3.  
 A;Reference number: PH0891; MUID:92078857; PMID:1836012  
 A;Accession: PH0919  
 A;Molecule type: mRNA  
 A;Residues: 1-11 <GOL>  
 A;Experimental source: concanavalin A-activated lymphoblast  
 A;Note: the authors translated the codon CAG for residue 11 as Glu  
 C;Keywords: T-cell receptor

Query Match 18.2%; Score 2; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 3e+04;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SR 4  
 ||  
 Db 3 SR 4

#### RESULT 72

PH0914

T-cell receptor beta chain V-D-J region (isolate 7) - rat (fragment)

C;Species: Rattus norvegicus (Norway rat)  
 C;Date: 09-Oct-1992 #sequence\_revision 09-Oct-1992 #text\_change 30-May-1997  
 C;Accession: PH0914  
 R;Gold, D.P.; Offner, H.; Sun, D.; Wiley, S.; Vandenbark, A.A.; Wilson, D.B.

J. Exp. Med. 174, 1467-1476, 1991

A;Title: Analysis of T cell receptor beta chains in Lewis rats with experimental allergic encephalomyelitis: conserved complementarity determining region 3.

A;Reference number: PH0891; MUID:92078857; PMID:1836012

A;Accession: PH0914

A;Molecule type: mRNA

A;Residues: 1-11 <GOL>

A;Experimental source: myelin basic protein-immunized lymph node

C;Keywords: T-cell receptor

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SS 9  
||  
Db 3 SS 4

#### RESULT 73

PH0922

T-cell receptor beta chain V-D-J region (isolate 8) - rat (fragment)

C;Species: Rattus norvegicus (Norway rat)

C;Date: 09-Oct-1992 #sequence\_revision 09-Oct-1992 #text\_change 30-May-1997

C;Accession: PH0922

R;Gold, D.P.; Offner, H.; Sun, D.; Wiley, S.; Vandenbark, A.A.; Wilson, D.B.

J. Exp. Med. 174, 1467-1476, 1991

A;Title: Analysis of T cell receptor beta chains in Lewis rats with experimental allergic encephalomyelitis: conserved complementarity determining region 3.

A;Reference number: PH0891; MUID:92078857; PMID:1836012

A;Accession: PH0922

A;Molecule type: mRNA

A;Residues: 1-11 <GOL>

A;Experimental source: concanavalin A-activated lymphoblast

C;Keywords: T-cell receptor

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SS 9  
||  
Db 3 SS 4

#### RESULT 74

PH0906

T-cell receptor beta chain V-D-J region (isolates 2, 8, 9) - rat (fragment)

C;Species: Rattus norvegicus (Norway rat)

C;Date: 09-Oct-1992 #sequence\_revision 09-Oct-1992 #text\_change 30-May-1997

C;Accession: PH0906

R;Gold, D.P.; Offner, H.; Sun, D.; Wiley, S.; Vandenbark, A.A.; Wilson, D.B.

J. Exp. Med. 174, 1467-1476, 1991

A;Title: Analysis of T cell receptor beta chains in Lewis rats with experimental allergic encephalomyelitis: conserved complementarity determining region 3.

A;Reference number: PH0891; MUID:92078857; PMID:1836012

A;Accession: PH0906

A;Molecule type: mRNA  
A;Residues: 1-11 <GOL>  
A;Experimental source: myelin basic protein-immunized lymph node  
C;Keywords: T-cell receptor

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SS 9  
||  
Db 3 SS 4

RESULT 75

A34243

H-hyosophorin - Japanese flounder (fragment)

C;Species: Paralichthys olivaceus (Japanese flounder)

C;Date: 07-Sep-1990 #sequence\_revision 07-Sep-1990 #text\_change 12-Feb-1999

C;Accession: A34243

R;Seko, A.; Kitajima, K.; Iwasaki, M.; Inoue, S.; Inoue, Y.

J. Biol. Chem. 264, 15922-15929, 1989

A;Title: Structural studies of fertilization-associated carbohydrate-rich glycoproteins (Hyosophorin) isolated from the fertilized and unfertilized eggs of flounder, Paralichthys olivaceus. Presence of a novel penta-antennary N-linked glycan chain in the tandem repeating glycopeptide unit of hyosophorin.

A;Reference number: A34243; MUID:89380184; PMID:2777771

A;Accession: A34243

A;Molecule type: protein

A;Residues: 1-11 <SEK>

A;Note: 3-Ala, 4-Ala, 5-Pro or Gln, and 6-Val were also found

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 3e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 GN 7  
||  
Db 6 GN 7

Search completed: April 8, 2004, 15:49:28

Job time : 8.61538 secs

OM protein - protein search, using sw model

Run on: April 8, 2004, 15:47:33 ; Search time 30.3077 Seconds  
(without alignments)  
95.432 Million cell updates/sec

Title: US-09-787-443A-21  
Perfect score: 11  
Sequence: 1 AKSRKGNSSLM 11

Scoring table: OLIGO  
Gapop 60.0 , Gapext 60.0

Searched: 1073127 seqs, 262937947 residues

Word size : 0

Total number of hits satisfying chosen parameters: 9223

Minimum DB seq length: 11  
Maximum DB seq length: 11

Post-processing: Listing first 100 summaries

Database : Published Applications\_AA:\*

- 1: /cgn2\_6/ptodata/1/pubpaa/US07\_PUBCOMB.pep:\*
- 2: /cgn2\_6/ptodata/1/pubpaa/PCT\_NEW\_PUB.pep:\*
- 3: /cgn2\_6/ptodata/1/pubpaa/US06\_NEW\_PUB.pep:\*
- 4: /cgn2\_6/ptodata/1/pubpaa/US06\_PUBCOMB.pep:\*
- 5: /cgn2\_6/ptodata/1/pubpaa/US07\_NEW\_PUB.pep:\*
- 6: /cgn2\_6/ptodata/1/pubpaa/PCTUS\_PUBCOMB.pep:\*
- 7: /cgn2\_6/ptodata/1/pubpaa/US08\_NEW\_PUB.pep:\*
- 8: /cgn2\_6/ptodata/1/pubpaa/US08\_PUBCOMB.pep:\*
- 9: /cgn2\_6/ptodata/1/pubpaa/US09A\_PUBCOMB.pep:\*
- 10: /cgn2\_6/ptodata/1/pubpaa/US09B\_PUBCOMB.pep:\*
- 11: /cgn2\_6/ptodata/1/pubpaa/US09C\_PUBCOMB.pep:\*
- 12: /cgn2\_6/ptodata/1/pubpaa/US09\_NEW\_PUB.pep:\*
- 13: /cgn2\_6/ptodata/1/pubpaa/US10A\_PUBCOMB.pep:\*
- 14: /cgn2\_6/ptodata/1/pubpaa/US10B\_PUBCOMB.pep:\*
- 15: /cgn2\_6/ptodata/1/pubpaa/US10C\_PUBCOMB.pep:\*
- 16: /cgn2\_6/ptodata/1/pubpaa/US10\_NEW\_PUB.pep:\*
- 17: /cgn2\_6/ptodata/1/pubpaa/US60\_NEW\_PUB.pep:\*
- 18: /cgn2\_6/ptodata/1/pubpaa/US60\_PUBCOMB.pep:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

| Result | Query                    |             |
|--------|--------------------------|-------------|
| No.    | Score Match Length DB ID | Description |

|    |   |      |    |    |                    |                   |
|----|---|------|----|----|--------------------|-------------------|
| 1  | 4 | 36.4 | 11 | 10 | US-09-876-904A-83  | Sequence 83, Appl |
| 2  | 4 | 36.4 | 11 | 14 | US-10-211-088-246  | Sequence 246, App |
| 3  | 3 | 27.3 | 11 | 8  | US-08-779-457-43   | Sequence 43, Appl |
| 4  | 3 | 27.3 | 11 | 9  | US-09-780-070-25   | Sequence 25, Appl |
| 5  | 3 | 27.3 | 11 | 9  | US-09-780-070-26   | Sequence 26, Appl |
| 6  | 3 | 27.3 | 11 | 9  | US-09-823-649A-18  | Sequence 18, Appl |
| 7  | 3 | 27.3 | 11 | 9  | US-09-056-160B-17  | Sequence 17, Appl |
| 8  | 3 | 27.3 | 11 | 9  | US-09-896-251-11   | Sequence 11, Appl |
| 9  | 3 | 27.3 | 11 | 9  | US-09-896-251-18   | Sequence 18, Appl |
| 10 | 3 | 27.3 | 11 | 9  | US-09-896-245-11   | Sequence 11, Appl |
| 11 | 3 | 27.3 | 11 | 9  | US-09-896-245-18   | Sequence 18, Appl |
| 12 | 3 | 27.3 | 11 | 9  | US-09-935-682-28   | Sequence 28, Appl |
| 13 | 3 | 27.3 | 11 | 9  | US-09-873-637-13   | Sequence 13, Appl |
| 14 | 3 | 27.3 | 11 | 9  | US-09-825-584-1    | Sequence 1, Appli |
| 15 | 3 | 27.3 | 11 | 9  | US-09-192-854-170  | Sequence 170, App |
| 16 | 3 | 27.3 | 11 | 9  | US-09-811-384-8    | Sequence 8, Appli |
| 17 | 3 | 27.3 | 11 | 9  | US-09-832-723-35   | Sequence 35, Appl |
| 18 | 3 | 27.3 | 11 | 9  | US-09-226-248B-27  | Sequence 27, Appl |
| 19 | 3 | 27.3 | 11 | 9  | US-09-966-871-31   | Sequence 31, Appl |
| 20 | 3 | 27.3 | 11 | 9  | US-09-848-664-6    | Sequence 6, Appli |
| 21 | 3 | 27.3 | 11 | 9  | US-09-071-838-286  | Sequence 286, App |
| 22 | 3 | 27.3 | 11 | 9  | US-09-968-561A-298 | Sequence 298, App |
| 23 | 3 | 27.3 | 11 | 9  | US-09-969-244-11   | Sequence 11, Appl |
| 24 | 3 | 27.3 | 11 | 9  | US-09-969-244-18   | Sequence 18, Appl |
| 25 | 3 | 27.3 | 11 | 9  | US-09-757-774-13   | Sequence 13, Appl |
| 26 | 3 | 27.3 | 11 | 10 | US-09-999-724-76   | Sequence 76, Appl |
| 27 | 3 | 27.3 | 11 | 10 | US-09-876-904A-369 | Sequence 369, App |
| 28 | 3 | 27.3 | 11 | 10 | US-09-876-904A-509 | Sequence 509, App |
| 29 | 3 | 27.3 | 11 | 10 | US-09-774-381-59   | Sequence 59, Appl |
| 30 | 3 | 27.3 | 11 | 10 | US-09-852-910-259  | Sequence 259, App |
| 31 | 3 | 27.3 | 11 | 10 | US-09-802-083-14   | Sequence 14, Appl |
| 32 | 3 | 27.3 | 11 | 10 | US-09-776-191-59   | Sequence 59, Appl |
| 33 | 3 | 27.3 | 11 | 10 | US-09-968-744A-298 | Sequence 298, App |
| 34 | 3 | 27.3 | 11 | 11 | US-09-795-798-16   | Sequence 16, Appl |
| 35 | 3 | 27.3 | 11 | 11 | US-09-969-322-11   | Sequence 11, Appl |
| 36 | 3 | 27.3 | 11 | 11 | US-09-969-322-18   | Sequence 18, Appl |
| 37 | 3 | 27.3 | 11 | 11 | US-09-833-245-301  | Sequence 301, App |
| 38 | 3 | 27.3 | 11 | 12 | US-09-968-561A-298 | Sequence 298, App |
| 39 | 3 | 27.3 | 11 | 12 | US-10-289-456-91   | Sequence 91, Appl |
| 40 | 3 | 27.3 | 11 | 12 | US-10-417-895A-63  | Sequence 63, Appl |
| 41 | 3 | 27.3 | 11 | 12 | US-10-417-895A-66  | Sequence 66, Appl |
| 42 | 3 | 27.3 | 11 | 12 | US-10-356-824-3    | Sequence 3, Appli |
| 43 | 3 | 27.3 | 11 | 12 | US-10-430-685-35   | Sequence 35, Appl |
| 44 | 3 | 27.3 | 11 | 12 | US-10-430-685-37   | Sequence 37, Appl |
| 45 | 3 | 27.3 | 11 | 12 | US-10-430-685-39   | Sequence 39, Appl |
| 46 | 3 | 27.3 | 11 | 12 | US-10-600-152-3    | Sequence 3, Appli |
| 47 | 3 | 27.3 | 11 | 12 | US-10-609-217-980  | Sequence 980, App |
| 48 | 3 | 27.3 | 11 | 12 | US-10-398-104-179  | Sequence 179, App |
| 49 | 3 | 27.3 | 11 | 12 | US-10-458-860-31   | Sequence 31, Appl |
| 50 | 3 | 27.3 | 11 | 12 | US-10-149-135-15   | Sequence 15, Appl |
| 51 | 3 | 27.3 | 11 | 12 | US-10-149-135-59   | Sequence 59, Appl |
| 52 | 3 | 27.3 | 11 | 12 | US-10-149-135-83   | Sequence 83, Appl |
| 53 | 3 | 27.3 | 11 | 12 | US-10-149-135-217  | Sequence 217, App |
| 54 | 3 | 27.3 | 11 | 12 | US-10-149-135-278  | Sequence 278, App |
| 55 | 3 | 27.3 | 11 | 12 | US-10-149-135-406  | Sequence 406, App |
| 56 | 3 | 27.3 | 11 | 12 | US-10-149-135-409  | Sequence 409, App |

|     |   |      |    |    |                    |                   |
|-----|---|------|----|----|--------------------|-------------------|
| 57  | 3 | 27.3 | 11 | 12 | US-10-149-135-414  | Sequence 414, App |
| 58  | 3 | 27.3 | 11 | 12 | US-10-149-135-469  | Sequence 469, App |
| 59  | 3 | 27.3 | 11 | 12 | US-10-149-135-506  | Sequence 506, App |
| 60  | 3 | 27.3 | 11 | 12 | US-10-149-135-699  | Sequence 699, App |
| 61  | 3 | 27.3 | 11 | 12 | US-10-149-135-738  | Sequence 738, App |
| 62  | 3 | 27.3 | 11 | 12 | US-10-149-135-843  | Sequence 843, App |
| 63  | 3 | 27.3 | 11 | 12 | US-10-149-135-878  | Sequence 878, App |
| 64  | 3 | 27.3 | 11 | 12 | US-10-149-135-903  | Sequence 903, App |
| 65  | 3 | 27.3 | 11 | 12 | US-10-149-135-905  | Sequence 905, App |
| 66  | 3 | 27.3 | 11 | 12 | US-10-149-135-912  | Sequence 912, App |
| 67  | 3 | 27.3 | 11 | 12 | US-10-149-135-948  | Sequence 948, App |
| 68  | 3 | 27.3 | 11 | 12 | US-10-149-135-961  | Sequence 961, App |
| 69  | 3 | 27.3 | 11 | 12 | US-10-149-135-991  | Sequence 991, App |
| 70  | 3 | 27.3 | 11 | 12 | US-10-149-135-999  | Sequence 999, App |
| 71  | 3 | 27.3 | 11 | 12 | US-10-149-135-1018 | Sequence 1018, Ap |
| 72  | 3 | 27.3 | 11 | 12 | US-10-149-135-1020 | Sequence 1020, Ap |
| 73  | 3 | 27.3 | 11 | 12 | US-10-149-135-1041 | Sequence 1041, Ap |
| 74  | 3 | 27.3 | 11 | 12 | US-10-149-135-1049 | Sequence 1049, Ap |
| 75  | 3 | 27.3 | 11 | 12 | US-10-149-135-1057 | Sequence 1057, Ap |
| 76  | 3 | 27.3 | 11 | 12 | US-10-149-135-1059 | Sequence 1059, Ap |
| 77  | 3 | 27.3 | 11 | 12 | US-10-149-135-1253 | Sequence 1253, Ap |
| 78  | 3 | 27.3 | 11 | 12 | US-10-149-135-1303 | Sequence 1303, Ap |
| 79  | 3 | 27.3 | 11 | 12 | US-10-149-135-1322 | Sequence 1322, Ap |
| 80  | 3 | 27.3 | 11 | 12 | US-10-149-135-1356 | Sequence 1356, Ap |
| 81  | 3 | 27.3 | 11 | 12 | US-10-149-135-1399 | Sequence 1399, Ap |
| 82  | 3 | 27.3 | 11 | 12 | US-10-149-135-1498 | Sequence 1498, Ap |
| 83  | 3 | 27.3 | 11 | 12 | US-10-149-135-1515 | Sequence 1515, Ap |
| 84  | 3 | 27.3 | 11 | 12 | US-10-149-135-1525 | Sequence 1525, Ap |
| 85  | 3 | 27.3 | 11 | 12 | US-10-149-135-1539 | Sequence 1539, Ap |
| 86  | 3 | 27.3 | 11 | 12 | US-10-149-135-1596 | Sequence 1596, Ap |
| 87  | 3 | 27.3 | 11 | 12 | US-10-149-135-1669 | Sequence 1669, Ap |
| 88  | 3 | 27.3 | 11 | 12 | US-10-149-135-1689 | Sequence 1689, Ap |
| 89  | 3 | 27.3 | 11 | 12 | US-10-149-135-1768 | Sequence 1768, Ap |
| 90  | 3 | 27.3 | 11 | 12 | US-10-149-135-1785 | Sequence 1785, Ap |
| 91  | 3 | 27.3 | 11 | 12 | US-10-149-135-1794 | Sequence 1794, Ap |
| 92  | 3 | 27.3 | 11 | 12 | US-10-149-135-1895 | Sequence 1895, Ap |
| 93  | 3 | 27.3 | 11 | 12 | US-10-149-135-2256 | Sequence 2256, Ap |
| 94  | 3 | 27.3 | 11 | 12 | US-10-398-616-4    | Sequence 4, Appli |
| 95  | 3 | 27.3 | 11 | 12 | US-10-398-616-10   | Sequence 10, Appl |
| 96  | 3 | 27.3 | 11 | 12 | US-10-632-388-980  | Sequence 980, App |
| 97  | 3 | 27.3 | 11 | 12 | US-10-404-286-8    | Sequence 8, Appli |
| 98  | 3 | 27.3 | 11 | 12 | US-10-433-596-11   | Sequence 11, Appl |
| 99  | 3 | 27.3 | 11 | 12 | US-10-433-596-18   | Sequence 18, Appl |
| 100 | 3 | 27.3 | 11 | 12 | US-10-651-723-980  | Sequence 980, App |

#### ALIGNMENTS

##### RESULT 1

US-09-876-904A-83

; Sequence 83, Application US/09876904A

; Publication No. US20030072794A1

; GENERAL INFORMATION:

; APPLICANT: BOULIKAS, TENI

; TITLE OF INVENTION: ENCAPSULATION OF PLASMID DNA (LIPOGENES TM) AND  
THERAPEUTIC



; TITLE OF INVENTION: AGENTS WITH NUCLEAR LOCALIZATION SIGNAL/FUSOGENIC PEPTIDE  
 ; TITLE OF INVENTION: CONJUGATES INTO TARGETED LIPOSOME COMPLEXES  
 ; FILE REFERENCE: TB-2002.00  
 ; CURRENT APPLICATION NUMBER: US/09/876,904A  
 ; CURRENT FILING DATE: 2001-06-08  
 ; PRIOR APPLICATION NUMBER: US 60/210,925  
 ; PRIOR FILING DATE: 2000-06-09  
 ; NUMBER OF SEQ ID NOS: 629  
 ; SOFTWARE: PatentIn Ver. 2.1  
 ; SEQ ID NO 83  
 ; LENGTH: 11  
 ; TYPE: PRT  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Description of Artificial Sequence: Synthetic T-DNA-linked VirD2  
 ; OTHER INFORMATION: endonuclease of the Agrobacterium tumefaciens tumor-inducing  
 ; OTHER INFORMATION: plasmid  
 US-09-876-904A-83

Query Match 36.4%; Score 4; DB 10; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1e+03;  
 Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SRKG 6  
 ||||  
 Db 4 SRKG 7

## RESULT 2

US-10-211-088-246  
 ; Sequence 246, Application US/10211088  
 ; Publication No. US20030104479A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Bright, Gary R.  
 ; APPLICANT: Premkumar, D. David  
 ; APPLICANT: Chen, Yih-Tai  
 ; TITLE OF INVENTION: No. US20030104479A1el Fusion Proteins And Assays For Molecular Binding  
 ; FILE REFERENCE: 01-1022-US  
 ; CURRENT APPLICATION NUMBER: US/10/211,088  
 ; CURRENT FILING DATE: 2002-10-15  
 ; PRIOR APPLICATION NUMBER: 60/309,395  
 ; PRIOR FILING DATE: 2001-08-01  
 ; PRIOR APPLICATION NUMBER: 60/341,589  
 ; PRIOR FILING DATE: 2001-12-13  
 ; NUMBER OF SEQ ID NOS: 366  
 ; SOFTWARE: PatentIn version 3.1  
 ; SEQ ID NO 246  
 ; LENGTH: 11  
 ; TYPE: PRT  
 ; ORGANISM: Artificial sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Nuclear localization signal  
 US-10-211-088-246

Query Match 36.4%; Score 4; DB 14; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1e+03;  
Matches 4; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 SRKG 6  
||||  
Db 4 SRKG 7

RESULT 3

US-08-779-457-43

; Sequence 43, Application US/08779457

; Publication No. US20020193571A1

; GENERAL INFORMATION:

; APPLICANT: Carter, Paul J.

; APPLICANT: Chiang, Nancy Y.

; APPLICANT: Kyung, Jin Kim

; APPLICANT: Matthews, William

; APPLICANT: Rodrigues, Maria L.

; TITLE OF INVENTION: WSX RECEPTOR AGONIST ANTIBODIES

; NUMBER OF SEQUENCES: 51

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Genentech, Inc.

; STREET: 460 Point San Bruno Blvd

; CITY: South San Francisco

; STATE: California

; COUNTRY: USA

; ZIP: 94080

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: WinPatin (Genentech)

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/779,457

; FILING DATE:

; CLASSIFICATION: 435

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/667197

; FILING DATE: 06/20/96

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/585005

; FILING DATE: 01/08/96

; ATTORNEY/AGENT INFORMATION:

; NAME: Lee, Wendy M.

; REGISTRATION NUMBER: 40,378

; REFERENCE/DOCKET NUMBER: P0986P2

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 415/225-1994

; TELEFAX: 415/952-9881

; TELEX: 910/371-7168

; INFORMATION FOR SEQ ID NO: 43:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 11 amino acids

; TYPE: Amino Acid

; TOPOLOGY: Linear

US-08-779-457-43

Query Match 27.3%; Score 3; DB 8; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 NSS 9  
|||  
Db 3 NSS 5

RESULT 4

US-09-780-070-25

; Sequence 25, Application US/09780070

; Patent No. US20020009752A1

; GENERAL INFORMATION:

; APPLICANT: Burke, James

; APPLICANT: Strittmater, Warren

; APPLICANT: Nagai, Yoshitaka

; TITLE OF INVENTION: COMPOUNDS THAT SELECTIVELY BIND TO EXPANDED POLYGLUTAMINE  
REPEAT DOMAINS

; TITLE OF INVENTION: AND METHODS OF USE THEREOF

; FILE REFERENCE: 5405.242

; CURRENT APPLICATION NUMBER: US/09/780,070

; CURRENT FILING DATE: 2001-02-09

; PRIOR APPLICATION NUMBER: 60/189,781

; PRIOR FILING DATE: 2000-03-16

; NUMBER OF SEQ ID NOS: 40

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 25

; LENGTH: 11

; TYPE: PRT

; ORGANISM: synthetic construct

US-09-780-070-25

Query Match 27.3%; Score 3; DB 9; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 KGN 7  
|||  
Db 6 KGN 8

RESULT 5

US-09-780-070-26

; Sequence 26, Application US/09780070

; Patent No. US20020009752A1

; GENERAL INFORMATION:

; APPLICANT: Burke, James

; APPLICANT: Strittmater, Warren

; APPLICANT: Nagai, Yoshitaka

; TITLE OF INVENTION: COMPOUNDS THAT SELECTIVELY BIND TO EXPANDED POLYGLUTAMINE  
REPEAT DOMAINS

; TITLE OF INVENTION: AND METHODS OF USE THEREOF

; FILE REFERENCE: 5405.242

; CURRENT APPLICATION NUMBER: US/09/780,070

; CURRENT FILING DATE: 2001-02-09  
; PRIOR APPLICATION NUMBER: 60/189,781  
; PRIOR FILING DATE: 2000-03-16  
; NUMBER OF SEQ ID NOS: 40  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 26  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: synthetic construct  
US-09-780-070-26

Query Match 27.3%; Score 3; DB 9; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 SLM 11  
   | | |  
Db 2 SLM 4

RESULT 6

US-09-823-649A-18

; Sequence 18, Application US/09823649A  
; Patent No. US20020012970A1  
; GENERAL INFORMATION:  
; APPLICANT: Smith, Edward  
; APPLICANT: Elfstrom, Carita  
; APPLICANT: Gelfand, David  
; APPLICANT: Higuchi, Russell  
; APPLICANT: Myers, Thomas  
; APPLICANT: Schoenbrunner, Nancy  
; APPLICANT: Wang, Alice  
; TITLE OF INVENTION: HIGH TEMPERATURE REVERSE TRANSCRIPTION USING MUTANT DNA  
POLYMERASES  
; FILE REFERENCE: RPA1006  
; CURRENT APPLICATION NUMBER: US/09/823,649A  
; CURRENT FILING DATE: 2001-03-30  
; PRIOR APPLICATION NUMBER: US 60/198,336  
; PRIOR FILING DATE: 2000-04-18  
; NUMBER OF SEQ ID NOS: 21  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 18  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Bacillus caldotenax  
US-09-823-649A-18

Query Match 27.3%; Score 3; DB 9; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SRK 5  
   | | |  
Db 8 SRK 10

RESULT 7

US-09-056-160B-17  
; Sequence 17, Application US/09056160B  
; Patent No. US20020032315A1  
; GENERAL INFORMATION:  
; APPLICANT: Baca, Manuel  
; APPLICANT: Wells, James A.  
; APPLICANT: Presta, Leonard G.  
; APPLICANT: Lowman, Henry B.  
; APPLICANT: Chen, Yvonne M.  
; TITLE OF INVENTION: ANTI-VEGF ANTIBODIES  
; NUMBER OF SEQUENCES: 131  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Genentech, Inc.  
; STREET: 1 DNA Way  
; CITY: South San Francisco  
; STATE: California  
; COUNTRY: USA  
; ZIP: 94080  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: WinPatin (Genentech)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/056,160B  
; FILING DATE: 06-Apr-1998  
; CLASSIFICATION: 424  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/054,856  
; FILING DATE: 06-AUG-1997  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Hasak, Janet E.  
; REGISTRATION NUMBER: 28,616  
; REFERENCE/DOCKET NUMBER: P1093R2  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 650/225-1896  
; TELEFAX: 650/952-9881  
; INFORMATION FOR SEQ ID NO: 17:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 11 amino acids  
; TYPE: Amino Acid  
; TOPOLOGY: Linear  
US-09-056-160B-17

Query Match 27.3%; Score 3; DB 9; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 NSS 9  
|||  
Db 3 NSS 5

RESULT 8  
US-09-896-251-11  
; Sequence 11, Application US/09896251  
; Patent No. US20020041880A1

```
; GENERAL INFORMATION:
; APPLICANT: Merck & Co., Inc.
; APPLICANT: DeFeo-Jones, Deborah
; APPLICANT: Heimbrosk, David C.
; APPLICANT: Jones, Raymond E.
; TITLE OF INVENTION: A METHOD OF TREATING CANCER
; FILE REFERENCE: 20662
; CURRENT APPLICATION NUMBER: US/09/896,251
; CURRENT FILING DATE: 2001-06-29
; PRIOR APPLICATION NUMBER: 60/215,934
; PRIOR FILING DATE: 2000-07-05
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 11
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: completely synthetic amino acid sequence
; NAME/KEY: ACETYLATION
; LOCATION: (1)...(1)
; OTHER INFORMATION: acetylated N-terminus amino acid
US-09-896-251-11
```

```
Query Match          27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+04;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;
```

```
Qy      8 SSL 10
      |||
Db      9 SSL 11
```

# RESULT 9

```
US-09-896-251-18
; Sequence 18, Application US/09896251
; Patent No. US20020041880A1
; GENERAL INFORMATION:
; APPLICANT: Merck & Co., Inc.
; APPLICANT: DeFeo-Jones, Deborah
; APPLICANT: Heimbrosk, David C.
; APPLICANT: Jones, Raymond E.
; TITLE OF INVENTION: A METHOD OF TREATING CANCER
; FILE REFERENCE: 20662
; CURRENT APPLICATION NUMBER: US/09/896,251
; CURRENT FILING DATE: 2001-06-29
; PRIOR APPLICATION NUMBER: 60/215,934
; PRIOR FILING DATE: 2000-07-05
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 18
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: completely synthetic amino acid sequence
; NAME/KEY: AMIDATION
```

; LOCATION: (11)...(11)  
; OTHER INFORMATION: leucinamide  
US-09-896-251-18

Query Match 27.3%; Score 3; DB 9; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
|||  
Db 9 SSL 11

RESULT 10

US-09-896-245-11  
; Sequence 11, Application US/09896245  
; Patent No. US20020042375A1  
; GENERAL INFORMATION:  
; APPLICANT: Merck & Co., Inc.  
; APPLICANT: Heimbrosok, David C.  
; APPLICANT: Yao, Siu-Long  
; TITLE OF INVENTION: A METHOD OF TREATING CANCER  
; FILE REFERENCE: 20664Y  
; CURRENT APPLICATION NUMBER: US/09/896,245  
; CURRENT FILING DATE: 2001-06-29  
; PRIOR APPLICATION NUMBER: 60/216,217  
; PRIOR FILING DATE: 2000-07-05  
; NUMBER OF SEQ ID NOS: 54  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 11  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: completely synthetic amino acid sequence  
; NAME/KEY: ACETYLATION  
; LOCATION: (1)...(1)  
; OTHER INFORMATION: acetylated N-terminus amino acid  
US-09-896-245-11

Query Match 27.3%; Score 3; DB 9; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
|||  
Db 9 SSL 11

RESULT 11

US-09-896-245-18  
; Sequence 18, Application US/09896245  
; Patent No. US20020042375A1  
; GENERAL INFORMATION:  
; APPLICANT: Merck & Co., Inc.  
; APPLICANT: Heimbrosok, David C.  
; APPLICANT: Yao, Siu-Long

```
; TITLE OF INVENTION: A METHOD OF TREATING CANCER
; FILE REFERENCE: 20664Y
; CURRENT APPLICATION NUMBER: US/09/896,245
; CURRENT FILING DATE: 2001-06-29
; PRIOR APPLICATION NUMBER: 60/216,217
; PRIOR FILING DATE: 2000-07-05
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 18
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: completely synthetic amino acid sequence
; NAME/KEY: AMIDATION
; LOCATION: (11)...(11)
; OTHER INFORMATION: leucinamide
US-09-896-245-18
```

```
Query Match          27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+04;
Matches      3; Conservative    0; Mismatches    0; Indels      0; Gaps      0;
```

```
Qy      8 SSL 10
        |||
Db      9 SSL 11
```

# RESULT 12

```
US-09-935-682-28
; Sequence 28, Application US/09935682
; Patent No. US20020059032A1
; GENERAL INFORMATION:
; APPLICANT: Societe de Conseils de Recherches et D'Applications Scientifiques
; APPLICANT: Ferrer, Camara Y.
; TITLE OF INVENTION: Rational Selection of Putative Peptides from Identified
Nucleotide or
; TITLE OF INVENTION: Peptide Sequences
; FILE REFERENCE: 58767.000005
; CURRENT APPLICATION NUMBER: US/09/935,682
; CURRENT FILING DATE: 2001-08-24
; PRIOR APPLICATION NUMBER: 09/257,525
; PRIOR FILING DATE: 1999-02-25
; PRIOR APPLICATION NUMBER: PCT/FR00/00460
; PRIOR FILING DATE: 2000-02-24
; NUMBER OF SEQ ID NOS: 73
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 28
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-935-682-28
```

```
Query Match          27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+04;
Matches      3; Conservative    0; Mismatches    0; Indels      0; Gaps      0;
```



Qy 9 SLM 11  
 |||  
Db 2 SLM 4

RESULT 13

US-09-873-637-13

; Sequence 13, Application US/09873637  
; Patent No. US20020061543A1  
; GENERAL INFORMATION:  
; APPLICANT: Ross, Jeffrey  
; TITLE OF INVENTION: THE C-MYC CODING REGION DETERMINANT-BINDING PROTEIN  
; TITLE OF INVENTION: (CRD-BP) AND ITS NUCLEIC ACID SEQUENCE  
; FILE REFERENCE: 960296.95131  
; CURRENT APPLICATION NUMBER: US/09/873,637  
; CURRENT FILING DATE: 2001-06-04  
; NUMBER OF SEQ ID NOS: 46  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 13  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-873-637-13

Query Match 27.3%; Score 3; DB 9; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
 |||  
Db 3 SSL 5

RESULT 14

US-09-825-584-1

; Sequence 1, Application US/09825584  
; Patent No. US20020064805A1  
; GENERAL INFORMATION:  
; APPLICANT: Akita, Robert  
; Sliwkowski, Mark  
; TITLE OF INVENTION: ErbB3 Antibodies  
; NUMBER OF SEQUENCES: 5  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Genentech, Inc.  
; STREET: 1 DNA Way  
; CITY: South San Francisco  
; STATE: California  
; COUNTRY: USA  
; ZIP: 94080  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: WinPatin (Genentech)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/825,584  
; FILING DATE: 04-Apr-2001

```

; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/827,009
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Lee, Wendy M.
; REGISTRATION NUMBER: 40,378
; REFERENCE/DOCKET NUMBER: P1003R1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650/225-1994
; TELEFAX: 650/952-9881
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: Amino Acid
; TOPOLOGY: Linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-825-584-1

```

```

Query Match          27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+04;
Matches      3; Conservative    0; Mismatches    0; Indels      0; Gaps      0;

```

```

Qy      7 NSS 9
      |||
Db      3 NSS 5

```

# RESULT 15

```

US-09-192-854-170
; Sequence 170, Application US/09192854
; Patent No. US20020068276A1
; GENERAL INFORMATION:
; APPLICANT: Winter, Greg
; APPLICANT: Tomlinson, Ian
; TITLE OF INVENTION: Methods for Selecting Functional Peptides
; FILE REFERENCE: 3789/72916
; CURRENT APPLICATION NUMBER: US/09/192,854
; CURRENT FILING DATE: 1998-11-17
; EARLIER APPLICATION NUMBER: 60/066,729
; EARLIER FILING DATE: 1997-11-21
; NUMBER OF SEQ ID NOS: 212
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 170
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-192-854-170

```

```

Query Match          27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+04;
Matches      3; Conservative    0; Mismatches    0; Indels      0; Gaps      0;

```

```

Qy      8 SSL 10
      |||
Db      8 SSL 10

```

RESULT 16

US-09-811-384-8

; Sequence 8, Application US/09811384

; Patent No. US20020081294A1

; GENERAL INFORMATION:

; APPLICANT: Bednar, Martin M.

; Thomas, G. Roger

; Gross, Cordell E.

; TITLE OF INVENTION: ANTI-CD18 ANTIBODIES IN STROKE

; NUMBER OF SEQUENCES: 15

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Genentech, Inc.

; STREET: 1 DNA Way

; CITY: South San Francisco

; STATE: California

; COUNTRY: USA

; ZIP: 94080

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: WinPatin (Genentech)

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/811,384

; FILING DATE: 20-Dec-2000

; CLASSIFICATION: <Unknown>

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 09/251652

; FILING DATE: 17-FEB-2000

; APPLICATION NUMBER: 08/788800

; FILING DATE: 22-JAN-1997

; APPLICATION NUMBER: 60/093038

; FILING DATE: 23-JAN-1996

; ATTORNEY/AGENT INFORMATION:

; NAME: Love, Richard B.

; REGISTRATION NUMBER: 34,659

; REFERENCE/DOCKET NUMBER: P1729C1

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 650/225-5530

; TELEFAX: 650/952-9881

; INFORMATION FOR SEQ ID NO: 8:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 11 amino acids

; TYPE: Amino Acid

; TOPOLOGY: Linear

; SEQUENCE DESCRIPTION: SEQ ID NO: 8:

US-09-811-384-8

Query Match 27.3%; Score 3; DB 9; Length 11;

Best Local Similarity 100.0%; Pred. No. 1.1e+04;

Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 NSS 9

|||

Db 3 NSS 5

RESULT 17

US-09-832-723-35

; Sequence 35, Application US/09832723  
 ; Patent No. US20020098524A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Estell, David A.  
 ; APPLICANT: Chen, Yiyou  
 ; APPLICANT: Murray, Christopher J.  
 ; APPLICANT: Tijerina, Pilar  
 ; TITLE OF INVENTION: METHODS FOR SELECTIVE TARGETING  
 ; FILE REFERENCE: GC617-2  
 ; CURRENT APPLICATION NUMBER: US/09/832,723  
 ; CURRENT FILING DATE: 2001-04-11  
 ; PRIOR APPLICATION NUMBER: US 60/197,259  
 ; PRIOR FILING DATE: 2000-04-14  
 ; NUMBER OF SEQ ID NOS: 117  
 ; SOFTWARE: FastSEQ for Windows Version 4.0  
 ; SEQ ID NO 35  
 ; LENGTH: 11  
 ; TYPE: PRT  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: peptides screened from a phage display random  
 ; OTHER INFORMATION: peptide library  
 US-09-832-723-35

Query Match 27.3%; Score 3; DB 9; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 SLM 11  
 |||  
 Db 5 SLM 7

RESULT 18

US-09-226-248B-27

; Sequence 27, Application US/09226248B  
 ; Patent No. US20020106690A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: LEBERER, Ekkehard  
 ; APPLICANT: LEEUW, Thomas  
 ; APPLICANT: WHITEWAY, Malcolm  
 ; APPLICANT: THOMAS, David Y.  
 ; TITLE OF INVENTION: THE G-PROTEIN BETA SUBUNIT INTERACTION DOMAIN OF  
 ; TITLE OF INVENTION: STE20P/PAK FAMILY OF PROTEIN KINASES AND USES THEREOF  
 ; TITLE OF INVENTION: IN BIOASSAYS  
 ; FILE REFERENCE: 00122199  
 ; CURRENT APPLICATION NUMBER: US/09/226,248B  
 ; CURRENT FILING DATE: 1999-01-07  
 ; NUMBER OF SEQ ID NOS: 31  
 ; SOFTWARE: PatentIn Ver. 2.1  
 ; SEQ ID NO 27  
 ; LENGTH: 11  
 ; TYPE: PRT  
 ; ORGANISM: Artificial Sequence

```

; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: consensus
; OTHER INFORMATION: sequence
; NAME/KEY: VARIANT
; LOCATION: (4)
; OTHER INFORMATION: Xaa = A, I, L, M, S, T
; NAME/KEY: VARIANT
; LOCATION: (7)
; OTHER INFORMATION: Xaa = I, V
; NAME/KEY: VARIANT
; LOCATION: (8)
; OTHER INFORMATION: Xaa = any amino acid
; NAME/KEY: VARIANT
; LOCATION: (9)..(10)
; OTHER INFORMATION: Xaa = A, I, L, M, S, T
US-09-226-248B-27

```

```

Query Match          27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+04;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      8 SSL 10
        |||
Db      1 SSL 3

```

# RESULT 19

```

US-09-966-871-31
; Sequence 31, Application US/09966871
; Patent No. US20020127539A1
; GENERAL INFORMATION:
; APPLICANT: Kopin, Alan S.
; TITLE OF INVENTION: Assays for Identifying Receptors Having
; TITLE OF INVENTION: Alterations in Signaling
; FILE REFERENCE: 00398/512002
; CURRENT APPLICATION NUMBER: US/09/966,871
; CURRENT FILING DATE: 2001-09-28
; PRIOR APPLICATION NUMBER: US 60/236,302
; PRIOR FILING DATE: 2000-09-28
; PRIOR APPLICATION NUMBER: US 60/288,644
; PRIOR FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 87
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 31
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-966-871-31

```

```

Query Match          27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+04;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      1 AKS 3
        |||
Db      5 AKS 7

```

RESULT 20

US-09-848-664-6

; Sequence 6, Application US/09848664

; Patent No. US20020146414A1

; GENERAL INFORMATION:

; APPLICANT: Sakiyama-Elbert, Shelly E.

; APPLICANT: Hubbell, Jeffrey A.

; TITLE OF INVENTION: Controlled Release of No. US20020146414A1-Heparin Binding Growth

; TITLE OF INVENTION: Factors from Heparin Containing Matrices

; FILE REFERENCE: ETH 108

; CURRENT APPLICATION NUMBER: US/09/848,664

; CURRENT FILING DATE: 2001-05-03

; PRIOR APPLICATION NUMBER: 09/298,084

; PRIOR FILING DATE: 1999-04-22

; NUMBER OF SEQ ID NOS: 31

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 6

; LENGTH: 11

; TYPE: PRT

; ORGANISM: Homo sapiens

US-09-848-664-6

Query Match 27.3%; Score 3; DB 9; Length 11;

Best Local Similarity 100.0%; Pred. No. 1.1e+04;

Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SRK 5

|||

Db 4 SRK 6

RESULT 21

US-09-071-838-286

; Sequence 286, Application US/09071838

; Patent No. US20020152501A1

; GENERAL INFORMATION:

; APPLICANT: Fischer, Robert L.

; APPLICANT: Ohad, Nir

; APPLICANT: Kiyosue, Tomohiro

; APPLICANT: Yadegari, Ramin

; APPLICANT: Margossian, Linda

; APPLICANT: Harada, John

; APPLICANT: Goldberg, Robert B.

; TITLE OF INVENTION: Nucleic Acids That Control Seed and

; TITLE OF INVENTION: Fruit Development in Plants

; NUMBER OF SEQUENCES: 324

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Townsend and Townsend and Crew LLP

; STREET: Two Embarcadero Center, Eighth Floor

; CITY: San Francisco

; STATE: California

; COUNTRY: USA

; ZIP: 94111-3834

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

```

;   COMPUTER:  IBM PC compatible
;   OPERATING SYSTEM:  PC-DOS/MS-DOS
;   SOFTWARE:  PatentIn Release #1.0, Version #1.30
;   CURRENT APPLICATION DATA:
;     APPLICATION NUMBER:  US/09/071,838
;     FILING DATE:  01-MAY-1998
;     CLASSIFICATION:  800
;   ATTORNEY/AGENT INFORMATION:
;     NAME:  Bastian, Kevin L.
;     REGISTRATION NUMBER:  34,774
;     REFERENCE/DOCKET NUMBER:  023070-086100US
;   TELECOMMUNICATION INFORMATION:
;     TELEPHONE:  (415) 576-0200
;     TELEFAX:  (415) 576-0300
;   INFORMATION FOR SEQ ID NO:  286:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  11 amino acids
;       TYPE:  amino acid
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  peptide
US-09-071-838-286

```

```

Query Match          27.3%;  Score 3;  DB 9;  Length 11;
Best Local Similarity 100.0%;  Pred. No. 1.1e+04;
Matches      3;  Conservative      0;  Mismatches      0;  Indels      0;  Gaps      0;

```

```

Qy      9 SLM 11
        |||
Db      1 SLM 3

```

# RESULT 22

```

US-09-968-561A-298
; Sequence 298, Application US/09968561A
; Patent No. US20020164642A1
; GENERAL INFORMATION:
;   APPLICANT: Tomlinson, Ian M
;   APPLICANT: Winter, Gregory
;   TITLE OF INVENTION: Method to Screen Phage Display Libraries with Different
Ligands
;   FILE REFERENCE: 8039/1073B
;   CURRENT APPLICATION NUMBER: US/09/968,561A
;   CURRENT FILING DATE: 2001-10-01
;   PRIOR APPLICATION NUMBER: GB 9722131.1
;   PRIOR FILING DATE: 1997-10-20
;   PRIOR APPLICATION NUMBER: US 60/065,248
;   PRIOR FILING DATE: 1997-11-13
;   PRIOR APPLICATION NUMBER: US 60/066,729
;   PRIOR FILING DATE: 1997-11-21
;   PRIOR APPLICATION NUMBER: PCT/GB98/03135
;   PRIOR FILING DATE: 1998-10-20
;   PRIOR APPLICATION NUMBER: US 09/511,939
;   PRIOR FILING DATE: 2000-02-24
;   NUMBER OF SEQ ID NOS: 350
;   SOFTWARE: PatentIn version 3.1
; SEQ ID NO 298
;   LENGTH: 11

```

; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-968-561A-298

Query Match 27.3%; Score 3; DB 9; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
|||  
Db 8 SSL 10

RESULT 23

US-09-969-244-11

; Sequence 11, Application US/09969244  
; Patent No. US20020173451A1  
; GENERAL INFORMATION:  
; APPLICANT: Merck & Co., Inc.  
; APPLICANT: Yao, Siu-Long  
; APPLICANT: Jones, Raymond E.  
; APPLICANT: Defeo-Jones, Deborah  
; APPLICANT: Heimbrook, David C.  
; APPLICANT: Rhymer, Patricia A.  
; APPLICANT: Wasserbly, Pamela J.  
; TITLE OF INVENTION: A METHOD OF TREATING CANCER  
; FILE REFERENCE: 20665  
; CURRENT APPLICATION NUMBER: US/09/969,244  
; CURRENT FILING DATE: 2001-10-02  
; PRIOR APPLICATION NUMBER: 60/242,815  
; PRIOR FILING DATE: 2000-10-24  
; NUMBER OF SEQ ID NOS: 46  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 11  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: completely synthetic amino acid sequence  
; NAME/KEY: ACETYLATION  
; LOCATION: (1)...(1)  
; OTHER INFORMATION: acetylated N-terminus amino acid  
US-09-969-244-11

Query Match 27.3%; Score 3; DB 9; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
|||  
Db 9 SSL 11

RESULT 24

US-09-969-244-18

; Sequence 18, Application US/09969244  
; Patent No. US20020173451A1



```
; GENERAL INFORMATION:
; APPLICANT: Merck & Co., Inc.
; APPLICANT: Yao, Siu-Long
; APPLICANT: Jones, Raymond E.
; APPLICANT: Defeo-Jones, Deborah
; APPLICANT: Heimbroke, David C.
; APPLICANT: Rhymer, Patricia A.
; APPLICANT: Wasserbly, Pamela J.
; TITLE OF INVENTION: A METHOD OF TREATING CANCER
; FILE REFERENCE: 20665
; CURRENT APPLICATION NUMBER: US/09/969,244
; CURRENT FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: 60/242,815
; PRIOR FILING DATE: 2000-10-24
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 18
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: completely synthetic amino acid sequence
; NAME/KEY: AMIDATION
; LOCATION: (11)...(11)
; OTHER INFORMATION: leucinamide
US-09-969-244-18
```

```
Query Match          27.3%; Score 3; DB 9; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+04;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;
```

```
Qy          8 SSL 10
            |||
Db          9 SSL 11
```

# RESULT 25

US-09-757-774-13

```
; Sequence 13, Application US/09757774
; Publication No. US20020187156A1
; GENERAL INFORMATION:
; APPLICANT: Dintzis, Howard M.
; APPLICANT: Dintzis, Renee
; APPLICANT: Blodgett, James
; APPLICANT: Cheronis, John
; TITLE OF INVENTION: THERAPEUTIC SUPPRESSION OF SPECIFIC IMMUNE RESPONSES BY
; TITLE OF INVENTION: ADMINISTRATION OF OLIGOMERIC FORMS OF ANTIGEN OF
CONTROLLED
; TITLE OF INVENTION: CHEMISTRY
; FILE REFERENCE: 07265/124004
; CURRENT APPLICATION NUMBER: US/09/757,774
; CURRENT FILING DATE: 2001-01-09
; PRIOR APPLICATION NUMBER: US 08/440,322
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: US 07/808,797
; PRIOR FILING DATE: 1991-12-17
; PRIOR APPLICATION NUMBER: US 07/628,858
```

; PRIOR FILING DATE: 1990-12-17  
; PRIOR APPLICATION NUMBER: US 07/354,710  
; PRIOR FILING DATE: 1989-05-22  
; PRIOR APPLICATION NUMBER: US 07/248,293  
; PRIOR FILING DATE: 1988-09-21  
; PRIOR APPLICATION NUMBER: US 06/869,808  
; PRIOR FILING DATE: 1986-05-29  
; PRIOR APPLICATION NUMBER: US 06/460,266  
; PRIOR FILING DATE: 1983-01-24  
; NUMBER OF SEQ ID NOS: 23  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 13  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Mus musculus  
US-09-757-774-13

Query Match 27.3%; Score 3; DB 9; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AKS 3  
   |||  
Db 3 AKS 5

RESULT 26

US-09-999-724-76

; Sequence 76, Application US/09999724  
; Publication No. US20030022355A1  
; GENERAL INFORMATION:  
; APPLICANT: WICKHAM, THOMAS J.  
; APPLICANT: KOVESDI, IMRE  
; APPLICANT: BROUGH, DOUGLAS E.  
; TITLE OF INVENTION: VECTORS AND METHODS FOR GENE TRANSFER  
; FILE REFERENCE: 212960  
; CURRENT APPLICATION NUMBER: US/09/999,724  
; CURRENT FILING DATE: 2001-10-24  
; PRIOR APPLICATION NUMBER: US 09/101,751  
; PRIOR FILING DATE: 1999-01-29  
; PRIOR APPLICATION NUMBER: WO 96US19150  
; PRIOR FILING DATE: 1996-11-27  
; PRIOR APPLICATION NUMBER: US 08/700,846  
; PRIOR FILING DATE: 1996-08-21  
; PRIOR APPLICATION NUMBER: US 08/701,124  
; PRIOR FILING DATE: 1996-08-21  
; PRIOR APPLICATION NUMBER: US 08/563,368  
; PRIOR FILING DATE: 1995-11-28  
; NUMBER OF SEQ ID NOS: 94  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 76  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-09-999-724-76

Query Match 27.3%; Score 3; DB 10; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SRK 5  
|||  
Db 1 SRK 3

RESULT 27

US-09-876-904A-369  
; Sequence 369, Application US/09876904A  
; Publication No. US20030072794A1  
; GENERAL INFORMATION:  
; APPLICANT: BOULIKAS, TENI  
; TITLE OF INVENTION: ENCAPSULATION OF PLASMID DNA (LIPOGENES TM) AND  
THERAPEUTIC  
; TITLE OF INVENTION: AGENTS WITH NUCLEAR LOCALIZATION SIGNAL/FUSOGENIC  
PEPTIDE  
; TITLE OF INVENTION: CONJUGATES INTO TARGETED LIPOSOME COMPLEXES  
; FILE REFERENCE: TB-2002.00  
; CURRENT APPLICATION NUMBER: US/09/876,904A  
; CURRENT FILING DATE: 2001-06-08  
; PRIOR APPLICATION NUMBER: US 60/210,925  
; PRIOR FILING DATE: 2000-06-09  
; NUMBER OF SEQ ID NOS: 629  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 369  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Drosophila Suvar  
; FEATURE:  
; OTHER INFORMATION: (3) 7 gene product involved in  
; OTHER INFORMATION: position-effect variegation (932 aas).  
US-09-876-904A-369

Query Match 27.3%; Score 3; DB 10; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SRK 5  
|||  
Db 4 SRK 6

RESULT 28

US-09-876-904A-509  
; Sequence 509, Application US/09876904A  
; Publication No. US20030072794A1  
; GENERAL INFORMATION:  
; APPLICANT: BOULIKAS, TENI  
; TITLE OF INVENTION: ENCAPSULATION OF PLASMID DNA (LIPOGENES TM) AND  
THERAPEUTIC  
; TITLE OF INVENTION: AGENTS WITH NUCLEAR LOCALIZATION SIGNAL/FUSOGENIC  
PEPTIDE  
; TITLE OF INVENTION: CONJUGATES INTO TARGETED LIPOSOME COMPLEXES

; FILE REFERENCE: TB-2002.00  
; CURRENT APPLICATION NUMBER: US/09/876,904A  
; CURRENT FILING DATE: 2001-06-08  
; PRIOR APPLICATION NUMBER: US 60/210,925  
; PRIOR FILING DATE: 2000-06-09  
; NUMBER OF SEQ ID NOS: 629  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 509  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Unknown Organism  
; FEATURE:  
; OTHER INFORMATION: Description of Unknown Organism: Ig/EBP-1 (immunoglobulin  
; OTHER INFORMATION: gene enhancer-binding protein).  
US-09-876-904A-509

Query Match 27.3%; Score 3; DB 10; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 KSR 4  
|||  
Db 3 KSR 5

RESULT 29

US-09-774-381-59

; Sequence 59, Application US/09774381  
; Publication No. US20030082677A1  
; GENERAL INFORMATION:  
; APPLICANT: Holtzman, Douglas A.  
; APPLICANT: McCarthy, Sean A.  
; APPLICANT: Pan, Yang  
; APPLICANT: Gearing, David P.  
; TITLE OF INVENTION: NOVEL EDIRF, MTR-1, LSP-1, TAP-1, AND PA-I MOLECULES  
; TITLE OF INVENTION: AND USES THEREFOR  
; FILE REFERENCE: MNI-107CP2  
; CURRENT APPLICATION NUMBER: US/09/774,381  
; CURRENT FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: 08/941,354  
; PRIOR FILING DATE: 1999-09-30  
; PRIOR APPLICATION NUMBER: 09/010,674  
; PRIOR FILING DATE: 1998-01-22  
; PRIOR APPLICATION NUMBER: 60/061,149  
; PRIOR FILING DATE: 1997-10-06  
; PRIOR APPLICATION NUMBER: 09/014,347  
; PRIOR FILING DATE: 1998-01-27  
; PRIOR APPLICATION NUMBER: 60/061,159  
; PRIOR FILING DATE: 1997-10-06  
; PRIOR APPLICATION NUMBER: 09/474,151  
; PRIOR FILING DATE: 2000-12-21  
; PRIOR APPLICATION NUMBER: 09/004,206  
; PRIOR FILING DATE: 1998-01-08  
; PRIOR APPLICATION NUMBER: 60/061,143  
; PRIOR FILING DATE: 1997-10-06  
; PRIOR APPLICATION NUMBER: 09/483,414  
; PRIOR FILING DATE: 2000-01-14

; PRIOR APPLICATION NUMBER: 09/213,571  
; PRIOR FILING DATE: 1998-12-18  
; PRIOR APPLICATION NUMBER: 08/994,890  
; PRIOR FILING DATE: 1997-12-19  
; NUMBER OF SEQ ID NOS: 59  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 59  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Mus musculus  
US-09-774-381-59

Query Match 27.3%; Score 3; DB 10; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 RKG 6  
|||  
Db 7 RKG 9

RESULT 30

US-09-852-910-259

; Sequence 259, Application US/09852910  
; Publication No. US20030096297A1  
; GENERAL INFORMATION:  
; APPLICANT: Hamm, Heidi  
; APPLICANT: Gilchrist, Annette  
; TITLE OF INVENTION: Method For Identifying Inhibitors of G Protein Coupled  
Receptor Signaling  
; FILE REFERENCE: 2661-101  
; CURRENT APPLICATION NUMBER: US/09/852,910  
; CURRENT FILING DATE: 2001-09-18  
; PRIOR APPLICATION NUMBER: US 60/275,472  
; PRIOR FILING DATE: 2001-03-14  
; NUMBER OF SEQ ID NOS: 271  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 259  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; NAME/KEY: misc\_feature  
; LOCATION: (1)..(11)  
; OTHER INFORMATION: G11 library peptide  
US-09-852-910-259

Query Match 27.3%; Score 3; DB 10; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 SIM 11  
|||  
Db 9 SIM 11

RESULT 31

US-09-802-083-14

; Sequence 14, Application US/09802083  
; Publication No. US20030119075A1  
; GENERAL INFORMATION:  
; APPLICANT: Kirchhofer, Daniel K.  
; APPLICANT: Lowe, David G.  
; APPLICANT: Presta, Leonard G.  
; TITLE OF INVENTION: Anti-Tissue Factor Antibodies with Enhanced  
; TITLE OF INVENTION: Anticoagulant Potency  
; FILE REFERENCE: P1736R1  
; CURRENT APPLICATION NUMBER: US/09/802,083  
; CURRENT FILING DATE: 2001-03-08  
; PRIOR APPLICATION NUMBER: US 60/189,775  
; PRIOR FILING DATE: 2000-03-16  
; NUMBER OF SEQ ID NOS: 28  
; SEQ ID NO 14  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-802-083-14

Query Match 27.3%; Score 3; DB 10; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 NSS 9  
|||  
Db 3 NSS 5

#### RESULT 32

US-09-776-191-59

; Sequence 59, Application US/09776191  
; Publication No. US20030119168A1  
; GENERAL INFORMATION:  
; APPLICANT: Edwin L. Madison  
; APPLICANT: Edgar O. Ong  
; APPLICANT: Jiunn-Chern Yeh  
; APPLICANT: Corvas International, Inc.  
; TITLE OF INVENTION: NUCLEIC ACID MOLECULES ENCODING  
; TITLE OF INVENTION: TRANSMEMBRANE SERINE PROTEASES, THE ENCODED PROTEINS AND  
; TITLE OF INVENTION: METHODS BASED THEREON  
; FILE REFERENCE: 24745-1607  
; CURRENT APPLICATION NUMBER: US/09/776,191  
; CURRENT FILING DATE: 2001-02-02  
; PRIOR APPLICATION NUMBER: 60/213,124  
; PRIOR FILING DATE: 2000-06-22  
; PRIOR APPLICATION NUMBER: 60/234,840  
; PRIOR FILING DATE: 2000-06-22  
; PRIOR APPLICATION NUMBER: 60/179,982  
; PRIOR FILING DATE: 2000-02-03  
; PRIOR APPLICATION NUMBER: 60/183,542  
; PRIOR FILING DATE: 2000-02-18  
; PRIOR APPLICATION NUMBER: 09/657,968  
; PRIOR FILING DATE: 2000-02-08  
; NUMBER OF SEQ ID NOS: 72  
; SOFTWARE: FastSEQ for Windows Version 4.0

; SEQ ID NO 59  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Homo Sapien  
US-09-776-191-59

Query Match 27.3%; Score 3; DB 10; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
|||  
Db 8 SSL 10

RESULT 33

US-09-968-744A-298

; Sequence 298, Application US/09968744A  
; Publication No. US20030148372A1  
; GENERAL INFORMATION:  
; APPLICANT: Tomlinson, Ian M  
; APPLICANT: Winter, Gregory  
; TITLE OF INVENTION: Method to Screen Phage Display Libraries with Different  
Ligands  
; FILE REFERENCE: 8039/1073  
; CURRENT APPLICATION NUMBER: US/09/968,744A  
; CURRENT FILING DATE: 2003-01-13  
; PRIOR APPLICATION NUMBER: GB 9722131.1  
; PRIOR FILING DATE: 1997-10-20  
; PRIOR APPLICATION NUMBER: US 60/065,248  
; PRIOR FILING DATE: 1997-11-13  
; PRIOR APPLICATION NUMBER: US 60/066,729  
; PRIOR FILING DATE: 1997-11-21  
; PRIOR APPLICATION NUMBER: PCT/GB98/03135  
; PRIOR FILING DATE: 1998-10-20  
; PRIOR APPLICATION NUMBER: US 09/511,939  
; PRIOR FILING DATE: 2000-02-24  
; NUMBER OF SEQ ID NOS: 350  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 298  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-968-744A-298

Query Match 27.3%; Score 3; DB 10; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
|||  
Db 8 SSL 10

RESULT 34

US-09-795-798-16

; Sequence 16, Application US/09795798

```

; Publication No. US20030207336A1
; GENERAL INFORMATION:
; APPLICANT: Presta, Leonard G.
; Jardieu, Paula M.
; TITLE OF INVENTION: Humanized Anti-CD11a Antibodies
; NUMBER OF SEQUENCES: 24
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Genentech, Inc.
; STREET: 1 DNA Way
; CITY: South San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94080
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WinPatin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/795,798
; FILING DATE: 28-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/974,899
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Lee, Wendy M.
; REGISTRATION NUMBER: 40,378
; REFERENCE/DOCKET NUMBER: P1014R1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650/225-1994
; TELEFAX: 650/952-9881
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 11 amino acids
; TYPE: Amino Acid
; TOPOLOGY: Linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-09-795-798-16

```

```

Query Match          27.3%; Score 3; DB 11; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+04;
Matches      3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      7 NSS 9
      |||
Db      3 NSS 5

```

```

RESULT 35
US-09-969-322-11
; Sequence 11, Application US/09969322
; Publication No. US20030215456A1
; GENERAL INFORMATION:
; APPLICANT: Merck & Co., Inc.
; APPLICANT: Yao, Siu-Long
; APPLICANT: Jones, Raymond E.

```



```
; APPLICANT: Defeo-Jones, Deborah
; APPLICANT: Heimbrosk, David C.
; APPLICANT: Rhymer, Patricia A.
; APPLICANT: Wasserbly, Pamela J.
; TITLE OF INVENTION: A METHOD OF TREATING CANCER
; FILE REFERENCE: 20663
; CURRENT APPLICATION NUMBER: US/09/969,322
; CURRENT FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: 60/242,847
; PRIOR FILING DATE: 2000-10-24
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 11
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: completely synthetic amino acid sequence
; NAME/KEY: ACETYLATION
; LOCATION: (1)...(1)
; OTHER INFORMATION: acetylated N-terminus amino acid
US-09-969-322-11
```

```
Query Match          27.3%; Score 3; DB 11; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+04;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;
```

```
Qy          8 SSL 10
            |||
Db          9 SSL 11
```

# RESULT 36

```
US-09-969-322-18
; Sequence 18, Application US/09969322
; Publication No. US20030215456A1
; GENERAL INFORMATION:
; APPLICANT: Merck & Co., Inc.
; APPLICANT: Yao, Siu-Long
; APPLICANT: Jones, Raymond E.
; APPLICANT: Defeo-Jones, Deborah
; APPLICANT: Heimbrosk, David C.
; APPLICANT: Rhymer, Patricia A.
; APPLICANT: Wasserbly, Pamela J.
; TITLE OF INVENTION: A METHOD OF TREATING CANCER
; FILE REFERENCE: 20663
; CURRENT APPLICATION NUMBER: US/09/969,322
; CURRENT FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: 60/242,847
; PRIOR FILING DATE: 2000-10-24
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 18
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
```

; OTHER INFORMATION: completely synthetic amino acid sequence  
; NAME/KEY: AMIDATION  
; LOCATION: (11)...(11)  
; OTHER INFORMATION: leucinamide  
US-09-969-322-18

Query Match 27.3%; Score 3; DB 11; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
| | |  
Db 9 SSL 11

RESULT 37

US-09-833-245-301  
; Sequence 301, Application US/09833245  
; Publication No. US20040010134A1  
; GENERAL INFORMATION:  
; APPLICANT: Human Genome Sciences, Inc.  
; TITLE OF INVENTION: Albumin Fusion Proteins  
; FILE REFERENCE: PF546PCT  
; CURRENT APPLICATION NUMBER: US/09/833,245  
; CURRENT FILING DATE: 2001-04-12  
; PRIOR APPLICATION NUMBER: 60/229, 358  
; PRIOR FILING DATE: 2000-04-12  
; PRIOR APPLICATION NUMBER: 60/256, 931  
; PRIOR FILING DATE: 2000-12-21  
; PRIOR APPLICATION NUMBER: 60/199, 384  
; PRIOR FILING DATE: 2000-04-25  
; NUMBER OF SEQ ID NOS: 2267  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 301  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-833-245-301

Query Match 27.3%; Score 3; DB 11; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
| | |  
Db 1 SSL 3

RESULT 38

US-09-968-561A-298  
; Sequence 298, Application US/09968561A  
; Publication No. US20040038291A2  
; GENERAL INFORMATION:  
; APPLICANT: Tomlinson, Ian M  
; APPLICANT: Winter, Gregory  
; TITLE OF INVENTION: Method to Screen Phage Display Libraries with Different Ligands

; FILE REFERENCE: 8039/1073B  
; CURRENT APPLICATION NUMBER: US/09/968,561A  
; CURRENT FILING DATE: 2001-10-01  
; PRIOR APPLICATION NUMBER: GB 9722131.1  
; PRIOR FILING DATE: 1997-10-20  
; PRIOR APPLICATION NUMBER: US 60/065,248  
; PRIOR FILING DATE: 1997-11-13  
; PRIOR APPLICATION NUMBER: US 60/066,729  
; PRIOR FILING DATE: 1997-11-21  
; PRIOR APPLICATION NUMBER: PCT/GB98/03135  
; PRIOR FILING DATE: 1998-10-20  
; PRIOR APPLICATION NUMBER: US 09/511,939  
; PRIOR FILING DATE: 2000-02-24  
; NUMBER OF SEQ ID NOS: 350  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 298  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-09-968-561A-298

Query Match 27.3%; Score 3; DB 12; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
|||  
Db 8 SSL 10

#### RESULT 39

US-10-289-456-91  
; Sequence 91, Application US/10289456  
; Publication No. US20040033211A1  
; GENERAL INFORMATION:  
; APPLICANT: Bachmann, Martin  
; APPLICANT: Maurer, Patrick  
; APPLICANT: Spohn, Gunther  
; TITLE OF INVENTION: Antigen Arrays for Treatment of Bone Disease  
; FILE REFERENCE: 1700.0330001  
; CURRENT APPLICATION NUMBER: US/10/289,456  
; CURRENT FILING DATE: 2002-11-07  
; PRIOR APPLICATION NUMBER: PCT/IB02/00166  
; PRIOR FILING DATE: 2002-01-21  
; PRIOR APPLICATION NUMBER: US 10/050,902  
; PRIOR FILING DATE: 2002-01-18  
; PRIOR APPLICATION NUMBER: US 60/396,635  
; PRIOR FILING DATE: 2002-07-19  
; PRIOR APPLICATION NUMBER: US 60/331,045  
; PRIOR FILING DATE: 2001-11-07  
; NUMBER OF SEQ ID NOS: 170  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 91  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:

; OTHER INFORMATION: RANKL peptide EF loop  
US-10-289-456-91

Query Match 27.3%; Score 3; DB 12; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 GNS 8  
|||  
Db 5 GNS 7

RESULT 40

US-10-417-895A-63

; Sequence 63, Application US/10417895A  
; Publication No. US20040033569A1  
; GENERAL INFORMATION:  
; APPLICANT: Crea, Roberto  
; APPLICANT: Cappuccilli, Guido  
; TITLE OF INVENTION: "DOPING" IN WALK-THROUGH MUTAGENESIS  
; FILE REFERENCE: 1551.2002-001  
; CURRENT APPLICATION NUMBER: US/10/417,895A  
; CURRENT FILING DATE: 2003-04-16  
; PRIOR APPLICATION NUMBER: 60/373,686  
; PRIOR FILING DATE: 2002-04-17  
; NUMBER OF SEQ ID NOS: 86  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 63  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: variant peptide for third complementarity  
; OTHER INFORMATION: determining region of Fv region of an  
; OTHER INFORMATION: immunoglobulin

US-10-417-895A-63

Query Match 27.3%; Score 3; DB 12; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 NSS 9  
|||  
Db 1 NSS 3

RESULT 41

US-10-417-895A-66

; Sequence 66, Application US/10417895A  
; Publication No. US20040033569A1  
; GENERAL INFORMATION:  
; APPLICANT: Crea, Roberto  
; APPLICANT: Cappuccilli, Guido  
; TITLE OF INVENTION: "DOPING" IN WALK-THROUGH MUTAGENESIS  
; FILE REFERENCE: 1551.2002-001  
; CURRENT APPLICATION NUMBER: US/10/417,895A  
; CURRENT FILING DATE: 2003-04-16

; PRIOR APPLICATION NUMBER: 60/373,686  
 ; PRIOR FILING DATE: 2002-04-17  
 ; NUMBER OF SEQ ID NOS: 86  
 ; SOFTWARE: FastSEQ for Windows Version 4.0  
 ; SEQ ID NO 66  
 ; LENGTH: 11  
 ; TYPE: PRT  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: variant peptide for third complementarity  
 ; OTHER INFORMATION: determining region of Fv region of an  
 ; OTHER INFORMATION: immunoglobulin  
 US-10-417-895A-66

Query Match 27.3%; Score 3; DB 12; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 NSS 9  
 |||  
 Db 1 NSS 3

#### RESULT 42

US-10-356-824-3

; Sequence 3, Application US/10356824  
 ; Publication No. US20040037823A9  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Shak, Steve  
 ; APPLICANT: Paton, Virginia  
 ; TITLE OF INVENTION: TREATMENT WITH ANTI-ErbB2 ANTIBODIES  
 ; FILE REFERENCE: P1256R1  
 ; CURRENT APPLICATION NUMBER: US/10/356,824  
 ; CURRENT FILING DATE: 2003-02-03  
 ; PRIOR APPLICATION NUMBER: US/09/208,649  
 ; PRIOR FILING DATE: 1998-12-10  
 ; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/069,346  
 ; PRIOR FILING DATE: EARLIER FILING DATE: 1997-12-12  
 ; NUMBER OF SEQ ID NOS: 9  
 ; SEQ ID NO 3  
 ; LENGTH: 11  
 ; TYPE: PRT  
 ; ORGANISM: Homo sapiens  
 US-10-356-824-3

Query Match 27.3%; Score 3; DB 12; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 NSS 9  
 |||  
 Db 3 NSS 5

#### RESULT 43

US-10-430-685-35

; Sequence 35, Application US/10430685

; Publication No. US20040039543A1  
; GENERAL INFORMATION:  
; APPLICANT: KECK, Peter  
; TITLE OF INVENTION: COMPUTER METHOD AND APPARATUS FOR CLASSIFYING OBJECTS  
; FILE REFERENCE: 63040-010210  
; CURRENT APPLICATION NUMBER: US/10/430,685  
; CURRENT FILING DATE: 2003-05-06  
; PRIOR APPLICATION NUMBER: PCT/US01/44000  
; PRIOR FILING DATE: 2001-11-06  
; PRIOR APPLICATION NUMBER: 60/246,196  
; PRIOR FILING DATE: 2000-11-06  
; NUMBER OF SEQ ID NOS: 240  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 35  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-430-685-35

Query Match 27.3%; Score 3; DB 12; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SRK 5  
|||  
Db 2 SRK 4

RESULT 44

US-10-430-685-37  
; Sequence 37, Application US/10430685  
; Publication No. US20040039543A1  
; GENERAL INFORMATION:  
; APPLICANT: KECK, Peter  
; TITLE OF INVENTION: COMPUTER METHOD AND APPARATUS FOR CLASSIFYING OBJECTS  
; FILE REFERENCE: 63040-010210  
; CURRENT APPLICATION NUMBER: US/10/430,685  
; CURRENT FILING DATE: 2003-05-06  
; PRIOR APPLICATION NUMBER: PCT/US01/44000  
; PRIOR FILING DATE: 2001-11-06  
; PRIOR APPLICATION NUMBER: 60/246,196  
; PRIOR FILING DATE: 2000-11-06  
; NUMBER OF SEQ ID NOS: 240  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 37  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Homo sapiens  
US-10-430-685-37

Query Match 27.3%; Score 3; DB 12; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SRK 5  
|||  
Db 2 SRK 4

RESULT 45

US-10-430-685-39

; Sequence 39, Application US/10430685  
 ; Publication No. US20040039543A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: KECK, Peter  
 ; TITLE OF INVENTION: COMPUTER METHOD AND APPARATUS FOR CLASSIFYING OBJECTS  
 ; FILE REFERENCE: 63040-010210  
 ; CURRENT APPLICATION NUMBER: US/10/430,685  
 ; CURRENT FILING DATE: 2003-05-06  
 ; PRIOR APPLICATION NUMBER: PCT/US01/44000  
 ; PRIOR FILING DATE: 2001-11-06  
 ; PRIOR APPLICATION NUMBER: 60/246,196  
 ; PRIOR FILING DATE: 2000-11-06  
 ; NUMBER OF SEQ ID NOS: 240  
 ; SOFTWARE: PatentIn version 3.2  
 ; SEQ ID NO 39  
 ; LENGTH: 11  
 ; TYPE: PRT  
 ; ORGANISM: Homo sapiens  
 US-10-430-685-39

Query Match 27.3%; Score 3; DB 12; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SRK 5  
 |||  
 Db 2 SRK 4

RESULT 46

US-10-600-152-3

; Sequence 3, Application US/10600152  
 ; Publication No. US20040037824A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Baughman, Sharon A.  
 ; APPLICANT: Shak Steven  
 ; TITLE OF INVENTION: Dosages for Treatment with Anti-ErbB2 Antibodies  
 ; FILE REFERENCE: P1775R1  
 ; CURRENT APPLICATION NUMBER: US/10/600,152  
 ; CURRENT FILING DATE: 2003-06-20  
 ; PRIOR APPLICATION NUMBER: 09/648,067  
 ; PRIOR FILING DATE: 2000-08-25  
 ; PRIOR APPLICATION NUMBER: US 60/151,018  
 ; PRIOR FILING DATE: 1999-08-27  
 ; PRIOR APPLICATION NUMBER: US 60/213,822  
 ; PRIOR FILING DATE: 2000-06-23  
 ; NUMBER OF SEQ ID NOS: 15  
 ; SEQ ID NO 3  
 ; LENGTH: 11  
 ; TYPE: PRT  
 ; ORGANISM: Artificial sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: salvage receptor binding epitope

US-10-600-152-3

Query Match 27.3%; Score 3; DB 12; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 NSS 9  
|||  
Db 3 NSS 5

RESULT 47

US-10-609-217-980

; Sequence 980, Application US/10609217  
; Publication No. US20040044188A1  
; GENERAL INFORMATION:  
; APPLICANT: FEIGE, ULRICH  
; APPLICANT: LIU, CHUAN-FA  
; APPLICANT: CHEETHAM, JANET C.  
; APPLICANT: BOONE, THOMAS CHARLES  
; TITLE OF INVENTION: MODIFIED PEPTIDES AS THERAPEUTIC AGENTS  
; FILE REFERENCE: A-527  
; CURRENT APPLICATION NUMBER: US/10/609,217  
; CURRENT FILING DATE: 2003-06-27  
; PRIOR APPLICATION NUMBER: US/09/428,082B  
; PRIOR FILING DATE: 1999-10-22  
; PRIOR APPLICATION NUMBER: 60/105,371  
; PRIOR FILING DATE: 1998-10-23  
; NUMBER OF SEQ ID NOS: 1133  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 980  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: IL-1 ANTAGONIST PEPTIDE  
US-10-609-217-980

Query Match 27.3%; Score 3; DB 12; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 NSS 9  
|||  
Db 2 NSS 4

RESULT 48

US-10-398-104-179

; Sequence 179, Application US/10398104  
; Publication No. US20040047880A1  
; GENERAL INFORMATION:  
; APPLICANT: De Bolle, Xavier Thomas  
; APPLICANT: Letesson, Jean-Jacques  
; APPLICANT: Lobet, Yves  
; APPLICANT: Mertens, Pascal Yvon  
; APPLICANT: Poolman, Jan



```
; APPLICANT: Voet, Pierre
; TITLE OF INVENTION: COMPONENT FOR VACCINE
; FILE REFERENCE: B45242
; CURRENT APPLICATION NUMBER: US/10/398,104
; CURRENT FILING DATE: 2003-01-04
; PRIOR APPLICATION NUMBER: PCT/EP01/11409
; PRIOR FILING DATE: 2001-10-03
; PRIOR APPLICATION NUMBER: GB 0024200.8
; PRIOR FILING DATE: 2000-10-03
; NUMBER OF SEQ ID NOS: 352
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 179
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: LOS peptide mimotope sequence
US-10-398-104-179
```

```
Query Match          27.3%; Score 3; DB 12; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+04;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;
```

```
Qy      8 SSL 10
        |||
Db      2 SSL 4
```

#### RESULT 49

```
US-10-458-860-31
; Sequence 31, Application US/10458860
; Publication No. US20040049800A1
; GENERAL INFORMATION:
; APPLICANT: Kopin, Alan S.
; APPLICANT: Beinborn, Martin
; TITLE OF INVENTION: Rapid Methods For Assessing Therapeutic
; TITLE OF INVENTION: Activity Using Animals Expressing Constitutively Active
G
; TITLE OF INVENTION: Protein-Coupled Receptors
; FILE REFERENCE: 00398/517002
; CURRENT APPLICATION NUMBER: US/10/458,860
; CURRENT FILING DATE: 2003-06-11
; PRIOR APPLICATION NUMBER: US 60/388,450
; PRIOR FILING DATE: 2002-06-13
; NUMBER OF SEQ ID NOS: 87
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 31
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic fragment
US-10-458-860-31
```

```
Query Match          27.3%; Score 3; DB 12; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+04;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;
```

Qy 1 AKS 3  
|||  
Db 5 AKS 7

RESULT 50

US-10-149-135-15

; Sequence 15, Application US/10149135  
; Publication No. US20040053822A1  
; GENERAL INFORMATION:  
; APPLICANT: Fikes, John  
; APPLICANT: Sette, Alessandro  
; APPLICANT: Sidney, John  
; APPLICANT: Southwood, Scott  
; APPLICANT: Chesnut, Robert  
; APPLICANT: Celis, Esteban  
; APPLICANT: Keogh, Elissa  
; TITLE OF INVENTION: Inducing Cellular Immune Responses to  
; TITLE OF INVENTION: MAGE2/3 Using Peptide and Nucleic Acid Compositions  
; FILE REFERENCE: 2060.0130001  
; CURRENT APPLICATION NUMBER: US/10/149,135  
; CURRENT FILING DATE: 2000-12-11  
; PRIOR APPLICATION NUMBER: PCT/US00/33545  
; PRIOR FILING DATE: 2000-12-11  
; PRIOR APPLICATION NUMBER: US 09/458,298  
; PRIOR FILING DATE: 1999-12-10  
; PRIOR APPLICATION NUMBER: US 09/189,702  
; PRIOR FILING DATE: 1998-11-10  
; PRIOR APPLICATION NUMBER: US 08/205,713  
; PRIOR FILING DATE: 1994-03-04  
; PRIOR APPLICATION NUMBER: US 08/159,184  
; PRIOR FILING DATE: 1993-11-29  
; PRIOR APPLICATION NUMBER: US 08/073,205  
; PRIOR FILING DATE: 1993-06-04  
; PRIOR APPLICATION NUMBER: US 08/027,146  
; PRIOR FILING DATE: 1993-03-05  
; NUMBER OF SEQ ID NOS: 2479  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 15  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Artificial Peptide  
US-10-149-135-15

Query Match 27.3%; Score 3; DB 12; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SRK 5  
|||  
Db 2 SRK 4

RESULT 51

US-10-149-135-59

; Sequence 59, Application US/10149135  
; Publication No. US20040053822A1  
; GENERAL INFORMATION:  
; APPLICANT: Fikes, John  
; APPLICANT: Sette, Alessandro  
; APPLICANT: Sidney, John  
; APPLICANT: Southwood, Scott  
; APPLICANT: Chesnut, Robert  
; APPLICANT: Celis, Esteban  
; APPLICANT: Keogh, Elissa  
; TITLE OF INVENTION: Inducing Cellular Immune Responses to  
; TITLE OF INVENTION: MAGE2/3 Using Peptide and Nucleic Acid Compositions  
; FILE REFERENCE: 2060.0130001  
; CURRENT APPLICATION NUMBER: US/10/149,135  
; CURRENT FILING DATE: 2000-12-11  
; PRIOR APPLICATION NUMBER: PCT/US00/33545  
; PRIOR FILING DATE: 2000-12-11  
; PRIOR APPLICATION NUMBER: US 09/458,298  
; PRIOR FILING DATE: 1999-12-10  
; PRIOR APPLICATION NUMBER: US 09/189,702  
; PRIOR FILING DATE: 1998-11-10  
; PRIOR APPLICATION NUMBER: US 08/205,713  
; PRIOR FILING DATE: 1994-03-04  
; PRIOR APPLICATION NUMBER: US 08/159,184  
; PRIOR FILING DATE: 1993-11-29  
; PRIOR APPLICATION NUMBER: US 08/073,205  
; PRIOR FILING DATE: 1993-06-04  
; PRIOR APPLICATION NUMBER: US 08/027,146  
; PRIOR FILING DATE: 1993-03-05  
; NUMBER OF SEQ ID NOS: 2479  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 59  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Artificial Peptide

US-10-149-135-59

Query Match 27.3%; Score 3; DB 12; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SRK 5  
| | |  
Db 2 SRK 4

RESULT 52

US-10-149-135-83

; Sequence 83, Application US/10149135  
; Publication No. US20040053822A1  
; GENERAL INFORMATION:  
; APPLICANT: Fikes, John  
; APPLICANT: Sette, Alessandro  
; APPLICANT: Sidney, John

```

; APPLICANT: Southwood, Scott
; APPLICANT: Chesnut, Robert
; APPLICANT: Celis, Esteban
; APPLICANT: Keogh, Elissa
; TITLE OF INVENTION: Inducing Cellular Immune Responses to
; TITLE OF INVENTION: MAGE2/3 Using Peptide and Nucleic Acid Compositions
; FILE REFERENCE: 2060.0130001
; CURRENT APPLICATION NUMBER: US/10/149,135
; CURRENT FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: PCT/US00/33545
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: US 09/458,298
; PRIOR FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: US 09/189,702
; PRIOR FILING DATE: 1998-11-10
; PRIOR APPLICATION NUMBER: US 08/205,713
; PRIOR FILING DATE: 1994-03-04
; PRIOR APPLICATION NUMBER: US 08/159,184
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/073,205
; PRIOR FILING DATE: 1993-06-04
; PRIOR APPLICATION NUMBER: US 08/027,146
; PRIOR FILING DATE: 1993-03-05
; NUMBER OF SEQ ID NOS: 2479
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 83
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Artificial Peptide
US-10-149-135-83

```

```

Query Match          27.3%; Score 3; DB 12; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+04;
Matches      3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy      3 SRK 5
      |||
Db      4 SRK 6

```

```

RESULT 53
US-10-149-135-217
; Sequence 217, Application US/10149135
; Publication No. US20040053822A1
; GENERAL INFORMATION:
; APPLICANT: Fikes, John
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Chesnut, Robert
; APPLICANT: Celis, Esteban
; APPLICANT: Keogh, Elissa
; TITLE OF INVENTION: Inducing Cellular Immune Responses to
; TITLE OF INVENTION: MAGE2/3 Using Peptide and Nucleic Acid Compositions
; FILE REFERENCE: 2060.0130001

```

```

; CURRENT APPLICATION NUMBER: US/10/149,135
; CURRENT FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: PCT/US00/33545
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: US 09/458,298
; PRIOR FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: US 09/189,702
; PRIOR FILING DATE: 1998-11-10
; PRIOR APPLICATION NUMBER: US 08/205,713
; PRIOR FILING DATE: 1994-03-04
; PRIOR APPLICATION NUMBER: US 08/159,184
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/073,205
; PRIOR FILING DATE: 1993-06-04
; PRIOR APPLICATION NUMBER: US 08/027,146
; PRIOR FILING DATE: 1993-03-05
; NUMBER OF SEQ ID NOS: 2479
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 217
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Artificial Peptide
US-10-149-135-217

```

```

Query Match          27.3%; Score 3; DB 12; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+04;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      3 SRK 5
        |||
Db      5 SRK 7

```

# RESULT 54

US-10-149-135-278

```

; Sequence 278, Application US/10149135
; Publication No. US20040053822A1
; GENERAL INFORMATION:
; APPLICANT: Fikes, John
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Chesnut, Robert
; APPLICANT: Celis, Esteban
; APPLICANT: Keogh, Elissa
; TITLE OF INVENTION: Inducing Cellular Immune Responses to
; TITLE OF INVENTION: MAGE2/3 Using Peptide and Nucleic Acid Compositions
; FILE REFERENCE: 2060.0130001
; CURRENT APPLICATION NUMBER: US/10/149,135
; CURRENT FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: PCT/US00/33545
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: US 09/458,298
; PRIOR FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: US 09/189,702

```

; PRIOR FILING DATE: 1998-11-10  
; PRIOR APPLICATION NUMBER: US 08/205,713  
; PRIOR FILING DATE: 1994-03-04  
; PRIOR APPLICATION NUMBER: US 08/159,184  
; PRIOR FILING DATE: 1993-11-29  
; PRIOR APPLICATION NUMBER: US 08/073,205  
; PRIOR FILING DATE: 1993-06-04  
; PRIOR APPLICATION NUMBER: US 08/027,146  
; PRIOR FILING DATE: 1993-03-05  
; NUMBER OF SEQ ID NOS: 2479  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 278  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Artificial Peptide  
US-10-149-135-278

Query Match 27.3%; Score 3; DB 12; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SRK 5  
|||  
Db 4 SRK 6

RESULT 55

US-10-149-135-406

; Sequence 406, Application US/10149135  
; Publication No. US20040053822A1  
; GENERAL INFORMATION:  
; APPLICANT: Fikes, John  
; APPLICANT: Sette, Alessandro  
; APPLICANT: Sidney, John  
; APPLICANT: Southwood, Scott  
; APPLICANT: Chesnut, Robert  
; APPLICANT: Celis, Esteban  
; APPLICANT: Keogh, Elissa  
; TITLE OF INVENTION: Inducing Cellular Immune Responses to  
; TITLE OF INVENTION: MAGE2/3 Using Peptide and Nucleic Acid Compositions  
; FILE REFERENCE: 2060.0130001  
; CURRENT APPLICATION NUMBER: US/10/149,135  
; CURRENT FILING DATE: 2000-12-11  
; PRIOR APPLICATION NUMBER: PCT/US00/33545  
; PRIOR FILING DATE: 2000-12-11  
; PRIOR APPLICATION NUMBER: US 09/458,298  
; PRIOR FILING DATE: 1999-12-10  
; PRIOR APPLICATION NUMBER: US 09/189,702  
; PRIOR FILING DATE: 1998-11-10  
; PRIOR APPLICATION NUMBER: US 08/205,713  
; PRIOR FILING DATE: 1994-03-04  
; PRIOR APPLICATION NUMBER: US 08/159,184  
; PRIOR FILING DATE: 1993-11-29  
; PRIOR APPLICATION NUMBER: US 08/073,205  
; PRIOR FILING DATE: 1993-06-04

; PRIOR APPLICATION NUMBER: US 08/027,146  
; PRIOR FILING DATE: 1993-03-05  
; NUMBER OF SEQ ID NOS: 2479  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 406  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Artificial Peptide  
US-10-149-135-406

Query Match 27.3%; Score 3; DB 12; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
|||  
Db 5 SSL 7

RESULT 56

US-10-149-135-409

; Sequence 409, Application US/10149135  
; Publication No. US20040053822A1  
; GENERAL INFORMATION:  
; APPLICANT: Fikes, John  
; APPLICANT: Sette, Alessandro  
; APPLICANT: Sidney, John  
; APPLICANT: Southwood, Scott  
; APPLICANT: Chesnut, Robert  
; APPLICANT: Celis, Esteban  
; APPLICANT: Keogh, Elissa  
; TITLE OF INVENTION: Inducing Cellular Immune Responses to  
; TITLE OF INVENTION: MAGE2/3 Using Peptide and Nucleic Acid Compositions  
; FILE REFERENCE: 2060.0130001  
; CURRENT APPLICATION NUMBER: US/10/149,135  
; CURRENT FILING DATE: 2000-12-11  
; PRIOR APPLICATION NUMBER: PCT/US00/33545  
; PRIOR FILING DATE: 2000-12-11  
; PRIOR APPLICATION NUMBER: US 09/458,298  
; PRIOR FILING DATE: 1999-12-10  
; PRIOR APPLICATION NUMBER: US 09/189,702  
; PRIOR FILING DATE: 1998-11-10  
; PRIOR APPLICATION NUMBER: US 08/205,713  
; PRIOR FILING DATE: 1994-03-04  
; PRIOR APPLICATION NUMBER: US 08/159,184  
; PRIOR FILING DATE: 1993-11-29  
; PRIOR APPLICATION NUMBER: US 08/073,205  
; PRIOR FILING DATE: 1993-06-04  
; PRIOR APPLICATION NUMBER: US 08/027,146  
; PRIOR FILING DATE: 1993-03-05  
; NUMBER OF SEQ ID NOS: 2479  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 409  
; LENGTH: 11  
; TYPE: PRT

; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Artificial Peptide  
US-10-149-135-409

Query Match 27.3%; Score 3; DB 12; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
| | |  
Db 9 SSL 11

RESULT 57

US-10-149-135-414

; Sequence 414, Application US/10149135  
; Publication No. US20040053822A1  
; GENERAL INFORMATION:  
; APPLICANT: Fikes, John  
; APPLICANT: Sette, Alessandro  
; APPLICANT: Sidney, John  
; APPLICANT: Southwood, Scott  
; APPLICANT: Chesnut, Robert  
; APPLICANT: Celis, Esteban  
; APPLICANT: Keogh, Elissa  
; TITLE OF INVENTION: Inducing Cellular Immune Responses to  
; TITLE OF INVENTION: MAGE2/3 Using Peptide and Nucleic Acid Compositions  
; FILE REFERENCE: 2060.0130001  
; CURRENT APPLICATION NUMBER: US/10/149,135  
; CURRENT FILING DATE: 2000-12-11  
; PRIOR APPLICATION NUMBER: PCT/US00/33545  
; PRIOR FILING DATE: 2000-12-11  
; PRIOR APPLICATION NUMBER: US 09/458,298  
; PRIOR FILING DATE: 1999-12-10  
; PRIOR APPLICATION NUMBER: US 09/189,702  
; PRIOR FILING DATE: 1998-11-10  
; PRIOR APPLICATION NUMBER: US 08/205,713  
; PRIOR FILING DATE: 1994-03-04  
; PRIOR APPLICATION NUMBER: US 08/159,184  
; PRIOR FILING DATE: 1993-11-29  
; PRIOR APPLICATION NUMBER: US 08/073,205  
; PRIOR FILING DATE: 1993-06-04  
; PRIOR APPLICATION NUMBER: US 08/027,146  
; PRIOR FILING DATE: 1993-03-05  
; NUMBER OF SEQ ID NOS: 2479  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 414  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Artificial Peptide  
US-10-149-135-414

Query Match 27.3%; Score 3; DB 12; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;



Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SRK 5  
|||  
Db 5 SRK 7

RESULT 58

US-10-149-135-469

; Sequence 469, Application US/10149135  
; Publication No. US20040053822A1  
; GENERAL INFORMATION:  
; APPLICANT: Fikes, John  
; APPLICANT: Sette, Alessandro  
; APPLICANT: Sidney, John  
; APPLICANT: Southwood, Scott  
; APPLICANT: Chesnut, Robert  
; APPLICANT: Celis, Esteban  
; APPLICANT: Keogh, Elissa  
; TITLE OF INVENTION: Inducing Cellular Immune Responses to  
; TITLE OF INVENTION: MAGE2/3 Using Peptide and Nucleic Acid Compositions  
; FILE REFERENCE: 2060.0130001  
; CURRENT APPLICATION NUMBER: US/10/149,135  
; CURRENT FILING DATE: 2000-12-11  
; PRIOR APPLICATION NUMBER: PCT/US00/33545  
; PRIOR FILING DATE: 2000-12-11  
; PRIOR APPLICATION NUMBER: US 09/458,298  
; PRIOR FILING DATE: 1999-12-10  
; PRIOR APPLICATION NUMBER: US 09/189,702  
; PRIOR FILING DATE: 1998-11-10  
; PRIOR APPLICATION NUMBER: US 08/205,713  
; PRIOR FILING DATE: 1994-03-04  
; PRIOR APPLICATION NUMBER: US 08/159,184  
; PRIOR FILING DATE: 1993-11-29  
; PRIOR APPLICATION NUMBER: US 08/073,205  
; PRIOR FILING DATE: 1993-06-04  
; PRIOR APPLICATION NUMBER: US 08/027,146  
; PRIOR FILING DATE: 1993-03-05  
; NUMBER OF SEQ ID NOS: 2479  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 469  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Artificial Peptide  
US-10-149-135-469

Query Match 27.3%; Score 3; DB 12; Length 11;

Best Local Similarity 100.0%; Pred. No. 1.1e+04;

Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SRK 5  
|||  
Db 9 SRK 11

RESULT 59

US-10-149-135-506

```
; Sequence 506, Application US/10149135
; Publication No. US20040053822A1
; GENERAL INFORMATION:
; APPLICANT: Fikes, John
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Chesnut, Robert
; APPLICANT: Celis, Esteban
; APPLICANT: Keogh, Elissa
; TITLE OF INVENTION: Inducing Cellular Immune Responses to
; TITLE OF INVENTION: MAGE2/3 Using Peptide and Nucleic Acid Compositions
; FILE REFERENCE: 2060.0130001
; CURRENT APPLICATION NUMBER: US/10/149,135
; CURRENT FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: PCT/US00/33545
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: US 09/458,298
; PRIOR FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: US 09/189,702
; PRIOR FILING DATE: 1998-11-10
; PRIOR APPLICATION NUMBER: US 08/205,713
; PRIOR FILING DATE: 1994-03-04
; PRIOR APPLICATION NUMBER: US 08/159,184
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/073,205
; PRIOR FILING DATE: 1993-06-04
; PRIOR APPLICATION NUMBER: US 08/027,146
; PRIOR FILING DATE: 1993-03-05
; NUMBER OF SEQ ID NOS: 2479
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 506
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Artificial Peptide
US-10-149-135-506
```

```
Query Match          27.3%; Score 3; DB 12; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+04;
Matches      3; Conservative    0; Mismatches    0; Indels      0; Gaps      0;
```

```
Qy      3 SRK 5
        |||
Db      9 SRK 11
```

RESULT 60

US-10-149-135-699

```
; Sequence 699, Application US/10149135
; Publication No. US20040053822A1
; GENERAL INFORMATION:
; APPLICANT: Fikes, John
; APPLICANT: Sette, Alessandro
```

```

; APPLICANT:  Sidney, John
; APPLICANT:  Southwood, Scott
; APPLICANT:  Chesnut, Robert
; APPLICANT:  Celis, Esteban
; APPLICANT:  Keogh, Elissa
; TITLE OF INVENTION:  Inducing Cellular Immune Responses to
; TITLE OF INVENTION:  MAGE2/3 Using Peptide and Nucleic Acid Compositions
; FILE REFERENCE:  2060.0130001
; CURRENT APPLICATION NUMBER:  US/10/149,135
; CURRENT FILING DATE:  2000-12-11
; PRIOR APPLICATION NUMBER:  PCT/US00/33545
; PRIOR FILING DATE:  2000-12-11
; PRIOR APPLICATION NUMBER:  US 09/458,298
; PRIOR FILING DATE:  1999-12-10
; PRIOR APPLICATION NUMBER:  US 09/189,702
; PRIOR FILING DATE:  1998-11-10
; PRIOR APPLICATION NUMBER:  US 08/205,713
; PRIOR FILING DATE:  1994-03-04
; PRIOR APPLICATION NUMBER:  US 08/159,184
; PRIOR FILING DATE:  1993-11-29
; PRIOR APPLICATION NUMBER:  US 08/073,205
; PRIOR FILING DATE:  1993-06-04
; PRIOR APPLICATION NUMBER:  US 08/027,146
; PRIOR FILING DATE:  1993-03-05
; NUMBER OF SEQ ID NOS:  2479
; SOFTWARE:  PatentIn version 3.1
; SEQ ID NO 699
;   LENGTH:  11
;   TYPE:  PRT
;   ORGANISM:  Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION:  Artificial Peptide
US-10-149-135-699

```

```

Query Match          27.3%;  Score 3;  DB 12;  Length 11;
Best Local Similarity 100.0%;  Pred. No. 1.1e+04;
Matches      3;  Conservative      0;  Mismatches      0;  Indels      0;  Gaps      0;

```

```

Qy          8 SSL 10
            |||
Db          7 SSL 9

```

```

RESULT 61
US-10-149-135-738
; Sequence 738, Application US/10149135
; Publication No. US20040053822A1
; GENERAL INFORMATION:
; APPLICANT:  Fikes, John
; APPLICANT:  Sette, Alessandro
; APPLICANT:  Sidney, John
; APPLICANT:  Southwood, Scott
; APPLICANT:  Chesnut, Robert
; APPLICANT:  Celis, Esteban
; APPLICANT:  Keogh, Elissa
; TITLE OF INVENTION:  Inducing Cellular Immune Responses to
; TITLE OF INVENTION:  MAGE2/3 Using Peptide and Nucleic Acid Compositions

```

; FILE REFERENCE: 2060.0130001  
 ; CURRENT APPLICATION NUMBER: US/10/149,135  
 ; CURRENT FILING DATE: 2000-12-11  
 ; PRIOR APPLICATION NUMBER: PCT/US00/33545  
 ; PRIOR FILING DATE: 2000-12-11  
 ; PRIOR APPLICATION NUMBER: US 09/458,298  
 ; PRIOR FILING DATE: 1999-12-10  
 ; PRIOR APPLICATION NUMBER: US 09/189,702  
 ; PRIOR FILING DATE: 1998-11-10  
 ; PRIOR APPLICATION NUMBER: US 08/205,713  
 ; PRIOR FILING DATE: 1994-03-04  
 ; PRIOR APPLICATION NUMBER: US 08/159,184  
 ; PRIOR FILING DATE: 1993-11-29  
 ; PRIOR APPLICATION NUMBER: US 08/073,205  
 ; PRIOR FILING DATE: 1993-06-04  
 ; PRIOR APPLICATION NUMBER: US 08/027,146  
 ; PRIOR FILING DATE: 1993-03-05  
 ; NUMBER OF SEQ ID NOS: 2479  
 ; SOFTWARE: PatentIn version 3.1  
 ; SEQ ID NO 738  
 ; LENGTH: 11  
 ; TYPE: PRT  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Artificial Peptide  
 US-10-149-135-738

Query Match 27.3%; Score 3; DB 12; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
 |||  
 Db 9 SSL 11

# RESULT 62

US-10-149-135-843

; Sequence 843, Application US/10149135  
 ; Publication No. US20040053822A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Fikes, John  
 ; APPLICANT: Sette, Alessandro  
 ; APPLICANT: Sidney, John  
 ; APPLICANT: Southwood, Scott  
 ; APPLICANT: Chesnut, Robert  
 ; APPLICANT: Celis, Esteban  
 ; APPLICANT: Keogh, Elissa  
 ; TITLE OF INVENTION: Inducing Cellular Immune Responses to  
 ; TITLE OF INVENTION: MAGE2/3 Using Peptide and Nucleic Acid Compositions  
 ; FILE REFERENCE: 2060.0130001  
 ; CURRENT APPLICATION NUMBER: US/10/149,135  
 ; CURRENT FILING DATE: 2000-12-11  
 ; PRIOR APPLICATION NUMBER: PCT/US00/33545  
 ; PRIOR FILING DATE: 2000-12-11  
 ; PRIOR APPLICATION NUMBER: US 09/458,298  
 ; PRIOR FILING DATE: 1999-12-10

; PRIOR APPLICATION NUMBER: US 09/189,702  
; PRIOR FILING DATE: 1998-11-10  
; PRIOR APPLICATION NUMBER: US 08/205,713  
; PRIOR FILING DATE: 1994-03-04  
; PRIOR APPLICATION NUMBER: US 08/159,184  
; PRIOR FILING DATE: 1993-11-29  
; PRIOR APPLICATION NUMBER: US 08/073,205  
; PRIOR FILING DATE: 1993-06-04  
; PRIOR APPLICATION NUMBER: US 08/027,146  
; PRIOR FILING DATE: 1993-03-05  
; NUMBER OF SEQ ID NOS: 2479  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 843  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Artificial Peptide  
US-10-149-135-843

Query Match 27.3%; Score 3; DB 12; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
|||  
Db 9 SSL 11

RESULT 63

US-10-149-135-878  
; Sequence 878, Application US/10149135  
; Publication No. US20040053822A1  
; GENERAL INFORMATION:  
; APPLICANT: Fikes, John  
; APPLICANT: Sette, Alessandro  
; APPLICANT: Sidney, John  
; APPLICANT: Southwood, Scott  
; APPLICANT: Chesnut, Robert  
; APPLICANT: Celis, Esteban  
; APPLICANT: Keogh, Elissa  
; TITLE OF INVENTION: Inducing Cellular Immune Responses to  
; TITLE OF INVENTION: MAGE2/3 Using Peptide and Nucleic Acid Compositions  
; FILE REFERENCE: 2060.0130001  
; CURRENT APPLICATION NUMBER: US/10/149,135  
; CURRENT FILING DATE: 2000-12-11  
; PRIOR APPLICATION NUMBER: PCT/US00/33545  
; PRIOR FILING DATE: 2000-12-11  
; PRIOR APPLICATION NUMBER: US 09/458,298  
; PRIOR FILING DATE: 1999-12-10  
; PRIOR APPLICATION NUMBER: US 09/189,702  
; PRIOR FILING DATE: 1998-11-10  
; PRIOR APPLICATION NUMBER: US 08/205,713  
; PRIOR FILING DATE: 1994-03-04  
; PRIOR APPLICATION NUMBER: US 08/159,184  
; PRIOR FILING DATE: 1993-11-29  
; PRIOR APPLICATION NUMBER: US 08/073,205

; PRIOR FILING DATE: 1993-06-04  
; PRIOR APPLICATION NUMBER: US 08/027,146  
; PRIOR FILING DATE: 1993-03-05  
; NUMBER OF SEQ ID NOS: 2479  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 878  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Artificial Peptide  
US-10-149-135-878

Query Match 27.3%; Score 3; DB 12; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SRK 5  
|||  
Db 1 SRK 3

RESULT 64

US-10-149-135-903

; Sequence 903, Application US/10149135  
; Publication No. US20040053822A1  
; GENERAL INFORMATION:  
; APPLICANT: Fikes, John  
; APPLICANT: Sette, Alessandro  
; APPLICANT: Sidney, John  
; APPLICANT: Southwood, Scott  
; APPLICANT: Chesnut, Robert  
; APPLICANT: Celis, Esteban  
; APPLICANT: Keogh, Elissa  
; TITLE OF INVENTION: Inducing Cellular Immune Responses to  
; TITLE OF INVENTION: MAGE2/3 Using Peptide and Nucleic Acid Compositions  
; FILE REFERENCE: 2060.0130001  
; CURRENT APPLICATION NUMBER: US/10/149,135  
; CURRENT FILING DATE: 2000-12-11  
; PRIOR APPLICATION NUMBER: PCT/US00/33545  
; PRIOR FILING DATE: 2000-12-11  
; PRIOR APPLICATION NUMBER: US 09/458,298  
; PRIOR FILING DATE: 1999-12-10  
; PRIOR APPLICATION NUMBER: US 09/189,702  
; PRIOR FILING DATE: 1998-11-10  
; PRIOR APPLICATION NUMBER: US 08/205,713  
; PRIOR FILING DATE: 1994-03-04  
; PRIOR APPLICATION NUMBER: US 08/159,184  
; PRIOR FILING DATE: 1993-11-29  
; PRIOR APPLICATION NUMBER: US 08/073,205  
; PRIOR FILING DATE: 1993-06-04  
; PRIOR APPLICATION NUMBER: US 08/027,146  
; PRIOR FILING DATE: 1993-03-05  
; NUMBER OF SEQ ID NOS: 2479  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 903  
; LENGTH: 11

; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Artificial Peptide  
US-10-149-135-903

Query Match 27.3%; Score 3; DB 12; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
|||  
Db 5 SSL 7

RESULT 65

US-10-149-135-905  
; Sequence 905, Application US/10149135  
; Publication No. US20040053822A1  
; GENERAL INFORMATION:  
; APPLICANT: Fikes, John  
; APPLICANT: Sette, Alessandro  
; APPLICANT: Sidney, John  
; APPLICANT: Southwood, Scott  
; APPLICANT: Chesnut, Robert  
; APPLICANT: Celis, Esteban  
; APPLICANT: Keogh, Elissa  
; TITLE OF INVENTION: Inducing Cellular Immune Responses to  
; TITLE OF INVENTION: MAGE2/3 Using Peptide and Nucleic Acid Compositions  
; FILE REFERENCE: 2060.0130001  
; CURRENT APPLICATION NUMBER: US/10/149,135  
; CURRENT FILING DATE: 2000-12-11  
; PRIOR APPLICATION NUMBER: PCT/US00/33545  
; PRIOR FILING DATE: 2000-12-11  
; PRIOR APPLICATION NUMBER: US 09/458,298  
; PRIOR FILING DATE: 1999-12-10  
; PRIOR APPLICATION NUMBER: US 09/189,702  
; PRIOR FILING DATE: 1998-11-10  
; PRIOR APPLICATION NUMBER: US 08/205,713  
; PRIOR FILING DATE: 1994-03-04  
; PRIOR APPLICATION NUMBER: US 08/159,184  
; PRIOR FILING DATE: 1993-11-29  
; PRIOR APPLICATION NUMBER: US 08/073,205  
; PRIOR FILING DATE: 1993-06-04  
; PRIOR APPLICATION NUMBER: US 08/027,146  
; PRIOR FILING DATE: 1993-03-05  
; NUMBER OF SEQ ID NOS: 2479  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 905  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Artificial Peptide  
US-10-149-135-905

Query Match 27.3%; Score 3; DB 12; Length 11;

Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SRK 5  
|||  
Db 1 SRK 3

RESULT 66

US-10-149-135-912

; Sequence 912, Application US/10149135  
; Publication No. US20040053822A1  
; GENERAL INFORMATION:  
; APPLICANT: Fikes, John  
; APPLICANT: Sette, Alessandro  
; APPLICANT: Sidney, John  
; APPLICANT: Southwood, Scott  
; APPLICANT: Chesnut, Robert  
; APPLICANT: Celis, Esteban  
; APPLICANT: Keogh, Elissa  
; TITLE OF INVENTION: Inducing Cellular Immune Responses to  
; TITLE OF INVENTION: MAGE2/3 Using Peptide and Nucleic Acid Compositions  
; FILE REFERENCE: 2060.0130001  
; CURRENT APPLICATION NUMBER: US/10/149,135  
; CURRENT FILING DATE: 2000-12-11  
; PRIOR APPLICATION NUMBER: PCT/US00/33545  
; PRIOR FILING DATE: 2000-12-11  
; PRIOR APPLICATION NUMBER: US 09/458,298  
; PRIOR FILING DATE: 1999-12-10  
; PRIOR APPLICATION NUMBER: US 09/189,702  
; PRIOR FILING DATE: 1998-11-10  
; PRIOR APPLICATION NUMBER: US 08/205,713  
; PRIOR FILING DATE: 1994-03-04  
; PRIOR APPLICATION NUMBER: US 08/159,184  
; PRIOR FILING DATE: 1993-11-29  
; PRIOR APPLICATION NUMBER: US 08/073,205  
; PRIOR FILING DATE: 1993-06-04  
; PRIOR APPLICATION NUMBER: US 08/027,146  
; PRIOR FILING DATE: 1993-03-05  
; NUMBER OF SEQ ID NOS: 2479  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 912  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Artificial Peptide  
US-10-149-135-912

Query Match 27.3%; Score 3; DB 12; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SRK 5  
|||  
Db 4 SRK 6



RESULT 67

US-10-149-135-948

; Sequence 948, Application US/10149135  
 ; Publication No. US20040053822A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Fikes, John  
 ; APPLICANT: Sette, Alessandro  
 ; APPLICANT: Sidney, John  
 ; APPLICANT: Southwood, Scott  
 ; APPLICANT: Chesnut, Robert  
 ; APPLICANT: Celis, Esteban  
 ; APPLICANT: Keogh, Elissa  
 ; TITLE OF INVENTION: Inducing Cellular Immune Responses to  
 ; TITLE OF INVENTION: MAGE2/3 Using Peptide and Nucleic Acid Compositions  
 ; FILE REFERENCE: 2060.0130001  
 ; CURRENT APPLICATION NUMBER: US/10/149,135  
 ; CURRENT FILING DATE: 2000-12-11  
 ; PRIOR APPLICATION NUMBER: PCT/US00/33545  
 ; PRIOR FILING DATE: 2000-12-11  
 ; PRIOR APPLICATION NUMBER: US 09/458,298  
 ; PRIOR FILING DATE: 1999-12-10  
 ; PRIOR APPLICATION NUMBER: US 09/189,702  
 ; PRIOR FILING DATE: 1998-11-10  
 ; PRIOR APPLICATION NUMBER: US 08/205,713  
 ; PRIOR FILING DATE: 1994-03-04  
 ; PRIOR APPLICATION NUMBER: US 08/159,184  
 ; PRIOR FILING DATE: 1993-11-29  
 ; PRIOR APPLICATION NUMBER: US 08/073,205  
 ; PRIOR FILING DATE: 1993-06-04  
 ; PRIOR APPLICATION NUMBER: US 08/027,146  
 ; PRIOR FILING DATE: 1993-03-05  
 ; NUMBER OF SEQ ID NOS: 2479  
 ; SOFTWARE: PatentIn version 3.1  
 ; SEQ ID NO 948  
 ; LENGTH: 11  
 ; TYPE: PRT  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Artificial Peptide  
 US-10-149-135-948

Query Match 27.3%; Score 3; DB 12; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SRK 5  
 |||  
 Db 2 SRK 4

RESULT 68

US-10-149-135-961

; Sequence 961, Application US/10149135  
 ; Publication No. US20040053822A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Fikes, John

```

; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Chesnut, Robert
; APPLICANT: Celis, Esteban
; APPLICANT: Keogh, Elissa
; TITLE OF INVENTION: Inducing Cellular Immune Responses to
; TITLE OF INVENTION: MAGE2/3 Using Peptide and Nucleic Acid Compositions
; FILE REFERENCE: 2060.0130001
; CURRENT APPLICATION NUMBER: US/10/149,135
; CURRENT FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: PCT/US00/33545
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: US 09/458,298
; PRIOR FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: US 09/189,702
; PRIOR FILING DATE: 1998-11-10
; PRIOR APPLICATION NUMBER: US 08/205,713
; PRIOR FILING DATE: 1994-03-04
; PRIOR APPLICATION NUMBER: US 08/159,184
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/073,205
; PRIOR FILING DATE: 1993-06-04
; PRIOR APPLICATION NUMBER: US 08/027,146
; PRIOR FILING DATE: 1993-03-05
; NUMBER OF SEQ ID NOS: 2479
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 961
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Artificial Peptide
US-10-149-135-961

```

```

Query Match          27.3%; Score 3; DB 12; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+04;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;

```

```

Qy      3 SRK 5
      |||
Db      5 SRK 7

```

```

RESULT 69
US-10-149-135-991
; Sequence 991, Application US/10149135
; Publication No. US20040053822A1
; GENERAL INFORMATION:
; APPLICANT: Fikes, John
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Chesnut, Robert
; APPLICANT: Celis, Esteban
; APPLICANT: Keogh, Elissa
; TITLE OF INVENTION: Inducing Cellular Immune Responses to

```

; TITLE OF INVENTION: MAGE2/3 Using Peptide and Nucleic Acid Compositions  
 ; FILE REFERENCE: 2060.0130001  
 ; CURRENT APPLICATION NUMBER: US/10/149,135  
 ; CURRENT FILING DATE: 2000-12-11  
 ; PRIOR APPLICATION NUMBER: PCT/US00/33545  
 ; PRIOR FILING DATE: 2000-12-11  
 ; PRIOR APPLICATION NUMBER: US 09/458,298  
 ; PRIOR FILING DATE: 1999-12-10  
 ; PRIOR APPLICATION NUMBER: US 09/189,702  
 ; PRIOR FILING DATE: 1998-11-10  
 ; PRIOR APPLICATION NUMBER: US 08/205,713  
 ; PRIOR FILING DATE: 1994-03-04  
 ; PRIOR APPLICATION NUMBER: US 08/159,184  
 ; PRIOR FILING DATE: 1993-11-29  
 ; PRIOR APPLICATION NUMBER: US 08/073,205  
 ; PRIOR FILING DATE: 1993-06-04  
 ; PRIOR APPLICATION NUMBER: US 08/027,146  
 ; PRIOR FILING DATE: 1993-03-05  
 ; NUMBER OF SEQ ID NOS: 2479  
 ; SOFTWARE: PatentIn version 3.1  
 ; SEQ ID NO 991  
 ; LENGTH: 11  
 ; TYPE: PRT  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Artificial Peptide  
 US-10-149-135-991

Query Match 27.3%; Score 3; DB 12; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SRK 5  
 |||  
 Db 4 SRK 6

# RESULT 70

US-10-149-135-999  
 ; Sequence 999, Application US/10149135  
 ; Publication No. US20040053822A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Fikes, John  
 ; APPLICANT: Sette, Alessandro  
 ; APPLICANT: Sidney, John  
 ; APPLICANT: Southwood, Scott  
 ; APPLICANT: Chesnut, Robert  
 ; APPLICANT: Celis, Esteban  
 ; APPLICANT: Keogh, Elissa  
 ; TITLE OF INVENTION: Inducing Cellular Immune Responses to  
 ; TITLE OF INVENTION: MAGE2/3 Using Peptide and Nucleic Acid Compositions  
 ; FILE REFERENCE: 2060.0130001  
 ; CURRENT APPLICATION NUMBER: US/10/149,135  
 ; CURRENT FILING DATE: 2000-12-11  
 ; PRIOR APPLICATION NUMBER: PCT/US00/33545  
 ; PRIOR FILING DATE: 2000-12-11  
 ; PRIOR APPLICATION NUMBER: US 09/458,298

```
; PRIOR FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: US 09/189,702
; PRIOR FILING DATE: 1998-11-10
; PRIOR APPLICATION NUMBER: US 08/205,713
; PRIOR FILING DATE: 1994-03-04
; PRIOR APPLICATION NUMBER: US 08/159,184
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/073,205
; PRIOR FILING DATE: 1993-06-04
; PRIOR APPLICATION NUMBER: US 08/027,146
; PRIOR FILING DATE: 1993-03-05
; NUMBER OF SEQ ID NOS: 2479
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 999
;   LENGTH: 11
;   TYPE: PRT
;   ORGANISM: Artificial Sequence
;   FEATURE:
;   OTHER INFORMATION: Artificial Peptide
US-10-149-135-999
```

```
Query Match          27.3%; Score 3; DB 12; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+04;
Matches      3; Conservative    0; Mismatches    0; Indels      0; Gaps      0;
```

```
Qy          8 SSL 10
            |||
Db          3 SSL 5
```

# RESULT 71

```
US-10-149-135-1018
; Sequence 1018, Application US/10149135
; Publication No. US20040053822A1
; GENERAL INFORMATION:
; APPLICANT: Fikes, John
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Chesnut, Robert
; APPLICANT: Celis, Esteban
; APPLICANT: Keogh, Elissa
; TITLE OF INVENTION: Inducing Cellular Immune Responses to
; TITLE OF INVENTION: MAGE2/3 Using Peptide and Nucleic Acid Compositions
; FILE REFERENCE: 2060.0130001
; CURRENT APPLICATION NUMBER: US/10/149,135
; CURRENT FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: PCT/US00/33545
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: US 09/458,298
; PRIOR FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: US 09/189,702
; PRIOR FILING DATE: 1998-11-10
; PRIOR APPLICATION NUMBER: US 08/205,713
; PRIOR FILING DATE: 1994-03-04
; PRIOR APPLICATION NUMBER: US 08/159,184
; PRIOR FILING DATE: 1993-11-29
```

; PRIOR APPLICATION NUMBER: US 08/073,205  
; PRIOR FILING DATE: 1993-06-04  
; PRIOR APPLICATION NUMBER: US 08/027,146  
; PRIOR FILING DATE: 1993-03-05  
; NUMBER OF SEQ ID NOS: 2479  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 1018  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Artificial Peptide  
US-10-149-135-1018

Query Match 27.3%; Score 3; DB 12; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
|||  
Db 6 SSL 8

RESULT 72

US-10-149-135-1020

; Sequence 1020, Application US/10149135  
; Publication No. US20040053822A1  
; GENERAL INFORMATION:  
; APPLICANT: Fikes, John  
; APPLICANT: Sette, Alessandro  
; APPLICANT: Sidney, John  
; APPLICANT: Southwood, Scott  
; APPLICANT: Chesnut, Robert  
; APPLICANT: Celis, Esteban  
; APPLICANT: Keogh, Elissa  
; TITLE OF INVENTION: Inducing Cellular Immune Responses to  
; TITLE OF INVENTION: MAGE2/3 Using Peptide and Nucleic Acid Compositions  
; FILE REFERENCE: 2060.0130001  
; CURRENT APPLICATION NUMBER: US/10/149,135  
; CURRENT FILING DATE: 2000-12-11  
; PRIOR APPLICATION NUMBER: PCT/US00/33545  
; PRIOR FILING DATE: 2000-12-11  
; PRIOR APPLICATION NUMBER: US 09/458,298  
; PRIOR FILING DATE: 1999-12-10  
; PRIOR APPLICATION NUMBER: US 09/189,702  
; PRIOR FILING DATE: 1998-11-10  
; PRIOR APPLICATION NUMBER: US 08/205,713  
; PRIOR FILING DATE: 1994-03-04  
; PRIOR APPLICATION NUMBER: US 08/159,184  
; PRIOR FILING DATE: 1993-11-29  
; PRIOR APPLICATION NUMBER: US 08/073,205  
; PRIOR FILING DATE: 1993-06-04  
; PRIOR APPLICATION NUMBER: US 08/027,146  
; PRIOR FILING DATE: 1993-03-05  
; NUMBER OF SEQ ID NOS: 2479  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 1020

; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Artificial Peptide  
US-10-149-135-1020

Query Match 27.3%; Score 3; DB 12; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
|||  
Db 3 SSL 5

RESULT 73

US-10-149-135-1041

; Sequence 1041, Application US/10149135  
; Publication No. US20040053822A1  
; GENERAL INFORMATION:  
; APPLICANT: Fikes, John  
; APPLICANT: Sette, Alessandro  
; APPLICANT: Sidney, John  
; APPLICANT: Southwood, Scott  
; APPLICANT: Chesnut, Robert  
; APPLICANT: Celis, Esteban  
; APPLICANT: Keogh, Elissa  
; TITLE OF INVENTION: Inducing Cellular Immune Responses to  
; TITLE OF INVENTION: MAGE2/3 Using Peptide and Nucleic Acid Compositions  
; FILE REFERENCE: 2060.0130001  
; CURRENT APPLICATION NUMBER: US/10/149,135  
; CURRENT FILING DATE: 2000-12-11  
; PRIOR APPLICATION NUMBER: PCT/US00/33545  
; PRIOR FILING DATE: 2000-12-11  
; PRIOR APPLICATION NUMBER: US 09/458,298  
; PRIOR FILING DATE: 1999-12-10  
; PRIOR APPLICATION NUMBER: US 09/189,702  
; PRIOR FILING DATE: 1998-11-10  
; PRIOR APPLICATION NUMBER: US 08/205,713  
; PRIOR FILING DATE: 1994-03-04  
; PRIOR APPLICATION NUMBER: US 08/159,184  
; PRIOR FILING DATE: 1993-11-29  
; PRIOR APPLICATION NUMBER: US 08/073,205  
; PRIOR FILING DATE: 1993-06-04  
; PRIOR APPLICATION NUMBER: US 08/027,146  
; PRIOR FILING DATE: 1993-03-05  
; NUMBER OF SEQ ID NOS: 2479  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 1041  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Artificial Peptide  
US-10-149-135-1041

Query Match 27.3%; Score 3; DB 12; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SRK 5  
|||  
Db 2 SRK 4

RESULT 74

US-10-149-135-1049

; Sequence 1049, Application US/10149135  
; Publication No. US20040053822A1  
; GENERAL INFORMATION:  
; APPLICANT: Fikes, John  
; APPLICANT: Sette, Alessandro  
; APPLICANT: Sidney, John  
; APPLICANT: Southwood, Scott  
; APPLICANT: Chesnut, Robert  
; APPLICANT: Celis, Esteban  
; APPLICANT: Keogh, Elissa  
; TITLE OF INVENTION: Inducing Cellular Immune Responses to  
; TITLE OF INVENTION: MAGE2/3 Using Peptide and Nucleic Acid Compositions  
; FILE REFERENCE: 2060.0130001  
; CURRENT APPLICATION NUMBER: US/10/149,135  
; CURRENT FILING DATE: 2000-12-11  
; PRIOR APPLICATION NUMBER: PCT/US00/33545  
; PRIOR FILING DATE: 2000-12-11  
; PRIOR APPLICATION NUMBER: US 09/458,298  
; PRIOR FILING DATE: 1999-12-10  
; PRIOR APPLICATION NUMBER: US 09/189,702  
; PRIOR FILING DATE: 1998-11-10  
; PRIOR APPLICATION NUMBER: US 08/205,713  
; PRIOR FILING DATE: 1994-03-04  
; PRIOR APPLICATION NUMBER: US 08/159,184  
; PRIOR FILING DATE: 1993-11-29  
; PRIOR APPLICATION NUMBER: US 08/073,205  
; PRIOR FILING DATE: 1993-06-04  
; PRIOR APPLICATION NUMBER: US 08/027,146  
; PRIOR FILING DATE: 1993-03-05  
; NUMBER OF SEQ ID NOS: 2479  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 1049  
; LENGTH: 11  
; TYPE: PRT  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Artificial Peptide

US-10-149-135-1049

Query Match 27.3%; Score 3; DB 12; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SRK 5  
|||  
Db 5 SRK 7

RESULT 75

US-10-149-135-1057

```
; Sequence 1057, Application US/10149135
; Publication No. US20040053822A1
; GENERAL INFORMATION:
; APPLICANT: Fikes, John
; APPLICANT: Sette, Alessandro
; APPLICANT: Sidney, John
; APPLICANT: Southwood, Scott
; APPLICANT: Chesnut, Robert
; APPLICANT: Celis, Esteban
; APPLICANT: Keogh, Elissa
; TITLE OF INVENTION: Inducing Cellular Immune Responses to
; TITLE OF INVENTION: MAGE2/3 Using Peptide and Nucleic Acid Compositions
; FILE REFERENCE: 2060.0130001
; CURRENT APPLICATION NUMBER: US/10/149,135
; CURRENT FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: PCT/US00/33545
; PRIOR FILING DATE: 2000-12-11
; PRIOR APPLICATION NUMBER: US 09/458,298
; PRIOR FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: US 09/189,702
; PRIOR FILING DATE: 1998-11-10
; PRIOR APPLICATION NUMBER: US 08/205,713
; PRIOR FILING DATE: 1994-03-04
; PRIOR APPLICATION NUMBER: US 08/159,184
; PRIOR FILING DATE: 1993-11-29
; PRIOR APPLICATION NUMBER: US 08/073,205
; PRIOR FILING DATE: 1993-06-04
; PRIOR APPLICATION NUMBER: US 08/027,146
; PRIOR FILING DATE: 1993-03-05
; NUMBER OF SEQ ID NOS: 2479
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1057
; LENGTH: 11
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Artificial Peptide
US-10-149-135-1057
```

```
Query Match          27.3%; Score 3; DB 12; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.1e+04;
Matches      3; Conservative      0; Mismatches      0; Indels      0; Gaps      0;
```

```
Qy          8 SSL 10
            |||
Db          1 SSL 3
```

Search completed: April 8, 2004, 16:35:50  
Job time : 31.3077 secs



GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: April 8, 2004, 15:30:07 ; Search time 27.7692 Seconds  
(without alignments)  
124.984 Million cell updates/sec

Title: US-09-787-443A-21  
Perfect score: 11  
Sequence: 1 AKSRKGNSSLM 11

Scoring table: OLIGO  
Gapop 60.0 , Gapext 60.0

Searched: 1017041 seqs, 315518202 residues

Word size : 0

Total number of hits satisfying chosen parameters: 460

Minimum DB seq length: 11  
Maximum DB seq length: 11

Post-processing: Listing first 100 summaries

Database : SPTREMBL\_25:\*  
1: sp\_archaea:\*  
2: sp\_bacteria:\*  
3: sp\_fungi:\*  
4: sp\_human:\*  
5: sp\_invertebrate:\*  
6: sp\_mammal:\*  
7: sp\_mhc:\*  
8: sp\_organelle:\*  
9: sp\_phage:\*  
10: sp\_plant:\*  
11: sp\_rodent:\*  
12: sp\_virus:\*  
13: sp\_vertebrate:\*  
14: sp\_unclassified:\*  
15: sp\_rvirus:\*  
16: sp\_bacteriap:\*  
17: sp\_archeap:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

%

| Result | Query |       |        |    |    |             |
|--------|-------|-------|--------|----|----|-------------|
| No.    | Score | Match | Length | DB | ID | Description |
| <hr/>  |       |       |        |    |    |             |

|    |   |      |    |   |        |        |             |
|----|---|------|----|---|--------|--------|-------------|
| 1  | 3 | 27.3 | 11 | 2 | Q9R872 | Q9r872 | escherichia |
| 2  | 3 | 27.3 | 11 | 5 | Q9BJ61 | Q9bj61 | dictyosteli |
| 3  | 3 | 27.3 | 11 | 8 | Q9G622 | Q9g622 | salea horsf |
| 4  | 3 | 27.3 | 11 | 8 | Q9G616 | Q9g616 | ceratophora |
| 5  | 3 | 27.3 | 11 | 8 | Q9G610 | Q9g610 | lyriocephal |
| 6  | 3 | 27.3 | 11 | 8 | Q9G619 | Q9g619 | ceratophora |
| 7  | 3 | 27.3 | 11 | 8 | Q8WER7 | Q8wer7 | ceratophora |
| 8  | 3 | 27.3 | 11 | 8 | Q8WD50 | Q8wd50 | ceratophora |
| 9  | 3 | 27.3 | 11 | 8 | Q9G613 | Q9g613 | cophotis ce |
| 10 | 3 | 27.3 | 11 | 8 | Q9G5Z5 | Q9g5z5 | japalura sp |
| 11 | 3 | 27.3 | 11 | 8 | Q8WER4 | Q8wer4 | ceratophora |
| 12 | 2 | 18.2 | 11 | 2 | Q9R790 | Q9r790 | borrelia ga |
| 13 | 2 | 18.2 | 11 | 2 | Q47602 | Q47602 | escherichia |
| 14 | 2 | 18.2 | 11 | 2 | P77404 | P77404 | escherichia |
| 15 | 2 | 18.2 | 11 | 2 | Q9EUZ3 | Q9euz3 | escherichia |
| 16 | 2 | 18.2 | 11 | 2 | Q47600 | Q47600 | escherichia |
| 17 | 2 | 18.2 | 11 | 2 | Q8RMI8 | Q8rmi8 | enterococcu |
| 18 | 2 | 18.2 | 11 | 2 | P71228 | P71228 | escherichia |
| 19 | 2 | 18.2 | 11 | 2 | P95518 | P95518 | pasteurella |
| 20 | 2 | 18.2 | 11 | 2 | Q47345 | Q47345 | escherichia |
| 21 | 2 | 18.2 | 11 | 2 | Q47420 | Q47420 | escherichia |
| 22 | 2 | 18.2 | 11 | 2 | Q56413 | Q56413 | escherichia |
| 23 | 2 | 18.2 | 11 | 2 | Q9R446 | Q9r446 | neisseria g |
| 24 | 2 | 18.2 | 11 | 4 | Q14759 | Q14759 | homo sapien |
| 25 | 2 | 18.2 | 11 | 4 | Q9UCP2 | Q9ucp2 | homo sapien |
| 26 | 2 | 18.2 | 11 | 4 | Q9Y3G2 | Q9y3g2 | homo sapien |
| 27 | 2 | 18.2 | 11 | 4 | Q16427 | Q16427 | homo sapien |
| 28 | 2 | 18.2 | 11 | 4 | O75811 | O75811 | homo sapien |
| 29 | 2 | 18.2 | 11 | 4 | O94785 | O94785 | homo sapien |
| 30 | 2 | 18.2 | 11 | 4 | Q16234 | Q16234 | homo sapien |
| 31 | 2 | 18.2 | 11 | 4 | Q8NI03 | Q8ni03 | homo sapien |
| 32 | 2 | 18.2 | 11 | 4 | Q8TDA8 | Q8tda8 | homo sapien |
| 33 | 2 | 18.2 | 11 | 5 | Q9UAR8 | Q9uar8 | aedes aegyp |
| 34 | 2 | 18.2 | 11 | 5 | Q26092 | Q26092 | pisaster oc |
| 35 | 2 | 18.2 | 11 | 5 | Q9TWX6 | Q9twx6 | manduca sex |
| 36 | 2 | 18.2 | 11 | 5 | Q99292 | Q99292 | drosophila  |
| 37 | 2 | 18.2 | 11 | 5 | Q25916 | Q25916 | plasmodium  |
| 38 | 2 | 18.2 | 11 | 5 | Q9NFX0 | Q9nfx0 | drosophila  |
| 39 | 2 | 18.2 | 11 | 5 | Q8MPQ3 | Q8mpq3 | caenorhabdi |
| 40 | 2 | 18.2 | 11 | 5 | P82698 | P82698 | leucophaea  |
| 41 | 2 | 18.2 | 11 | 5 | P82699 | P82699 | leucophaea  |
| 42 | 2 | 18.2 | 11 | 5 | P82700 | P82700 | leucophaea  |
| 43 | 2 | 18.2 | 11 | 6 | Q9XSP7 | Q9xsp7 | pygathrix n |
| 44 | 2 | 18.2 | 11 | 6 | Q9XSP2 | Q9xsp2 | hylobates s |
| 45 | 2 | 18.2 | 11 | 6 | Q9TRX2 | Q9trx2 | bos taurus  |
| 46 | 2 | 18.2 | 11 | 6 | Q9XSP5 | Q9xsp5 | pan troglod |
| 47 | 2 | 18.2 | 11 | 6 | Q9XSP8 | Q9xsp8 | presbytis j |
| 48 | 2 | 18.2 | 11 | 6 | Q9XSP6 | Q9xsp6 | pongo pygma |
| 49 | 2 | 18.2 | 11 | 6 | Q9XSQ4 | Q9xsq4 | gorilla gor |
| 50 | 2 | 18.2 | 11 | 7 | O77900 | O77900 | oreochromis |
| 51 | 2 | 18.2 | 11 | 7 | O77917 | O77917 | oreochromis |
| 52 | 2 | 18.2 | 11 | 7 | O77902 | O77902 | oreochromis |
| 53 | 2 | 18.2 | 11 | 7 | O77921 | O77921 | pseudotroph |
| 54 | 2 | 18.2 | 11 | 7 | Q9TQB3 | Q9tqb3 | homo sapien |
| 55 | 2 | 18.2 | 11 | 7 | O77901 | O77901 | oreochromis |
| 56 | 2 | 18.2 | 11 | 7 | O77892 | O77892 | oreochromis |
| 57 | 2 | 18.2 | 11 | 7 | O77916 | O77916 | oreochromis |

|     |   |      |    |    |        |                    |
|-----|---|------|----|----|--------|--------------------|
| 58  | 2 | 18.2 | 11 | 7  | O77885 | O77885 oreochromis |
| 59  | 2 | 18.2 | 11 | 7  | O77905 | O77905 oreochromis |
| 60  | 2 | 18.2 | 11 | 7  | O77884 | O77884 oreochromis |
| 61  | 2 | 18.2 | 11 | 7  | O77906 | O77906 oreochromis |
| 62  | 2 | 18.2 | 11 | 7  | O77899 | O77899 oreochromis |
| 63  | 2 | 18.2 | 11 | 7  | O77918 | O77918 pseudotroph |
| 64  | 2 | 18.2 | 11 | 7  | O77893 | O77893 oreochromis |
| 65  | 2 | 18.2 | 11 | 7  | O78121 | O78121 oreochromis |
| 66  | 2 | 18.2 | 11 | 7  | O77904 | O77904 oreochromis |
| 67  | 2 | 18.2 | 11 | 7  | O77903 | O77903 oreochromis |
| 68  | 2 | 18.2 | 11 | 7  | O77913 | O77913 oreochromis |
| 69  | 2 | 18.2 | 11 | 8  | Q9G5Y6 | Q9g5y6 agama agama |
| 70  | 2 | 18.2 | 11 | 8  | Q8MEL7 | Q8mel7 sida hooker |
| 71  | 2 | 18.2 | 11 | 8  | Q9G5Y0 | Q9g5y0 pseudotrape |
| 72  | 2 | 18.2 | 11 | 8  | Q8MEM2 | Q8mem2 lagunaria p |
| 73  | 2 | 18.2 | 11 | 8  | Q8MES5 | Q8mes5 abelmoschus |
| 74  | 2 | 18.2 | 11 | 8  | Q8WD17 | Q8wdl7 ctenophorus |
| 75  | 2 | 18.2 | 11 | 8  | Q9G368 | Q9g368 draco blanf |
| 76  | 2 | 18.2 | 11 | 8  | Q8MEP0 | Q8mep0 hibiscus pe |
| 77  | 2 | 18.2 | 11 | 8  | Q32704 | Q32704 nicotiana t |
| 78  | 2 | 18.2 | 11 | 8  | Q8MES1 | Q8mes1 alyogyne pi |
| 79  | 2 | 18.2 | 11 | 8  | Q8MEP3 | Q8mep3 hibiscus no |
| 80  | 2 | 18.2 | 11 | 8  | Q8MEQ7 | Q8meq7 hibiscus dr |
| 81  | 2 | 18.2 | 11 | 8  | Q35374 | Q35374 paramecium  |
| 82  | 2 | 18.2 | 11 | 8  | Q8MEL9 | Q8mel9 pavonia has |
| 83  | 2 | 18.2 | 11 | 8  | Q8MER0 | Q8mer0 hibiscus co |
| 84  | 2 | 18.2 | 11 | 8  | Q8MES3 | Q8mes3 alyogyne cr |
| 85  | 2 | 18.2 | 11 | 8  | Q9G658 | Q9g658 hydrosaurus |
| 86  | 2 | 18.2 | 11 | 8  | Q34380 | Q34380 drosophila  |
| 87  | 2 | 18.2 | 11 | 8  | Q8MEP5 | Q8mep5 hibiscus mi |
| 88  | 2 | 18.2 | 11 | 8  | Q8MER1 | Q8mer1 hibiscus ca |
| 89  | 2 | 18.2 | 11 | 8  | Q8MER7 | Q8mer7 fioria viti |
| 90  | 2 | 18.2 | 11 | 8  | Q9G5Y3 | Q9g5y3 agama impal |
| 91  | 2 | 18.2 | 11 | 9  | Q37925 | Q37925 bacteriopha |
| 92  | 2 | 18.2 | 11 | 10 | Q9S8Z8 | Q9s8z8 psophocarpu |
| 93  | 2 | 18.2 | 11 | 10 | O65901 | O65901 leavenworth |
| 94  | 2 | 18.2 | 11 | 10 | Q8RV30 | Q8rv30 zea mays (m |
| 95  | 2 | 18.2 | 11 | 10 | Q39784 | Q39784 gossypium h |
| 96  | 2 | 18.2 | 11 | 10 | O82070 | O82070 triticum ae |
| 97  | 2 | 18.2 | 11 | 10 | Q94IR5 | Q94ir5 pinus radia |
| 98  | 2 | 18.2 | 11 | 10 | Q04131 | Q04131 lycopersico |
| 99  | 2 | 18.2 | 11 | 10 | P82436 | P82436 nicotiana t |
| 100 | 2 | 18.2 | 11 | 10 | Q7X9Y3 | Q7x9y3 cucumis sat |

# ALIGNMENTS

## RESULT 1

Q9R872

ID Q9R872 PRELIMINARY; PRT; 11 AA.

AC Q9R872;

DT 01-MAY-2000 (TrEMBLrel. 13, Created)

DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)

DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)

DE Dihydrofolate reductase (Fragment).

GN DFR1.

OS Escherichia coli.  
 OG Plasmid r483.  
 OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;  
 OC Enterobacteriaceae; Escherichia.  
 OX NCBI\_TaxID=562;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TRANSPOSON=Tn7;  
 RA Hansson K., Sundstrom L., Pelletier A., Roy P.H.;  
 RT "Sequence and function of the second type of integron in Tn7.";  
 RL Submitted (SEP-1997) to the EMBL/GenBank/DDBJ databases.  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC TRANSPOSON=Tn7;  
 RX MEDLINE=82220022; PubMed=6283361;  
 RA Lichtenstein C., Brenner S.;  
 RT "Unique insertion site of Tn7 in the E. coli chromosome.";  
 RL Nature 297:601-603(1982).  
 RN [3]  
 RP SEQUENCE FROM N.A.  
 RC TRANSPOSON=Tn7;  
 RX MEDLINE=83290694; PubMed=6411680;  
 RA Simonsen C.C., Chen E.Y., Levinson A.D.;  
 RT "Identification of the type I trimethoprim-resistant dihydrofolate  
 RT reductase specified by the Escherichia coli R-plasmid R483: Comparison  
 RT with procaryotic and eucaryotic dihydrofolate reductases.";  
 RL J. Bacteriol. 155:1001-1008(1983).  
 RN [4]  
 RP SEQUENCE FROM N.A.  
 RC TRANSPOSON=Tn7;  
 RX MEDLINE=83272957; PubMed=6308574;  
 RA Fling M.E., Richards C.;  
 RT "The nucleotide sequence of the trimethoprim-resistant dihydrofolate  
 RT reductase gene harbored by Tn7.";  
 RL Nucleic Acids Res. 11:5147-5158(1983).  
 DR EMBL; AJ001816; CAA05032.1; -.  
 DR GO; GO:0046821; C:extrachromosomal DNA; IEA.  
 KW Plasmid.  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1221 MW; 92014864C2C69735 CRC64;

Query Match 27.3%; Score 3; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 9.4e+03;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 SLM 11  
 |||  
 Db 4 SLM 6

## RESULT 2

Q9BJ61

ID Q9BJ61 PRELIMINARY; PRT; 11 AA.  
 AC Q9BJ61;  
 DT 01-JUN-2001 (TrEMBLrel. 17, Created)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)  
 DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)

DE G-box binding factor (Fragment).  
 OS Dictyostelium discoideum (Slime mold).  
 OC Eukaryota; Mycetoza; Dictyosteliida; Dictyostelium.  
 OX NCBI\_TaxID=44689;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=21290831; PubMed=11397018;  
 RA Brown J.M., Firtel R.A.;  
 RT "Functional and regulatory analysis of the Dictyostelium G-box binding  
 RT factor.";  
 RL Dev. Biol. 234:521-534(2001).  
 DR EMBL; AF337815; AAK21290.1; -.  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1248 MW; 87356B5FD1E1E1F1 CRC64;

Query Match 27.3%; Score 3; DB 5; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 9.4e+03;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 GNS 8  
 |||  
 Db 9 GNS 11

# RESULT 3

Q9G622

ID Q9G622 PRELIMINARY; PRT; 11 AA.  
 AC Q9G622;  
 DT 01-MAR-2001 (TrEMBLrel. 16, Created)  
 DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)  
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)  
 DE Cytochrome c oxidase subunit I (Fragment).  
 GN COI.  
 OS Salea horsfieldii.  
 OG Mitochondrion.  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Lepidosauria; Squamata; Iguania; Acrodonta; Agamidae; Draconinae;  
 OC Salea.  
 OX NCBI\_TaxID=118233;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=22114082; PubMed=12118408;  
 RA Macey J.R., Schulte J.A. II, Larson A.;  
 RT "Evolution and information content of the mitochondrial genomic  
 RT structural features illustrated with acrodont lizards.";  
 RL Syst. Biol. 49:257-277(2000).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=22114081; PubMed=12118407;  
 RA Macey J.R., Schulte J.A. II, Larson A., Ananjeva N.B., Wang Y.,  
 RA Pethiyagoda R., Rastegar-Pouyani N., Papenfuss T.J.;  
 RT "Evaluating Trans-Tethys migration: An example using Acrodont lizard  
 RT phylogenetics.";  
 RL Syst. Biol. 49:233-256(2000).  
 DR EMBL; AF128490; AAG00707.1; -.  
 DR GO; GO:0005739; C:mitochondrion; IEA.  
 KW Mitochondrion.

FT NON\_TER 11 11  
SQ SEQUENCE 11 AA; 1264 MW; 5B2C371E33640DD7 CRC64;

Query Match 27.3%; Score 3; DB 8; Length 11;  
Best Local Similarity 100.0%; Pred. No. 9.4e+03;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
|||  
Db 2 SSL 4

RESULT 4

Q9G616

ID Q9G616 PRELIMINARY; PRT; 11 AA.

AC Q9G616;

DT 01-MAR-2001 (TrEMBLrel. 16, Created)

DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)

DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)

DE Cytochrome c oxidase subunit I (Fragment).

GN COI.

OS Ceratophora stoddartii.

OG Mitochondrion.

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Lepidosauria; Squamata; Iguania; Acrodonta; Agamidae; Draconinae;

OC Ceratophora.

OX NCBI\_TaxID=118196;

RN [1]

RP SEQUENCE FROM N.A.

RX MEDLINE=22114082; PubMed=12118408;

RA Macey J.R., Schulte J.A. II, Larson A.;

RT "Evolution and information content of the mitochondrial genomic  
RT structural features illustrated with acrodont lizards.";

RL Syst. Biol. 49:257-277(2000).

RN [2]

RP SEQUENCE FROM N.A.

RX MEDLINE=22114081; PubMed=12118407;

RA Macey J.R., Schulte J.A. II, Larson A., Ananjeva N.B., Wang Y.,

RA Pethiyagoda R., Rastegar-Pouyani N., Papenfuss T.J.;

RT "Evaluating Trans-Tethys migration: An example using Acrodont lizard  
RT phylogenetics.";

RL Syst. Biol. 49:233-256(2000).

RN [3]

RP SEQUENCE FROM N.A.

RX MEDLINE=21655505; PubMed=11796034;

RA Schulte J.A. II, Macey J.R., Pethiyagoda R., Larson A.;

RT "Rostral Horn Evolution among Agamid Lizards of the Genus Ceratophora  
RT Endemic to Sri Lanka.";

RL Mol. Phylogenet. Evol. 22:111-117(2002).

DR EMBL; AF128492; AAG00713.1; -.

DR EMBL; AF364054; AAL68027.1; -.

DR GO; GO:0005739; C:mitochondrion; IEA.

KW Mitochondrion.

FT NON\_TER 11 11

SQ SEQUENCE 11 AA; 1295 MW; 5B2C371E336411A7 CRC64;

Query Match 27.3%; Score 3; DB 8; Length 11;

Best Local Similarity 100.0%; Pred. No. 9.4e+03;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
|||  
Db 2 SSL 4

RESULT 5

Q9G610

ID Q9G610 PRELIMINARY; PRT; 11 AA.  
AC Q9G610;  
DT 01-MAR-2001 (TrEMBLrel. 16, Created)  
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)  
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)  
DE Cytochrome c oxidase subunit I (Fragment).  
GN COI.  
OS Lyriocephalus scutatus.  
OG Mitochondrion.  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Lepidosauria; Squamata; Iguania; Acrodonta; Agamidae; Draconinae;  
OC Lyriocephalus.  
OX NCBI\_TaxID=118218;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=22114082; PubMed=12118408;  
RA Macey J.R., Schulte J.A. II, Larson A.;  
RT "Evolution and information content of the mitochondrial genomic  
RT structural features illustrated with acrodont lizards.";  
RL Syst. Biol. 49:257-277(2000).  
RN [2]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=22114081; PubMed=12118407;  
RA Macey J.R., Schulte J.A. II, Larson A., Ananjeva N.B., Wang Y.,  
RA Pethiyagoda R., Rastegar-Pouyani N., Papenfuss T.J.;  
RT "Evaluating Trans-Tethys migration: An example using Acrodont lizard  
RT phylogenetics.";  
RL Syst. Biol. 49:233-256(2000).  
RN [3]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=21655505; PubMed=11796034;  
RA Schulte J.A. II, Macey J.R., Pethiyagoda R., Larson A.;  
RT "Rostral Horn Evolution among Agamid Lizards of the Genus Ceratophora  
RT Endemic to Sri Lanka.";  
RL Mol. Phylogenet. Evol. 22:111-117(2002).  
DR EMBL; AF128494; AAG00719.1; -.  
DR EMBL; AF364052; AAL68021.1; -.  
DR GO; GO:0005739; C:mitochondrion; IEA.  
KW Mitochondrion.  
FT NON\_TER 11 11  
SQ SEQUENCE 11 AA; 1295 MW; 5B2C371E336411A7 CRC64;

Query Match 27.3%; Score 3; DB 8; Length 11;  
Best Local Similarity 100.0%; Pred. No. 9.4e+03;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10

Db                    |||  
                      2 SSL 4

RESULT 6

Q9G619

ID    Q9G619            PRELIMINARY;            PRT;        11 AA.  
AC    Q9G619;  
DT    01-MAR-2001 (TrEMBLrel. 16, Created)  
DT    01-MAR-2001 (TrEMBLrel. 16, Last sequence update)  
DT    01-JUN-2003 (TrEMBLrel. 24, Last annotation update)  
DE    Cytochrome c oxidase subunit I (Fragment).  
GN    COI.  
OS    Ceratophora aspera.  
OG    Mitochondrion.  
OC    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC    Lepidosauria; Squamata; Iguania; Acrodonta; Agamidae; Draconinae;  
OC    Ceratophora.  
OX    NCBI\_TaxID=118195;  
RN    [1]  
RP    SEQUENCE FROM N.A.  
RX    MEDLINE=22114082; PubMed=12118408;  
RA    Macey J.R., Schulte J.A. II, Larson A.;  
RT    "Evolution and information content of the mitochondrial genomic  
RT    structural features illustrated with acrodont lizards.";  
RL    Syst. Biol. 49:257-277(2000).  
RN    [2]  
RP    SEQUENCE FROM N.A.  
RX    MEDLINE=22114081; PubMed=12118407;  
RA    Macey J.R., Schulte J.A. II, Larson A., Ananjeva N.B., Wang Y.,  
RA    Pethiyagoda R., Rastegar-Pouyani N., Papenfuss T.J.;  
RT    "Evaluating Trans-Tethys migration: An example using Acrodont lizard  
RT    phylogenetics.";  
RL    Syst. Biol. 49:233-256(2000).  
DR    EMBL; AF128491; AAG00710.1; -.  
DR    GO; GO:0005739; C:mitochondrion; IEA.  
KW    Mitochondrion.  
FT    NON\_TER        11        11  
SQ    SEQUENCE    11 AA;    1264 MW;    5B2C371E33640DD7 CRC64;

Query Match                    27.3%;    Score 3;    DB 8;    Length 11;  
Best Local Similarity    100.0%;    Pred. No. 9.4e+03;  
Matches        3;    Conservative    0;    Mismatches    0;    Indels        0;    Gaps        0;

Qy                    8 SSL 10  
                      |||  
Db                    2 SSL 4

RESULT 7

Q8WER7

ID    Q8WER7            PRELIMINARY;            PRT;        11 AA.  
AC    Q8WER7;  
DT    01-MAR-2002 (TrEMBLrel. 20, Created)  
DT    01-MAR-2002 (TrEMBLrel. 20, Last sequence update)  
DT    01-JUN-2003 (TrEMBLrel. 24, Last annotation update)  
DE    Cytochrome c oxidase subunit I (Fragment).



GN COI.  
 OS Ceratophora tennentii.  
 OG Mitochondrion.  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Lepidosauria; Squamata; Iguania; Acrodonta; Agamidae; Draconinae;  
 OC Ceratophora.  
 OX NCBI\_TaxID=118087;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=22114082; PubMed=12118408;  
 RA Macey J.R., Schulte J.A. II, Larson A.;  
 RT "Evolution and phylogenetic information content of mitochondrial  
 RT genomic structural features illustrated with acrodont lizards.";  
 RL Syst. Biol. 49:257-277(2000).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=21655505; PubMed=11796034;  
 RA Schulte J.A. II, Macey J.R., Pethiyagoda R., Larson A.;  
 RT "Rostral Horn Evolution among Agamid Lizards of the Genus Ceratophora  
 RT Endemic to Sri Lanka.";  
 RL Mol. Phylogenet. Evol. 22:111-117(2002).  
 DR EMBL; AF128521; AAL67607.1; -.  
 DR GO; GO:0005739; C:mitochondrion; IEA.  
 KW Mitochondrion.  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1264 MW; 5B2C371E33640DD7 CRC64;

Query Match 27.3%; Score 3; DB 8; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 9.4e+03;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
 |||  
 Db 2 SSL 4

# RESULT 8

Q8WD50

ID Q8WD50 PRELIMINARY; PRT; 11 AA.  
 AC Q8WD50;  
 DT 01-MAR-2002 (TrEMBLrel. 20, Created)  
 DT 01-MAR-2002 (TrEMBLrel. 20, Last sequence update)  
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)  
 DE Cytochrome c oxidase subunit I (Fragment).  
 GN COI.  
 OS Ceratophora stoddartii.  
 OG Mitochondrion.  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Lepidosauria; Squamata; Iguania; Acrodonta; Agamidae; Draconinae;  
 OC Ceratophora.  
 OX NCBI\_TaxID=118196;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=21655505; PubMed=11796034;  
 RA Schulte J.A. II, Macey J.R., Pethiyagoda R., Larson A.;  
 RT "Rostral Horn Evolution among Agamid Lizards of the Genus Ceratophora  
 RT Endemic to Sri Lanka.";

RL Mol. Phylogenet. Evol. 22:111-117(2002).  
 DR EMBL; AF364053; AAL68024.1; -.  
 DR GO; GO:0005739; C:mitochondrion; IEA.  
 KW Mitochondrion.  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1264 MW; 5B2C371E33640DD7 CRC64;

Query Match 27.3%; Score 3; DB 8; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 9.4e+03;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
 |||  
 Db 2 SSL 4

# RESULT 9

Q9G613

ID Q9G613 PRELIMINARY; PRT; 11 AA.  
 AC Q9G613;  
 DT 01-MAR-2001 (TrEMBLrel. 16, Created)  
 DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)  
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)  
 DE Cytochrome c oxidase subunit I (Fragment).  
 GN COI.  
 OS Cophotis ceylanica.  
 OG Mitochondrion.  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Lepidosauria; Squamata; Iguania; Acrodonta; Agamidae; Draconinae;  
 OC Cophotis.  
 OX NCBI\_TaxID=118202;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=22114082; PubMed=12118408;  
 RA Macey J.R., Schulte J.A. II, Larson A.;  
 RT "Evolution and information content of the mitochondrial genomic  
 RT structural features illustrated with acrodont lizards."  
 RL Syst. Biol. 49:257-277(2000).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=22114081; PubMed=12118407;  
 RA Macey J.R., Schulte J.A. II, Larson A., Ananjeva N.B., Wang Y.,  
 RA Pethiyagoda R., Rastegar-Pouyani N., Papenfuss T.J.;  
 RT "Evaluating Trans-Tethys migration: An example using Acrodont lizard  
 RT phylogenetics."  
 RL Syst. Biol. 49:233-256(2000).  
 DR EMBL; AF128493; AAG00716.1; -.  
 DR GO; GO:0005739; C:mitochondrion; IEA.  
 KW Mitochondrion.  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1295 MW; 5B2C371E336411A7 CRC64;

Query Match 27.3%; Score 3; DB 8; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 9.4e+03;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10

Db                    |||  
                      2 SSL 4

RESULT 10

Q9G5Z5

ID    Q9G5Z5            PRELIMINARY;            PRT;        11 AA.  
AC    Q9G5Z5;  
DT    01-MAR-2001 (TrEMBLrel. 16, Created)  
DT    01-MAR-2001 (TrEMBLrel. 16, Last sequence update)  
DT    01-JUN-2003 (TrEMBLrel. 24, Last annotation update)  
DE    Cytochrome c oxidase subunit I (Fragment).  
GN    COI.  
OS    Japalura splendida.  
OG    Mitochondrion.  
OC    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC    Lepidosauria; Squamata; Iguania; Acrodonta; Agamidae; Draconinae;  
OC    Japalura.  
OX    NCBI\_TaxID=118209;  
RN    [1]  
RP    SEQUENCE FROM N.A.  
RX    MEDLINE=22114082; PubMed=12118408;  
RA    Macey J.R., Schulte J.A. II, Larson A.;  
RT    "Evolution and information content of the mitochondrial genomic  
RT    structural features illustrated with acrodont lizards.";  
RL    Syst. Biol. 49:257-277(2000).  
RN    [2]  
RP    SEQUENCE FROM N.A.  
RX    MEDLINE=22114081; PubMed=12118407;  
RA    Macey J.R., Schulte J.A. II, Larson A., Ananjeva N.B., Wang Y.,  
RA    Pethiyagoda R., Rastegar-Pouyani N., Papenfuss T.J.;  
RT    "Evaluating Trans-Tethys migration: An example using Acrodont lizard  
RT    phylogenetics.";  
RL    Syst. Biol. 49:233-256(2000).  
DR    EMBL; AF128501; AAG00740.1; -.  
DR    GO; GO:0005739; C:mitochondrion; IEA.  
KW    Mitochondrion.  
FT    NON TER            11        11  
SQ    SEQUENCE    11 AA;    1295 MW;    5B2C371E336411A7 CRC64;

Query Match                    27.3%; Score 3; DB 8; Length 11;  
Best Local Similarity    100.0%; Pred. No. 9.4e+03;  
Matches        3; Conservative    0; Mismatches        0; Indels        0; Gaps        0;

Qy                    8 SSL 10  
                      |||  
Db                    2 SSL 4

RESULT 11

Q8WER4

ID    Q8WER4            PRELIMINARY;            PRT;        11 AA.  
AC    Q8WER4;  
DT    01-MAR-2002 (TrEMBLrel. 20, Created)  
DT    01-MAR-2002 (TrEMBLrel. 20, Last sequence update)  
DT    01-JUN-2003 (TrEMBLrel. 24, Last annotation update)  
DE    Cytochrome c oxidase subunit I (Fragment).

GN COI.  
 OS Ceratophora erdeleni.  
 OG Mitochondrion.  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Lepidosauria; Squamata; Iguania; Acrodonta; Agamidae; Draconinae;  
 OC Ceratophora.  
 OX NCBI\_TaxID=118085;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=22114082; PubMed=12118408;  
 RA Macey J.R., Schulte J.A. II, Larson A.;  
 RT "Evolution and phylogenetic information content of mitochondrial  
 RT genomic structural features illustrated with acrodont lizards.";  
 RL Syst. Biol. 49:257-277(2000).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=21655505; PubMed=11796034;  
 RA Schulte J.A. II, Macey J.R., Pethiyagoda R., Larson A.;  
 RT "Rostral Horn Evolution among Agamid Lizards of the Genus Ceratophora  
 RT Endemic to Sri Lanka.";  
 RL Mol. Phylogenet. Evol. 22:111-117(2002).  
 DR EMBL; AF128522; AAL67610.1; -.  
 DR GO; GO:0005739; C:mitochondrion; IEA.  
 KW Mitochondrion.  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1264 MW; 5B2C371E33640DD7 CRC64;

Query Match 27.3%; Score 3; DB 8; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 9.4e+03;  
 Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SSL 10  
 |||  
 Db 2 SSL 4

# RESULT 12

Q9R790

ID Q9R790 PRELIMINARY; PRT; 11 AA.  
 AC Q9R790;  
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)  
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)  
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)  
 DE Outer surface protein C (Fragment).  
 GN OSPC.  
 OS Borrelia garinii.  
 OC Bacteria; Spirochaetes; Spirochaetales; Spirochaetaceae; Borrelia.  
 OX NCBI\_TaxID=29519;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=G25;  
 RX MEDLINE=97426044; PubMed=9282748;  
 RA Tilly K., Casjens S., Stevenson B., Bono J.L., Samuels D.S., Hogan D.,  
 RA Rosa P.;  
 RT "The Borrelia burgdorferi circular plasmid cp26: conservation of  
 RT plasmid structure and targeted inactivation of the ospC gene.";  
 RL Mol. Microbiol. 25:361-374(1997).

DR EMBL; U93700; AAC45535.1; -.  
 DR GO; GO:0009279; C:external outer membrane (sensu Gram-negativ. . .; IEA.  
 DR GO; GO:0003793; F:defense/immunity protein activity; IEA.  
 DR GO; GO:0006952; P:defense response; IEA.  
 DR InterPro; IPR001800; Lipoprotein\_6.  
 DR Pfam; PF01441; Lipoprotein\_6; 1.  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1250 MW; 0868D864C5B731A4 CRC64;

Query Match 18.2%; Score 2; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 LM 11  
 ||  
 Db 10 LM 11

#### RESULT 13

Q47602

ID Q47602 PRELIMINARY; PRT; 11 AA.  
 AC Q47602;  
 DT 01-NOV-1996 (TrEMBLrel. 01, Created)  
 DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)  
 DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
 DE REase protein (Fragment).  
 GN REASE.  
 OS Escherichia coli.  
 OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;  
 OC Enterobacteriaceae; Escherichia.  
 OX NCBI\_TaxID=562;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=91139577; PubMed=1995588;  
 RA Tao T., Bourne J.C., Blumenthal R.M.;  
 RT "A family of regulatory genes associated with type II restriction-  
 RT modification systems."  
 RL J. Bacteriol. 173:1367-1375(1991).  
 DR EMBL; M63620; AAA24558.1; -.  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1412 MW; 80ABB190C736DAAA CRC64;

Query Match 18.2%; Score 2; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SR 4  
 ||  
 Db 2 SR 3

#### RESULT 14

P77404

ID P77404 PRELIMINARY; PRT; 11 AA.  
 AC P77404;  
 DT 01-FEB-1997 (TrEMBLrel. 02, Created)  
 DT 01-FEB-1997 (TrEMBLrel. 02, Last sequence update)

DT 01-NOV-1998 (TrEMBLrel. 08, Last annotation update)  
 DE DNA sequence downstream of the ECOPRRI HSD locus (Fragment).  
 GN HSDR.  
 OS Escherichia coli.  
 OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;  
 OC Enterobacteriaceae; Escherichia.  
 OX NCBI\_TaxID=562;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=97206151; PubMed=9157244;  
 RA Tyndall C., Lehnherr H., Sandmeier U., Kulik E., Bickle T.A.;  
 RT "The type IC hsd loci of the enterobacteria are flanked by DNA with  
 RT high homology to the phage P1 genome: implications for the evolution  
 RT and spread of DNA restriction systems."  
 RL Mol. Microbiol. 23:729-736(1997).  
 DR EMBL; X98145; CAA66840.1; -.  
 DR EMBL; X98144; CAA66839.1; -.  
 FT NON\_TER 1 1  
 SQ SEQUENCE 11 AA; 1259 MW; 714AB092A4072734 CRC64;

Query Match 18.2%; Score 2; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 KS 3  
 ||  
 Db 1 KS 2

RESULT 15  
 Q9EUZ3

ID Q9EUZ3 PRELIMINARY; PRT; 11 AA.  
 AC Q9EUZ3;  
 DT 01-MAR-2001 (TrEMBLrel. 16, Created)  
 DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)  
 DT 01-MAR-2001 (TrEMBLrel. 16, Last annotation update)  
 DE Ribosome binding factor A (Fragment).  
 GN RBFA.  
 OS Escherichia coli.  
 OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;  
 OC Enterobacteriaceae; Escherichia.  
 OX NCBI\_TaxID=562;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=IQ490;  
 RA Hedegaard J., Kristensen J.E., Nakamura Y., Sperling-Petersen H.U.,  
 RA Mortensen K.K.;  
 RT "Sequence of the infB gene from Escherichia coli strain IQ489 and  
 RT IQ490."  
 RL Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases.  
 DR EMBL; AJ132862; CAC20133.1; -.  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1319 MW; 6B234CFE740879CB CRC64;

Query Match 18.2%; Score 2; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AK 2  
||  
Db 2 AK 3

RESULT 16

Q47600

ID Q47600 PRELIMINARY; PRT; 11 AA.  
AC Q47600;  
DT 01-NOV-1996 (TrEMBLrel. 01, Created)  
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)  
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
DE REase protein (Fragment).  
GN REASE.  
OS Escherichia coli.  
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;  
OC Enterobacteriaceae; Escherichia.  
OX NCBI\_TaxID=562;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=91139577; PubMed=1995588;  
RA Tao T., Bourne J.C., Blumenthal R.M.;  
RT "A family of regulatory genes associated with type II restriction-  
RT modification systems.";  
RL J. Bacteriol. 173:1367-1375(1991).  
DR EMBL; M63619; AAA24556.1; -.  
FT NON\_TER 11 11  
SQ SEQUENCE 11 AA; 1232 MW; 63175479572AB5A4 CRC64;

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 SL 10  
||  
Db 2 SL 3

RESULT 17

Q8RMI8

ID Q8RMI8 PRELIMINARY; PRT; 11 AA.  
AC Q8RMI8;  
DT 01-JUN-2002 (TrEMBLrel. 21, Created)  
DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)  
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)  
DE ErmB (Fragment).  
GN ERMB.  
OS Enterococcus hirae.  
OG Plasmid pMKH1.  
OC Bacteria; Firmicutes; Lactobacillales; Enterococcaceae; Enterococcus.  
OX NCBI\_TaxID=1354;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Borgen K., Sorum M., Wasteson Y., Kruse H., Oppegaard H.;  
RT "Genetic linkage between ermB and vanA in Enterococcus hirae of  
RT poultry origin.";

RL Submitted (MAR-2002) to the EMBL/GenBank/DDBJ databases.  
DR EMBL; AF493942; AAM18554.1; -.  
DR GO; GO:0046821; C:extrachromosomal DNA; IEA.  
KW Plasmid.  
FT NON\_TER 1 1  
SQ SEQUENCE 11 AA; 1359 MW; 08A7A8AA49C7273B CRC64;

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 RK 5  
||  
Db 10 RK 11

RESULT 18

P71228

ID P71228 PRELIMINARY; PRT; 11 AA.  
AC P71228;  
DT 01-FEB-1997 (TrEMBLrel. 02, Created)  
DT 01-JUL-1997 (TrEMBLrel. 04, Last sequence update)  
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)  
DE Nitrate/nitrite sensor transmitter (Fragment).  
GN NARQ.  
OS Escherichia coli.  
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;  
OC Enterobacteriaceae; Escherichia.  
OX NCBI\_TaxID=562;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=K-12;  
RX MEDLINE=92374842; PubMed=1508040;  
RA Chiang R.C., Cavicchioli R., Gunsalus R.P.;  
RT "Identification and characterization of narQ, a second nitrate sensor  
RT for nitrate-dependent gene regulation in Escherichia coli.";  
RL Mol. Microbiol. 6:1913-1923(1992).  
RN [2]  
RP SEQUENCE FROM N.A.  
RC STRAIN=K-12;  
RX MEDLINE=97113461; PubMed=8955321;  
RA Cavicchioli R., Kolesnikow T., Chiang R.C., Gunsalus R.P.;  
RT "Characterization of the aegA locus of Escherichia coli: control of  
RT gene expression in response to anaerobiosis and nitrate.";  
RL J. Bacteriol. 178:6968-6974(1996).  
DR EMBL; L34011; AAB46943.1; -.  
FT NON\_TER 11 11  
SQ SEQUENCE 11 AA; 1200 MW; 52E1CFFCA2D77403 CRC64;

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 SL 10  
||  
Db 10 SL 11



RESULT 19

P95518

ID P95518 PRELIMINARY; PRT; 11 AA.  
 AC P95518;  
 DT 01-MAY-1997 (TrEMBLrel. 03, Created)  
 DT 01-MAY-1997 (TrEMBLrel. 03, Last sequence update)  
 DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
 DE Ribosomal protein RpsA (Fragment).  
 GN RPSA.  
 OS Pasteurella haemolytica.  
 OC Bacteria; Proteobacteria; Gammaproteobacteria; Pasteurellales;  
 OC Pasteurellaceae; Mannheimia.  
 OX NCBI\_TaxID=75985;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=PHL101;  
 RX MEDLINE=97164347; PubMed=9011038;  
 RA Highlander S.K., Garza O., Brown B.J., Koby S., Oppenheim A.B.;  
 RT "Isolation and characterization of the integration host factor genes  
 RT of Pasteurella haemolytica."  
 RL FEMS Microbiol. Lett. 146:181-188(1997).  
 DR EMBL; U56139; AAC44845.1; -.  
 FT NON TER 1 1  
 SQ SEQUENCE 11 AA; 1168 MW; 7A4BFD38D339CDDDB CRC64;

Query Match 18.2%; Score 2; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AK 2  
 ||  
 Db 8 AK 9

RESULT 20

Q47345

ID Q47345 PRELIMINARY; PRT; 11 AA.  
 AC Q47345;  
 DT 01-NOV-1996 (TrEMBLrel. 01, Created)  
 DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)  
 DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
 DE Leader peptide.  
 OS Escherichia coli.  
 OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;  
 OC Enterobacteriaceae; Escherichia.  
 OX NCBI\_TaxID=562;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=K12;  
 RA Faber F., van Giezen M., Van Gorcom R.F.M., Harder W.;  
 RT "Identification of two Escherichia coli K12 proteins which are induced  
 RT in response to pollutant stress."  
 RL Submitted (APR-1996) to the EMBL/GenBank/DDBJ databases.  
 RN [2]  
 RP SEQUENCE OF 2-11 FROM N.A.  
 RC STRAIN=K12;

RX MEDLINE=85134883; PubMed=6396419;  
RA Hudson G.S., Davidson B.E.;  
RT "Nucleotide sequence and transcription of the phenylalanine and  
tyrosine operons of Escherichia coli K12.";  
RL J. Mol. Biol. 180:1023-1051(1984).  
DR EMBL; Z70523; CAA94435.1; -.  
SQ SEQUENCE 11 AA; 1402 MW; 87AB199204141775 CRC64;

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 NS 8  
||  
Db 3 NS 4

RESULT 21

Q47420

ID Q47420 PRELIMINARY; PRT; 11 AA.  
AC Q47420;  
DT 01-NOV-1996 (TrEMBLrel. 01, Created)  
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)  
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)  
DE ORF11 protein.  
OS Escherichia coli.  
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;  
OC Enterobacteriaceae; Escherichia.  
OX NCBI\_TaxID=562;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=K12;  
RX MEDLINE=92041688; PubMed=1657895;  
RA Sharples G.J., Lloyd R.G.;  
RT "Resolution of Holliday junctions in Escherichia coli: Identification  
of the ruvC gene product as a 19-Kilodalton protein.";  
RL J. Bacteriol. 173:7711-7715(1991).  
DR EMBL; X59551; CAA42127.1; -.  
DR PIR; S19015; S19015.  
SQ SEQUENCE 11 AA; 1215 MW; DD8D6D4D56C6D33D CRC64;

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AK 2  
||  
Db 4 AK 5

RESULT 22

Q56413

ID Q56413 PRELIMINARY; PRT; 11 AA.  
AC Q56413;  
DT 01-NOV-1996 (TrEMBLrel. 01, Created)  
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)  
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)

DE IS602L region DNA, 5' end (Fragment).  
 OS Escherichia coli.  
 OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;  
 OC Enterobacteriaceae; Escherichia.  
 OX NCBI\_TaxID=562;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TRANSPOSON=Transposon Tn602;  
 RX MEDLINE=87318208; PubMed=2819910;  
 RA Stibitz S., Davies J.E.;  
 RT "Tn602: A naturally occurring relative of Tn903 with direct repeats."  
 RL Plasmid 17:202-209(1987).  
 DR EMBL; M22735; AAA27464.1; -.  
 FT NON\_TER 1 1  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1361 MW; 447E8354A05339C3 CRC64;

Query Match 18.2%; Score 2; DB 2; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AK 2  
 ||  
 Db 1 AK 2

# RESULT 23

Q9R446

ID Q9R446 PRELIMINARY; PRT; 11 AA.  
 AC Q9R446;  
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)  
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)  
 DT 01-MAY-2000 (TrEMBLrel. 13, Last annotation update)  
 DE Carbamoyl-phosphate synthase subunit A (Fragment).  
 GN CARA.  
 OS Neisseria gonorrhoeae.  
 OC Bacteria; Proteobacteria; Betaproteobacteria; Neisseriales;  
 OC Neisseriaceae; Neisseria.  
 OX NCBI\_TaxID=485;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=MS11, and FA1090;  
 RX MEDLINE=95291461; PubMed=7773412;  
 RA Lawson F.S., Billowes F.M., Dillon J.A.;  
 RT "Organization of carbamoyl-phosphate synthase genes in Neisseria  
 RT gonorrhoeae includes a large, variable intergenic sequence which is  
 RT also present in other Neisseria species."  
 RL Microbiology 141:0-0(0).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=MS11, and FA1090;  
 RA Brinkman F.S.L., Francis F.M., Dillon J.R.;  
 RT "Complexity of the variable sequence between the carbamoyl-phosphate  
 RT synthase genes of Neisseria species."  
 RL Submitted (OCT-1997) to the EMBL/GenBank/DDBJ databases.  
 DR EMBL; AF029363; AAC78453.1; -.  
 DR EMBL; AF029362; AAC78452.1; -.

FT NON\_TER 1 1  
SQ SEQUENCE 11 AA; 1178 MW; 0C07A8E3DDD33694 CRC64;

Query Match 18.2%; Score 2; DB 2; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AK 2  
||  
Db 8 AK 9

RESULT 24

Q14759

ID Q14759 PRELIMINARY; PRT; 11 AA.  
AC Q14759;  
DT 01-NOV-1996 (TrEMBLrel. 01, Created)  
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)  
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
DE Lymphocyte cytosolic protein 2 (Fragment).  
GN LCP2.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Sunden S.L.F., Carr L.L., Clements J.L., Motto D.G., Koretzky G.A.;  
RT "Polymorphism in and localization of the gene encoding the 76 kDa SH2  
RT domain-containing Leukocyte Protein (SLP-76) to chromosome 5q33.1-  
RT qter.";  
RL Genomics 0:0-0(1995).  
DR EMBL; U44065; AAA93308.1; -.  
FT NON\_TER 1 1  
FT NON\_TER 11 11  
SQ SEQUENCE 11 AA; 1242 MW; D695104224072DDD CRC64;

Query Match 18.2%; Score 2; DB 4; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 RK 5  
||  
Db 7 RK 8

RESULT 25

Q9UCP2

ID Q9UCP2 PRELIMINARY; PRT; 11 AA.  
AC Q9UCP2;  
DT 01-MAY-2000 (TrEMBLrel. 13, Created)  
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)  
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)  
DE cGMP-inhibited LOW K(M) cAMP phosphodiesterase PEAK 43, CGI-PDE  
DE (Fragment).  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE.  
 RX MEDLINE=92283180; PubMed=1317779;  
 RA LeBon T.R., Kasuya J., Paxton R.J., Belfrage P., Hockman S.,  
 RA Manganiello V.C., Fujita Yamaguchi Y.;  
 RT "Purification and characterization of guanosine 3',5'-monophosphate-  
 RT inhibited low K(m) adenosine 3',5'-monophosphate phosphodiesterase  
 RT from human placental cytosolic fractions.";  
 RL Endocrinology 130:3265-3274(1992).  
 DR GO; GO:0005829; C:cytosol; TAS.  
 DR GO; GO:0004115; F:cAMP-specific phosphodiesterase activity; TAS.  
 DR GO; GO:0007165; P:signal transduction; NAS.  
 FT NON\_TER 1 1  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1220 MW; 7DF1FDF2D44735BB CRC64;

Query Match 18.2%; Score 2; DB 4; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 SL 10  
 ||  
 Db 1 SL 2

# RESULT 26

Q9Y3G2

ID Q9Y3G2 PRELIMINARY; PRT; 11 AA.  
 AC Q9Y3G2;  
 DT 01-NOV-1999 (TrEMBLrel. 12, Created)  
 DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)  
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)  
 DE LSFR2 protein (Fragment).  
 GN LSFR2.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=99299247; PubMed=10369878;  
 RA Gilley J., Fried M.;  
 RT "Extensive gene order differences within regions of conserved synten  
 RT between the Fugu and human genomes: implications for chromosomal  
 RT volution and the cloning of disease genes.";  
 RL Hum. Mol. Genet. 8:1313-1320(1999).  
 DR EMBL; Y17456; CAB44349.1; -.  
 FT NON\_TER 1 1  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1342 MW; 68C5E5D7A8772324 CRC64;

Query Match 18.2%; Score 2; DB 4; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 RK 5  
||  
Db 4 RK 5

RESULT 27

Q16427

ID Q16427 PRELIMINARY; PRT; 11 AA.  
AC Q16427;  
DT 01-NOV-1996 (TrEMBLrel. 01, Created)  
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)  
DT 01-MAY-1999 (TrEMBLrel. 10, Last annotation update)  
DE Dystrophin protein (Fragment).  
GN DYSTROPHIN.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=96163501; PubMed=8566960;  
RA Holder E., Maeda M., Bies R.D.;  
RT "Expression and regulation of the dystrophin Purkinje promoter in  
RT human skeletal muscle, heart, and brain."  
RL Hum. Genet. 97:232-239(1996).  
DR EMBL; S81419; AAD14362.1; -.  
FT NON\_TER 11 11  
SQ SEQUENCE 11 AA; 1299 MW; DDCC84321AB5A5A2 CRC64;

Query Match 18.2%; Score 2; DB 4; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SS 9  
||  
Db 5 SS 6

RESULT 28

O75811

ID O75811 PRELIMINARY; PRT; 11 AA.  
AC O75811;  
DT 01-NOV-1998 (TrEMBLrel. 08, Created)  
DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)  
DT 01-NOV-1998 (TrEMBLrel. 08, Last annotation update)  
DE ErbB-3 R2 (Fragment).  
GN C-ERBB-3.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Ovarian carcinoma;  
RX MEDLINE=98345147; PubMed=9681822;  
RA Lee H., Maihle N.J.;  
RT "Isolation and characterization of four alternate c-erbB3 transcripts

RT expressed in ovarian carcinoma-derived cell lines and normal human  
RT tissues.";  
RL Oncogene 16:3243-3252(1998).  
DR EMBL; U88358; AAC39858.1; -.  
FT NON\_TER 1 1  
SQ SEQUENCE 11 AA; 1017 MW; 21B236366EB72878 CRC64;

Query Match 18.2%; Score 2; DB 4; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5 KG 6  
||  
Db 9 KG 10

RESULT 29

O94785

ID O94785 PRELIMINARY; PRT; 11 AA.  
AC O94785;  
DT 01-MAY-1999 (TrEMBLrel. 10, Created)  
DT 01-MAY-1999 (TrEMBLrel. 10, Last sequence update)  
DT 01-MAY-1999 (TrEMBLrel. 10, Last annotation update)  
DE Thrombopoietin (Fragment).  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Sasaki Y., Takahashi T., Nakamura K., Okuno Y., Nakao K.;  
RT "Production of Thrombopoietin by Human Carcinomas and Its Novel mRNA  
RT Isoforms.";  
RL Submitted (MAY-1998) to the EMBL/GenBank/DDBJ databases.  
DR EMBL; AB014683; BAA34932.1; -.  
FT NON\_TER 1 1  
SQ SEQUENCE 11 AA; 1203 MW; 5FE19F44B6C1A877 CRC64;

Query Match 18.2%; Score 2; DB 4; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 9 SL 10  
||  
Db 2 SL 3

RESULT 30

Q16234

ID Q16234 PRELIMINARY; PRT; 11 AA.  
AC Q16234;  
DT 01-NOV-1996 (TrEMBLrel. 01, Created)  
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)  
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)  
DE HuD protein (Fragment).  
GN HUD.  
OS Homo sapiens (Human).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=94349312; PubMed=8069866;  
 RA Sekido Y., Bader S.A., Carbone D.P., Johnson B.E., Minna J.D.;  
 RT "Molecular analysis of the HuD gene encoding a paraneoplastic  
 RT encephalomyelitis antigen in human lung cancer cell lines."  
 RL Cancer Res. 54:4988-4992(1994).  
 DR EMBL; S73887; AAD14142.1; -.  
 DR PIR; I52708; I52708.  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1289 MW; 2EDCF20E204415A7 CRC64;

Query Match 18.2%; Score 2; DB 4; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SR 4  
 ||  
 Db 5 SR 6

# RESULT 31

Q8NI03

ID Q8NI03 PRELIMINARY; PRT; 11 AA.  
 AC Q8NI03;  
 DT 01-OCT-2002 (TrEMBLrel. 22, Created)  
 DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)  
 DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)  
 DE 25 hydroxyvitamin d3 1-alpha hydroxylase (Fragment).  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RA Ebert R., Schneider D., Jovanovic M., Adamski J., Jakob F.;  
 RL Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.  
 DR EMBL; AF500480; AAM21669.1; -.  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1298 MW; 82C14E84CB533731 CRC64;

Query Match 18.2%; Score 2; DB 4; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SR 4  
 ||  
 Db 9 SR 10

# RESULT 32

Q8TDA8

ID Q8TDA8 PRELIMINARY; PRT; 11 AA.  
 AC Q8TDA8;



DT 01-JUN-2002 (TrEMBLrel. 21, Created)  
 DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)  
 DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)  
 DE Glutathione synthetase (Fragment).  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RA Cho Y.-W., Lee Y.-Y., Lim C.-J.;  
 RT "Cloning and characterization of glutathione synthetase gene from  
 RT human placenta DNA.";  
 RL Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases.  
 DR EMBL; AF485789; AAL91591.1; -.  
 FT NON TER 11 11  
 SQ SEQUENCE 11 AA; 1235 MW; 1CE28D1E35B86374 CRC64;

Query Match 18.2%; Score 2; DB 4; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 SL 10  
 ||  
 Db 7 SL 8

# RESULT 33

## Q9UAR8

ID Q9UAR8 PRELIMINARY; PRT; 11 AA.  
 AC Q9UAR8;  
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)  
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)  
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)  
 DE Sialokinin I preproprotein (Fragment).  
 OS Aedes aegypti (Yellowfever mosquito).  
 OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
 OC Neoptera; Endopterygota; Diptera; Nematocera; Culicoidea; Aedes.  
 OX NCBI\_TaxID=7159;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=Rockefeller/Red; TISSUE=Salivary gland;  
 RX MEDLINE=20099025; PubMed=10620041;  
 RA Beerntsen B.T., Champagne D.E., Coleman J.L., Campos Y.A., James A.A.;  
 RT "Characterization of the Sialokinin I gene encoding the salivary  
 RT vasodilator of the yellow fever mosquito, Aedes aegypti.";  
 RL Insect Mol. Biol. 8:459-467(1999).  
 DR EMBL; AF108100; AAD16884.1; -.  
 DR GO; GO:0007268; P:synaptic transmission; IEA.  
 DR GO; GO:0007217; P:tachykinin signaling pathway; IEA.  
 DR InterPro; IPR002040; Tachy\_Neurokinin.  
 DR PROSITE; PS00267; TACHYKININ; 1.  
 FT NON TER 1 1  
 SQ SEQUENCE 11 AA; 1203 MW; 8BAD77C6B59C33A CRC64;

Query Match 18.2%; Score 2; DB 5; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 LM 11  
||  
Db 9 LM 10

RESULT 34

Q26092

ID Q26092 PRELIMINARY; PRT; 11 AA.  
AC Q26092;  
DT 01-NOV-1996 (TrEMBLrel. 01, Created)  
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)  
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
DE Sea StAR histone H2B gene 5'region (Fragment).  
OS Pisaster ochraceus (Sea star).  
OC Eukaryota; Metazoa; Echinodermata; Eleutherozoa; Asterozoa;  
OC Asteroidea; Forcipulatacea; Forcipulatida; Asteriidae; Pisaster.  
OX NCBI\_TaxID=7612;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Sperm;  
RA Howell A.M., Cool D., Hewitt J., Ydenberg B., Smith M.J., Honda B.M.;  
RT "Organization and Unusual Expression of Histone Genes in the Sea Star  
RT Pisaster ochraceus.";  
RL J. Mol. Evol. 25:29-36(1987).  
DR EMBL; X05619; CAA29106.1; -.  
FT NON\_TER 11 11  
SQ SEQUENCE 11 AA; 1128 MW; 5173974A3865BDD3 CRC64;

Query Match 18.2%; Score 2; DB 5; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 KG 6.  
||  
Db 8 KG 9

RESULT 35

Q9TWX6

ID Q9TWX6 PRELIMINARY; PRT; 11 AA.  
AC Q9TWX6;  
DT 01-MAY-2000 (TrEMBLrel. 13, Created)  
DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)  
DT 01-JUN-2002 (TrEMBLrel. 21, Last annotation update)  
DE Juvenile hormone binding protein, JHBP=12.5 kDa CNBR peptide  
DE (Fragment).  
OS Manduca sexta (Tobacco hawkmoth) (Tobacco hornworm).  
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
OC Neoptera; Endopterygota; Lepidoptera; Glossata; Ditrysia; Sphingioidea;  
OC Sphingidae; Sphinginae; Manduca.  
OX NCBI\_TaxID=7130;  
RN [1]  
RP SEQUENCE.  
RX MEDLINE=92134256; PubMed=1734862;  
RA Touhara K., Prestwich G.D.;

RT "Binding site mapping of a photoaffinity-labeled juvenile hormone  
 RT binding protein.";  
 RL Biochem. Biophys. Res. Commun. 182:466-473(1992).  
 FT NON\_TER 1 1  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1071 MW; D232A98E705045BD CRC64;

Query Match 18.2%; Score 2; DB 5; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 AK 2  
 ||  
 Db 10 AK 11

RESULT 36

Q99292

ID Q99292 PRELIMINARY; PRT; 11 AA.  
 AC Q99292;  
 DT 01-NOV-1996 (TrEMBLrel. 01, Created)  
 DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)  
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)  
 DE Bicoid protein (Fragment).  
 GN BCD.  
 OS Drosophila heteroneura (Fruit fly).  
 OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
 OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;  
 OC Ephydroidea; Drosophilidae; Drosophila.  
 OX NCBI\_TaxID=32382;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=91184004; PubMed=2081457;  
 RA MacDonald P.M.;  
 RT "bicoid mRNA localization signal: phylogenetic conservation of  
 RT function and RNA secondary structure.";  
 RL Development 110:161-171(1990).  
 CC -!- FUNCTION: BICOID IS SEGMENT-POLARITY PROTEIN THAT PROVIDES  
 CC POSITIONAL CUES FOR THE DEVELOPMENT OF HEAD AND THORACIC SEGMENTS.  
 CC BCD REGULATES THE EXPRESSION OF ZYGOTIC GENES, POSSIBLY THROUGH  
 CC ITS HOMEODOMAIN, AND INHIBITS THE ACTIVITY OF OTHER MATERNAL GENE  
 CC PRODUCTS. IT IS POSSIBLE THAT BCD ALSO BINDS RNA.  
 DR EMBL; M32125; AAA28386.1; -.  
 DR FlyBase; FBgn0012352; Dhet\bcd.  
 DR GO; GO:0005634; C:nucleus; IEA.  
 DR GO; GO:0003677; F:DNA binding; IEA.  
 DR GO; GO:0003723; F:RNA binding; IEA.  
 DR GO; GO:0007275; P:development; IEA.  
 DR GO; GO:0006355; P:regulation of transcription, DNA-dependent; IEA.  
 DR GO; GO:0007367; P:segment polarity determination; IEA.  
 KW DNA-binding; Developmental protein; Homeobox; Nuclear protein;  
 KW RNA-binding; Segmentation polarity protein; Transcription regulation.  
 FT NON\_TER 1 1  
 SQ SEQUENCE 11 AA; 1221 MW; 8CE802305DD9D6C1 CRC64;

Query Match 18.2%; Score 2; DB 5; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 GN 7  
||  
Db 2 GN 3

RESULT 37

Q25916

ID Q25916 PRELIMINARY; PRT; 11 AA.  
AC Q25916;  
DT 01-NOV-1996 (TrEMBLrel. 01, Created)  
DT 01-NOV-1996 (TrEMBLrel. 01, Last sequence update)  
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
DE Malaria antigen (7H8/2) (Fragment).  
OS Plasmodium falciparum.  
OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.  
OX NCBI\_TaxID=5833;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=91164876; PubMed=1706114;  
RA Limpiaiboon T., Taylor D., Jones G., Geysen H.M., Saul A.;  
RT "Characterization of a Plasmodium falciparum epitope recognized by a  
RT monoclonal antibody with broad isolate and species specificity.";  
RL Southeast Asian J. Trop. Med. Public Health 21:388-396(1990).  
DR EMBL; M31305; AAA29645.1; -.  
FT NON\_TER 1 1  
SQ SEQUENCE 11 AA; 1415 MW; DB03D3BC42C33699 CRC64;

Query Match 18.2%; Score 2; DB 5; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 KS 3  
||  
Db 1 KS 2

RESULT 38

Q9NFX0

ID Q9NFX0 PRELIMINARY; PRT; 11 AA.  
AC Q9NFX0;  
DT 01-OCT-2000 (TrEMBLrel. 15, Created)  
DT 01-OCT-2000 (TrEMBLrel. 15, Last sequence update)  
DT 01-JUN-2001 (TrEMBLrel. 17, Last annotation update)  
DE Mitochondrial aconitase (Fragment).  
GN ACON OR MAC OR CG9244.  
OS Drosophila melanogaster (Fruit fly).  
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;  
OC Ephydroidea; Drosophilidae; Drosophila.  
OX NCBI\_TaxID=7227;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=CANTON S;  
RA Lind M.I.;  
RT "Charaterisation of two iron regulatory proteins and mitochondrial

RT aconitase in *Drosophila melanogaster*.";  
RL Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases.  
DR EMBL; AJ252019; CAB93522.1; -.  
DR FlyBase; FBgn0010100; Acon.  
FT NON\_TER 11 11  
SQ SEQUENCE 11 AA; 1204 MW; 7C889CE4D4469734 CRC64;

Query Match 18.2%; Score 2; DB 5; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 LM 11  
||  
Db 5 LM 6

RESULT 39

Q8MPQ3

ID Q8MPQ3 PRELIMINARY; PRT; 11 AA.  
AC Q8MPQ3;  
DT 01-OCT-2002 (TrEMBLrel. 22, Created)  
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)  
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)  
DE Hypothetical protein Y23H5A.8b.  
GN Y23H5A.8.  
OS *Caenorhabditis elegans*.  
OC Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditoidea;  
OC Rhabditidae; Peloderinae; *Caenorhabditis*.  
OX NCBI\_TaxID=6239;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=Bristol N2;  
RX MEDLINE=99069613; PubMed=9851916;  
RA Waterston R.;  
RT "Genome sequence of the nematode *C. elegans*: a platform for  
RT investigating biology. The *C. elegans* Sequencing Consortium."  
RL Science 282:2012-2018(1998).  
RN [2]  
RP SEQUENCE FROM N.A.  
RC STRAIN=Bristol N2;  
RA Dempsey S., Le T.T.;  
RT "The sequence of *C. elegans* cosmid Y23H5A."  
RL Submitted (JUL-1998) to the EMBL/GenBank/DDBJ databases.  
RN [3]  
RP SEQUENCE FROM N.A.  
RC STRAIN=Bristol N2;  
RA Waterston R.;  
RL Submitted (JUN-2002) to the EMBL/GenBank/DDBJ databases.  
DR EMBL; AF077541; AAM54173.1; -.  
DR WormPep; Y23H5A.8b; CE31097.  
KW Hypothetical protein.  
SQ SEQUENCE 11 AA; 1319 MW; 6920D63A21B77414 CRC64;

Query Match 18.2%; Score 2; DB 5; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SR 4  
||  
Db 3 SR 4

RESULT 40

P82698

ID P82698 PRELIMINARY; PRT; 11 AA.  
AC P82698;  
DT 01-MAR-2001 (TrEMBLrel. 16, Created)  
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)  
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)  
DE Periviscerokinin-1 (LEM-PVK-1).  
OS Leucophaea maderae (Madeira cockroach),  
OS Nauphoeta cinerea (Cinereous cockroach) (Gray cockroach),  
OS Blaberus craniifer,  
OS Blaptica dubia, and  
OS Gromphadorina portentosa (Cockroach).  
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
OC Neoptera; Orthopteroidea; Dictyoptera; Blattaria; Blaberoidea;  
OC Blaberidae; Leucophaea.  
OX NCBI\_TaxID=6988, 6990, 6982, 132935, 36953;  
RN [1]  
RP SEQUENCE, FUNCTION, AND MASS SPECTROSCOPY.  
RC TISSUE=ABDOMINAL PERISYMPATHETIC ORGANS;  
RX MEDLINE=20307624; PubMed=10849006;  
RA Predel R., Kellner R., Baggerman G., Steinmetzer T., Schoofs L.;  
RT "Identification of novel periviscerokinins from single neurohaemal  
RT release sites in insects. MS/MS fragmentation complemented by Edman  
RT degradation.";  
RL Eur. J. Biochem. 267:3869-3873(2000).  
CC -!- FUNCTION: MEDIATES VISCERAL MUSCLE CONTRACTILE ACTIVITY  
CC (MYOTROPIC ACTIVITY).  
CC -!- MASS SPECTROMETRY: MW=1090.6; METHOD=MALDI.  
DR GO; GO:0007218; P:neuropeptide signaling pathway; IEA.  
KW Neuropeptide; Amidation.  
FT MOD\_RES 11 11 AMIDATION.  
SQ SEQUENCE 11 AA; 1091 MW; 2C2D80E2D7605728 CRC64;

Query Match 18.2%; Score 2; DB 5; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SS 9  
||  
Db 2 SS 3

RESULT 41

P82699

ID P82699 PRELIMINARY; PRT; 11 AA.  
AC P82699;  
DT 01-MAR-2001 (TrEMBLrel. 16, Created)  
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)  
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)  
DE Periviscerokinin-2 (LEM-PVK-2).  
OS Leucophaea maderae (Madeira cockroach),

OS Nauphoeta cinerea (Cinereous cockroach) (Gray cockroach),  
 OS Blaberus craniifer,  
 OS Blaptica dubia, and  
 OS Gromphadorina portentosa (Cockroach).  
 OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
 OC Neoptera; Orthopteroidea; Dictyoptera; Blattaria; Blaberoidea;  
 OC Blaberidae; Leucophaea.  
 OX NCBI\_TaxID=6988, 6990, 6982, 132935, 36953;  
 RN [1]  
 RP SEQUENCE, FUNCTION, AND MASS SPECTROSCOPY.  
 RC TISSUE=ABDOMINAL PERISYMPATHETIC ORGANS;  
 RX MEDLINE=20307624; PubMed=10849006;  
 RA Predel R., Kellner R., Baggerman G., Steinmetzer T., Schoofs L.;  
 RT "Identification of novel periviscerokinins from single neurohaemal  
 RT release sites in insects. MS/MS fragmentation complemented by Edman  
 RT degradation.";  
 RL Eur. J. Biochem. 267:3869-3873(2000).  
 CC -!- FUNCTION: MEDIATES VISCERAL MUSCLE CONTRACTILE ACTIVITY  
 CC (MYOTROPIC ACTIVITY).  
 CC -!- MASS SPECTROMETRY: MW=1102.6; METHOD=MALDI.  
 DR GO; GO:0007218; P:neuropeptide signaling pathway; IEA.  
 KW Neuropeptide; Amidation.  
 FT MOD\_RES 11 11 AMIDATION.  
 SQ SEQUENCE 11 AA; 1103 MW; 2F4D9FFD85B05728 CRC64;

Query Match 18.2%; Score 2; DB 5; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SS 9  
 ||  
 Db 2 SS 3

#### RESULT 42

P82700

ID P82700 PRELIMINARY; PRT; 11 AA.  
 AC P82700;  
 DT 01-MAR-2001 (TrEMBLrel. 16, Created)  
 DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)  
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)  
 DE Periviscerokinin-3 (LEM-PVK-3).  
 OS Leucophaea maderae (Madeira cockroach),  
 OS Nauphoeta cinerea (Cinereous cockroach) (Gray cockroach),  
 OS Blaberus craniifer,  
 OS Blaptica dubia (Argentinian wood cockroach), and  
 OS Gromphadorina portentosa (Cockroach).  
 OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
 OC Neoptera; Orthopteroidea; Dictyoptera; Blattaria; Blaberoidea;  
 OC Blaberidae; Leucophaea.  
 OX NCBI\_TaxID=6988, 6990, 6982, 132935, 36953;  
 RN [1]  
 RP SEQUENCE, FUNCTION, AND MASS SPECTROSCOPY.  
 RC TISSUE=ABDOMINAL PERISYMPATHETIC ORGANS;  
 RX MEDLINE=20307624; PubMed=10849006;  
 RA Predel R., Kellner R., Baggerman G., Steinmetzer T., Schoofs L.;  
 RT "Identification of novel periviscerokinins from single neurohaemal

RT release sites in insects. MS/MS fragmentation complemented by Edman  
 RT degradation.";  
 RL Eur. J. Biochem. 267:3869-3873(2000).  
 CC -!- FUNCTION: MEDIATES VISCERAL MUSCLE CONTRACTILE ACTIVITY  
 CC (MYOTROPIC ACTIVITY).  
 CC -!- MASS SPECTROMETRY: MW=1146.6; METHOD=MALDI.  
 DR GO; GO:0007218; P:neuropeptide signaling pathway; IEA.  
 KW Neuropeptide; Amidation.  
 FT MOD RES 11 11 AMIDATION.  
 SQ SEQUENCE 11 AA; 1147 MW; 2F4D9FF2D7605698 CRC64;

Query Match 18.2%; Score 2; DB 5; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 SS 9  
 ||  
 Db 2 SS 3

#### RESULT 43

Q9XSP7

ID Q9XSP7 PRELIMINARY; PRT; 11 AA.  
 AC Q9XSP7;  
 DT 01-NOV-1999 (TrEMBLrel. 12, Created)  
 DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)  
 DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
 DE Platelet-derived growth factor A chain (Fragment).  
 GN PDGFA.  
 OS Pygathrix nemaeus (Dove langur).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Cercopithecidae; Colobinae;  
 OC Pygathrix.  
 OX NCBI\_TaxID=54133;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=20065871; PubMed=10598812;  
 RA Bonthron D.T., Smith S.L., Campbell R.;  
 RT "Complex patterns of intragenic polymorphism at the PDGFA locus."  
 RL Hum. Genet. 105:452-459(1999).  
 DR EMBL; AJ243282; CAB45924.1; -.  
 FT NON\_TER 1 1  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1345 MW; 7FB881F101E1E044 CRC64;

Query Match 18.2%; Score 2; DB 6; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SR 4  
 ||  
 Db 3 SR 4

#### RESULT 44

Q9XSP2

ID Q9XSP2 PRELIMINARY; PRT; 11 AA.



AC Q9XSP2;  
 DT 01-NOV-1999 (TrEMBLrel. 12, Created)  
 DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)  
 DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
 DE Platelet-derived growth factor A chain (Fragment).  
 GN PDGFA.  
 OS Hylobates syndactylus (Siamang) (Symphalangus syndactylus).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hylobatidae; Hylobates.  
 OX NCBI\_TaxID=9590;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=20065871; PubMed=10598812;  
 RA Bonthron D.T., Smith S.L., Campbell R.;  
 RT "Complex patterns of intragenic polymorphism at the PDGFA locus."  
 RL Hum. Genet. 105:452-459(1999).  
 DR EMBL; AJ243280; CAB45927.1; -.  
 FT NON\_TER 1 1  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1345 MW; 7FB881F101E1E044 CRC64;

Query Match 18.2%; Score 2; DB 6; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 SR 4  
 ||  
 Db 3 SR 4

#### RESULT 45

##### Q9TRX2

ID Q9TRX2 PRELIMINARY; PRT; 11 AA.  
 AC Q9TRX2;  
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)  
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)  
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)  
 DE Glutamate dehydrogenase (EC 1.4.1.3) (Fragment).  
 OS Bos taurus (Bovine).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovoidea;  
 OC Bovidae; Bovinae; Bos.  
 OX NCBI\_TaxID=9913;  
 RN [1]  
 RP SEQUENCE.  
 RX MEDLINE=91308094; PubMed=1854724;  
 RA Ozturk D.H., Colman R.F.;  
 RT "Identification of cysteine-319 as the target amino acid of 8-[(4-bromo-2,3-dioxobutyl)thio]adenosine 5'-triphosphate in bovine liver glutamate dehydrogenase."  
 RL Biochemistry 30:7126-7134(1991).  
 DR GO; GO:0004353; F:glutamate dehydrogenase [NAD(P)] activity; IEA.  
 SQ SEQUENCE 11 AA; 1207 MW; F46BF756A771B401 CRC64;

Query Match 18.2%; Score 2; DB 6; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 KG 6  
||  
Db 9 KG 10

RESULT 46

Q9XSP5

ID Q9XSP5 PRELIMINARY; PRT; 11 AA.  
AC Q9XSP5;  
DT 01-NOV-1999 (TrEMBLrel. 12, Created)  
DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)  
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
DE Platelet-derived growth factor A chain (Fragment).  
GN PDGFA.  
OS Pan troglodytes (Chimpanzee).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pan.  
OX NCBI\_TaxID=9598;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=20065871; PubMed=10598812;  
RA Bonthron D.T., Smith S.L., Campbell R.;  
RT "Complex patterns of intragenic polymorphism at the PDGFA locus."  
RL Hum. Genet. 105:452-459(1999).  
DR EMBL; AJ243277; CAB45926.1; -.  
FT NON\_TER 1 1  
FT NON\_TER 11 11  
SQ SEQUENCE 11 AA; 1331 MW; 7FB881F101E1F2D4 CRC64;

Query Match 18.2%; Score 2; DB 6; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SR 4  
||  
Db 3 SR 4

RESULT 47

Q9XSP8

ID Q9XSP8 PRELIMINARY; PRT; 11 AA.  
AC Q9XSP8;  
DT 01-NOV-1999 (TrEMBLrel. 12, Created)  
DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)  
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
DE Platelet-derived growth factor A chain (Fragment).  
GN PDGFA.  
OS Presbytis johnii.  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Cercopithecidae; Colobinae;  
OC Presbytis.  
OX NCBI\_TaxID=98375;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=20065871; PubMed=10598812;  
RA Bonthron D.T., Smith S.L., Campbell R.;

RT "Complex patterns of intragenic polymorphism at the PDGFA locus."  
 RL Hum. Genet. 105:452-459(1999).  
 DR EMBL; AJ243281; CAB46013.1; -.  
 FT NON\_TER 1 1  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1345 MW; 7FB881F101E1E044 CRC64;

Query Match 18.2%; Score 2; DB 6; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 SR 4  
 ||  
 Db 3 SR 4

#### RESULT 48

Q9XSP6

ID Q9XSP6 PRELIMINARY; PRT; 11 AA.  
 AC Q9XSP6;  
 DT 01-NOV-1999 (TrEMBLrel. 12, Created)  
 DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)  
 DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
 DE Platelet-derived growth factor A chain (Fragment).  
 GN PDGFA.  
 OS Pongo pygmaeus (Orangutan).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pongo.  
 OX NCBI\_TaxID=9600;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=20065871; PubMed=10598812;  
 RA Bonthron D.T., Smith S.L., Campbell R.;  
 RT "Complex patterns of intragenic polymorphism at the PDGFA locus."  
 RL Hum. Genet. 105:452-459(1999).  
 DR EMBL; AJ243279; CAB45925.1; -.  
 FT NON\_TER 1 1  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1345 MW; 7FB881F101E1E044 CRC64;

Query Match 18.2%; Score 2; DB 6; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 SR 4  
 ||  
 Db 3 SR 4

#### RESULT 49

Q9XSQ4

ID Q9XSQ4 PRELIMINARY; PRT; 11 AA.  
 AC Q9XSQ4;  
 DT 01-NOV-1999 (TrEMBLrel. 12, Created)  
 DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)  
 DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
 DE Platelet-derived growth factor A chain (Fragment).

GN PDGFA.  
 OS Gorilla gorilla (gorilla).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Gorilla.  
 OX NCBI\_TaxID=9593;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=20065871; PubMed=10598812;  
 RA Bonthron D.T., Smith S.L., Campbell R.;  
 RT "Complex patterns of intragenic polymorphism at the PDGFA locus."  
 RL Hum. Genet. 105:452-459(1999).  
 DR EMBL; AJ243278; CAB45916.1; -.  
 FT NON\_TER 1 1  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1331 MW; 7FB881F101E1F2D4 CRC64;

Query Match 18.2%; Score 2; DB 6; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SR 4  
 ||  
 Db 3 SR 4

#### RESULT 50

O77900

ID O77900 PRELIMINARY; PRT; 11 AA.  
 AC O77900;  
 DT 01-NOV-1998 (TrEMBLrel. 08, Created)  
 DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)  
 DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
 DE MHC class II B locus 14 (Fragment).  
 OS Oreochromis niloticus (Nile tilapia) (Tilapia nilotica).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;  
 OC Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes; Labroidae;  
 OC Cichlidae; Oreochromis.  
 OX NCBI\_TaxID=8128;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=98315113; PubMed=9649539;  
 RA Malaga-Trillo E., Zaleska-Rutczynska Z., McAndrew B., Vincek V.,  
 RA Figueroa F., Sultmann H., Klein J.;  
 RT "Linkage relationships and haplotype polymorphism among cichlid mhc  
 class II B loci."  
 RL Genetics 149:1527-1537(1998).  
 DR EMBL; AF050010; AAC41349.1; -.  
 FT NON\_TER 1 1  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1349 MW; 81C12D8EB7341B41 CRC64;

Query Match 18.2%; Score 2; DB 7; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SR 4

Db                    ||  
                      8 SR 9

RESULT 51

O77917

ID    O77917            PRELIMINARY;            PRT;       11 AA.  
AC    O77917;  
DT    01-NOV-1998 (TrEMBLrel. 08, Created)  
DT    01-NOV-1998 (TrEMBLrel. 08, Last sequence update)  
DT    01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
DE    MHC class II B locus 14 (Fragment).  
OS    Oreochromis niloticus (Nile tilapia) (Tilapia nilotica).  
OC    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC    Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;  
OC    Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes; Labroidei;  
OC    Cichlidae; Oreochromis.  
OX    NCBI\_TaxID=8128;  
RN    [1]  
RP    SEQUENCE FROM N.A.  
RX    MEDLINE=98315113; PubMed=9649539;  
RA    Malaga-Trillo E., Zaleska-Rutczynska Z., McAndrew B., Vincek V.,  
RA    Figueroa F., Sultmann H., Klein J.;  
RT    "Linkage relationships and haplotype polymorphism among cichlid mhc  
RT    class II B loci."  
RL    Genetics 149:1527-1537(1998).  
DR    EMBL; AF050030; AAC41369.1; -.  
FT    NON\_TER           1           1  
FT    NON\_TER           11          11  
SQ    SEQUENCE       11 AA;    1349 MW;    81C12D8EB7341B41 CRC64;

Query Match                    18.2%;    Score 2;    DB 7;    Length 11;  
Best Local Similarity       100.0%;    Pred. No. 1.1e+05;  
Matches       2;    Conservative       0;    Mismatches       0;    Indels       0;    Gaps       0;

Qy                    3 SR 4  
                      ||  
Db                    8 SR 9

RESULT 52

O77902

ID    O77902            PRELIMINARY;            PRT;       11 AA.  
AC    O77902;  
DT    01-NOV-1998 (TrEMBLrel. 08, Created)  
DT    01-NOV-1998 (TrEMBLrel. 08, Last sequence update)  
DT    01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
DE    MHC class II B locus 14 (Fragment).  
OS    Oreochromis niloticus (Nile tilapia) (Tilapia nilotica).  
OC    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC    Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;  
OC    Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes; Labroidei;  
OC    Cichlidae; Oreochromis.  
OX    NCBI\_TaxID=8128;  
RN    [1]  
RP    SEQUENCE FROM N.A.  
RX    MEDLINE=98315113; PubMed=9649539;

RA Malaga-Trillo E., Zaleska-Rutczynska Z., McAndrew B., Vincek V.,  
 RA Figueroa F., Sultmann H., Klein J.;  
 RT "Linkage relationships and haplotype polymorphism among cichlid mhc  
 RT class II B loci.";  
 RL Genetics 149:1527-1537(1998).  
 DR EMBL; AF050012; AAC41351.1; -.  
 FT NON\_TER 1 1  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1349 MW; 81C12D8EB7341B41 CRC64;

Query Match 18.2%; Score 2; DB 7; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SR 4  
 ||  
 Db 8 SR 9

# RESULT 53

077921

ID 077921 PRELIMINARY; PRT; 11 AA.  
 AC 077921;  
 DT 01-NOV-1998 (TrEMBLrel. 08, Created)  
 DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)  
 DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
 DE MHC class II B locus 14 (Fragment).  
 OS Pseudotropheus sp. 'Pseudotropheus tropheops complex'.  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;  
 OC Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes; Labroidei;  
 OC Cichlidae; Pseudotropheus.  
 OX NCBI\_TaxID=51796;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=98315113; PubMed=9649539;  
 RA Malaga-Trillo E., Zaleska-Rutczynska Z., McAndrew B., Vincek V.,  
 RA Figueroa F., Sultmann H., Klein J.;  
 RT "Linkage relationships and haplotype polymorphism among cichlid mhc  
 RT class II B loci.";  
 RL Genetics 149:1527-1537(1998).  
 DR EMBL; AF050034; AAC41373.1; -.  
 FT NON\_TER 1 1  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1349 MW; 81C12D8EB7341B41 CRC64;

Query Match 18.2%; Score 2; DB 7; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SR 4  
 ||  
 Db 8 SR 9

# RESULT 54

Q9TQB3

ID Q9TQB3 PRELIMINARY; PRT; 11 AA.  
 AC Q9TQB3;  
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)  
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)  
 DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
 DE MHC class I related protein 1 (Fragment).  
 GN MR1.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=98451457; PubMed=9780177;  
 RA Riegert P., Wanner V., Bahram S.;  
 RT "Genomics, isoforms, expression, and phylogeny of the MHC class I-  
 RT related MR1 gene.";  
 RL J. Immunol. 161:4066-4077(1998).  
 DR EMBL; AF039526; AAD02172.1; -.  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1235 MW; 5E71A31E29CDD697 CRC64;  
  
 Query Match 18.2%; Score 2; DB 7; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
 Qy 10 LM 11  
 ||  
 Db 4 LM 5

RESULT 55

O77901

ID O77901 PRELIMINARY; PRT; 11 AA.  
 AC O77901;  
 DT 01-NOV-1998 (TrEMBLrel. 08, Created)  
 DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)  
 DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
 DE MHC class II B locus 14 (Fragment).  
 OS Oreochromis niloticus (Nile tilapia) (Tilapia nilotica).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;  
 OC Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes; Labroidae;  
 OC Cichlidae; Oreochromis.  
 OX NCBI\_TaxID=8128;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=98315113; PubMed=9649539;  
 RA Malaga-Trillo E., Zaleska-Rutczynska Z., McAndrew B., Vincek V.,  
 RA Figueroa F., Sultmann H., Klein J.;  
 RT "Linkage relationships and haplotype polymorphism among cichlid mhc  
 RT class II B loci.";  
 RL Genetics 149:1527-1537(1998).  
 DR EMBL; AF050011; AAC41350.1; -.  
 FT NON\_TER 1 1  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1349 MW; 81C12D8EB7341B41 CRC64;

Query Match 18.2%; Score 2; DB 7; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SR 4  
||  
Db 8 SR 9

RESULT 56

077892

ID 077892 PRELIMINARY; PRT; 11 AA.  
AC 077892;  
DT 01-NOV-1998 (TrEMBLrel. 08, Created)  
DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)  
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
DE MHC class II B locus 10 (Fragment).  
OS Oreochromis niloticus (Nile tilapia) (Tilapia nilotica).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;  
OC Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes; Labroidei;  
OC Cichlidae; Oreochromis.  
OX NCBI\_TaxID=8128;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=98315113; PubMed=9649539;  
RA Malaga-Trillo E., Zaleska-Rutczynska Z., McAndrew B., Vincek V.,  
RA Figueroa F., Sultmann H., Klein J.;  
RT "Linkage relationships and haplotype polymorphism among cichlid mhc  
RT class II B loci.";  
RL Genetics 149:1527-1537(1998).  
DR EMBL; AF050002; AAC41341.1; -.  
FT NON\_TER 1 1  
FT NON\_TER 11 11  
SQ SEQUENCE 11 AA; 1277 MW; 74855B73786B572B CRC64;

Query Match 18.2%; Score 2; DB 7; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 SL 10  
||  
Db 9 SL 10

RESULT 57

077916

ID 077916 PRELIMINARY; PRT; 11 AA.  
AC 077916;  
DT 01-NOV-1998 (TrEMBLrel. 08, Created)  
DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)  
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
DE MHC class II B locus 14 (Fragment).  
OS Oreochromis niloticus (Nile tilapia) (Tilapia nilotica).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;



OC Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes; Labroidei;  
 OC Cichlidae; Oreochromis.  
 OX NCBI\_TaxID=8128;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=98315113; PubMed=9649539;  
 RA Malaga-Trillo E., Zaleska-Rutczynska Z., McAndrew B., Vincek V.,  
 RA Figueroa F., Sultmann H., Klein J.;  
 RT "Linkage relationships and haplotype polymorphism among cichlid mhc  
 RT class II B loci."  
 RL Genetics 149:1527-1537(1998).  
 DR EMBL; AF050029; AAC41368.1; -.  
 FT NON\_TER 1 1  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1349 MW; 81C12D8EB7341B41 CRC64;

Query Match 18.2%; Score 2; DB 7; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SR 4  
 ||  
 Db 8 SR 9

# RESULT 58

O77885

ID O77885 PRELIMINARY; PRT; 11 AA.  
 AC O77885;  
 DT 01-NOV-1998 (TrEMBLrel. 08, Created)  
 DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)  
 DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
 DE MHC class II B locus 4 (Fragment).  
 OS Oreochromis niloticus (Nile tilapia) (Tilapia nilotica).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;  
 OC Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes; Labroidei;  
 OC Cichlidae; Oreochromis.  
 OX NCBI\_TaxID=8128;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=98315113; PubMed=9649539;  
 RA Malaga-Trillo E., Zaleska-Rutczynska Z., McAndrew B., Vincek V.,  
 RA Figueroa F., Sultmann H., Klein J.;  
 RT "Linkage relationships and haplotype polymorphism among cichlid mhc  
 RT class II B loci."  
 RL Genetics 149:1527-1537(1998).  
 DR EMBL; AF049994; AAC41333.1; -.  
 FT NON\_TER 1 1  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1253 MW; 72325B701EA5B72B CRC64;

Query Match 18.2%; Score 2; DB 7; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 SL 10

Db            9 SL 10

RESULT 59

O77905

ID O77905            PRELIMINARY;            PRT;        11 AA.  
AC O77905;  
DT 01-NOV-1998 (TrEMBLrel. 08, Created)  
DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)  
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
DE MHC class II B locus 14 (Fragment).  
OS Oreochromis niloticus (Nile tilapia) (Tilapia nilotica).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;  
OC Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes; Labroidei;  
OC Cichlidae; Oreochromis.  
OX NCBI\_TaxID=8128;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=98315113; PubMed=9649539;  
RA Malaga-Trillo E., Zaleska-Rutczynska Z., McAndrew B., Vincek V.,  
RA Figueroa F., Sultmann H., Klein J.;  
RT "Linkage relationships and haplotype polymorphism among cichlid mhc  
RT class II B loci.";  
RL Genetics 149:1527-1537(1998).  
DR EMBL; AF050015; AAC41354.1; -.  
FT NON\_TER            1            1  
FT NON\_TER            11          11  
SQ SEQUENCE    11 AA;    1349 MW;    81C12D8EB7341B41 CRC64;

Query Match                    18.2%; Score 2; DB 7; Length 11;  
Best Local Similarity    100.0%; Pred. No. 1.1e+05;  
Matches        2; Conservative        0; Mismatches        0; Indels        0; Gaps        0;

Qy            3 SR 4  
              ||  
Db            8 SR 9

RESULT 60

O77884

ID O77884            PRELIMINARY;            PRT;        11 AA.  
AC O77884;  
DT 01-NOV-1998 (TrEMBLrel. 08, Created)  
DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)  
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
DE MHC class II B locus 4 (Fragment).  
OS Oreochromis niloticus (Nile tilapia) (Tilapia nilotica).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;  
OC Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes; Labroidei;  
OC Cichlidae; Oreochromis.  
OX NCBI\_TaxID=8128;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=98315113; PubMed=9649539;

RA Malaga-Trillo E., Zaleska-Rutczynska Z., McAndrew B., Vincek V.,  
 RA Figueroa F., Sultmann H., Klein J.;  
 RT "Linkage relationships and haplotype polymorphism among cichlid mhc  
 RT class II B loci.";  
 RL Genetics 149:1527-1537(1998).  
 DR EMBL; AF049993; AAC41332.1; -.  
 FT NON\_TER 1 1  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1253 MW; 72325B701EA5B72B CRC64;

Query Match 18.2%; Score 2; DB 7; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 SL 10  
 ||  
 Db 9 SL 10

RESULT 61  
 O77906

ID O77906 PRELIMINARY; PRT; 11 AA.  
 AC O77906;  
 DT 01-NOV-1998 (TrEMBLrel. 08, Created)  
 DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)  
 DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
 DE MHC class II B locus 1 (Fragment).  
 OS Oreochromis niloticus (Nile tilapia) (Tilapia nilotica).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;  
 OC Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes; Labroidei;  
 OC Cichlidae; Oreochromis.  
 OX NCBI\_TaxID=8128;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=98315113; PubMed=9649539;  
 RA Malaga-Trillo E., Zaleska-Rutczynska Z., McAndrew B., Vincek V.,  
 RA Figueroa F., Sultmann H., Klein J.;  
 RT "Linkage relationships and haplotype polymorphism among cichlid mhc  
 RT class II B loci.";  
 RL Genetics 149:1527-1537(1998).  
 DR EMBL; AF050016; AAC41355.1; -.  
 FT NON\_TER 1 1  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1277 MW; 74855B73786B572B CRC64;

Query Match 18.2%; Score 2; DB 7; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 SL 10  
 ||  
 Db 9 SL 10

RESULT 62  
 O77899

ID O77899 PRELIMINARY; PRT; 11 AA.  
AC O77899;  
DT 01-NOV-1998 (TrEMBLrel. 08, Created)  
DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)  
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
DE MHC class II B locus 14 (Fragment).  
OS Oreochromis niloticus (Nile tilapia) (Tilapia nilotica).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;  
OC Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes; Labroidae;  
OC Cichlidae; Oreochromis.  
OX NCBI\_TaxID=8128;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=98315113; PubMed=9649539;  
RA Malaga-Trillo E., Zaleska-Rutczynska Z., McAndrew B., Vincek V.,  
RA Figueroa F., Sultmann H., Klein J.;  
RT "Linkage relationships and haplotype polymorphism among cichlid mhc  
RT class II B loci.";  
RL Genetics 149:1527-1537(1998).  
DR EMBL; AF050009; AAC41348.1; -.  
FT NON\_TER 1 1  
FT NON\_TER 11 11  
SQ SEQUENCE 11 AA; 1349 MW; 81C12D8EB7341B41 CRC64;

Query Match 18.2%; Score 2; DB 7; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SR 4  
||  
Db 8 SR 9

# RESULT 63

O77918

ID O77918 PRELIMINARY; PRT; 11 AA.  
AC O77918;  
DT 01-NOV-1998 (TrEMBLrel. 08, Created)  
DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)  
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
DE MHC class II B locus 1 (Fragment).  
OS Pseudotropheus sp. 'Pseudotropheus tropheops complex'.  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;  
OC Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes; Labroidae;  
OC Cichlidae; Pseudotropheus.  
OX NCBI\_TaxID=51796;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=98315113; PubMed=9649539;  
RA Malaga-Trillo E., Zaleska-Rutczynska Z., McAndrew B., Vincek V.,  
RA Figueroa F., Sultmann H., Klein J.;  
RT "Linkage relationships and haplotype polymorphism among cichlid mhc  
RT class II B loci.";  
RL Genetics 149:1527-1537(1998).  
DR EMBL; AF050031; AAC41370.1; -.

FT NON\_TER 1 1  
FT NON\_TER 11 11  
SQ SEQUENCE 11 AA; 1320 MW; 74855B69C86B572B CRC64;

Query Match 18.2%; Score 2; DB 7; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 SL 10  
||  
Db 9 SL 10

RESULT 64

O77893

ID O77893 PRELIMINARY; PRT; 11 AA.  
AC O77893;  
DT 01-NOV-1998 (TrEMBLrel. 08, Created)  
DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)  
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
DE MHC class II B locus 10 (Fragment).  
OS Oreochromis niloticus (Nile tilapia) (Tilapia nilotica).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;  
OC Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes; Labroidae;  
OC Cichlidae; Oreochromis.  
OX NCBI\_TaxID=8128;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=98315113; PubMed=9649539;  
RA Malaga-Trillo E., Zaleska-Rutczynska Z., McAndrew B., Vincek V.,  
RA Figueroa F., Sultmann H., Klein J.;  
RT "Linkage relationships and haplotype polymorphism among cichlid mhc  
RT class II B loci."  
RL Genetics 149:1527-1537(1998).  
DR EMBL; AF050003; AAC41342.1; -.  
FT NON\_TER 1 1  
FT NON\_TER 11 11  
SQ SEQUENCE 11 AA; 1296 MW; 68775B73786B572B CRC64;

Query Match 18.2%; Score 2; DB 7; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 SL 10  
||  
Db 9 SL 10

RESULT 65

O78121

ID O78121 PRELIMINARY; PRT; 11 AA.  
AC O78121;  
DT 01-NOV-1998 (TrEMBLrel. 08, Created)  
DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)  
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
DE MHC class II B locus 12 (Fragment).

OS Oreochromis niloticus (Nile tilapia) (Tilapia nilotica).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;  
 OC Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes; Labroidae;  
 OC Cichlidae; Oreochromis.  
 OX NCBI\_TaxID=8128;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=98315113; PubMed=9649539;  
 RA Malaga-Trillo E., Zaleska-Rutczynska Z., McAndrew B., Vincek V.,  
 RA Figueroa F., Sultmann H., Klein J.;  
 RT "Linkage relationships and haplotype polymorphism among cichlid mhc  
 RT class II B loci.";  
 RL Genetics 149:1527-1537(1998).  
 DR EMBL; AF050027; AAC41366.1; -.  
 FT NON\_TER 1 1  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1362 MW; 03C12D8EB7341B54 CRC64;

Query Match 18.2%; Score 2; DB 7; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SR 4  
 ||  
 Db 8 SR 9

# RESULT 66

O77904

ID O77904 PRELIMINARY; PRT; 11 AA.  
 AC O77904;  
 DT 01-NOV-1998 (TrEMBLrel. 08, Created)  
 DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)  
 DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
 DE MHC class II B locus 14 (Fragment).  
 OS Oreochromis niloticus (Nile tilapia) (Tilapia nilotica).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;  
 OC Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes; Labroidae;  
 OC Cichlidae; Oreochromis.  
 OX NCBI\_TaxID=8128;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=98315113; PubMed=9649539;  
 RA Malaga-Trillo E., Zaleska-Rutczynska Z., McAndrew B., Vincek V.,  
 RA Figueroa F., Sultmann H., Klein J.;  
 RT "Linkage relationships and haplotype polymorphism among cichlid mhc  
 RT class II B loci.";  
 RL Genetics 149:1527-1537(1998).  
 DR EMBL; AF050014; AAC41353.1; -.  
 FT NON\_TER 1 1  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1349 MW; 81C12D8EB7341B41 CRC64;

Query Match 18.2%; Score 2; DB 7; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;

Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SR 4  
||  
Db 8 SR 9

RESULT 67

O77903

ID O77903 PRELIMINARY; PRT; 11 AA.  
AC O77903;  
DT 01-NOV-1998 (TrEMBLrel. 08, Created)  
DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)  
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
DE MHC class II B locus 14 (Fragment).  
OS Oreochromis niloticus (Nile tilapia) (Tilapia nilotica).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;  
OC Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes; Labroidei;  
OC Cichlidae; Oreochromis.  
OX NCBI\_TaxID=8128;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=98315113; PubMed=9649539;  
RA Malaga-Trillo E., Zaleska-Rutczynska Z., McAndrew B., Vincek V.,  
RA Figueroa F., Sultmann H., Klein J.;  
RT "Linkage relationships and haplotype polymorphism among cichlid mhc  
RT class II B loci.";  
RL Genetics 149:1527-1537(1998).  
DR EMBL; AF050013; AAC41352.1; -.  
FT NON\_TER 1 1  
FT NON\_TER 11 11  
SQ SEQUENCE 11 AA; 1349 MW; 81C12D8EB7341B41 CRC64;

Query Match 18.2%; Score 2; DB 7; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SR 4  
||  
Db 8 SR 9

RESULT 68

O77913

ID O77913 PRELIMINARY; PRT; 11 AA.  
AC O77913;  
DT 01-NOV-1998 (TrEMBLrel. 08, Created)  
DT 01-NOV-1998 (TrEMBLrel. 08, Last sequence update)  
DT 01-DEC-2001 (TrEMBLrel. 19, Last annotation update)  
DE MHC class II B locus 4 (Fragment).  
OS Oreochromis niloticus (Nile tilapia) (Tilapia nilotica).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;  
OC Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes; Labroidei;  
OC Cichlidae; Oreochromis.  
OX NCBI\_TaxID=8128;

RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=98315113; PubMed=9649539;  
 RA Malaga-Trillo E., Zaleska-Rutczynska Z., McAndrew B., Vincek V.,  
 RA Figueroa F., Sultmann H., Klein J.;  
 RT "Linkage relationships and haplotype polymorphism among cichlid mhc  
 RT class II B loci.";  
 RL Genetics 149:1527-1537(1998).  
 DR EMBL; AF050024; AAC41363.1; -.  
 FT NON\_TER 1 1  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1181 MW; 72325B737EA5B72B CRC64;

Query Match 18.2%; Score 2; DB 7; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 SL 10  
 ||  
 Db 9 SL 10

# RESULT 69

Q9G5Y6

ID Q9G5Y6 PRELIMINARY; PRT; 11 AA.  
 AC Q9G5Y6;  
 DT 01-MAR-2001 (TrEMBLrel. 16, Created)  
 DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)  
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)  
 DE Cytochrome c oxidase subunit I (Fragment).  
 GN COI.  
 OS Agama agama (Red-headed rock agama).  
 OG Mitochondrion.  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Lepidosauria; Squamata; Iguania; Acrodonta; Agamidae; Agaminae; Agama.  
 OX NCBI\_TaxID=103336;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=22114082; PubMed=12118408;  
 RA Macey J.R., Schulte J.A. II, Larson A.;  
 RT "Evolution and information content of the mitochondrial genomic  
 RT structural features illustrated with acrodont lizards.";  
 RL Syst. Biol. 49:257-277(2000).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=22114081; PubMed=12118407;  
 RA Macey J.R., Schulte J.A. II, Larson A., Ananjeva N.B., Wang Y.,  
 RA Pethiyagoda R., Rastegar-Pouyani N., Papenfuss T.J.;  
 RT "Evaluating Trans-Tethys migration: An example using Acrodont lizard  
 RT phylogenetics.";  
 RL Syst. Biol. 49:233-256(2000).  
 DR EMBL; AF128504; AAG00749.1; -.  
 DR GO; GO:0005739; C:mitochondrion; IEA.  
 KW Mitochondrion.  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1324 MW; 9D52EC1E336415A1 CRC64;



Query Match 18.2%; Score 2; DB 8; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SR 4  
||  
Db 5 SR 6

RESULT 70

Q8MEL7

ID Q8MEL7 PRELIMINARY; PRT; 11 AA.  
AC Q8MEL7;  
DT 01-OCT-2002 (TrEMBLrel. 22, Created)  
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)  
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)  
DE Ribosomal protein 16 (Fragment).  
GN RPL16.  
OS Sida hookeriana.  
OG Chloroplast.  
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;  
OC eurosids II; Malvales; Malvaceae; Malvoideae; Sida.  
OX NCBI\_TaxID=108446;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Pfeil B.E., Brubaker C.L., Craven L.A., Crisp M.D.;  
RT "Phylogeny of Hibiscus and the tribe Hibisceae (Malvaceae) using  
RT chloroplast DNA sequences of ndhF and the rpl16 intron.";  
RL Syst. Bot. 27:333-350(2002).  
DR EMBL; AF384624; AAM50396.1; -.  
DR GO; GO:0009507; C:chloroplast; IEA.  
KW Chloroplast.  
FT NON\_TER 1 1  
FT NON\_TER 11 11  
SQ SEQUENCE 11 AA; 1470 MW; 7227C351D32409D4 CRC64;

Query Match 18.2%; Score 2; DB 8; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 RK 5  
||  
Db 6 RK 7

RESULT 71

Q9G5Y0

ID Q9G5Y0 PRELIMINARY; PRT; 11 AA.  
AC Q9G5Y0;  
DT 01-MAR-2001 (TrEMBLrel. 16, Created)  
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)  
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)  
DE Cytochrome c oxidase subunit I (Fragment).  
GN COI.  
OS Pseudotrapelus sinaitus.  
OG Mitochondrion.

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Lepidosauria; Squamata; Iguania; Acrodonta; Agamidae; Agaminae;  
 OC Pseudotrapelus.  
 OX NCBI\_TaxID=118229;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=22114082; PubMed=12118408;  
 RA Macey J.R., Schulte J.A. II, Larson A.;  
 RT "Evolution and information content of the mitochondrial genomic  
 RT structural features illustrated with acrodont lizards.";  
 RL Syst. Biol. 49:257-277(2000).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=22114081; PubMed=12118407;  
 RA Macey J.R., Schulte J.A. II, Larson A., Ananjeva N.B., Wang Y.,  
 RA Pethiyagoda R., Rastegar-Pouyani N., Papenfuss T.J.;  
 RT "Evaluating Trans-Tethys migration: An example using Acrodont lizard  
 RT phylogenetics.";  
 RL Syst. Biol. 49:233-256(2000).  
 DR EMBL; AF128507; AAG00758.1; -.  
 DR GO; GO:0005739; C:mitochondrion; IEA.  
 KW Mitochondrion.  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1374 MW; B05439FE336415B6 CRC64;

Query Match 18.2%; Score 2; DB 8; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 SR 4  
 ||  
 Db 5 SR 6

# RESULT 72

## Q8MEM2

ID Q8MEM2 PRELIMINARY; PRT; 11 AA.  
 AC Q8MEM2;  
 DT 01-OCT-2002 (TrEMBLrel. 22, Created)  
 DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)  
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)  
 DE Ribosomal protein 16 (Fragment).  
 GN RPL16.  
 OS Lagunaria patersonia.  
 OG Chloroplast.  
 OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
 OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;  
 OC eurosids II; Malvales; Malvaceae; Malvoideae; Lagunaria.  
 OX NCBI\_TaxID=183274;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RA Pfeil B.E., Brubaker C.L., Craven L.A., Crisp M.D.;  
 RT "Phylogeny of Hibiscus and the tribe Hibisceae (Malvaceae) using  
 RT chloroplast DNA sequences of ndhF and the rpl16 intron.";  
 RL Syst. Bot. 27:333-350(2002).  
 DR EMBL; AF384616; AAM50388.1; -.  
 DR GO; GO:0009507; C:chloroplast; IEA.

KW Chloroplast.  
FT NON\_TER 1 1  
FT NON\_TER 11 11  
SQ SEQUENCE 11 AA; 1470 MW; 7227C351D32409D4 CRC64;

Query Match 18.2%; Score 2; DB 8; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 RK 5  
||  
Db 6 RK 7

RESULT 73

Q8MES5

ID Q8MES5 PRELIMINARY; PRT; 11 AA.  
AC Q8MES5;  
DT 01-OCT-2002 (TrEMBLrel. 22, Created)  
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)  
DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)  
DE Ribosomal protein 16 (Fragment).  
GN RPL16.  
OS Abelmoschus manihot.  
OG Chloroplast.  
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;  
OC eurosids II; Malvales; Malvaceae; Malvoideae; Abelmoschus.  
OX NCBI\_TaxID=183220;  
RN [1]  
RP SEQUENCE FROM N.A.  
RA Pfeil B.E., Brubaker C.L., Craven L.A., Crisp M.D.;  
RT "Phylogeny of Hibiscus and the tribe Hibisceae (Malvaceae) using  
RT chloroplast DNA sequences of ndhF and the rpl16 intron."  
RL Syst. Bot. 27:333-350(2002).  
DR EMBL; AF384561; AAM50399.1; -.  
DR GO; GO:0009507; C:chloroplast; IEA.  
KW Chloroplast.  
FT NON\_TER 1 1  
FT NON\_TER 11 11  
SQ SEQUENCE 11 AA; 1470 MW; 7227C351D32409D4 CRC64;

Query Match 18.2%; Score 2; DB 8; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 RK 5  
||  
Db 6 RK 7

RESULT 74

Q8WD17

ID Q8WD17 PRELIMINARY; PRT; 11 AA.  
AC Q8WD17;  
DT 01-MAR-2002 (TrEMBLrel. 20, Created)  
DT 01-MAR-2002 (TrEMBLrel. 20, Last sequence update)

DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)  
 DE Cytochrome c oxidase subunit I (Fragment).  
 GN COI.  
 OS Ctenophorus reticulatus (Western netted dragon).  
 OG Mitochondrion.  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Lepidosauria; Squamata; Iguania; Acrodonta; Agamidae; Amphibolurinae;  
 OC Ctenophorus.  
 OX NCBI\_TaxID=180002;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RA Melville J., Schulte J.A. II, Larson A.;  
 RT "A molecular phylogenetic study of ecological diversification in the  
 RT Australian lizard genus Ctenophorus."  
 RL Submitted (MAY-2001) to the EMBL/GenBank/DDBJ databases.  
 DR EMBL; AF375634; AAL40433.1; -.  
 DR GO; GO:0005739; C:mitochondrion; IEA.  
 KW Mitochondrion.  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1313 MW; A8F7371E336415B6 CRC64;

Query Match 18.2%; Score 2; DB 8; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 SR 4  
 ||  
 Db 5 SR 6

# RESULT 75

Q9G368

ID Q9G368 PRELIMINARY; PRT; 11 AA.  
 AC Q9G368;  
 DT 01-MAR-2001 (TrEMBLrel. 16, Created)  
 DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)  
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)  
 DE Cytochrome c oxidase subunit I (Fragment).  
 GN COI.  
 OS Draco blanfordii.  
 OG Mitochondrion.  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Lepidosauria; Squamata; Iguania; Acrodonta; Agamidae; Draconinae;  
 OC Draco.  
 OX NCBI\_TaxID=89021;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=97153820; PubMed=9000751;  
 RA Macey J.R., Larson A., Ananjeva N.B., Papenfuss T.J.;  
 RT "Replication slippage may cause parallel evolution in the secondary  
 RT structures of mitochondrial transfer RNAs."  
 RL Mol. Biol. Evol. 14:30-39(1997).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=22114082; PubMed=12118408;  
 RA Macey J.R., Schulte J.A. II, Larson A.;  
 RT "Evolution and information content of the mitochondrial genomic

RT structural features illustrated with acrodont lizards.";  
 RL Syst. Biol. 49:257-277(2000).  
 RN [3]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=22114081; PubMed=12118407;  
 RA Macey J.R., Schulte J.A. II, Larson A., Ananjeva N.B., Wang Y.,  
 RA Pethiyagoda R., Rastegar-Pouyani N., Papenfuss T.J.;  
 RT "Evaluating Trans-Tethys migration: An example using Acrodont lizard  
 RT phylogenetics.";  
 RL Syst. Biol. 49:233-256(2000).  
 DR EMBL; AF128477; AAG00668.1; -.  
 DR GO; GO:0005739; C:mitochondrion; IEA.  
 KW Mitochondrion.  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1341 MW; 4B2D371E336415B7 CRC64;

Query Match 18.2%; Score 2; DB 8; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+05;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SR 4  
 ||  
 Db 5 SR 6

Search completed: April 8, 2004, 15:46:10  
 Job time : 28.7692 secs

OM protein - protein search, using sw model

Run on: April 8, 2004, 15:30:07 ; Search time 5.15385 Seconds  
(without alignments)  
111.135 Million cell updates/sec

Title: US-09-787-443A-21  
Perfect score: 11  
Sequence: 1 AKSRKGNSSLM 11

Scoring table: OLIGO  
Gapop 60.0 , Gapext 60.0

Searched: 141681 seqs, 52070155 residues

Word size : 0

Total number of hits satisfying chosen parameters: 70

Minimum DB seq length: 11  
Maximum DB seq length: 11

Post-processing: Listing first 100 summaries

Database : SwissProt\_42:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

| Result No. | Score | Query |        | DB | ID         | Description        |
|------------|-------|-------|--------|----|------------|--------------------|
|            |       | Match | Length |    |            |                    |
| 1          | 3     | 27.3  | 11     | 1  | Q2OA_COMTE | P80464 comamonas t |
| 2          | 2     | 18.2  | 11     | 1  | BRK_MEGFL  | P12797 megascolia  |
| 3          | 2     | 18.2  | 11     | 1  | CORZ_PERAM | P11496 periplaneta |
| 4          | 2     | 18.2  | 11     | 1  | HS70_PINPS | P81672 pinus pinas |
| 5          | 2     | 18.2  | 11     | 1  | NXSN_PSETE | P59072 pseudonaja  |
| 6          | 2     | 18.2  | 11     | 1  | OAIF_SARBU | P83518 sarcophaga  |
| 7          | 2     | 18.2  | 11     | 1  | RS30_ONCMY | P83328 oncorhynchu |
| 8          | 2     | 18.2  | 11     | 1  | TKC2_CALVO | P41518 calliphora  |
| 9          | 2     | 18.2  | 11     | 1  | TKN1_PSEGU | P42986 pseudophryn |
| 10         | 2     | 18.2  | 11     | 1  | TKN1_UPEIN | P82026 uperoleia i |
| 11         | 2     | 18.2  | 11     | 1  | TKN1_UPERU | P08612 uperoleia r |
| 12         | 2     | 18.2  | 11     | 1  | TKN2_PSEGU | P42987 pseudophryn |
| 13         | 2     | 18.2  | 11     | 1  | TKN2_UPERU | P08616 uperoleia r |
| 14         | 2     | 18.2  | 11     | 1  | TKN3_PSEGU | P42988 pseudophryn |
| 15         | 2     | 18.2  | 11     | 1  | TKN4_PSEGU | P42989 pseudophryn |
| 16         | 2     | 18.2  | 11     | 1  | TKN5_PSEGU | P42990 pseudophryn |
| 17         | 2     | 18.2  | 11     | 1  | TKNA_CHICK | P19850 gallus gall |

|    |   |      |    |   |            |        |             |
|----|---|------|----|---|------------|--------|-------------|
| 18 | 2 | 18.2 | 11 | 1 | TKNA_GADMO | P28498 | gadus morhu |
| 19 | 2 | 18.2 | 11 | 1 | TKNA_HORSE | P01290 | equus cabal |
| 20 | 2 | 18.2 | 11 | 1 | TKNA_ONCMY | P28499 | oncorhynchu |
| 21 | 2 | 18.2 | 11 | 1 | TKNA_RANCA | P22688 | rana catesb |
| 22 | 2 | 18.2 | 11 | 1 | TKNA_RANRI | P29207 | rana ridibu |
| 23 | 2 | 18.2 | 11 | 1 | TKNA_SCYCA | P41333 | scyliorhinu |
| 24 | 2 | 18.2 | 11 | 1 | TKN_ELEMO  | P01293 | eledone mos |
| 25 | 2 | 18.2 | 11 | 1 | TKN_PHYFU  | P08615 | physalaemus |
| 26 | 2 | 18.2 | 11 | 1 | UXB2_YEAST | P99013 | saccharomyc |
| 27 | 1 | 9.1  | 11 | 1 | ANGT_CRIGE | P09037 | crinia geor |
| 28 | 1 | 9.1  | 11 | 1 | ASL1_BACSE | P83146 | bacteroides |
| 29 | 1 | 9.1  | 11 | 1 | ASL2_BACSE | P83147 | bacteroides |
| 30 | 1 | 9.1  | 11 | 1 | BPP3_BOTIN | P30423 | bothrops in |
| 31 | 1 | 9.1  | 11 | 1 | BPP4_BOTIN | P30424 | bothrops in |
| 32 | 1 | 9.1  | 11 | 1 | BPPB_AGKHA | P01021 | agkistrodon |
| 33 | 1 | 9.1  | 11 | 1 | BPP_AGKHP  | P04562 | agkistrodon |
| 34 | 1 | 9.1  | 11 | 1 | CA21_LITCI | P82087 | litoria cit |
| 35 | 1 | 9.1  | 11 | 1 | CA22_LITCI | P82088 | litoria cit |
| 36 | 1 | 9.1  | 11 | 1 | CA31_LITCI | P82089 | litoria cit |
| 37 | 1 | 9.1  | 11 | 1 | CA32_LITCI | P82090 | litoria cit |
| 38 | 1 | 9.1  | 11 | 1 | CA41_LITCI | P82091 | litoria cit |
| 39 | 1 | 9.1  | 11 | 1 | CA42_LITCI | P82092 | litoria cit |
| 40 | 1 | 9.1  | 11 | 1 | CEP1_ACHFU | P22790 | achatina fu |
| 41 | 1 | 9.1  | 11 | 1 | COXA_CANFA | P99501 | canis famil |
| 42 | 1 | 9.1  | 11 | 1 | CSI5_BACSU | P81095 | bacillus su |
| 43 | 1 | 9.1  | 11 | 1 | CX5A_CONAL | P58848 | conus aulic |
| 44 | 1 | 9.1  | 11 | 1 | CX5B_CONAL | P58849 | conus aulic |
| 45 | 1 | 9.1  | 11 | 1 | CXL1_CONMR | P58807 | conus marmo |
| 46 | 1 | 9.1  | 11 | 1 | EFG_CLOPA  | P81350 | clostridium |
| 47 | 1 | 9.1  | 11 | 1 | ES1_RAT    | P56571 | rattus norv |
| 48 | 1 | 9.1  | 11 | 1 | FAR6_PENMO | P83321 | penaeus mon |
| 49 | 1 | 9.1  | 11 | 1 | FAR9_CALVO | P41864 | calliphora  |
| 50 | 1 | 9.1  | 11 | 1 | LADD_ONCMY | P81018 | oncorhynchu |
| 51 | 1 | 9.1  | 11 | 1 | LPW_THETH  | P05624 | thermus the |
| 52 | 1 | 9.1  | 11 | 1 | LSK1_LEUMA | P04428 | leucophaea  |
| 53 | 1 | 9.1  | 11 | 1 | LSKP_PERAM | P36885 | periplaneta |
| 54 | 1 | 9.1  | 11 | 1 | MHBI_KLEPN | P80580 | klebsiella  |
| 55 | 1 | 9.1  | 11 | 1 | MLG_THETS  | P41989 | theromyzon  |
| 56 | 1 | 9.1  | 11 | 1 | MORN_HUMAN | P01163 | homo sapien |
| 57 | 1 | 9.1  | 11 | 1 | NUHM_CANFA | P49820 | canis famil |
| 58 | 1 | 9.1  | 11 | 1 | PKC1_CARMO | P82684 | carausius m |
| 59 | 1 | 9.1  | 11 | 1 | PQQC_PSEFL | P55173 | pseudomonas |
| 60 | 1 | 9.1  | 11 | 1 | PVK1_PERAM | P41837 | periplaneta |
| 61 | 1 | 9.1  | 11 | 1 | RANC_RANPI | P08951 | rana pipien |
| 62 | 1 | 9.1  | 11 | 1 | RE41_LITRU | P82074 | litoria rub |
| 63 | 1 | 9.1  | 11 | 1 | RR2_CONAM  | P42341 | conopholis  |
| 64 | 1 | 9.1  | 11 | 1 | RRPL_CHAV  | P13179 | chandipura  |
| 65 | 1 | 9.1  | 11 | 1 | T2P1_PROVU | P31031 | proteus vul |
| 66 | 1 | 9.1  | 11 | 1 | TIN1_HOPTI | P82651 | hoplobatrac |
| 67 | 1 | 9.1  | 11 | 1 | TIN4_HOPTI | P82654 | hoplobatrac |
| 68 | 1 | 9.1  | 11 | 1 | TKND_RANCA | P22691 | rana catesb |
| 69 | 1 | 9.1  | 11 | 1 | UF05_MOUSE | P38643 | mus musculu |
| 70 | 1 | 9.1  | 11 | 1 | ULAG_HUMAN | P31933 | homo sapien |

#### ALIGNMENTS

# RESULT 1

## Q2OA\_COMTE

ID Q2OA\_COMTE STANDARD; PRT; 11 AA.  
AC P80464;  
DT 01-NOV-1995 (Rel. 32, Created)  
DT 01-NOV-1995 (Rel. 32, Last sequence update)  
DT 16-OCT-2001 (Rel. 40, Last annotation update)  
DE Quinoline 2-oxidoreductase, alpha chain (EC 1.3.99.17) (Fragment).  
OS Comamonas testosteroni (Pseudomonas testosteroni).  
OC Bacteria; Proteobacteria; Betaproteobacteria; Burkholderiales;  
OC Comamonadaceae; Comamonas.  
OX NCBI\_TaxID=285;  
RN [1]  
RP SEQUENCE.  
RC STRAIN=63;  
RX MEDLINE=96035889; PubMed=7556204;  
RA Schach S., Tshisuaka B., Fetzner S., Lingens F.;  
RT "Quinoline 2-oxidoreductase and 2-oxo-1,2-dihydroquinoline 5,6-  
RT dioxygenase from Comamonas testosteroni 63. The first two enzymes in  
RT quinoline and 3-methylquinoline degradation.";  
RL Eur. J. Biochem. 232:536-544(1995).  
CC -!- FUNCTION: Converts (3-methyl-)-quinoline to (3-methyl-)-2-oxo-  
CC 1,2-dihydroquinoline.  
CC -!- CATALYTIC ACTIVITY: Quinoline + acceptor + H(2)O = isoquinolin-  
CC 1(2H)-one + reduced acceptor.  
CC -!- COFACTOR: FAD, molybdenum and iron-sulfur.  
CC -!- PATHWAY: Degradation of quinoline and (3-methyl-)-quinoline; first  
CC step.  
CC -!- SUBUNIT: Heterohexamer of two alpha chains, two beta chains, and  
CC two gamma chains (Probable).  
DR PIR; S66606; S66606.  
KW Oxidoreductase; Flavoprotein; FAD; Molybdenum.  
FT NON\_TER 11 11  
SQ SEQUENCE 11 AA; 1213 MW; 869094322B1DC2CA CRC64;

Query Match 27.3%; Score 3; DB 1; Length 11;  
Best Local Similarity 100.0%; Pred. No. 8.8e+02;  
Matches 3; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AKS 3  
|||  
Db 1 AKS 3

# RESULT 2

## BRK\_MEGFL

ID BRK\_MEGFL STANDARD; PRT; 11 AA.  
AC P12797;  
DT 01-OCT-1989 (Rel. 12, Created)  
DT 01-OCT-1989 (Rel. 12, Last sequence update)  
DT 28-FEB-2003 (Rel. 41, Last annotation update)  
DE Megascoliakinin ([Thr6]bradykinin-Lys-Ala) [Contains: Bradykinin-like  
DE peptide ([Thr6]bradykinin)].  
OS Megascolia flavifrons (Garden dagger wasp) (Solitary wasp).  
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
OC Neoptera; Endopterygota; Hymenoptera; Apocrita; Aculeata; Vespoidea;



OC Scoliididae; Megascolia.  
 OX NCBI\_TaxID=7437;  
 RN [1]  
 RP SEQUENCE.  
 RC TISSUE=Venom;  
 RX MEDLINE=87293024; PubMed=3617088;  
 RA Yasuhara T., Mantel P., Nakajima T., Piek T.;  
 RT "Two kinins isolated from an extract of the venom reservoirs of the  
 RT solitary wasp *Megascolia flavifrons*.";   
 RL Toxicon 25:527-535(1987).  
 RN [2]  
 RP SEQUENCE.  
 RC TISSUE=Venom;  
 RA Nakajima T., Piek T., Yashuara T., Mantel P.;  
 RT "Two kinins isolated from the venom of *Megascolia flavifrons*.";   
 RL Toxicon 26:34-34(1988).  
 CC -!- FUNCTION: Both proteins have bradykinin-like, although lower  
 CC activities (e.g. smooth muscle contraction).  
 CC -!- SUBCELLULAR LOCATION: Secreted; wasp venom reservoirs.  
 CC -!- SIMILARITY: Belongs to the bradykinin family.  
 DR PIR; B26744; B26744.  
 DR GO; GO:0005615; C:extracellular space; IDA.  
 DR GO; GO:0045776; P:negative regulation of blood pressure; ISS.  
 DR GO; GO:0045987; P:positive regulation of smooth muscle contra. . .; TAS.  
 KW Bradykinin; Vasodilator.  
 FT PEPTIDE 1 11 MEGASCOLIAKININ.  
 FT PEPTIDE 1 9 BRADYKININ-LIKE PEPTIDE.  
 SQ SEQUENCE 11 AA; 1273 MW; 33867393D771A9C8 CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 RK 5  
 ||  
 Db 9 RK 10

# RESULT 3

CORZ\_PERAM  
 ID CORZ\_PERAM STANDARD; PRT; 11 AA.  
 AC P11496;  
 DT 01-OCT-1989 (Rel. 12, Created)  
 DT 01-FEB-1994 (Rel. 28, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Corazonin.  
 OS *Periplaneta americana* (American cockroach).  
 OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
 OC Neoptera; Orthopteroidea; Dictyoptera; Blattaria; Blattoidea;  
 OC Blattidae; *Periplaneta*.  
 OX NCBI\_TaxID=6978;  
 RN [1]  
 RP SEQUENCE.  
 RC TISSUE=Corpora cardiaca;  
 RX MEDLINE=89325572; PubMed=2753132;  
 RA Veenstra J.A.;  
 RT "Isolation and structure of corazonin, a cardioactive peptide from

RT the American cockroach.";  
 RL FEBS Lett. 250:231-234(1989).  
 CC -!- FUNCTION: Cardioactive peptide. Corazonin is probably involved  
 CC in the physiological regulation of the heart beat.  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 DR PIR; S05002; S05002.  
 KW Neuropeptide; Amidation; Pyrrolidone carboxylic acid.  
 FT MOD\_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.  
 FT MOD\_RES 11 11 AMIDATION.  
 SQ SEQUENCE 11 AA; 1387 MW; C7CFF32D6415AB46 CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 SR 4  
 ||  
 Db 6 SR 7

#### RESULT 4

HS70\_PINPS  
 ID HS70\_PINPS STANDARD; PRT; 11 AA.  
 AC P81672;  
 DT 15-JUL-1999 (Rel. 38, Created)  
 DT 15-JUL-1999 (Rel. 38, Last sequence update)  
 DT 15-MAR-2004 (Rel. 43, Last annotation update)  
 DE Heat shock 70 kDa protein (Fragment).  
 OS Pinus pinaster (Maritime pine).  
 OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
 OC Spermatophyta; Coniferopsida; Coniferales; Pinaceae; Pinus.  
 OX NCBI\_TaxID=71647;  
 RN [1]  
 RP SEQUENCE.  
 RC TISSUE=Needle;  
 RX MEDLINE=99274088; PubMed=10344291;  
 RA Costa P., Pionneau C., Bauw G., Dubos C., Bahrman N., Kremer A.,  
 RA Frigerio J.-M., Plomion C.;  
 RT "Separation and characterization of needle and xylem maritime pine  
 RT proteins.";  
 RL Electrophoresis 20:1098-1108(1999).  
 CC -!- MISCELLANEOUS: On the 2D-gel the determined pI of this protein  
 CC (spot N164) is: 5.4, its MW is: 73 kDa.  
 CC -!- SIMILARITY: Belongs to the heat shock protein 70 family.  
 KW ATP-binding; Heat shock; Multigene family.  
 FT NON\_TER 1 1  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1228 MW; 037C1BE8DAA44DD0 CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 GN 7  
 ||  
 Db 9 GN 10

RESULT 5

NXSN\_PSETE

ID NXSN\_PSETE STANDARD; PRT; 11 AA.  
 AC P59072;  
 DT 28-FEB-2003 (Rel. 41, Created)  
 DT 28-FEB-2003 (Rel. 41, Last sequence update)  
 DT 28-FEB-2003 (Rel. 41, Last annotation update)  
 DE Short neurotoxin N1 (Alpha neurotoxin) (Fragment).  
 OS Pseudonaja textilis (Eastern brown snake).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Lepidosauria; Squamata; Scleroglossa; Serpentes; Colubroidea;  
 OC Elapidae; Acanthophiinae; Pseudonaja.  
 OX NCBI\_TaxID=8673;  
 RN [1]  
 RP SEQUENCE, AND MASS SPECTROMETRY.  
 RC TISSUE=Venom;  
 RX MEDLINE=99449602; PubMed=10518793;  
 RA Gong N.L., Armugam A., Jeyaseelan K.;  
 RT "Postsynaptic short-chain neurotoxins from Pseudonaja textilis: cDNA  
 RT cloning, expression and protein characterization.";  
 RL Eur. J. Biochem. 265:982-989(1999).  
 CC -!- FUNCTION: Lethal neurotoxin, binds and inhibits nicotinic  
 CC acetylcholine receptors (nAChR).  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- TISSUE SPECIFICITY: Expressed by the venom gland.  
 CC -!- MASS SPECTROMETRY: MW=6236; METHOD=Electrospray.  
 CC -!- MISCELLANEOUS: LD(50) is 0.84 mg/kg by intravenous injection.  
 CC -!- SIMILARITY: Belongs to the snake toxin family.  
 DR InterPro; IPR003571; Snake\_toxin.  
 DR PROSITE; PS00272; SNAKE\_TOXIN; PARTIAL.  
 KW Toxin; Neurotoxin; Postsynaptic neurotoxin;  
 KW Acetylcholine receptor inhibitor; Multigene family.  
 FT UNSURE 3 3  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1319 MW; 0D1EF0C81B58732B CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 5 KG 6  
 ||  
 Db 5 KG 6

RESULT 6

OAIF\_SARBU

ID OAIF\_SARBU STANDARD; PRT; 11 AA.  
 AC P83518;  
 DT 10-OCT-2003 (Rel. 42, Created)  
 DT 10-OCT-2003 (Rel. 42, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Ovary-derived ACE interactive factor (Neb-ODAIF) [Contains: Neb-  
 DE ODAIF(1-9); Neb-ODAIF(1-7)].  
 OS Sarcophaga bullata (Grey flesh fly) (Neobellieria bullata).  
 OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;

OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha; Oestroidea;  
 OC Sarcophagidae; Sarcophaga.  
 OX NCBI\_TaxID=7385;  
 RN [1]  
 RP SEQUENCE, SYNTHESIS, CHARACTERIZATION, AND MASS SPECTROMETRY.  
 RC TISSUE=Ovary;  
 RX MEDLINE=22272747; PubMed=12383874;  
 RA Vandingenen A., Hens K., Baggerman G., Macours N., Schoofs L.,  
 RA De Loof A., Huybrechts R.;  
 RT "Isolation and characterization of an angiotensin converting enzyme  
 RT substrate from vitellogenic ovaries of *Neobellieria bullata*.";  
 RL Peptides 23:1853-1863(2002).  
 CC -!- FUNCTION: Substrate for angiotensin converting enzyme (ACE) in  
 CC vitro.  
 CC -!- PTM: ACE hydrolyzes Neb-ODAIF by sequentially cleaving off two C-  
 CC terminal dipeptides.  
 CC -!- MASS SPECTROMETRY: MW=1312.7; METHOD=MALDI; RANGE=1-11.  
 CC -!- SIMILARITY: To the N-terminal part of insect vitellogenins.  
 FT PEPTIDE 1 11 NEB-ODAIF.  
 FT PEPTIDE 1 9 NEB-ODAIF(1-9).  
 FT PEPTIDE 1 7 NEB-ODAIF(1-7).  
 SQ SEQUENCE 11 AA; 1314 MW; 4E114BB566C5A763 CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 SL 10  
 ||  
 Db 10 SL 11

#### RESULT 7

##### RS30\_ONCMY

ID RS30\_ONCMY STANDARD; PRT; 11 AA.  
 AC P83328;  
 DT 28-FEB-2003 (Rel. 41, Created)  
 DT 28-FEB-2003 (Rel. 41, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE 40S ribosomal protein S30 (Fragment).  
 GN FAU.  
 OS *Oncorhynchus mykiss* (Rainbow trout) (*Salmo gairdneri*).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Actinopterygii; Neopterygii; Teleostei; Euteleostei;  
 OC Protacanthopterygii; Salmoniformes; Salmonidae; *Oncorhynchus*.  
 OX NCBI\_TaxID=8022;  
 RN [1]  
 RP SEQUENCE, FUNCTION, AND MASS SPECTROMETRY.  
 RC TISSUE=Skin mucus;  
 RX MEDLINE=22142142; PubMed=12147245;  
 RA Fernandes J.M.O., Smith V.J.;  
 RT "A novel antimicrobial function for a ribosomal peptide from rainbow  
 RT trout skin.";  
 RL Biochem. Biophys. Res. Commun. 296:167-171(2002).  
 CC -!- FUNCTION: Has antibacterial activity against Gram-positive  
 CC bacteria.  
 CC -!- MASS SPECTROMETRY: MW=6676.6; METHOD=MALDI.

CC -!- SIMILARITY: Belongs to the S30E family of ribosomal proteins.  
KW Ribosomal protein; Antibiotic.  
FT NON\_TER 11 11  
SQ SEQUENCE 11 AA; 1123 MW; 2312AB630DD735B8 CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 9 SL 10  
||  
Db 5 SL 6

RESULT 8

TKC2\_CALVO  
ID TKC2\_CALVO STANDARD; PRT; 11 AA.  
AC P41518;  
DT 01-NOV-1995 (Rel. 32, Created)  
DT 01-NOV-1995 (Rel. 32, Last sequence update)  
DT 10-OCT-2003 (Rel. 42, Last annotation update)  
DE Callitachykinin II.  
OS Calliphora vomitoria (Blue blowfly).  
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha; Oestroidea;  
OC Calliphoridae; Calliphora.  
OX NCBI\_TaxID=27454;  
RN [1]  
RP SEQUENCE, AND SYNTHESIS.  
RX MEDLINE=95075727; PubMed=7984492;  
RA Lundquist C.T., Clottens F.L., Holman G.M., Nichols R., Nachman R.J.,  
RA Naessel D.R.;  
RT "Callitachykinin I and II, two novel myotropic peptides isolated from  
RT the blowfly, Calliphora vomitoria, that have resemblances to  
RT tachykinins.";  
RL Peptides 15:761-768(1994).  
CC -!- FUNCTION: Myoactive peptide.  
CC -!- SUBCELLULAR LOCATION: Secreted.  
CC -!- SIMILARITY: SOME SIMILARITY TO TACHYKININS.  
KW Tachykinin; Neuropeptide; Amidation.  
FT MOD\_RES 11 11 AMIDATION.  
SQ SEQUENCE 11 AA; 1103 MW; 15D7E3F9C9CDD444 CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 6 GN 7  
||  
Db 3 GN 4

RESULT 9

TKN1\_PSEGU  
ID TKN1\_PSEGU STANDARD; PRT; 11 AA.  
AC P42986;  
DT 01-NOV-1995 (Rel. 32, Created)

DT 01-NOV-1995 (Rel. 32, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Kassinin-like peptide K-I (PG-KI).  
 OS Pseudophryne guentheri (Guenther's toadlet).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Amphibia; Batrachia; Anura; Neobatrachia; Hyla; Myobatrachidae;  
 OC Myobatrachinae; Pseudophryne.  
 OX NCBI\_TaxID=30349;  
 RN [1]  
 RP SEQUENCE.  
 RC TISSUE=Skin secretion;  
 RX MEDLINE=90287814; PubMed=2356157;  
 RA Simmaco M., Severini C., de Biase D., Barra D., Bossa F.,  
 RA Roberts J.D., Melchiorri P., Erspamer V.;  
 RT "Six novel tachykinin- and bombesin-related peptides from the skin of  
 RT the Australian frog Pseudophryne guentheri.";  
 RL Peptides 11:299-304(1990).  
 CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,  
 CC evoke behavioral responses, are potent vasodilators and  
 CC secretagogues, and contract (directly or indirectly) many smooth  
 CC muscles.  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- TISSUE SPECIFICITY: Skin.  
 CC -!- SIMILARITY: Belongs to the tachykinin family.  
 DR PIR; B60409; B60409.  
 DR InterPro; IPR002040; Tachy\_Neurokinin.  
 DR InterPro; IPR008215; Tachykinin.  
 DR Pfam; PF02202; Tachykinin; 1.  
 DR SMART; SM00203; TK; 1.  
 DR PROSITE; PS00267; TACHYKININ; 1.  
 KW Amphibian defense peptide; Tachykinin; Neuropeptide; Amidation;  
 KW Pyrrolidone carboxylic acid.  
 FT MOD\_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.  
 FT MOD\_RES 11 11 AMIDATION.  
 SQ SEQUENCE 11 AA; 1269 MW; 3DBA7C37C9CB1AB7 CRC64;  
  
 Query Match 18.2%; Score 2; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
 QY 10 LM 11  
 ||  
 Db 10 LM 11

# RESULT 10

## TKN1\_UPEIN

ID TKN1\_UPEIN STANDARD; PRT; 11 AA.  
 AC P82026;  
 DT 30-MAY-2000 (Rel. 39, Created)  
 DT 30-MAY-2000 (Rel. 39, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Uperin 1.1.  
 OS Uperoleia inundata (Floodplain toadlet).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Amphibia; Batrachia; Anura; Neobatrachia; Hyla; Myobatrachidae;  
 OC Myobatrachinae; Uperoleia.

OX NCBI\_TaxID=104953;  
 RN [1]  
 RP SEQUENCE, AND MASS SPECTROMETRY.  
 RC TISSUE=Skin secretion;  
 RA Bradford A.M., Raftery M.J., Bowie J.H., Tyler M.J., Wallace J.C.,  
 RA Adams G.W., Severini C.;  
 RT "Novel uperin peptides from the dorsal glands of the australian  
 RT floodplain toadlet Uperoleia inundata.";  
 RL Aust. J. Chem. 49:475-484(1996).  
 CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,  
 CC evoke behavioral responses, are potent vasodilators and  
 CC secretagogues, and contract (directly or indirectly) many smooth  
 CC muscles.  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- TISSUE SPECIFICITY: Skin dorsal glands.  
 CC -!- MASS SPECTROMETRY: MW=1208; METHOD=FAB.  
 CC -!- SIMILARITY: Belongs to the tachykinin family.  
 DR InterPro; IPR002040; Tachy\_Neurokinin.  
 DR Pfam; PF02202; Tachykinin; 1.  
 DR PROSITE; PS00267; TACHYKININ; 1.  
 KW Amphibian defense peptide; Tachykinin; Neuropeptide; Amidation;  
 KW Pyrrolidone carboxylic acid.  
 FT MOD\_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.  
 FT MOD\_RES 11 11 AMIDATION.  
 SQ SEQUENCE 11 AA; 1226 MW; 3293693E59CDD457 CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 LM 11  
 ||  
 Db 10 LM 11

# RESULT 11

TKN1\_UPERU  
 ID TKN1\_UPERU STANDARD; PRT; 11 AA.  
 AC P08612;  
 DT 01-AUG-1988 (Rel. 08, Created)  
 DT 01-FEB-1994 (Rel. 28, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Uperolein.  
 OS Uperoleia rugosa (Wrinkled toadlet).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Myobatrachidae;  
 OC Myobatrachinae; Uperoleia.  
 OX NCBI\_TaxID=8368;  
 RN [1]  
 RP SEQUENCE.  
 RC TISSUE=Skin secretion;  
 RX MEDLINE=75131227; PubMed=1120493;  
 RA Anastasi A., Erspamer V., Endean R.;  
 RT "Structure of uperolein, a physalaemin-like endecapeptide occurring  
 RT in the skin of Uperoleia rugosa and Uperoleia marmorata.";  
 RL Experientia 31:394-395(1975).  
 CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,

CC evoke behavioral responses, are potent vasodilators and  
 CC secretagogues, and contract (directly or indirectly) many smooth  
 CC muscles.  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- TISSUE SPECIFICITY: Skin.  
 CC -!- SIMILARITY: Belongs to the tachykinin family.  
 DR InterPro; IPR002040; Tachy\_Neurokinin.  
 DR InterPro; IPR008215; Tachykinin.  
 DR Pfam; PF02202; Tachykinin; 1.  
 DR SMART; SM00203; TK; 1.  
 DR PROSITE; PS00267; TACHYKININ; 1.  
 KW Amphibian defense peptide; Tachykinin; Neuropeptide; Amidation;  
 KW Pyrrolidone carboxylic acid.  
 FT MOD\_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.  
 FT MOD\_RES 11 11 AMIDATION.  
 SQ SEQUENCE 11 AA; 1252 MW; 32867C3E59CDD457 CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 10 LM 11  
 ||  
 Db 10 LM 11

# RESULT 12

## TKN2\_PSEGU

ID TKN2\_PSEGU STANDARD; PRT; 11 AA.  
 AC P42987;  
 DT 01-NOV-1995 (Rel. 32, Created)  
 DT 01-NOV-1995 (Rel. 32, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Kassinin-like peptide K-II (PG-KII).  
 OS Pseudophryne guentheri (Guenther's toadlet).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Myobatrachidae;  
 OC Myobatrachinae; Pseudophryne.  
 OX NCBI\_TaxID=30349;  
 RN [1]  
 RP SEQUENCE.  
 RC TISSUE=Skin secretion;  
 RX MEDLINE=90287814; PubMed=2356157;  
 RA Simmaco M., Severini C., de Biase D., Barra D., Bossa F.,  
 RA Roberts J.D., Melchiorri P., Erspamer V.;  
 RT "Six novel tachykinin- and bombesin-related peptides from the skin of  
 RT the Australian frog Pseudophryne guntheri."  
 RL Peptides 11:299-304(1990).  
 CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,  
 CC evoke behavioral responses, are potent vasodilators and  
 CC secretagogues, and contract (directly or indirectly) many smooth  
 CC muscles.  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- TISSUE SPECIFICITY: Skin.  
 CC -!- SIMILARITY: Belongs to the tachykinin family.  
 DR PIR; C60409; C60409.  
 DR InterPro; IPR002040; Tachy\_Neurokinin.



DR InterPro; IPR008215; Tachykinin.  
 DR Pfam; PF02202; Tachykinin; 1.  
 DR SMART; SM00203; TK; 1.  
 DR PROSITE; PS00267; TACHYKININ; 1.  
 KW Amphibian defense peptide; Tachykinin; Neuropeptide; Amidation;  
 KW Pyrrolidone carboxylic acid.  
 FT MOD\_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.  
 FT MOD\_RES 11 11 AMIDATION.  
 SQ SEQUENCE 11 AA; 1246 MW; 3A247C37C9CB1AB7 CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 LM 11  
 ||  
 Db 10 LM 11

# RESULT 13

## TKN2\_UPERU

ID TKN2\_UPERU STANDARD; PRT; 11 AA.  
 AC P08616;  
 DT 01-AUG-1988 (Rel. 08, Created)  
 DT 01-FEB-1994 (Rel. 28, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Rugosauperolein II ([Lys5,Thr6]physalaemin).  
 OS Uperoleia rugosa (Wrinkled toadlet).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Myobatrachidae;  
 OC Myobatrachinae; Uperoleia.  
 OX NCBI\_TaxID=8368;  
 RN [1]  
 RP SEQUENCE.  
 RC TISSUE=Skin secretion;  
 RX MEDLINE=80223080; PubMed=7389029;  
 RA Nakajima T., Yasuhara T., Erspamer V., Erspamer G.F., Negri L.;  
 RT "Physalaemin- and bombesin-like peptides in the skin of the  
 RT Australian leptodactylid frog Uperoleia rugosa.";  
 RL Chem. Pharm. Bull. 28:689-695(1980).  
 CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,  
 CC evoke behavioral responses, are potent vasodilators and  
 CC secretagogues, and contract (directly or indirectly) many smooth  
 CC muscles.  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- TISSUE SPECIFICITY: Skin.  
 CC -!- SIMILARITY: Belongs to the tachykinin family.  
 DR InterPro; IPR002040; Tachy\_Neurokinin.  
 DR Pfam; PF02202; Tachykinin; 1.  
 DR PROSITE; PS00267; TACHYKININ; 1.  
 KW Amphibian defense peptide; Tachykinin; Neuropeptide; Amidation;  
 KW Pyrrolidone carboxylic acid.  
 FT MOD\_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.  
 FT MOD\_RES 11 11 AMIDATION.  
 SQ SEQUENCE 11 AA; 1270 MW; 3293693E59D1A327 CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;

Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 LM 11  
||  
Db 10 LM 11

RESULT 14

TKN3\_PSEGU

ID TKN3\_PSEGU STANDARD; PRT; 11 AA.  
AC P42988;  
DT 01-NOV-1995 (Rel. 32, Created)  
DT 01-NOV-1995 (Rel. 32, Last sequence update)  
DT 10-OCT-2003 (Rel. 42, Last annotation update)  
DE Kassinin-like peptide K-III (PG-KIII).  
OS Pseudophryne guentheri (Guenther's toadlet).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Myobatrachidae;  
OC Myobatrachinae; Pseudophryne.  
OX NCBI\_TaxID=30349;  
RN [1]  
RP SEQUENCE.  
RC TISSUE=Skin secretion;  
RX MEDLINE=90287814; PubMed=2356157;  
RA Simmaco M., Severini C., de Biase D., Barra D., Bossa F.,  
RA Roberts J.D., Melchiorri P., Erspamer V.;  
RT "Six novel tachykinin- and bombesin-related peptides from the skin of  
RT the Australian frog Pseudophryne guentheri.";  
RL Peptides 11:299-304(1990).  
CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,  
CC evoke behavioral responses, are potent vasodilators and  
CC secretagogues, and contract (directly or indirectly) many smooth  
CC muscles.  
CC -!- SUBCELLULAR LOCATION: Secreted.  
CC -!- TISSUE SPECIFICITY: Skin.  
CC -!- SIMILARITY: Belongs to the tachykinin family.  
DR PIR; D60409; D60409.  
DR InterPro; IPR002040; Tachy\_Neurokinin.  
DR InterPro; IPR008215; Tachykinin.  
DR Pfam; PF02202; Tachykinin; 1.  
DR SMART; SM00203; TK; 1.  
DR PROSITE; PS00267; TACHYKININ; 1.  
KW Amphibian defense peptide; Tachykinin; Neuropeptide; Amidation;  
KW Pyrrolidone carboxylic acid.  
FT MOD\_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.  
FT MOD\_RES 11 11 AMIDATION.  
SQ SEQUENCE 11 AA; 1268 MW; 3DBA7C37C9CB1457 CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 LM 11  
||  
Db 10 LM 11

RESULT 15

TKN4\_PSEGU

ID TKN4\_PSEGU STANDARD; PRT; 11 AA.  
 AC P42989;  
 DT 01-NOV-1995 (Rel. 32, Created)  
 DT 01-NOV-1995 (Rel. 32, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Substance P-like peptide I (PG-SPI).  
 OS Pseudophryne guentheri (Guenther's toadlet).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Myobatrachidae;  
 OC Myobatrachinae; Pseudophryne.  
 OX NCBI\_TaxID=30349;  
 RN [1]  
 RP SEQUENCE.  
 RC TISSUE=Skin secretion;  
 RX MEDLINE=90287814; PubMed=2356157;  
 RA Simmaco M., Severini C., de Biase D., Barra D., Bossa F.,  
 RA Roberts J.D., Melchiorri P., Erspamer V.;  
 RT "Six novel tachykinin- and bombesin-related peptides from the skin of  
 RT the Australian frog Pseudophryne guentheri.";  
 RL Peptides 11:299-304(1990).  
 CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,  
 CC evoke behavioral responses, are potent vasodilators and  
 CC secretagogues, and contract (directly or indirectly) many smooth  
 CC muscles.  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- TISSUE SPECIFICITY: Skin.  
 CC -!- SIMILARITY: Belongs to the tachykinin family.  
 DR PIR; E60409; E60409.  
 DR InterPro; IPR002040; Tachy\_Neurokinin.  
 DR InterPro; IPR008215; Tachykinin.  
 DR Pfam; PF02202; Tachykinin; 1.  
 DR SMART; SM00203; TK; 1.  
 DR PROSITE; PS00267; TACHYKININ; 1.  
 KW Amphibian defense peptide; Tachykinin; Neuropeptide; Amidation;  
 KW Pyrrolidone carboxylic acid.  
 FT MOD\_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.  
 FT MOD\_RES 11 11 AMIDATION.  
 SQ SEQUENCE 11 AA; 1294 MW; 3A247C2CC9CB1AB7 CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 10 LM 11  
 ||  
 Db 10 LM 11

RESULT 16

TKN5\_PSEGU

ID TKN5\_PSEGU STANDARD; PRT; 11 AA.  
 AC P42990;  
 DT 01-NOV-1995 (Rel. 32, Created)  
 DT 01-NOV-1995 (Rel. 32, Last sequence update)

DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Substance P-like peptide II (PG-SPII).  
 OS Pseudophryne guentheri (Guenther's toadlet).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Myobatrachidae;  
 OC Myobatrachinae; Pseudophryne.  
 OX NCBI\_TaxID=30349;  
 RN [1]  
 RP SEQUENCE.  
 RC TISSUE=Skin secretion;  
 RX MEDLINE=90287814; PubMed=2356157;  
 RA Simmaco M., Severini C., de Biase D., Barra D., Bossa F.,  
 RA Roberts J.D., Melchiorri P., Erspamer V.;  
 RT "Six novel tachykinin- and bombesin-related peptides from the skin of  
 RT the Australian frog Pseudophryne guentheri.";  
 RL Peptides 11:299-304(1990).  
 CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,  
 CC evoke behavioral responses, are potent vasodilators and  
 CC secretagogues, and contract (directly or indirectly) many smooth  
 CC muscles.  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- TISSUE SPECIFICITY: Skin.  
 CC -!- SIMILARITY: Belongs to the tachykinin family.  
 DR PIR; F60409; F60409.  
 DR InterPro; IPR002040; Tachy\_Neurokinin.  
 DR InterPro; IPR008215; Tachykinin.  
 DR Pfam; PF02202; Tachykinin; 1.  
 DR SMART; SM00203; TK; 1.  
 DR PROSITE; PS00267; TACHYKININ; 1.  
 KW Amphibian defense peptide; Tachykinin; Neuropeptide; Amidation;  
 KW Pyrrolidone carboxylic acid.  
 FT MOD\_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.  
 FT MOD\_RES 11 11 AMIDATION.  
 SQ SEQUENCE 11 AA; 1293 MW; 3A247C2CC9CB1457 CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 10 LM 11  
 ||  
 Db 10 LM 11

#### RESULT 17

##### TKNA\_CHICK

ID TKNA\_CHICK STANDARD; PRT; 11 AA.  
 AC P19850;  
 DT 01-FEB-1991 (Rel. 17, Created)  
 DT 01-FEB-1991 (Rel. 17, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Substance P.  
 OS Gallus gallus (Chicken).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;  
 OC Gallus.  
 OX NCBI\_TaxID=9031;

RN [1]  
 RP SEQUENCE.  
 RC TISSUE=Intestine;  
 RX MEDLINE=88204263; PubMed=2452461;  
 RA Conlon J.M., Katsoulis S., Schmidt W.E., Thim L.;  
 RT "[Arg3]substance P and neurokinin A from chicken small intestine."  
 RL Regul. Pept. 20:171-180(1988).  
 CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,  
 CC evoke behavioral responses, are potent vasodilators and  
 CC secretagogues, and contract (directly or indirectly) many smooth  
 CC muscles.  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- SIMILARITY: Belongs to the tachykinin family.  
 DR PIR; JN0023; JN0023.  
 DR InterPro; IPR002040; Tachy\_Neurokinin.  
 DR Pfam; PF02202; Tachykinin; 1.  
 DR PROSITE; PS00267; TACHYKININ; 1.  
 KW Tachykinin; Neuropeptide; Amidation; Neurotransmitter.  
 FT MOD\_RES 11 11 AMIDATION.  
 SQ SEQUENCE 11 AA; 1377 MW; 21487FE3C9D6C6C7 CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 10 LM 11  
 ||  
 Db 10 LM 11

#### RESULT 18

##### TKNA\_GADMO

ID TKNA\_GADMO STANDARD; PRT; 11 AA.  
 AC P28498;  
 DT 01-DEC-1992 (Rel. 24, Created)  
 DT 01-DEC-1992 (Rel. 24, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Substance P.  
 OS Gadus morhua (Atlantic cod).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;  
 OC Acanthomorpha; Paracanthopterygii; Gadiformes; Gadidae; Gadus.  
 OX NCBI\_TaxID=8049;  
 RN [1]  
 RP SEQUENCE.  
 RC TISSUE=Brain;  
 RX MEDLINE=92298992; PubMed=1376687;  
 RA Jensen J., Conlon J.M.;  
 RT "Substance-P-related and neurokinin-A-related peptides from the brain  
 RT of the cod and trout."  
 RL Eur. J. Biochem. 206:659-664(1992).  
 CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,  
 CC evoke behavioral responses, are potent vasodilators and  
 CC secretagogues, and contract (directly or indirectly) many smooth  
 CC muscles.  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- SIMILARITY: Belongs to the tachykinin family.

DR PIR; S23306; S23306.  
 DR InterPro; IPR002040; Tachy\_Neurokinin.  
 DR InterPro; IPR008215; Tachykinin.  
 DR Pfam; PF02202; Tachykinin; 1.  
 DR SMART; SM00203; TK; 1.  
 DR PROSITE; PS00267; TACHYKININ; 1.  
 KW Tachykinin; Neuropeptide; Amidation; Neurotransmitter.  
 FT MOD\_RES 11 11 AMIDATION (BY SIMILARITY).  
 SQ SEQUENCE 11 AA; 1315 MW; 214860D759D6C6C7 CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 LM 11  
 ||  
 Db 10 LM 11

# RESULT 19

## TKNA\_HORSE

ID TKNA\_HORSE STANDARD; PRT; 11 AA.  
 AC P01290;  
 DT 21-JUL-1986 (Rel. 01, Created)  
 DT 21-JUL-1986 (Rel. 01, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Substance P.  
 GN TAC1 OR NKNA OR TAC2 OR NKA.  
 OS Equus caballus (Horse), and  
 OS Cavia porcellus (Guinea pig).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Perissodactyla; Equidae; Equus.  
 OX NCBI\_TaxID=9796, 10141;  
 RN [1]  
 RP SEQUENCE.  
 RC SPECIES=Horse;  
 RA Studer R.O., Trzeciak A., Lergier W.;  
 RT "Isolation and amino-acid sequence of substance P from horse  
 RT intestine.";  
 RL Helv. Chim. Acta 56:860-866(1973).  
 RN [2]  
 RP SEQUENCE.  
 RC SPECIES=C.porcellus;  
 RX MEDLINE=90044685; PubMed=2478925;  
 RA Murphy R.;  
 RT "Primary amino acid sequence of guinea-pig substance P.";  
 RL Neuropeptides 14:105-110(1989).  
 CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,  
 CC evoke behavioral responses, are potent vasodilators and  
 CC secretagogues, and contract (directly or indirectly) many smooth  
 CC muscles.  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- SIMILARITY: Belongs to the tachykinin family.  
 DR PIR; A01558; SPHO.  
 DR PIR; A60654; A60654.  
 DR InterPro; IPR002040; Tachy\_Neurokinin.  
 DR InterPro; IPR008215; Tachykinin.

DR Pfam; PF02202; Tachykinin; 1.  
 DR SMART; SM00203; TK; 1.  
 DR PROSITE; PS00267; TACHYKININ; 1.  
 KW Tachykinin; Neuropeptide; Amidation; Neurotransmitter.  
 FT MOD\_RES 11 11 AMIDATION.  
 SQ SEQUENCE 11 AA; 1349 MW; 3E757FE3C9D6C6C7 CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 LM 11  
 ||  
 Db 10 LM 11

# RESULT 20

## TKNA\_ONCMY

ID TKNA\_ONCMY STANDARD; PRT; 11 AA.  
 AC P28499;  
 DT 01-DEC-1992 (Rel. 24, Created)  
 DT 01-DEC-1992 (Rel. 24, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Substance P.  
 OS Oncorhynchus mykiss (Rainbow trout) (Salmo gairdneri).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Actinopterygii; Neopterygii; Teleostei; Euteleostei;  
 OC Protacanthopterygii; Salmoniformes; Salmonidae; Oncorhynchus.  
 OX NCBI\_TaxID=8022;  
 RN [1]  
 RP SEQUENCE.  
 RC TISSUE=Brain;  
 RX MEDLINE=92298992; PubMed=1376687;  
 RA Jensen J., Conlon J.M.;  
 RT "Substance-P-related and neurokinin-A-related peptides from the brain  
 RT of the cod and trout."  
 RL Eur. J. Biochem. 206:659-664(1992).  
 CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,  
 CC evoke behavioral responses, are potent vasodilators and  
 CC secretagogues, and contract (directly or indirectly) many smooth  
 CC muscles.  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- SIMILARITY: Belongs to the tachykinin family.  
 DR PIR; S23308; S23308.  
 DR InterPro; IPR002040; Tachy\_Neurokinin.  
 DR InterPro; IPR008215; Tachykinin.  
 DR Pfam; PF02202; Tachykinin; 1.  
 DR SMART; SM00203; TK; 1.  
 DR PROSITE; PS00267; TACHYKININ; 1.  
 KW Tachykinin; Neuropeptide; Amidation; Neurotransmitter.  
 FT MOD\_RES 11 11 AMIDATION (BY SIMILARITY).  
 SQ SEQUENCE 11 AA; 1358 MW; 214860DEC9D6D1F7 CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 LM 11  
||  
Db 10 LM 11

RESULT 21

TKNA\_RANCA

ID TKNA\_RANCA STANDARD; PRT; 11 AA.  
AC P22688;  
DT 01-AUG-1991 (Rel. 19, Created)  
DT 01-AUG-1991 (Rel. 19, Last sequence update)  
DT 10-OCT-2003 (Rel. 42, Last annotation update)  
DE Ranatachykinin A (RTK A).  
OS Rana catesbeiana (Bull frog).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Amphibia; Batrachia; Anura; Neobatrachia; Ranoidea; Ranidae; Rana.  
OX NCBI\_TaxID=8400;  
RN [1]  
RP SEQUENCE, AND SYNTHESIS.  
RC TISSUE=Brain, and Intestine;  
RX MEDLINE=91254337; PubMed=2043143;  
RA Kozawa H., Hino J., Minamino N., Kangawa K., Matsuo H.;  
RT "Isolation of four novel tachykinins from frog (Rana catesbeiana)  
RT brain and intestine.";  
RL Biochem. Biophys. Res. Commun. 177:588-595(1991).  
RN [2]  
RP SEQUENCE.  
RC TISSUE=Intestine;  
RX MEDLINE=94023216; PubMed=8210506;  
RA Kangawa K., Kozawa H., Hino J., Minamino N., Matsuo H.;  
RT "Four novel tachykinins in frog (Rana catesbeiana) brain and  
RT intestine.";  
RL Regul. Pept. 46:81-88(1993).  
CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,  
CC evoke behavioral responses, are potent vasodilators and  
CC secretagogues, and contract (directly or indirectly) many smooth  
CC muscles.  
CC -!- SUBCELLULAR LOCATION: Secreted.  
CC -!- SIMILARITY: Belongs to the tachykinin family.  
DR PIR; A61033; A61033.  
DR InterPro; IPR002040; Tachy\_Neurokinin.  
DR InterPro; IPR008215; Tachykinin.  
DR Pfam; PF02202; Tachykinin; 1.  
DR SMART; SM00203; TK; 1.  
DR PROSITE; PS00267; TACHYKININ; 1.  
KW Tachykinin; Neuropeptide; Amidation.  
FT MOD\_RES 11 11 AMIDATION.  
SQ SEQUENCE 11 AA; 1311 MW; 200D60CC59D40AB7 CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 LM 11  
||  
Db 10 LM 11



RESULT 22

TKNA\_RANRI

ID TKNA\_RANRI STANDARD; PRT; 11 AA.  
 AC P29207;  
 DT 01-DEC-1992 (Rel. 24, Created)  
 DT 01-DEC-1992 (Rel. 24, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Ranakinin (Substance-P-related peptide).  
 OS Rana ridibunda (Laughing frog) (Marsh frog).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Amphibia; Batrachia; Anura; Neobatrachia; Ranoidea; Ranidae; Rana.  
 OX NCBI\_TaxID=8406;  
 RN [1]  
 RP SEQUENCE.  
 RC TISSUE=Brain;  
 RX MEDLINE=92044543; PubMed=1658233;  
 RA O'Harte F., Burcher E., Lovas S., Smith D.D., Vaudry H., Conlon J.M.;  
 RT "Ranakinin: a novel NK1 tachykinin receptor agonist isolated with  
 RT neurokinin B from the brain of the frog Rana ridibunda."  
 RL J. Neurochem. 57:2086-2091(1991).  
 CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,  
 CC evoke behavioral responses, are potent vasodilators and  
 CC secretagogues, and contract (directly or indirectly) many smooth  
 CC muscles.  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- SIMILARITY: Belongs to the tachykinin family.  
 DR InterPro; IPR002040; Tachy\_Neurokinin.  
 DR InterPro; IPR008215; Tachykinin.  
 DR Pfam; PF02202; Tachykinin; 1.  
 DR SMART; SM00203; TK; 1.  
 DR PROSITE; PS00267; TACHYKININ; 1.  
 KW Tachykinin; Neuropeptide; Amidation.  
 FT MOD\_RES 11 11 AMIDATION.  
 SQ SEQUENCE 11 AA; 1352 MW; 3A2460CC59D40B07 CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 LM 11  
 ||  
 Db 10 LM 11

RESULT 23

TKNA\_SCYCA

ID TKNA\_SCYCA STANDARD; PRT; 11 AA.  
 AC P41333;  
 DT 01-FEB-1995 (Rel. 31, Created)  
 DT 01-FEB-1995 (Rel. 31, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Substance P.  
 OS Scyliorhinus canicula (Spotted dogfish) (Spotted catshark).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Chondrichthyes;  
 OC Elasmobranchii; Galeomorphii; Galeoidea; Carcharhiniformes;  
 OC Scyliorhinidae; Scyliorhinus.

OX NCBI\_TaxID=7830;  
 RN [1]  
 RP SEQUENCE.  
 RC TISSUE=Brain;  
 RX MEDLINE=93292508; PubMed=7685693;  
 RA Waugh D., Wang Y., Hazon N., Balment R.J., Conlon J.M.;  
 RT "Primary structures and biological activities of substance-P-related  
 RT peptides from the brain of the dogfish, *Scyliorhinus canicula*.";  
 RL Eur. J. Biochem. 214:469-474(1993).  
 CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,  
 CC evoke behavioral responses, are potent vasodilators and  
 CC secretagogues, and contract (directly or indirectly) many smooth  
 CC muscles.  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- SIMILARITY: Belongs to the tachykinin family.  
 DR PIR; S33300; S33300.  
 DR InterPro; IPR002040; Tachy\_Neurokinin.  
 DR PROSITE; PS00267; TACHYKININ; 1.  
 KW Tachykinin; Neuropeptide; Amidation; Neurotransmitter.  
 FT MOD\_RES 11 11 AMIDATION.  
 SQ SEQUENCE 11 AA; 1278 MW; 214860DEC9D6D867 CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 10 LM 11  
 ||  
 Db 10 LM 11

#### RESULT 24

##### TKN\_ELEMO

ID TKN\_ELEMO STANDARD; PRT; 11 AA.  
 AC P01293;  
 DT 21-JUL-1986 (Rel. 01, Created)  
 DT 01-FEB-1994 (Rel. 28, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Eledoisin.  
 OS Eledone moschata (Musky octopus) (*Ozaena moschata*), and  
 OS Eledone cirrhosa (Curled octopus) (*Ozaena cirrosa*).  
 OC Eukaryota; Metazoa; Mollusca; Cephalopoda; Coleoidea; Neocoleoidea;  
 OC Octopodiformes; Octopoda; Incirrata; Octopodidae; Eledone.  
 OX NCBI\_TaxID=6641, 102876;  
 RN [1]  
 RP SEQUENCE.  
 RA Anastasi A., Erspamer V.;  
 RT "The isolation and amino acid sequence of eledoisin, the active  
 RT endecapeptide of the posterior salivary glands of Eledone.";  
 RL Arch. Biochem. Biophys. 101:56-65(1963).  
 CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,  
 CC evoke behavioral responses, are potent vasodilators and  
 CC secretagogues, and contract (directly or indirectly) many smooth  
 CC muscles.  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- TISSUE SPECIFICITY: Skin.  
 CC -!- SIMILARITY: Belongs to the tachykinin family.

DR PIR; A01561; EEOC.  
 DR PIR; B01561; EEOCC.  
 DR PDB; 1MXQ; 18-FEB-03.  
 DR InterPro; IPR002040; Tachy\_Neurokinin.  
 DR PROSITE; PS00267; TACHYKININ; 1.  
 KW Tachykinin; Neuropeptide; Amidation; Pyrrolidone carboxylic acid;  
 KW 3D-structure.  
 FT MOD\_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.  
 FT MOD\_RES 11 11 AMIDATION.  
 SQ SEQUENCE 11 AA; 1206 MW; 570D7C2559CDDAA3 CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
 Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 LM 11  
 ||  
 Db 10 LM 11

# RESULT 25

## TKN\_PHYFU

ID TKN\_PHYFU STANDARD; PRT; 11 AA.  
 AC P08615;  
 DT 01-AUG-1988 (Rel. 08, Created)  
 DT 01-FEB-1994 (Rel. 28, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Physalaemin.  
 OS Physalaemus fuscumaculatus (Neotropical frog).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Leptodactylidae;  
 OC Leptodactylinae; Physalaemus.  
 OX NCBI\_TaxID=8378;  
 RN [1]  
 RP SEQUENCE.  
 RC TISSUE=Skin secretion;  
 RX MEDLINE=66076612; PubMed=5857249;  
 RA Erspamer V., Anastasi A., Bertaccini G., Cei J.M.;  
 RT "Structure and pharmacological actions of physalaemin, the main  
 RT active polypeptide of the skin of Physalaemus fuscumaculatus.";  
 RL Experientia 20:489-490(1964).  
 CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,  
 CC evoke behavioral responses, are potent vasodilators and  
 CC secretagogues, and contract (directly or indirectly) many smooth  
 CC muscles.  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- TISSUE SPECIFICITY: Skin.  
 CC -!- SIMILARITY: Belongs to the tachykinin family.  
 DR PIR; S07201; S07201.  
 DR InterPro; IPR002040; Tachy\_Neurokinin.  
 DR Pfam; PF02202; Tachykinin; 1.  
 DR PROSITE; PS00267; TACHYKININ; 1.  
 KW Amphibian defense peptide; Tachykinin; Neuropeptide; Amidation;  
 KW Pyrrolidone carboxylic acid.  
 FT MOD\_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.  
 FT MOD\_RES 11 11 AMIDATION.  
 SQ SEQUENCE 11 AA; 1283 MW; 3293693E59C33457 CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 LM 11  
||  
Db 10 LM 11

RESULT 26

UXB2\_YEAST

ID UXB2\_YEAST STANDARD; PRT; 11 AA.  
AC P99013;  
DT 01-NOV-1995 (Rel. 32, Created)  
DT 01-NOV-1995 (Rel. 32, Last sequence update)  
DT 15-MAR-2004 (Rel. 43, Last annotation update)  
DE Unknown protein from 2D-page (Spot 2D-000K2F) (Fragment).  
OS Saccharomyces cerevisiae (Baker's yeast).  
OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;  
OC Saccharomycetales; Saccharomycetaceae; Saccharomyces.  
OX NCBI\_TaxID=4932;  
RN [1]  
RP SEQUENCE.  
RC STRAIN=X2180-1A;  
RA Sanchez J.-C., Golaz O., Schaller D., Morch F., Frutiger S.,  
RA Hughes G.J., Appel R.D., Deshusses J., Hochstrasser D.F.;  
RL Submitted (AUG-1995) to Swiss-Prot.  
CC -!- MISCELLANEOUS: On the 2D-gel the determined pI of this unknown  
CC protein is: 6.20, its MW is: 9.2 kDa.  
DR SWISS-2DPAGE; P99013; YEAST.  
FT NON\_TER 11 11  
SQ SEQUENCE 11 AA; 1328 MW; EC38021C0DCB42DA CRC64;

Query Match 18.2%; Score 2; DB 1; Length 11;  
Best Local Similarity 100.0%; Pred. No. 1.1e+04;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 RK 5  
||  
Db 8 RK 9

RESULT 27

ANGT\_CRIGE

ID ANGT\_CRIGE STANDARD; PRT; 11 AA.  
AC P09037;  
DT 01-NOV-1988 (Rel. 09, Created)  
DT 01-NOV-1988 (Rel. 09, Last sequence update)  
DT 10-OCT-2003 (Rel. 42, Last annotation update)  
DE Crinia-angiotensin II.  
OS Crinia georgiana (Quacking frog).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Myobatrachidae;  
OC Myobatrachinae; Crinia.  
OX NCBI\_TaxID=8374;  
RN [1]

RP SEQUENCE.  
 RC TISSUE=Skin secretion;  
 RX MEDLINE=80024575; PubMed=488254;  
 RA Erspamer V., Melchiorri P., Nakajima T., Yasuhara T., Endean R.;  
 RT "Amino acid composition and sequence of crinia-angiotensin, an  
 RT angiotensin II-like endecapeptide from the skin of the Australian  
 RT frog *Crinia georgiana*.";   
 RL Experientia 35:1132-1133(1979).  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- TISSUE SPECIFICITY: Skin.  
 DR PIR; S07207; S07207.  
 KW Vasoconstrictor.  
 SQ SEQUENCE 11 AA; 1271 MW; 8A0921F7DB50440A CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 A 1  
 |  
 Db 1 A 1

# RESULT 28

ASL1\_BACSE

ID ASL1\_BACSE STANDARD; PRT; 11 AA.  
 AC P83146;  
 DT 28-FEB-2003 (Rel. 41, Created)  
 DT 28-FEB-2003 (Rel. 41, Last sequence update)  
 DT 28-FEB-2003 (Rel. 41, Last annotation update)  
 DE Acharan sulfate lyase 1 (EC 4.2.2.-) (Fragment).  
 OS Bacteroides stercoris.  
 OC Bacteria; Bacteroidetes; Bacteroides (class); Bacteroidales;  
 OC Bacteroidaceae; Bacteroides.  
 OX NCBI\_TaxID=46506;  
 RN [1]  
 RP SEQUENCE, FUNCTION, ENZYME REGULATION, AND SUBUNIT.  
 RC STRAIN=HJ-15;  
 RX MEDLINE=21223019; PubMed=11322884;  
 RA Kim B.-T., Hong S.-W., Kim W.-S., Kim Y.S., Kim D.-H.;  
 RT "Purification and characterization of acharan sulfate lyases, two  
 RT novel heparinases, from *Bacteroides stercoris* HJ-15.";   
 RL Eur. J. Biochem. 268:2635-2641(2001).  
 CC -!- FUNCTION: Degrades acharan sulfate and, to a lesser extent,  
 CC heparin and heparan sulfate.  
 CC -!- ENZYME REGULATION: Inhibited by cupric ion, nitrogen and cobalt.  
 CC Activated by reducing agents, such as DL-dithiothreitol and 2-  
 CC mercaptoethanol.  
 CC -!- SUBUNIT: Monomer.  
 CC -!- PTM: The N-terminus is blocked.  
 CC -!- MISCELLANEOUS: Has an isoelectric point of 8.6. Its optimum pH is  
 CC 7.2 and optimum temperature 45 degrees Celsius.  
 KW Lyase; Heparin-binding.  
 FT NON\_TER 1 1  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1395 MW; 01B2DAA241E865AB CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 N 7  
|  
Db 1 N 1

RESULT 29

ASL2\_BACSE

ID ASL2\_BACSE STANDARD; PRT; 11 AA.  
AC P83147;  
DT 28-FEB-2003 (Rel. 41, Created)  
DT 28-FEB-2003 (Rel. 41, Last sequence update)  
DT 28-FEB-2003 (Rel. 41, Last annotation update)  
DE Acharan sulfate lyase 2 (EC 4.2.2.-) (Fragment).  
OS Bacteroides stercoris.  
OC Bacteria; Bacteroidetes; Bacteroides (class); Bacteroidales;  
OC Bacteroidaceae; Bacteroides.  
OX NCBI\_TaxID=46506;  
RN [1]  
RP SEQUENCE, FUNCTION, ENZYME REGULATION, AND SUBUNIT.  
RC STRAIN=HJ-15;  
RX MEDLINE=21223019; PubMed=11322884;  
RA Kim B.-T., Hong S.-W., Kim W.-S., Kim Y.S., Kim D.-H.;  
RT "Purification and characterization of acharan sulfate lyases, two  
RT novel heparinases, from Bacteroides stercoris HJ-15."  
RL Eur. J. Biochem. 268:2635-2641(2001).  
CC -!- FUNCTION: Degrades acharan sulfate and, to a lesser extent,  
CC heparin and heparan sulfate.  
CC -!- ENZYME REGULATION: Inhibited by cupric ion, nitrogen and lead.  
CC Activated by reducing agents, such as DL-dithiothreitol and 2-  
CC mercaptoethanol.  
CC -!- SUBUNIT: Monomer.  
CC -!- PTM: The N-terminus is blocked.  
CC -!- MISCELLANEOUS: Has an isoelectric point of 8.6. Its optimum pH is  
CC 7.2 and optimum temperature 45 degrees Celsius.  
KW Lyase; Heparin-binding.  
FT NON\_TER 1 1  
FT NON\_TER 11 11  
SQ SEQUENCE 11 AA; 1195 MW; D79D897C7AA451AD CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 A 1  
|  
Db 4 A 4

RESULT 30

BPP3\_BOTIN

ID BPP3\_BOTIN STANDARD; PRT; 11 AA.  
AC P30423;  
DT 01-APR-1993 (Rel. 25, Created)

DT 01-FEB-1994 (Rel. 28, Last sequence update)  
 DT 28-FEB-2003 (Rel. 41, Last annotation update)  
 DE Bradykinin-potentiating peptide S4,3,2 (10C) (Angiotensin-converting  
 DE enzyme inhibitor).  
 OS Bothrops insularis (Island jararaca) (Queimada jararaca).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Lepidosauria; Squamata; Scleroglossa; Serpentes; Colubroidea;  
 OC Viperidae; Crotalinae; Bothrops.  
 OX NCBI\_TaxID=8723;  
 RN [1]  
 RP SEQUENCE.  
 RC TISSUE=Venom;  
 RX MEDLINE=90351557; PubMed=2386615;  
 RA Cintra A.C.O., Vieira C.A., Giglio J.R.;  
 RT "Primary structure and biological activity of bradykinin potentiating  
 RT peptides from Bothrops insularis snake venom."  
 RL J. Protein Chem. 9:221-227(1990).  
 CC -!- FUNCTION: This peptide both inhibits the activity of the  
 CC angiotensin-converting enzyme and enhances the action of  
 CC bradykinin by inhibiting the kinases that inactivate it.  
 CC It acts as an indirect hypotensive agent.  
 DR PIR; C37196; C37196.  
 KW Hypotensive agent; Pyrrolidone carboxylic acid.  
 FT MOD\_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.  
 SQ SEQUENCE 11 AA; 1199 MW; 20B25813C7741777 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 6 G 6  
 |  
 Db 3 G 3

RESULT 31  
 BPP4\_BOTIN  
 ID BPP4\_BOTIN STANDARD; PRT; 11 AA.  
 AC P30424;  
 DT 01-APR-1993 (Rel. 25, Created)  
 DT 01-FEB-1994 (Rel. 28, Last sequence update)  
 DT 28-FEB-2003 (Rel. 41, Last annotation update)  
 DE Bradykinin-potentiating peptide S4,1,2 (Angiotensin-converting  
 DE enzyme inhibitor).  
 OS Bothrops insularis (Island jararaca) (Queimada jararaca).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Lepidosauria; Squamata; Scleroglossa; Serpentes; Colubroidea;  
 OC Viperidae; Crotalinae; Bothrops.  
 OX NCBI\_TaxID=8723;  
 RN [1]  
 RP SEQUENCE.  
 RC TISSUE=Venom;  
 RX MEDLINE=90351557; PubMed=2386615;  
 RA Cintra A.C.O., Vieira C.A., Giglio J.R.;  
 RT "Primary structure and biological activity of bradykinin potentiating  
 RT peptides from Bothrops insularis snake venom."  
 RL J. Protein Chem. 9:221-227(1990).

CC -!- FUNCTION: This peptide both inhibits the activity of the  
 CC angiotensin-converting enzyme and enhances the action of  
 CC bradykinin by inhibiting the kinases that inactivate it.  
 CC It acts as an indirect hypotensive agent.  
 DR PIR; D37196; D37196.  
 KW Hypotensive agent; Pyrrolidone carboxylic acid.  
 FT MOD\_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.  
 SQ SEQUENCE 11 AA; 1143 MW; 20BBBF13C7741777 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 G 6  
 |  
 Db 2 G 2

# RESULT 32

BPPB AGKHA

ID BPPB AGKHA STANDARD; PRT; 11 AA.  
 AC P01021;  
 DT 21-JUL-1986 (Rel. 01, Created)  
 DT 01-FEB-1994 (Rel. 28, Last sequence update)  
 DT 28-FEB-2003 (Rel. 41, Last annotation update)  
 DE Bradykinin-potentiating peptide B (Angiotensin-converting  
 DE enzyme inhibitor).  
 OS Agkistrodon halys blomhoffii (Mamushi) (Gloydus blomhoffii).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Lepidosauria; Squamata; Scleroglossa; Serpentes; Colubroidea;  
 OC Viperidae; Crotalinae; Gloydus.  
 OX NCBI\_TaxID=242054;  
 RN [1]  
 RP SEQUENCE.  
 RC TISSUE=Venom;  
 RA Kato H., Suzuki T.;  
 RT "Amino acid sequence of bradykinin-potentiating peptide isolated from  
 RT the venom of Agkistrodon halys blomhoffii."  
 RL Proc. Jpn. Acad., B, Phys. Biol. Sci. 46:176-181(1970).  
 CC -!- FUNCTION: This peptide both inhibits the activity of the  
 CC angiotensin-converting enzyme and enhances the action of  
 CC bradykinin by inhibiting the kinases that inactivate it.  
 CC It acts as an indirect hypotensive agent.  
 DR PIR; A01254; XASNBA.  
 KW Hypotensive agent; Pyrrolidone carboxylic acid.  
 FT MOD\_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.  
 SQ SEQUENCE 11 AA; 1199 MW; 295CBF0627741777 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 G 6  
 |  
 Db 2 G 2



RESULT 33

BPP\_AGKHP

ID BPP\_AGKHP STANDARD; PRT; 11 AA.  
 AC P04562;  
 DT 13-AUG-1987 (Rel. 05, Created)  
 DT 01-FEB-1994 (Rel. 28, Last sequence update)  
 DT 28-FEB-2003 (Rel. 41, Last annotation update)  
 DE Bradykinin-potentiating peptide (Angiotensin-converting  
 DE enzyme inhibitor).  
 OS Agkistrodon halys pallas (Chinese water mocassin) (Gloydus halys  
 OS pallas).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Lepidosauria; Squamata; Scleroglossa; Serpentes; Colubroidea;  
 OC Viperidae; Crotalinae; Gloydus.  
 OX NCBI\_TaxID=8714;  
 RN [1]  
 RP SEQUENCE.  
 RC TISSUE=Venom;  
 RX MEDLINE=86177022; PubMed=3008123;  
 RA Chi C.-W., Wang S.-Z., Xu L.-G., Wang M.-Y., Lo S.-S., Huang W.-D.;  
 RT "Structure-function studies on the bradykinin potentiating peptide  
 RT from Chinese snake venom (Agkistrodon halys pallas).";  
 RL Peptides 6 Suppl. 3:339-342(1985).  
 CC -!- FUNCTION: This peptide both inhibits the activity of the  
 CC angiotensin-converting enzyme and enhances the action of  
 CC bradykinin by inhibiting the kinases that inactivate it.  
 CC It acts as an indirect hypotensive agent.  
 DR PIR; JC0002; XAVIBH.  
 KW Hypotensive agent; Pyrrolidone carboxylic acid.  
 FT MOD RES 1 1 PYRROLIDONE CARBOXYLIC ACID.  
 SQ SEQUENCE 11 AA; 1112 MW; 30BABF1277686777 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 G 6  
 |  
 Db 2 G 2

RESULT 34

CA21\_LITCI

ID CA21\_LITCI STANDARD; PRT; 11 AA.  
 AC P82087;  
 DT 16-OCT-2001 (Rel. 40, Created)  
 DT 16-OCT-2001 (Rel. 40, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Caerulein 2.1/2.1Y4.  
 OS Litoria citropa (Australian blue mountains tree frog).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Hylidae;  
 OC Pelodyadinae; Litoria.  
 OX NCBI\_TaxID=94770;  
 RN [1]  
 RP SEQUENCE, AND MASS SPECTROMETRY.  
 RC TISSUE=Skin secretion;

RX MEDLINE=20057701; PubMed=10589099;  
 RA Wabnitz P.A., Bowie J.H., Tyler M.J.;  
 RT "Caerulein-like peptides from the skin glands of the Australian blue  
 RT mountains tree frog *Litoria citropa*. Part 1. Sequence determination  
 RT using electrospray mass spectrometry."  
 RL Rapid Commun. Mass Spectrom. 13:2498-2502(1999).  
 CC -!- FUNCTION: Hypotensive neuropeptide (Probable).  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- TISSUE SPECIFICITY: Skin dorsal glands.  
 CC -!- PTM: Isoform 2.1Y4 differs from isoform 2.1 in not being  
 CC sulfated.  
 CC -!- MASS SPECTROMETRY: MW=1372; METHOD=Electrospray.  
 CC -!- SIMILARITY: Belongs to the gastrin/cholecystokinin family.  
 DR InterPro; IPR001651; Gastrin.  
 DR PROSITE; PS00259; GASTRIN; FALSE\_NEG.  
 KW Amphibian defense peptide; Hypotensive agent; Amidation; Sulfation;  
 KW Pyrrolidone carboxylic acid.  
 FT MOD\_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.  
 FT MOD\_RES 4 4 SULFATION.  
 FT MOD\_RES 11 11 AMIDATION.  
 SQ SEQUENCE 11 AA; 1312 MW; 10DAB7C4EDD861BB CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 G 6  
 |  
 Db 6 G 6

# RESULT 35

## CA22\_LITCI

ID CA22\_LITCI STANDARD; PRT; 11 AA.  
 AC P82088;  
 DT 16-OCT-2001 (Rel. 40, Created)  
 DT 16-OCT-2001 (Rel. 40, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Caerulein 2.2/2.2Y4.  
 OS *Litoria citropa* (Australian blue mountains tree frog).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Hylidae;  
 OC Pelodyadinae; *Litoria*.  
 OX NCBI\_TaxID=94770;  
 RN [1]  
 RP SEQUENCE, AND MASS SPECTROMETRY.  
 RC TISSUE=Skin secretion;  
 RX MEDLINE=20057701; PubMed=10589099;  
 RA Wabnitz P.A., Bowie J.H., Tyler M.J.;  
 RT "Caerulein-like peptides from the skin glands of the Australian blue  
 RT mountains tree frog *Litoria citropa*. Part 1. Sequence determination  
 RT using electrospray mass spectrometry."  
 RL Rapid Commun. Mass Spectrom. 13:2498-2502(1999).  
 CC -!- FUNCTION: Hypotensive neuropeptide (Probable).  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- TISSUE SPECIFICITY: Skin dorsal glands.  
 CC -!- PTM: Isoform 2.2Y4 differs from isoform 2.2 in not being

CC sulfated.  
 CC -- MASS SPECTROMETRY: MW=1388; METHOD=Electrospray.  
 CC -- SIMILARITY: Belongs to the gastrin/cholecystokinin family.  
 DR InterPro; IPR001651; Gastrin.  
 DR PROSITE; PS00259; GASTRIN; FALSE\_NEG.  
 KW Amphibian defense peptide; Hypotensive agent; Amidation; Sulfation;  
 KW Pyrrolidone carboxylic acid.  
 FT MOD\_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.  
 FT MOD\_RES 4 4 SULFATION.  
 FT MOD\_RES 11 11 AMIDATION.  
 SQ SEQUENCE 11 AA; 1328 MW; 10DAB894EDD861BB CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 6 G 6  
 |  
 Db 6 G 6

# RESULT 36

CA31\_LITCI  
 ID CA31\_LITCI STANDARD; PRT; 11 AA.  
 AC P82089;  
 DT 16-OCT-2001 (Rel. 40, Created)  
 DT 16-OCT-2001 (Rel. 40, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Caerulein 3.1/3.1Y4.  
 OS Litoria citropa (Australian blue mountains tree frog).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Hylidae;  
 OC Pelodyadinae; Litoria.  
 OX NCBI\_TaxID=94770;  
 RN [1]  
 RP SEQUENCE, AND MASS SPECTROMETRY.  
 RC TISSUE=Skin secretion;  
 RX MEDLINE=20057701; PubMed=10589099;  
 RA Wabnitz P.A., Bowie J.H., Tyler M.J.;  
 RT "Caerulein-like peptides from the skin glands of the Australian blue  
 RT mountains tree frog Litoria citropa. Part 1. Sequence determination  
 RT using electrospray mass spectrometry."  
 RL Rapid Commun. Mass Spectrom. 13:2498-2502(1999).  
 CC -- FUNCTION: Hypotensive neuropeptide (Probable).  
 CC -- SUBCELLULAR LOCATION: Secreted.  
 CC -- TISSUE SPECIFICITY: Skin dorsal glands.  
 CC -- PTM: Isoform 3.1Y4 differs from isoform 3.1 in not being  
 CC sulfated.  
 CC -- MASS SPECTROMETRY: MW=1407; METHOD=Electrospray.  
 CC -- SIMILARITY: Belongs to the gastrin/cholecystokinin family.  
 DR InterPro; IPR001651; Gastrin.  
 DR PROSITE; PS00259; GASTRIN; FALSE\_NEG.  
 KW Amphibian defense peptide; Hypotensive agent; Amidation; Sulfation;  
 KW Pyrrolidone carboxylic acid.  
 FT MOD\_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.  
 FT MOD\_RES 4 4 SULFATION.  
 FT MOD\_RES 11 11 AMIDATION.

SQ SEQUENCE 11 AA; 1347 MW; 10DAB7D67861A86B CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 G 6  
|  
Db 5 G 5

RESULT 37

CA32\_LITCI

ID CA32\_LITCI STANDARD; PRT; 11 AA.  
AC P82090;  
DT 16-OCT-2001 (Rel. 40, Created)  
DT 16-OCT-2001 (Rel. 40, Last sequence update)  
DT 10-OCT-2003 (Rel. 42, Last annotation update)  
DE Caerulein 3.2/3.2Y4.  
OS Litoria citropa (Australian blue mountains tree frog).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Hylidae;  
OC Pelodryadinae; Litoria.  
OX NCBI\_TaxID=94770;  
RN [1]  
RP SEQUENCE, AND MASS SPECTROMETRY.  
RC TISSUE=Skin secretion;  
RX MEDLINE=20057701; PubMed=10589099;  
RA Wabnitz P.A., Bowie J.H., Tyler M.J.;  
RT "Caerulein-like peptides from the skin glands of the Australian blue  
RT mountains tree frog Litoria citropa. Part 1. Sequence determination  
RT using electrospray mass spectrometry."  
RL Rapid Commun. Mass Spectrom. 13:2498-2502(1999).  
CC -!- FUNCTION: Hypotensive neuropeptide (Probable).  
CC -!- SUBCELLULAR LOCATION: Secreted.  
CC -!- TISSUE SPECIFICITY: Skin dorsal glands.  
CC -!- PTM: Isoform 3.2Y4 differs from isoform 3.2 in not being  
CC sulfated.  
CC -!- MASS SPECTROMETRY: MW=1423; METHOD=Electrospray.  
CC -!- SIMILARITY: Belongs to the gastrin/cholecystokinin family.  
DR InterPro; IPR001651; Gastrin.  
DR PROSITE; PS00259; GASTRIN; FALSE\_NEG.  
KW Amphibian defense peptide; Hypotensive agent; Amidation; Sulfation;  
KW Pyrrolidone carboxylic acid.  
FT MOD\_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.  
FT MOD\_RES 4 4 SULFATION.  
FT MOD\_RES 11 11 AMIDATION.  
SQ SEQUENCE 11 AA; 1363 MW; 10DAB8867861A86B CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 G 6  
|  
Db 5 G 5

RESULT 38

CA41\_LITCI

ID CA41\_LITCI STANDARD; PRT; 11 AA.  
 AC P82091;  
 DT 16-OCT-2001 (Rel. 40, Created)  
 DT 16-OCT-2001 (Rel. 40, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Caerulein 4.1/4.1Y4.  
 OS Litoria citropa (Australian blue mountains tree frog).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Hylidae;  
 OC Pelodyadinae; Litoria.  
 OX NCBI\_TaxID=94770;  
 RN [1]  
 RP SEQUENCE, AND MASS SPECTROMETRY.  
 RC TISSUE=Skin secretion;  
 RX MEDLINE=20057701; PubMed=10589099;  
 RA Wabnitz P.A., Bowie J.H., Tyler M.J.;  
 RT "Caerulein-like peptides from the skin glands of the Australian blue  
 RT montains tree frog Litoria citropa. Part 1. Sequence determination  
 RT using electrospray mass spectrometry."  
 RL Rapid Commun. Mass Spectrom. 13:2498-2502(1999).  
 CC -!- FUNCTION: Hypotensive neuropeptide (Probable).  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- TISSUE SPECIFICITY: Skin dorsal glands.  
 CC -!- PTM: Isoform 4.1Y4 differs from isoform 4.1 in not being  
 CC sulfated.  
 CC -!- MASS SPECTROMETRY: MW=1388; METHOD=Electrospray.  
 CC -!- SIMILARITY: Belongs to the gastrin/cholecystokinin family.  
 DR InterPro; IPR001651; Gastrin.  
 DR PROSITE; PS00259; GASTRIN; FALSE\_NEG.  
 KW Amphibian defense peptide; Hypotensive agent; Amidation; Sulfation;  
 KW Pyrrolidone carboxylic acid.  
 FT MOD\_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.  
 FT MOD\_RES 4 4 SULFATION.  
 FT MOD\_RES 11 11 AMIDATION.  
 SQ SEQUENCE 11 AA; 1328 MW; 10DAB7C4F5B861BB CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 G 6  
 |  
 Db 6 G 6

RESULT 39

CA42\_LITCI

ID CA42\_LITCI STANDARD; PRT; 11 AA.  
 AC P82092;  
 DT 16-OCT-2001 (Rel. 40, Created)  
 DT 16-OCT-2001 (Rel. 40, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Caerulein 4.2/4.2Y4.  
 OS Litoria citropa (Australian blue mountains tree frog).

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Hylidae;  
 OC Pelodyadinae; Litoria.  
 OX NCBI\_TaxID=94770;  
 RN [1]  
 RP SEQUENCE, AND MASS SPECTROMETRY.  
 RC TISSUE=Skin secretion;  
 RX MEDLINE=20057701; PubMed=10589099;  
 RA Wabnitz P.A., Bowie J.H., Tyler M.J.;  
 RT "Caerulein-like peptides from the skin glands of the Australian blue  
 RT montains tree frog Litoria citropa. Part 1. Sequence determination  
 RT using electrospray mass spectrometry."  
 RL Rapid Commun. Mass Spectrom. 13:2498-2502(1999).  
 CC -!- FUNCTION: Hypotensive neuropeptide (Probable).  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- TISSUE SPECIFICITY: Skin dorsal glands.  
 CC -!- PTM: Isoform 4.2Y4 differs from isoform 4.2 in not being  
 CC sulfated.  
 CC -!- MASS SPECTROMETRY: MW=1404; METHOD=Electrospray.  
 CC -!- SIMILARITY: Belongs to the gastrin/cholecystokinin family.  
 DR InterPro; IPR001651; Gastrin.  
 DR PROSITE; PS00259; GASTRIN; FALSE\_NEG.  
 KW Amphibian defense peptide; Hypotensive agent; Amidation; Sulfation;  
 KW Pyrrolidone carboxylic acid.  
 FT MOD\_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.  
 FT MOD\_RES 4 4 SULFATION.  
 FT MOD\_RES 11 11 AMIDATION.  
 SQ SEQUENCE 11 AA; 1344 MW; 10DAB894F5B861BB CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 6 G 6  
 |  
 Db 6 G 6

#### RESULT 40

CEP1\_ACHFU

ID CEP1\_ACHFU STANDARD; PRT; 11 AA.  
 AC P22790;  
 DT 01-AUG-1991 (Rel. 19, Created)  
 DT 01-AUG-1991 (Rel. 19, Last sequence update)  
 DT 01-DEC-1992 (Rel. 24, Last annotation update)  
 DE Cardio-excitatory peptide-1 (ACEP-1).  
 OS Achatina fulica (Giant African snail).  
 OC Eukaryota; Metazoa; Mollusca; Gastropoda; Pulmonata; Stylommatophora;  
 OC Sigmurethra; Achatinoidea; Achatinidae; Achatina.  
 OX NCBI\_TaxID=6530;  
 RN [1]  
 RP SEQUENCE.  
 RC STRAIN=Ferussac; TISSUE=Heart atrium;  
 RX MEDLINE=90211261; PubMed=2322251;  
 RA Fujimoto K., Ohta N., Yoshida M., Kubota I., Muneoka Y., Kobayashi M.;  
 RT "A novel cardio-excitatory peptide isolated from the atria of the  
 RT African giant snail, Achatina fulica."

RL Biochem. Biophys. Res. Commun. 167:777-783(1990).  
 CC -!- FUNCTION: Potentiates the beat of the ventricle, and has also  
 CC excitatory actions on the penis retractor muscle, the buccal  
 CC muscle and the identified neurons controlling the buccal muscle  
 CC movement of achatina.  
 CC -!- SIMILARITY: TO POSSIBLE PEPTIDE L5 FROM APLYSIA.  
 DR PIR; A34662; A34662.  
 KW Hormone; Amidation.  
 FT MOD\_RES 11 11 AMIDATION.  
 SQ SEQUENCE 11 AA; 1305 MW; 82D6D5B9C7741365 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 S 3  
 |  
 Db 1 S 1

# RESULT 41

## COXA\_CANFA

ID COXA\_CANFA STANDARD; PRT; 11 AA.  
 AC P99501;  
 DT 15-JUL-1998 (Rel. 36, Created)  
 DT 15-JUL-1998 (Rel. 36, Last sequence update)  
 DT 30-MAY-2000 (Rel. 39, Last annotation update)  
 DE Cytochrome c oxidase polypeptide Va (EC 1.9.3.1) (Fragment).  
 GN COX5A.  
 OS Canis familiaris (Dog).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.  
 OX NCBI\_TaxID=9615;  
 RN [1]  
 RP SEQUENCE.  
 RC TISSUE=Heart;  
 RX MEDLINE=98163340; PubMed=9504812;  
 RA Dunn M.J., Corbett J.M., Wheeler C.H.;  
 RT "HSC-2DPAGE and the two-dimensional gel electrophoresis database of  
 RT dog heart proteins.";  
 RL Electrophoresis 18:2795-2802(1997).  
 CC -!- FUNCTION: This is the heme A-containing chain of cytochrome c  
 CC oxidase, the terminal oxidase in mitochondrial electron transport.  
 CC -!- CATALYTIC ACTIVITY: 4 ferrocytochrome c + O(2) = 4 ferricytochrome  
 CC c + 2 H(2)O.  
 CC -!- SUBCELLULAR LOCATION: Mitochondrial inner membrane.  
 CC -!- SIMILARITY: Belongs to the cytochrome c oxidase Va family.  
 DR HSC-2DPAGE; P99501; DOG.  
 DR InterPro; IPR003204; Cyt\_c\_ox5A.  
 DR Pfam; PF02284; COX5A; 1.  
 KW Oxidoreductase; Heme; Mitochondrion; Inner membrane.  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1274 MW; 910B35C5B1AB11F5 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 S 3  
|  
Db 1 S 1

RESULT 42

CSI5\_BACSU

ID CSI5\_BACSU STANDARD; PRT; 11 AA.  
AC P81095;  
DT 15-JUL-1998 (Rel. 36, Created)  
DT 15-JUL-1998 (Rel. 36, Last sequence update)  
DT 28-FEB-2003 (Rel. 41, Last annotation update)  
DE Cold shock protein CSI5 (11 kDa cold shock protein) (Fragment).  
OS Bacillus subtilis.  
OC Bacteria; Firmicutes; Bacillales; Bacillaceae; Bacillus.  
OX NCBI\_TaxID=1423;  
RN [1]  
RP SEQUENCE.  
RC STRAIN=168 / JH642;  
RA Graumann P.L., Schmid R., Marahiel M.A.;  
RL Submitted (OCT-1997) to Swiss-Prot.  
RN [2]  
RP CHARACTERIZATION.  
RC STRAIN=168 / JH642;  
RX MEDLINE=96345629; PubMed=8755892;  
RA Graumann P., Schroeder K., Schmid R., Marahiel M.A.;  
RT "Cold shock stress-induced proteins in Bacillus subtilis.";  
RL J. Bacteriol. 178:4611-4619(1996).  
CC -!- SUBCELLULAR LOCATION: Cytoplasmic.  
CC -!- INDUCTION: In response to low temperature.  
CC -!- CAUTION: Could not be found in the genome of B.subtilis 168.  
FT NON\_TER 11 11  
SQ SEQUENCE 11 AA; 1360 MW; 15F6ECEE6322C330 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 R 4  
|  
Db 2 R 2

RESULT 43

CX5A\_CONAL

ID CX5A\_CONAL STANDARD; PRT; 11 AA.  
AC P58848;  
DT 28-FEB-2003 (Rel. 41, Created)  
DT 28-FEB-2003 (Rel. 41, Last sequence update)  
DT 15-MAR-2004 (Rel. 43, Last annotation update)  
DE Conotoxin au5a.  
OS Conus aulicus (Court cone).  
OC Eukaryota; Metazoa; Mollusca; Gastropoda; Orthogastropoda;  
OC Apogastropoda; Caenogastropoda; Sorbeoconcha; Hypsogastropoda;  
OC Neogastropoda; Conoidea; Conidae; Conus.  
OX NCBI\_TaxID=89437;



RN [1]  
 RP SEQUENCE, SYNTHESIS, AND MASS SPECTROMETRY.  
 RC TISSUE=Venom;  
 RX MEDLINE=99452958; PubMed=10521453;  
 RA Walker C.S., Steel D., Jacobsen R.B., Lirazan M.B., Cruz L.J.,  
 RA Hooper D., Shetty R., DelaCruz R.C., Nielsen J.S., Zhou L.M.,  
 RA Bandyopadhyay P., Craig A.G., Olivera B.M.;  
 RT "The T-superfamily of conotoxins."  
 RL J. Biol. Chem. 274:30664-30671(1999).  
 RN [2]  
 RP ERRATUM.  
 RA Walker C.S., Steel D., Jacobsen R.B., Lirazan M.B., Cruz L.J.,  
 RA Hooper D., Shetty R., DelaCruz R.C., Nielsen J.S., Zhou L.M.,  
 RA Bandyopadhyay P., Craig A.G., Olivera B.M.;  
 RL J. Biol. Chem. 274:36030-36030(1999).  
 CC -!- FUNCTION: Causes dorsal fins drooping in fish. No effect is  
 CC observed when injected into mice.  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- TISSUE SPECIFICITY: Expressed by the venom duct.  
 CC -!- MASS SPECTROMETRY: MW=1436.6; METHOD=LSIMS.  
 CC -!- SIMILARITY: Belongs to the conotoxin T-superfamily.  
 DR PIR; A59146; A59146.  
 KW Toxin.  
 FT DISULFID 2 9  
 FT DISULFID 3 10  
 SQ SEQUENCE 11 AA; 1441 MW; 21A36775440059D7 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 R 4  
 |  
 Db 7 R 7

#### RESULT 44

##### CX5B\_CONAL

ID CX5B\_CONAL STANDARD; PRT; 11 AA.  
 AC P58849;  
 DT 28-FEB-2003 (Rel. 41, Created)  
 DT 28-FEB-2003 (Rel. 41, Last sequence update)  
 DT 15-MAR-2004 (Rel. 43, Last annotation update)  
 DE Conotoxin au5b.  
 OS Conus aulicus (Court cone).  
 OC Eukaryota; Metazoa; Mollusca; Gastropoda; Orthogastropoda;  
 OC Apogastropoda; Caenogastropoda; Sorbeoconcha; Hypsogastropoda;  
 OC Neogastropoda; Conoidea; Conidae; Conus.  
 OX NCBI\_TaxID=89437;  
 RN [1]  
 RP SEQUENCE, AND MASS SPECTROMETRY.  
 RC TISSUE=Venom;  
 RX MEDLINE=99452958; PubMed=10521453;  
 RA Walker C.S., Steel D., Jacobsen R.B., Lirazan M.B., Cruz L.J.,  
 RA Hooper D., Shetty R., DelaCruz R.C., Nielsen J.S., Zhou L.M.,  
 RA Bandyopadhyay P., Craig A.G., Olivera B.M.;  
 RT "The T-superfamily of conotoxins.";

RL J. Biol. Chem. 274:30664-30671(1999).  
 RN [2]  
 RP ERRATUM.  
 RA Walker C.S., Steel D., Jacobsen R.B., Lirazan M.B., Cruz L.J.,  
 RA Hooper D., Shetty R., DelaCruz R.C., Nielsen J.S., Zhou L.M.,  
 RA Bandyopadhyay P., Craig A.G., Olivera B.M.;  
 RL J. Biol. Chem. 274:36030-36030(1999).  
 CC -!- FUNCTION: Causes dorsal fins drooping in fish. No effect is  
 CC observed when injected into mice (By similarity).  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- TISSUE SPECIFICITY: Expressed by the venom duct.  
 CC -!- MASS SPECTROMETRY: MW=1388.6; METHOD=LSIMS.  
 CC -!- SIMILARITY: Belongs to the conotoxin T-superfamily.  
 DR PIR; B59146; B59146.  
 KW Toxin.  
 FT DISULFID 2 9  
 FT DISULFID 3 10  
 SQ SEQUENCE 11 AA; 1393 MW; 21A36775440042D7 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 R 4  
 |  
 Db 7 R 7

#### RESULT 45

CXL1\_CONMR  
 ID CXL1\_CONMR STANDARD; PRT; 11 AA.  
 AC P58807;  
 DT 28-FEB-2003 (Rel. 41, Created)  
 DT 28-FEB-2003 (Rel. 41, Last sequence update)  
 DT 28-FEB-2003 (Rel. 41, Last annotation update)  
 DE Lambda-conotoxin CMrVIA.  
 OS Conus marmoreus (Marble cone).  
 OC Eukaryota; Metazoa; Mollusca; Gastropoda; Orthogastropoda;  
 OC Apogastropoda; Caenogastropoda; Sorbeoconcha; Hypsogastropoda;  
 OC Neogastropoda; Conoidea; Conidae; Conus.  
 OX NCBI\_TaxID=42752;  
 RN [1]  
 RP SEQUENCE, SYNTHESIS, AND MASS SPECTROMETRY.  
 RC TISSUE=Venom;  
 RX MEDLINE=20564325; PubMed=10988292;  
 RA Balaji R.A., Ohtake A., Sato K., Gopalakrishnakone P., Kini R.M.,  
 RA Seow K.T., Bay B.-H.;  
 RT "Lambda-conotoxins, a new family of conotoxins with unique disulfide  
 RT pattern and protein folding. Isolation and characterization from the  
 RT venom of Conus marmoreus."  
 RL J. Biol. Chem. 275:39516-39522(2000).  
 CC -!- FUNCTION: Inhibits the neuronal noradrenaline transporter.  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- TISSUE SPECIFICITY: Expressed by the venom duct.  
 CC -!- MASS SPECTROMETRY: MW=1237.93; MW\_ERR=0.21; METHOD=Electrospray.  
 CC -!- SIMILARITY: Belongs to the chi/lambda-conotoxin family.  
 KW Neurotoxin; Toxin; Hydroxylation.

FT DISULFID 2 11  
 FT DISULFID 3 8  
 FT MOD\_RES 10 10 HYDROXYLATION.  
 SQ SEQUENCE 11 AA; 1226 MW; 277AAC60B7232B58 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 G 6  
 |  
 Db 4 G 4

#### RESULT 46

EFG\_CLOPA

ID EFG\_CLOPA STANDARD; PRT; 11 AA.

AC P81350;

DT 15-JUL-1998 (Rel. 36, Created)

DT 15-JUL-1998 (Rel. 36, Last sequence update)

DT 28-FEB-2003 (Rel. 41, Last annotation update)

DE Elongation factor G (EF-G) (CP 5) (Fragment).

GN FUSA.

OS Clostridium pasteurianum.

OC Bacteria; Firmicutes; Clostridia; Clostridiales; Clostridiaceae;

OC Clostridium.

OX NCBI\_TaxID=1501;

RN [1]

RP SEQUENCE.

RC STRAIN=W5;

RX MEDLINE=98291870; PubMed=9629918;

RA Flengsrud R., Skjeldal L.;

RT "Two-dimensional gel electrophoresis separation and N-terminal  
 sequence analysis of proteins from Clostridium pasteurianum W5.";

RL Electrophoresis 19:802-806(1998).

CC -!- FUNCTION: This protein promotes the GTP-dependent translocation of  
 the nascent protein chain from the A-site to the P-site of the  
 ribosome.

CC -!- SUBCELLULAR LOCATION: Cytoplasmic.

CC -!- SIMILARITY: Belongs to the GTP-binding elongation factor family.

CC EF-G/EF-2 subfamily.

DR InterPro; IPR000795; EF\_GTPbind.

DR PROSITE; PS00301; EFACTOR\_GTP; PARTIAL.

KW Elongation factor; Protein biosynthesis; GTP-binding.

FT NON\_TER 11 11

SQ SEQUENCE 11 AA; 1337 MW; 412E71F1D9C33B17 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 K 2  
 |  
 Db 1 K 1

#### RESULT 47

## ES1\_RAT

ID ES1\_RAT STANDARD; PRT; 11 AA.  
 AC P56571;  
 DT 15-DEC-1998 (Rel. 37, Created)  
 DT 15-DEC-1998 (Rel. 37, Last sequence update)  
 DT 15-MAR-2004 (Rel. 43, Last annotation update)  
 DE ES1 protein, mitochondrial (Fragment).  
 OS Rattus norvegicus (Rat).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.  
 OX NCBI\_TaxID=10116;  
 RN [1]  
 RP SEQUENCE.  
 RC STRAIN=Wistar; TISSUE=Heart;  
 RA Li X.-P., Pleissner K.-P., Scheler C., Regitz-Zagrosek V., Salikov J.,  
 RA Jungblut P.R.;  
 RL Submitted (SEP-1998) to Swiss-Prot.  
 CC -!- SUBCELLULAR LOCATION: Mitochondrial (Potential).  
 CC -!- MISCELLANEOUS: By 2D-PAGE, the determined pI of this protein (spot  
 CC P2) is: 8.9, its MW is: 25 kDa.  
 CC -!- SIMILARITY: BELONGS TO THE ES1 FAMILY.  
 KW Mitochondrion.  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1142 MW; D862272D32C72DC2 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 R 4  
 |  
 Db 1 R 1

## RESULT 48

## FAR6\_PENMO

ID FAR6\_PENMO STANDARD; PRT; 11 AA.  
 AC P83321;  
 DT 28-FEB-2003 (Rel. 41, Created)  
 DT 28-FEB-2003 (Rel. 41, Last sequence update)  
 DT 28-FEB-2003 (Rel. 41, Last annotation update)  
 DE FMRFamide-like neuropeptide FLP6 (DGRTPALRLRF-amide).  
 OS Penaeus monodon (Penaeid shrimp).  
 OC Eukaryota; Metazoa; Arthropoda; Crustacea; Malacostraca;  
 OC Eumalacostraca; Eucarida; Decapoda; Dendrobranchiata; Penaeoidea;  
 OC Penaeidae; Penaeus.  
 OX NCBI\_TaxID=6687;  
 RN [1]  
 RP SEQUENCE, AND MASS SPECTROMETRY.  
 RC TISSUE=Eyestalk;  
 RX MEDLINE=21956277; PubMed=11959015;  
 RA Sithigorngul P., Pupuem J., Krungkasem C., Longyant S.,  
 RA Chaivisuthangkura P., Sithigorngul W., Petsom A.;  
 RT "Seven novel FMRFamide-like neuropeptide sequences from the eyestalk  
 RT of the giant tiger prawn Penaeus monodon."  
 RL Comp. Biochem. Physiol. 131B:325-337(2002).  
 CC -!- SUBCELLULAR LOCATION: Secreted.

CC -!- MASS SPECTROMETRY: MW=1301.8; METHOD=MALDI.  
 CC -!- SIMILARITY: Belongs to the FARP (FMRFamide related peptide)  
 CC family.  
 DR GO; GO:0007218; P:neuropeptide signaling pathway; TAS.  
 KW Neuropeptide; Amidation.  
 FT MOD\_RES 11 11 AMIDATION.  
 SQ SEQUENCE 11 AA; 1301 MW; 9A19C860072DC771 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 G 6  
 |  
 Db 2 G 2

#### RESULT 49

FAR9\_CALVO

ID FAR9\_CALVO STANDARD; PRT; 11 AA.  
 AC P41864;  
 DT 01-NOV-1995 (Rel. 32, Created)  
 DT 01-NOV-1995 (Rel. 32, Last sequence update)  
 DT 01-NOV-1995 (Rel. 32, Last annotation update)  
 DE CalliFMRFamide 9.  
 OS Calliphora vomitoria (Blue blowfly).  
 OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
 OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha; Oestroidea;  
 OC Calliphoridae; Calliphora.  
 OX NCBI\_TaxID=27454;  
 RN [1]  
 RP SEQUENCE.  
 RC TISSUE=Thoracic ganglion;  
 RX MEDLINE=92196111; PubMed=1549595;  
 RA Duve H., Johnsen A.H., Sewell J.C., Scott A.G., Orchard I.,  
 RA Rehfeld J.F., Thorpe A.;  
 RT "Isolation, structure, and activity of -Phe-Met-Arg-Phe-NH2  
 RT neuropeptides (designated calliFMRFamides) from the blowfly  
 RT Calliphora vomitoria.";  
 RL Proc. Natl. Acad. Sci. U.S.A. 89:2326-2330(1992).  
 CC -!- SIMILARITY: Belongs to the FARP (FMRFamide related peptide)  
 CC family.  
 DR PIR; I41978; I41978.  
 KW Neuropeptide; Amidation.  
 FT MOD\_RES 11 11 AMIDATION.  
 SQ SEQUENCE 11 AA; 1359 MW; 8160CE46CAA44321 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 S 3  
 |  
 Db 1 S 1

#### RESULT 50

## LADD\_ONCMY

ID LADD\_ONCMY STANDARD; PRT; 11 AA.  
 AC P81018;  
 DT 01-NOV-1997 (Rel. 35, Created)  
 DT 01-NOV-1997 (Rel. 35, Last sequence update)  
 DT 15-DEC-1998 (Rel. 37, Last annotation update)  
 DE Ladderlectin (Fragment).  
 OS Oncorhynchus mykiss (Rainbow trout) (Salmo gairdneri).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Actinopterygii; Neopterygii; Teleostei; Euteleostei;  
 OC Protacanthopterygii; Salmoniformes; Salmonidae; Oncorhynchus.  
 OX NCBI\_TaxID=8022;  
 RN [1]  
 RP SEQUENCE.  
 RC TISSUE=Blood;  
 RX MEDLINE=97293418; PubMed=9149391;  
 RA Jensen L.E., Thiel S., Petersen T.E., Jensenuis J.C.;  
 RT "A rainbow trout lectin with multimeric structure."  
 RL Comp. Biochem. Physiol. 116B:385-390(1997).  
 CC -!- FUNCTION: Lectin that binds sepharose.  
 CC -!- COFACTOR: Calcium is essential for sepharose binding.  
 CC -!- SUBUNIT: Multimeric.  
 KW Lectin; Calcium.  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1163 MW; 0B26227FF6D45404 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 A 1  
 |  
 Db 1 A 1

## RESULT 51

## LPW\_THETH

ID LPW\_THETH STANDARD; PRT; 11 AA.  
 AC P05624;  
 DT 01-NOV-1988 (Rel. 09, Created)  
 DT 01-NOV-1988 (Rel. 09, Last sequence update)  
 DT 30-MAY-2000 (Rel. 39, Last annotation update)  
 DE Trp operon leader peptide.  
 GN TRPL.  
 OS Thermus thermophilus.  
 OC Bacteria; Deinococcus-Thermus; Deinococci; Thermales; Thermaceae;  
 OC Thermus.  
 OX NCBI\_TaxID=274;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=HB8 / ATCC 27634;  
 RX MEDLINE=89000781; PubMed=2844259;  
 RA Sato S., Nakada Y., Kanaya S., Tanaka T.;  
 RT "Molecular cloning and nucleotide sequence of Thermus thermophilus  
 RT HB8 trpE and trpG."  
 RL Biochim. Biophys. Acta 950:303-312(1988).  
 CC -!- FUNCTION: THIS PROTEIN IS INVOLVED IN CONTROL OF THE BIOSYNTHESIS

CC OF TRYPTOPHAN.

CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----

DR EMBL; X07744; CAA30565.1; -.  
KW Tryptophan biosynthesis; Leader peptide.  
SQ SEQUENCE 11 AA; 1228 MW; 364B295A772DC5A7 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 M 11  
|  
Db 1 M 1

#### RESULT 52

LSK1\_LEUMA

ID LSK1\_LEUMA STANDARD; PRT; 11 AA.

AC P04428;

DT 13-AUG-1987 (Rel. 05, Created)

DT 13-AUG-1987 (Rel. 05, Last sequence update)

DT 15-MAR-2004 (Rel. 43, Last annotation update)

DE Leucosulfakinin-I (LSK-I).

OS Leucophaea maderae (Madeira cockroach).

OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;

OC Neoptera; Orthopteroidea; Dictyoptera; Blattaria; Blaberoidea;

OC Blaberidae; Leucophaea.

OX NCBI\_TaxID=6988;

RN [1]

RP SEQUENCE.

RX MEDLINE=86315858; PubMed=3749893;

RA Nachman R.J., Holman G.M., Haddon W.F., Ling N.;

RT "Leucosulfakinin, a sulfated insect neuropeptide with homology to  
RT gastrin and cholecystokinin.";

RL Science 234:71-73(1986).

CC -!- FUNCTION: Change the frequency and amplitude of contractions of  
CC the hingat. Inhibits muscle contraction of hindgut.

CC -!- SIMILARITY: Belongs to the gastrin/cholecystokinin family.

DR PIR; A01622; GMROL.

DR InterPro; IPR001651; Gastrin.

DR PROSITE; PS00259; GASTRIN; 1.

KW Hormone; Amidation; Sulfation.

FT MOD\_RES 6 6 SULFATION.

FT MOD\_RES 11 11 AMIDATION.

SQ SEQUENCE 11 AA; 1459 MW; 7E4E0680E86B5AAB CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 R 4  
|  
Db 10 R 10

RESULT 53

LSKP\_PERAM

ID LSKP\_PERAM STANDARD; PRT; 11 AA.  
AC P36885;  
DT 01-JUN-1994 (Rel. 29, Created)  
DT 01-JUN-1994 (Rel. 29, Last sequence update)  
DT 01-FEB-1996 (Rel. 33, Last annotation update)  
DE Perisulfakinin (Pea-SK-I).  
OS Periplaneta americana (American cockroach).  
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
OC Neoptera; Orthopteroidea; Dictyoptera; Blattaria; Blattoidea;  
OC Blattidae; Periplaneta.  
OX NCBI\_TaxID=6978;  
RN [1]  
RP SEQUENCE.  
RC TISSUE=Corpora cardiaca;  
RX MEDLINE=90137190; PubMed=2615921;  
RA Veenstra J.A.;  
RT "Isolation and structure of two gastrin/CCK-like neuropeptides from  
RT the American cockroach homologous to the leucosulfakinins.";  
RL Neuropeptides 14:145-149(1989).  
CC -!- FUNCTION: Stimulates hindgut contractions.  
CC -!- SIMILARITY: Belongs to the gastrin/cholecystokinin family.  
DR PIR; A60656; A60656.  
DR InterPro; IPR001651; Gastrin.  
DR PROSITE; PS00259; GASTRIN; 1.  
KW Hormone; Amidation; Sulfation.  
FT MOD\_RES 6 6 SULFATION.  
FT MOD\_RES 11 11 AMIDATION.  
SQ SEQUENCE 11 AA; 1445 MW; 8B4E0680E86B5AAA CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 R 4  
|  
Db 10 R 10

RESULT 54

MHBI\_KLEPN

ID MHBI\_KLEPN STANDARD; PRT; 11 AA.  
AC P80580;  
DT 01-OCT-1996 (Rel. 34, Created)  
DT 01-OCT-1996 (Rel. 34, Last sequence update)  
DT 01-NOV-1997 (Rel. 35, Last annotation update)  
DE Maleylpyruvate isomerase (EC 5.2.1.4) (Fragment).  
GN MHBI.  
OS Klebsiella pneumoniae.  
OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;



OC Enterobacteriaceae; Klebsiella.  
 OX NCBI\_TaxID=573;  
 RN [1]  
 RP SEQUENCE.  
 RX MEDLINE=96349117; PubMed=8760924;  
 RA Robson N.D., Parrott S., Cooper R.A.;  
 RT "In vitro formation of a catabolic plasmid carrying Klebsiella  
 RT pneumoniae DNA that allows growth of Escherichia coli K-12 on 3-  
 RT hydroxybenzoate.";  
 RL Microbiology 142:2115-2120(1996).  
 CC -!- CATALYTIC ACTIVITY: 3-maleylpyruvate = 3-fumarylpyruvate.  
 KW Isomerase.  
 FT NON TER 11 11  
 SQ SEQUENCE 11 AA; 1387 MW; 1EE0E2DD49C9D5AB CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 11 M 11  
 |  
 Db 1 M 1

# RESULT 55

## MLG\_THETS

ID MLG\_THETS STANDARD; PRT; 11 AA.  
 AC P41989;  
 DT 01-NOV-1995 (Rel. 32, Created)  
 DT 01-NOV-1995 (Rel. 32, Last sequence update)  
 DT 16-OCT-2001 (Rel. 40, Last annotation update)  
 DE Melanotropin gamma (Gamma-melanocyte stimulating hormone) (Gamma-MSH).  
 OS Theromyzon tessulatum (Leech).  
 OC Eukaryota; Metazoa; Annelida; Clitellata; Hirudinida; Hirudinea;  
 OC Rhynchobdellida; Glossiphoniidae; Theromyzon.  
 OX NCBI\_TaxID=13286;  
 RN [1]  
 RP SEQUENCE.  
 RC TISSUE=Brain;  
 RX MEDLINE=94298944; PubMed=8026574;  
 RA Salzet M., Wattez C., Bulet P., Malecha J.;  
 RT "Isolation and structural characterization of a novel peptide related  
 RT to gamma-melanocyte stimulating hormone from the brain of the leech  
 RT Theromyzon tessulatum.";  
 RL FEBS Lett. 348:102-106(1994).  
 CC -!- SIMILARITY: Belongs to the POMC family.  
 DR PIR; S45698; S45698.  
 KW Hormone; Amidation.  
 FT MOD\_RES 11 11 AMIDATION.  
 SQ SEQUENCE 11 AA; 1486 MW; 2DB8FACE6409C1E8 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 6 G 6  
 |

## RESULT 56

## MORN\_HUMAN

ID MORN\_HUMAN STANDARD; PRT; 11 AA.  
AC P01163;  
DT 21-JUL-1986 (Rel. 01, Created)  
DT 21-JUL-1986 (Rel. 01, Last sequence update)  
DT 28-FEB-2003 (Rel. 41, Last annotation update)  
DE Morphogenetic neuropeptide (Head activator) (HA).  
OS Homo sapiens (Human),  
OS Rattus norvegicus (Rat),  
OS Bos taurus (Bovine),  
OS Anthopleura elegantissima (Sea anemone), and  
OS Hydra attenuata (Hydra) (Hydra vulgaris).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606, 10116, 9913, 6110, 6087;  
RN [1]  
RP SEQUENCE.  
RC SPECIES=Human, Rat, and Bovine;  
RX MEDLINE=82035850; PubMed=7290191;  
RA Bodenmuller H., Schaller H.C.;  
RT "Conserved amino acid sequence of a neuropeptide, the head activator,  
RT from coelenterates to humans.";  
RL Nature 293:579-580(1981).  
RN [2]  
RP SEQUENCE.  
RC SPECIES=A.elegantissima, and H.attenuata;  
RA Schaller H.C., Bodenmuller H.;  
RT "Isolation and amino acid sequence of a morphogenetic peptide from  
RT hydra.";  
RL Proc. Natl. Acad. Sci. U.S.A. 78:7000-7004(1981).  
RN [3]  
RP SYNTHESIS.  
RX MEDLINE=82050803; PubMed=7297679;  
RA Birr C., Zachmann B., Bodenmuller H., Schaller H.C.;  
RT "Synthesis of a new neuropeptide, the head activator from hydra.";  
RL FEBS Lett. 131:317-321(1981).  
RN [4]  
RP FUNCTION.  
RX MEDLINE=90059923; PubMed=2583101;  
RA Schaller H.C., Druffel-Augustin S., Dubel S.;  
RT "Head activator acts as an autocrine growth factor for NH15-CA2 cells  
RT in the G2/mitosis transition.";  
RL EMBO J. 8:3311-3318(1989).  
CC -!- FUNCTION: HA acts as an autocrine growth factor for neural cells  
CC in the G2/mitosis transition.  
CC -!- CAUTION: This peptide was first isolated from nerve cells of hydra  
CC and was called head activator by the authors, because it induced  
CC head-specific growth and differentiation in this animal. It has  
CC been found in mammalian intestine and hypothalamus.  
DR PIR; A01427; YHRT.  
DR PIR; A93900; YHXA.E.  
DR PIR; B01427; YHHU.  
DR PIR; B93900; YHJFHY.

DR PIR; C01427; YHBO.  
 DR GK; P01163; -.  
 KW Growth factor; Cell cycle; Mitosis; Pyrrolidone carboxylic acid.  
 FT MOD\_RES 1 1 PYRROLIDONE CARBOXYLIC ACID.  
 SQ SEQUENCE 11 AA; 1142 MW; 37927417C325B878 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 G 6  
 |  
 Db 4 G 4

# RESULT 57

## NUHM\_CANFA

ID NUHM\_CANFA STANDARD; PRT; 11 AA.  
 AC P49820;  
 DT 01-OCT-1996 (Rel. 34, Created)  
 DT 15-JUL-1998 (Rel. 36, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE NADH-ubiquinone oxidoreductase 24 kDa subunit (EC 1.6.5.3)  
 DE (EC 1.6.99.3) (Fragment).  
 GN NDUFV2.  
 OS Canis familiaris (Dog).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.  
 OX NCBI\_TaxID=9615;  
 RN [1]  
 RP SEQUENCE.  
 RC TISSUE=Heart;  
 RX MEDLINE=98163340; PubMed=9504812;  
 RA Dunn M.J., Corbett J.M., Wheeler C.H.;  
 RT "HSC-2DPAGE and the two-dimensional gel electrophoresis database of  
 RT dog heart proteins."  
 RL Electrophoresis 18:2795-2802(1997).  
 CC -!- FUNCTION: TRANSFER OF ELECTRONS FROM NADH TO THE RESPIRATORY  
 CC CHAIN. THE IMMEDIATE ELECTRON ACCEPTOR FOR THE ENZYME IS BELIEVED  
 CC TO BE UBIQUINONE. COMPONENT OF THE FLAVOPROTEIN-SULFUR (FP)  
 CC FRAGMENT OF THE ENZYME.  
 CC -!- CATALYTIC ACTIVITY: NADH + ubiquinone = NAD(+) + ubiquinol.  
 CC -!- CATALYTIC ACTIVITY: NADH + acceptor = NAD(+) + reduced acceptor.  
 CC -!- COFACTOR: Binds 1 2Fe-2S cluster (Potential).  
 CC -!- SUBUNIT: Mammalian complex I is composed of 45 different subunits.  
 CC -!- SUBCELLULAR LOCATION: Matrix and cytoplasmic side of the  
 CC mitochondrial inner membrane.  
 CC -!- SIMILARITY: Belongs to the complex I 24 kDa subunit family.  
 DR HSC-2DPAGE; P49820; DOG.  
 DR InterPro; IPR002023; Cmplx1\_24kDa.  
 DR PROSITE; PS01099; COMPLEX1\_24K; PARTIAL.  
 KW Oxidoreductase; NAD; Ubiquinone; Mitochondrion; Metal-binding;  
 KW Iron-sulfur; Iron; 2Fe-2S.  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1099 MW; 267F5369C9C72DD8 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;

Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 G 6  
|  
Db 1 G 1

RESULT 58

PKC1\_CARMO

ID PKC1\_CARMO STANDARD; PRT; 11 AA.  
AC P82684;  
DT 16-OCT-2001 (Rel. 40, Created)  
DT 16-OCT-2001 (Rel. 40, Last sequence update)  
DT 16-OCT-2001 (Rel. 40, Last annotation update)  
DE Pyrokinin-1 (Cam-PK-1) (FXPRL-Amide).  
OS Carausius morosus (Indian stick insect).  
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
OC Neoptera; Orthopteroidea; Phasmatodea; Euphasmida; Phasmatoidea;  
OC Heteronemiidae; Carausius.  
OX NCBI\_TaxID=7022;  
RN [1]  
RP SEQUENCE, FUNCTION, AND MASS SPECTROMETRY.  
RC TISSUE=Corpora cardiaca;  
RA Predel R., Kellner R., Gaede G.;  
RT "Myotropic neuropeptides from the retrocerebral complex of the stick  
RT insect, Carausius morosus (Phasmatodea: Lonchodidae).";  
RL Eur. J. Entomol. 96:275-278(1999).  
CC -!- FUNCTION: Mediates visceral muscle contractile activity (myotropic  
CC activity).  
CC -!- MASS SPECTROMETRY: MW=1235; METHOD=MALDI.  
CC -!- SIMILARITY: Belongs to the pyrokinin family.  
DR InterPro; IPR001484; Pyrokinin.  
DR PROSITE; PS00539; PYROKININ; FALSE\_NEG.  
KW Neuropeptide; Amidation; Pyrokinin.  
FT MOD RES 11 11 AMIDATION.  
SQ SEQUENCE 11 AA; 1236 MW; 2BFA5225BB46C1A8 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 R 4  
|  
Db 10 R 10

RESULT 59

PQQC\_PSEFL

ID PQQC\_PSEFL STANDARD; PRT; 11 AA.  
AC P55173;  
DT 01-OCT-1996 (Rel. 34, Created)  
DT 01-OCT-1996 (Rel. 34, Last sequence update)  
DT 10-OCT-2003 (Rel. 42, Last annotation update)  
DE Coenzyme PQQ synthesis protein C (Pyrroloquinoline quinone  
DE biosynthesis protein C) (Fragment).  
GN PQQC.

OS *Pseudomonas fluorescens*.  
 OC Bacteria; Proteobacteria; Gammaproteobacteria; Pseudomonadales;  
 OC Pseudomonadaceae; Pseudomonas.  
 OX NCBI\_TaxID=294;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=CHA0;  
 RX MEDLINE=96064397; PubMed=8526497;  
 RA Schnider U., Keel C., Defago G., Haas D.;  
 RT "Tn5-directed cloning of pqq genes from *Pseudomonas fluorescens* CHA0:  
 RT mutational inactivation of the genes results in overproduction of the  
 RT antibiotic pyoluteorin.";  
 RL Appl. Environ. Microbiol. 61:3856-3864(1995).  
 CC -!- PATHWAY: Pyrroloquinoline quinone (PQQ) biosynthesis.  
 CC -!- SIMILARITY: Belongs to the pqqC family.

-----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----

DR EMBL; X87299; CAA60734.1; -.  
 DR PIR; S58244; S58244.  
 DR HAMAP; MF\_00654; -; 1.  
 KW PQQ biosynthesis.  
 FT NON TER 11 11  
 SQ SEQUENCE 11 AA; 1182 MW; 89DF46E4C5B73771 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 M 11  
 |  
 Db 1 M 1

# RESULT 60

PVK1\_PERAM  
 ID PVK1\_PERAM STANDARD; PRT; 11 AA.  
 AC P41837;  
 DT 01-NOV-1995 (Rel. 32, Created)  
 DT 01-NOV-1995 (Rel. 32, Last sequence update)  
 DT 16-OCT-2001 (Rel. 40, Last annotation update)  
 DE Periviscerokinin-1 (Pea-PVK-1).  
 OS *Periplaneta americana* (American cockroach).  
 OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
 OC Neoptera; Orthopteroidea; Dictyoptera; Blattaria; Blattoidea;  
 OC Blattidae; *Periplaneta*.  
 OX NCBI\_TaxID=6978;  
 RN [1]  
 RP SEQUENCE, AND SYNTHESIS.  
 RC TISSUE=Abdominal perisymphathetic organs;  
 RX MEDLINE=95232021; PubMed=7716075;

RA Predel R., Linde D., Rapus J., Vettermann S., Penzlin H.;  
 RT "Periviscerokinin (Pea-PVK): a novel myotropic neuropeptide from the  
 RT perisymphathetic organs of the American cockroach.";  
 RL Peptides 16:61-66(1995).  
 CC -!- FUNCTION: MYOACTIVE PEPTIDE; HAS EXCITORY ACTIONS ON THE  
 CC HYPERNEURAL MUSCLE.  
 KW Neuropeptide; Amidation.  
 FT MOD\_RES 11 11 AMIDATION.  
 SQ SEQUENCE 11 AA; 1114 MW; 39DB5419D7605728 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 6 G 6  
 |  
 Db 1 G 1

# RESULT 61

## RANC\_RANPI

ID RANC\_RANPI STANDARD; PRT; 11 AA.  
 AC P08951;  
 DT 01-NOV-1988 (Rel. 09, Created)  
 DT 01-NOV-1988 (Rel. 09, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Ranatensin-C.  
 OS Rana pipiens (Northern leopard frog).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Amphibia; Batrachia; Anura; Neobatrachia; Ranoidea; Ranidae; Rana.  
 OX NCBI\_TaxID=8404;  
 RN [1]  
 RP SEQUENCE.  
 RC TISSUE=Skin secretion;  
 RX MEDLINE=84131098; PubMed=6141890;  
 RA Nakajima T.;  
 RL Unpublished results, cited by:  
 RL Erspamer V., Erspamer G.F., Mazzanti G., Endean R.;  
 RL Comp. Biochem. Physiol. 77C:99-108(1984).  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- TISSUE SPECIFICITY: Skin.  
 CC -!- SIMILARITY: Belongs to the bombesin/neuromedin B/ranatensin  
 CC family.  
 DR InterPro; IPR000874; Bombesin.  
 DR Pfam; PF02044; Bombesin; 1.  
 DR PROSITE; PS00257; BOMBESIN; 1.  
 KW Amphibian defense peptide; Bombesin family; Amidation.  
 FT MOD\_RES 11 11 AMIDATION.  
 SQ SEQUENCE 11 AA; 1304 MW; D6C9885A61ADC366 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 A 1  
 |  
 Db 6 A 6

## RESULT 62

RE41\_LITRU

ID RE41\_LITRU STANDARD; PRT; 11 AA.  
 AC P82074;  
 DT 28-FEB-2003 (Rel. 41, Created)  
 DT 28-FEB-2003 (Rel. 41, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Rubellidin 4.1.  
 OS Litoria rubella (Desert tree frog).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Amphibia; Batrachia; Anura; Neobatrachia; Hyloidea; Hylidae;  
 OC Pelodyadinae; Litoria.  
 OX NCBI\_TaxID=104895;  
 RN [1]  
 RP SEQUENCE, AND MASS SPECTROMETRY.  
 RC TISSUE=Skin secretion;  
 RA Steinborner S.T., Wabnitz P.A., Waugh R.J., Bowie J.H., Gao C.,  
 RA Tyler M.J., Wallace J.C.;  
 RT "The structure of new peptides from the Australin red tree frog  
 RT 'Litoria rubella'. The skin peptide profile as a probe for the study  
 RT of evolutionary trends of amphibians.";  
 RL Aust. J. Chem. 49:955-963(1996).  
 CC -!- FUNCTION: Shows neither neuropeptide activity nor antibiotic  
 CC activity.  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- TISSUE SPECIFICITY: Expressed by the skin dorsal glands.  
 CC -!- MASS SPECTROMETRY: MW=1039; METHOD=FAB.  
 KW Amphibian defense peptide; Amidation.  
 FT MOD\_RES 11 11 AMIDATION.  
 SQ SEQUENCE 11 AA; 1040 MW; 84ED5CBC2877205A CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 6 G 6  
 |  
 Db 1 G 1

## RESULT 63

RR2\_CONAM

ID RR2\_CONAM STANDARD; PRT; 11 AA.  
 AC P42341;  
 DT 01-NOV-1995 (Rel. 32, Created)  
 DT 01-NOV-1995 (Rel. 32, Last sequence update)  
 DT 28-FEB-2003 (Rel. 41, Last annotation update)  
 DE Chloroplast 30S ribosomal protein S2 (Fragment).  
 GN RPS2.  
 OS Conopholis americana (Squawroot).  
 OG Chloroplast.  
 OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
 OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; asterids;  
 OC lamiids; Lamiales; Orobanchaceae; Orobancheae; Conopholis.  
 OX NCBI\_TaxID=4179;

RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=92145776; PubMed=1723664;  
 RA Taylor G., Wolfe K.H., Morden C.W., Depamphilis C.W., Palmer J.D.;  
 RT "Lack of a functional plastid tRNA(Cys) gene is associated with loss  
 RT of photosynthesis in a lineage of parasitic plants.";  
 RL Curr. Genet. 20:515-518(1991).  
 CC -!- SIMILARITY: Belongs to the S2P family of ribosomal proteins.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL; X64567; CAA45868.1; -.  
 DR PIR; S32575; S32575.  
 DR HAMAP; MF\_00291; -; 1.  
 DR InterPro; IPR001865; Ribosomal\_S2.  
 DR PROSITE; PS00962; RIBOSOMAL\_S2\_1; PARTIAL.  
 DR PROSITE; PS00963; RIBOSOMAL\_S2\_2; PARTIAL.  
 KW Ribosomal protein; Chloroplast.  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1497 MW; 76CD719954536B44 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 11 M 11  
 |  
 Db 1 M 1

# RESULT 64

## RRPL\_CHAV

ID RRPL\_CHAV STANDARD; PRT; 11 AA.  
 AC P13179;  
 DT 01-JAN-1990 (Rel. 13, Created)  
 DT 01-JAN-1990 (Rel. 13, Last sequence update)  
 DT 28-FEB-2003 (Rel. 41, Last annotation update)  
 DE RNA polymerase beta subunit (EC 2.7.7.48) (Large structural protein)  
 DE (L protein) (Fragment).  
 GN L.  
 OS Chandipura virus (strain I653514).  
 OC Viruses; ssRNA negative-strand viruses; Mononegavirales;  
 OC Rhabdoviridae; Vesiculovirus.  
 OX NCBI\_TaxID=11273;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=89299473; PubMed=2741347;  
 RA Masters P.S., Bhella R.S., Butcher M., Patel B., Ghosh H.P.,  
 RA Banerjee A.K.;  
 RT "Structure and expression of the glycoprotein gene of Chandipura  
 RT virus.";



RL Virology 171:285-290(1989).

CC -!- FUNCTION: THIS PROTEIN IS PROBABLY A COMPONENT OF THE ACTIVE  
 CC POLYMERASE. IT MAY FUNCTION IN RNA SYNTHESIS, CAPPING, AS WELL AS  
 CC METHYLATION OF CAPS, AND POLY(A) SYNTHESIS.

CC -!- CATALYTIC ACTIVITY: N nucleoside triphosphate = N diphosphate +  
 CC {RNA} (N).

CC -!- SUBUNIT: THOUGHT TO FORM A TRANSCRIPTION COMPLEX WITH THE  
 CC NUCLEOCAPSID (N) PROTEIN.

CC -!- SIMILARITY: WITH THE L PROTEIN OF OTHER RHABDOVIRUSES AND  
 CC PARAMYXOVIRUSES.

CC -----

CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

CC -----

DR EMBL; J04350; AAA42917.1; -.

KW Transferase; RNA-directed RNA polymerase.

FT NON TER 11 11

SQ SEQUENCE 11 AA; 1189 MW; 0335D6E3AAB2D764 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 11 M 11  
 |  
 Db 1 M 1

# RESULT 65

## T2P1\_PROVU

ID T2P1\_PROVU STANDARD; PRT; 11 AA.

AC P31031;

DT 01-JUL-1993 (Rel. 26, Created)

DT 01-JUL-1993 (Rel. 26, Last sequence update)

DT 10-OCT-2003 (Rel. 42, Last annotation update)

DE Type II restriction enzyme PvuI (EC 3.1.21.4) (Endonuclease PvuI)

DE (R.PvuI) (Fragment).

GN PVUIR.

OS Proteus vulgaris.

OC Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales;

OC Enterobacteriaceae; Proteus.

OX NCBI\_TaxID=585;

RN [1]

RP SEQUENCE FROM N.A.

RC STRAIN=ATCC 13315;

RX MEDLINE=93087186; PubMed=1454536;

RA Smith M.D., Longo M., Gerard G.F., Chatterjee D.K.;

RT "Cloning and characterization of genes for the PvuI restriction and  
 RT modification system.";

RL Nucleic Acids Res. 20:5743-5747(1992).

CC -!- FUNCTION: RECOGNIZES THE DOUBLE-STRANDED SEQUENCE CGATCG AND  
 CC CLEAVES AFTER T-4.

CC -!- CATALYTIC ACTIVITY: Endonucleolytic cleavage of DNA to give  
 CC specific double-stranded fragments with terminal 5'-phosphates.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----  
 DR EMBL; L04163; AAA25660.1; -.  
 DR PIR; S35490; S35490.  
 DR REBASE; 1541; PvuI.  
 KW Restriction system; Hydrolase; Nuclease; Endonuclease.  
 FT NON\_TER 1 1  
 SQ SEQUENCE 11 AA; 1300 MW; 9F0CDE7955B72B1A CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 S 3  
 |  
 Db 2 S 2

# RESULT 66

TIN1\_HOPTI  
 ID TIN1\_HOPTI STANDARD; PRT; 11 AA.  
 AC P82651;  
 DT 16-OCT-2001 (Rel. 40, Created)  
 DT 16-OCT-2001 (Rel. 40, Last sequence update)  
 DT 15-MAR-2004 (Rel. 43, Last annotation update)  
 DE Tigerinin-1.  
 OS Hoplobatrachus tigerinus (Indian bull frog) (Rana tigerina).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Amphibia; Batrachia; Anura; Neobatrachia; Ranoidea; Ranidae;  
 OC Hoplobatrachus.  
 OX NCBI\_TaxID=103373;  
 RN [1]  
 RP SEQUENCE, FUNCTION, MASS SPECTROMETRY, AND DISULFIDE BONDS.  
 RC TISSUE=Skin secretion;  
 RX PubMed=11031261;  
 RA Purnà Sai K., Jaganadham M.V., Vairamani M., Raju N.P.,  
 RA Devi A.S., Nagaraj R., Sitaram N.;  
 RT "Tigerinins: novel antimicrobial peptides from the Indian frog Rana  
 RT tigerina.";  
 RL J. Biol. Chem. 276:2701-2707(2001).  
 CC -!- FUNCTION: Antibacterial activity against B.subtilis, E.coli,  
 CC S.aureus, M.luteus, P.putida and S.cerevisiae.  
 CC -!- SUBCELLULAR LOCATION: Secreted.  
 CC -!- TISSUE SPECIFICITY: Skin.  
 CC -!- MASS SPECTROMETRY: MW=1342; METHOD=MALDI.  
 KW Amphibian defense peptide; Antibiotic; Fungicide; Amidation.  
 FT DISULFID 2 10  
 FT MOD\_RES 11 11 AMIDATION.

SQ SEQUENCE 11 AA; 1344 MW; A2087DC960476056 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 R 4  
|  
Db 9 R 9

RESULT 67

TIN4\_HOPTI

ID TIN4\_HOPTI STANDARD; PRT; 11 AA.  
AC P82654;  
DT 16-OCT-2001 (Rel. 40, Created)  
DT 16-OCT-2001 (Rel. 40, Last sequence update)  
DT 10-OCT-2003 (Rel. 42, Last annotation update)  
DE Tigerinin-4.  
OS Hoplobatrachus tigerinus (Indian bull frog) (Rana tigerina).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Amphibia; Batrachia; Anura; Neobatrachia; Ranoidea; Ranidae;  
OC Hoplobatrachus.  
OX NCBI\_TaxID=103373;  
RN [1]  
RP SEQUENCE, FUNCTION, MASS SPECTROMETRY, AND DISULFIDE BONDS.  
RC TISSUE=Skin secretion;  
RX PubMed=11031261;  
RA Purna Sai K., Jaganadham M.V., Vairamani M., Raju N.P.,  
RA Devi A.S., Nagaraj R., Sitaram N.;  
RT "Tigerinins: novel antimicrobial peptides from the Indian frog Rana  
RT tigerina.";  
RL J. Biol. Chem. 276:2701-2707(2001).  
CC -!- FUNCTION: Antibacterial activity against B.subtilis, E.coli,  
CC S.aureus, M.luteus, P.putida and S.cerevisiae.  
CC -!- SUBCELLULAR LOCATION: Secreted.  
CC -!- TISSUE SPECIFICITY: Skin.  
CC -!- MASS SPECTROMETRY: MW=1247; METHOD=MALDI.  
KW Amphibian defense peptide; Antibiotic.  
FT DISULFID 3 11  
SQ SEQUENCE 11 AA; 1248 MW; 117D8EFD37605DCB CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 R 4  
|  
Db 1 R 1

RESULT 68

TKND\_RANCA

ID TKND\_RANCA STANDARD; PRT; 11 AA.  
AC P22691;  
DT 01-AUG-1991 (Rel. 19, Created)  
DT 01-AUG-1991 (Rel. 19, Last sequence update)

DT 10-OCT-2003 (Rel. 42, Last annotation update)  
DE Ranatachykinin D (RTK D).  
OS Rana catesbeiana (Bull frog).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Amphibia; Batrachia; Anura; Neobatrachia; Ranoidea; Ranidae; Rana.  
OX NCBI\_TaxID=8400;  
RN [1]  
RP SEQUENCE, AND SYNTHESIS.  
RC TISSUE=Intestine;  
RX MEDLINE=91254337; PubMed=2043143;  
RA Kozawa H., Hino J., Minamino N., Kangawa K., Matsuo H.;  
RT "Isolation of four novel tachykinins from frog (Rana catesbeiana)  
RT brain and intestine.";  
RL Biochem. Biophys. Res. Commun. 177:588-595(1991).  
RN [2]  
RP SEQUENCE.  
RC TISSUE=Intestine;  
RX MEDLINE=94023216; PubMed=8210506;  
RA Kangawa K., Kozawa H., Hino J., Minamino N., Matsuo H.;  
RT "Four novel tachykinins in frog (Rana catesbeiana) brain and  
RT intestine.";  
RL Regul. Pept. 46:81-88(1993).  
CC -!- FUNCTION: Tachykinins are active peptides which excite neurons,  
CC evoke behavioral responses, are potent vasodilators and  
CC secretagogues, and contract (directly or indirectly) many smooth  
CC muscles.  
CC -!- SUBCELLULAR LOCATION: Secreted.  
CC -!- SIMILARITY: Belongs to the tachykinin family.  
DR PIR; D61033; D61033.  
DR InterPro; IPR002040; Tachy\_Neurokinin.  
DR PROSITE; PS00267; TACHYKININ; FALSE\_NEG.  
KW Tachykinin; Neuropeptide; Amidation.  
FT MOD\_RES 11 11 AMIDATION.  
SQ SEQUENCE 11 AA; 1350 MW; 3A34256C59D40B07 CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 K 2  
|  
Db 1 K 1

# RESULT 69

UF05\_MOUSE  
ID UF05\_MOUSE STANDARD; PRT; 11 AA.  
AC P38643;  
DT 01-OCT-1994 (Rel. 30, Created)  
DT 01-OCT-1994 (Rel. 30, Last sequence update)  
DT 15-MAR-2004 (Rel. 43, Last annotation update)  
DE Unknown protein from 2D-page of fibroblasts (P48) (Fragment).  
OS Mus musculus (Mouse).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
OX NCBI\_TaxID=10090;  
RN [1]

RP SEQUENCE.  
 RC TISSUE=Fibroblast;  
 RX MEDLINE=95009907; PubMed=7523108;  
 RA Merrick B.A., Patterson R.M., Wichter L.L., He C., Selkirk J.K.;  
 RT "Separation and sequencing of familiar and novel murine proteins  
 RT using preparative two-dimensional gel electrophoresis.";  
 RL Electrophoresis 15:735-745(1994).  
 CC -!- MISCELLANEOUS: On the 2D-gel the determined pI of this unknown  
 CC protein is: 5.5, its MW is: 48 kDa.  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1328 MW; E54835E5CAAABAFa CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 K 2  
 |  
 Db 1 K 1

# RESULT 70

## ULAG\_HUMAN

ID ULAG\_HUMAN STANDARD; PRT; 11 AA.  
 AC P31933;  
 DT 01-JUL-1993 (Rel. 26, Created)  
 DT 01-JUL-1993 (Rel. 26, Last sequence update)  
 DT 15-MAR-2004 (Rel. 43, Last annotation update)  
 DE Unknown protein from 2D-page of liver tissue (Spot 118) (Fragment).  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE.  
 RC TISSUE=Liver;  
 RX MEDLINE=94147969; PubMed=8313870;  
 RA Hughes G.J., Frutiger S., Paquet N., Pasquali C., Sanchez J.-C.,  
 RA Tissot J.-D., Bairoch A., Appel R.D., Hochstrasser D.F.;  
 RT "Human liver protein map: update 1993.";  
 RL Electrophoresis 14:1216-1222(1993).  
 CC -!- MISCELLANEOUS: On the 2D-gel the determined pI of this unknown  
 CC protein is: 5.5, its MW is: 34 kDa.  
 DR SWISS-2DPAGE; P31933; HUMAN.  
 DR Siena-2DPAGE; P31933; -.  
 FT NON\_TER 11 11  
 SQ SEQUENCE 11 AA; 1219 MW; EDABD37F272DDB0A CRC64;

Query Match 9.1%; Score 1; DB 1; Length 11;  
 Best Local Similarity 100.0%; Pred. No. 8.7e+04;  
 Matches 1; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 A 1  
 |  
 Db 6 A 6

Search completed: April 8, 2004, 15:47:24  
Job time : 6.15385 secs